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IV. Abstract 
 
The negative symptoms of schizophrenia include impoverished speech, affective blunting, an 
inability to anticipate pleasure, asociality, and amotivation. Current effective treatment 
options are limited, which is a significant issue given their strong association to functional 
impairment. The primary aims of this thesis are to explore areas which may inform the design 
of clinical trials addressing these symptoms, build upon recent advances in negative symptom 
assessment, and further understand the impact of negative symptoms on outcomes. 
A meta-analysis examining the longitudinal course of negative symptoms demonstrated a 
consistent reduction in negative symptoms over the study period in all treatment conditions 
examined, including in studies which adopted different eligibility criteria to minimise the 
presence of secondary negative symptoms. A comparison of different eligibility criteria 
revealed that whilst these criteria reduce the association between negative and depressive 
symptoms, their association to positive symptoms remains largely unaffected, and can 
substantially reduce the proportion of available participants. 
Given existing negative symptom assessment tools have been identified as a significant barrier 
in the development of new treatments, a comparison of assessment methods was performed. 
Results revealed the Clinical Assessment Interview for Negative Symptoms to be a more 
sensitive instrument, and a better predictor of functional impairments, relative to the negative 
subscale of the Positive and Negative Syndrome Scale. Findings described here also 
demonstrate that the link between negative symptoms and subjective quality of life may be 
stronger than previously assumed, relating exclusively to experiential deficits. Finally, manic 
and positive symptoms, rather than negative symptoms, were found to be associated with 
inpatient treatment appraisal, an important factor in treatment outcomes.  
Overall, this thesis describes key findings which demonstrate the importance of the 
appropriate assessment of negative symptoms of schizophrenia, shine new light on symptom 
progression over time, and highlight a need to further refine clinical trial inclusion criteria. 
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Chapter 1. Introduction 
 
1.1. Introducing schizophrenia 
1.1.1. What is schizophrenia and why is it important? 
Schizophrenia is a serious mental health disorder characterised by a disruption in thinking and 
emotional responses. Whilst the point incidence is relatively low (2-10/10,000), the prevalence 
is much higher due to the chronic nature of the illness (70/10,000) (Saha et al., 2005). Despite 
recent evidence which suggests that the long term negative impact of the illness may have 
been previously overestimated due to sample biases (Morgan et al., 2014), it is clear that 
schizophrenia is a highly disabling condition in terms of physical, social, and functional 
outcomes.  
Mortality and suicide rates in those diagnosed with schizophrenia is disproportionately high 
relative to the general population (Hor and Taylor, 2010, McGrath et al., 2008, Reininghaus et 
al., 2015), and co-morbid disorders, particularly substance use disorders, are common (Buckley 
et al., 2009). Patients diagnosed with schizophrenia are more likely to suffer chronic physical 
conditions such as obesity, type II diabetes and coronary heart disease, and medications taken 
for schizophrenia have been associated with sexual dysfunction, obesity, movement-disorders, 
and cataracts (Marder et al., 2014). In the AESOP-10 study, almost three quarters of the 
participants assessed remained unemployed for at least 75% of the time over a period of ten 
years, and further psychiatric hospital admissions occurred in 88% of cases (Morgan et al., 
2014). Impairments in work and academic performance, interpersonal relations, and self-care 
are so intrinsic to our current definition of schizophrenia that these features form part of the 
diagnostic criterion for the illness (APA, 2013). In a cohort study spanning 15 years, 80% of 
participants were found to have a persistent impairment in social functioning (Wiersma et al., 
2000), and the disorder can result in substantial caregiver burden (McDonell et al., 2003). 
Following the first psychotic episode, only 13.7% of patients (95% CI= 6.4% - 20.9%) were 
found to meet criteria for full recovery for at least two of the following 5 years (Robinson et al., 
2014). 
In addition to the significant impact that the disorder can have on both the individual and 
caregivers, schizophrenia is also recognised to have a major economic cost. In 2012, the 
estimated annual cost of schizophrenia to English society was placed was £11.8 billion, £7.2 
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billion of which costed to the public sector (Andrew et al., 2012).  In summary, schizophrenia is 
recognised to have a substantial negative impact on the individual, families and care givers, 
and to society at large, and therefore presents a need for future research to help alleviate the 
devastating impact of this disorder.  
 
1.1.2. The typical course of schizophrenia 
Prior to the onset of schizophrenia individuals typically experience a period known as the 
prodromal phase, which can last for a number years before acute psychotic symptoms surface 
(Häfner et al., 1999). In his stage, which usually occurs in late teens or early adulthood, it is 
common for people to experience a decline in global functioning. This can include various 
forms of cognitive impairments such as deficits in executive function, general intelligence, 
verbal and visual memory, verbal fluency, attention, working memory, and social cognition 
(Fusar-Poli et al., 2012), in addition to depressed mood or anxiety, infrequent or attenuated 
psychotic symptoms, or negative symptoms such as social withdrawal (Häfner et al., 1999). 
During this period it is also common for patients to experience a decline in social, occupational 
or academic performance (Cornblatt et al., 2007). In a longitudinal study following those that 
qualify for prodromal syndrome, 35% of cases were found to go on to develop psychosis within 
a period of 30 months (Cannon et al., 2008). In those that do go on to develop schizophrenia, 
patients typically experience acute psychotic symptoms such as delusions, hallucinations, 
thought disorder, and a further deterioration in cognitive and social functioning. Following 
treatment, most patients transition on to the chronic phase of the disorder where psychotic 
symptoms diminish, but significant impairments in functioning and negative symptoms remain. 
Approximately 80% of patients in the acute phase of the disorder go on to experience a 
substantial reduction in psychotic symptoms, although many (~70%) will go on to experience a 
relapse into the acute phase again within 5-7 years (Wiersma et al., 1998). The antecedents of 
regressing back to the acute phase of the disorder are not entirely clear, however non-
adherence to mediation and social withdrawal have been found to be associated (Robinson et 
al., 1999). Other predictors identified include younger age, earlier illness onset, substance use 
disorder, and prior episodes of relapse (Ascher-Svanum et al., 2010). Whilst complete 
remission from the disorder is relatively rare (Jääskeläinen et al., 2013), in a more recent study 
there is evidence to suggest that periods of remission are more common than was previously 
believed (Morgan et al., 2014). 
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1.1.3. Factors associated with the development of schizophrenia 
Whilst the causes of schizophrenia are undetermined, a number of risk factors have been 
identified. Of these, having a positive family history has been recognised as the most 
influential factor. Lifetime risk is 6.5 times higher in people who have first degree relatives 
diagnosed with the disorder (Kendler and Diehl, 1993). Twin studies suggest a strong genetic 
component for this association, with the risk factor as high as 40% in monozygotic twins where 
one has been diagnosed with the disorder (Cardno et al., 1999). 
Two systematic reviews suggest that the incidence rate of schizophrenia is higher in males in 
comparison to females, with a male to female ratio of 1.4:1 (95% CI: 1.3 – 1.6) (Aleman et al., 
2003, McGrath et al., 2008). In addition, males appear to have an earlier age of onset, 
experience more severe negative symptoms, and report a worse outcome (Jablensky, 2000). 
However, as described in a review by McGrath et al. (McGrath et al., 2008) this higher 
incidence rate did not appear to translate to a higher prevalence rate in males. The reason for 
this is not entirely clear, however it is possible that this could be explained at least in part by 
the higher mortality rates in male schizophrenia patients in comparison to females sufferers 
(standardized mortality ratio’s, male=2.8, females=2.4) (Ösby et al., 2000). 
Another factor associated with developing psychosis is migrant status, with both the incidence 
and prevalence of schizophrenia significantly higher in migrants relative to native-born 
individuals (Fearon et al., 2006, McGrath, 2006). This higher incidence rate of psychosis was 
found in both first and second generation immigrants, which suggests that the difference is not 
attributable to events which occurred prior to immigration (Bourque et al., 2011). In addition, 
this risk appears to be inversely related to the proportion of migrants within their local 
community (Boydell et al., 2001). In the UK, higher incidence rates of psychosis in Caribbean 
migrants have been consistently reported (Fearon et al., 2006, Sharpley et al., 2001). However, 
with rates not found to be higher in the countries of origin, this suggests that the issue is 
related to being an immigrant, rather than having any genetic predisposition towards the 
illness (Messias et al., 2007). 
Despite the risk being relatively small, there has been consistent evidence which suggests that 
people that are born during the winter months are significantly more likely to develop 
psychosis (Davies et al., 2003). The reasons for this are not entirely clear, however a number of 
theories have been proposed. One hypothesis states that influenza infections during gestation 
may be related to increased rates of schizophrenia, however no evidence for this was found in 
a large epidemiological study (Morgan et al., 1997). Another theory proposes that this may be 
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associated with biometeorologic variables such as temperature, ultra-violet radiation and 
precipitation, which is supported by the finding that people born at higher latitudes have both 
higher prevalence and incidence rates (Saha et al., 2006). Related to this, McGrath went on to 
propose that low pre-natal vitamin D may be a risk modifying factor for schizophrenia 
(McGrath, 1999). To complicate the issue of birth seasonality and its impact on schizophrenia 
further, there is evidence to suggest that this effect is not consistent in all types of the illness. 
In a pooled analysis of 6 countries, patients diagnosed with the deficit syndrome of 
schizophrenia (see section 1.3.3 for a summary)  were significantly more likely to have been 
born in the months of June-July, relative to non-deficit syndrome schizophrenia patients 
(Messias et al., 2004). 
In addition to the season in which the gestational period occurs, prenatal and obstetric 
complications have also long been implicated in increase rates of schizophrenia (Kraepelin, 
1971). In a systematic review by Geddes and colleagues (Geddes et al., 1999) the diagnosis of 
schizophrenia was associated with premature rupture of membranes, a gestational age below 
37 weeks, and the use of resuscitation or an incubator. There was also evidence of a weak 
effect between low birth weight and a forceps delivery.  In a review by Cannon and colleagues 
(Cannon et al., 2002), different risk complications were grouped into three different factors; 
complications in pregnancy, abnormal foetal growth and development; and delivery 
complications, all of which were significantly associated schizophrenia. Different reasons why 
these complications are associated with higher incidence of schizophrenia have been 
proposed, including the effect of hypoxia and or Ischemia (Geddes et al., 1999, Zornberg et al., 
2000), malnutrition (Susser and Lin, 1992), or developmental impairments caused by 
premature birth (Nosarti et al., 2012). 
Another possible risk factor is paternal age, where there is evidence to suggest that this is 
positively associated with an increased risk of schizophrenia (Brown et al., 2014, Zammit et al., 
2003). In one cohort study an increase in relative risk by a factor of 2.96 (95% CI 1.60-5.47) was 
detected in the offspring of fathers over 55, in comparison to those aged 20-24 (Malaspina et 
al., 2001). Malaspina postulated that this effect may result from de novo mutations in sperm 
cells. In support of this argument, it has since been found that the positive association with 
paternal age is only significant among those without any family history of the disease (Sipos et 
al., 2004). 
In addition to obstetric complications and the link between paternal age and schizophrenia, 
there is evidence of link between the mother experiencing traumatic event up to six months 
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before or during pregnancy and increased later incidence of schizophrenia in the child 
(Khashan et al., 2008). Following birth, Larssen (Larsson et al., 2013) found that 85% of people 
assessed with psychosis reported experiencing childhood trauma, with emotional abuse and 
neglect particularly common (63% and 67% respectively). In a review by Read (Read et al., 
2005) the authors suggested a causal factor between childhood experience of abuse and 
schizophrenia, however Morgan and Fisher (Morgan and Fisher, 2007) urged caution in 
determining such a link based on the current evidence base. 
Since the 1930’s there has been evidence which suggests that the prevalence of schizophrenia 
is higher in urban, as opposed to semi-urban or rural sites (Faris and Dunham, 1939). Given the 
cross-sectional design of the analysis however it was argued that this difference may be 
attributable to a selection bias, where better access to healthcare in urban sites may result in 
improved illness detection, and encourage migration to major cities. In more recent studies 
this has been examined prospectively (Lewis et al., 1992, Marcelis et al., 1998), which again 
supported a higher prevalence in urban sites, leading to the conclusion that the higher 
prevalence is independent of selection (Krabbendam and Van Os, 2005). A number of possible 
reasons for this difference have been postulated, such as environmental pollutants (Pedersen 
and Mortensen, 2006) and overcrowding stresses (Cougnard et al., 2007). In the review by 
McGrath and colleagues (McGrath et al., 2008) a higher incidence of the disorder was 
detected, though no changes in prevalence were observed.  
Finally, there is evidence to suggest a link between schizophrenia and smoking cannabis. In a 
large cohort study in Sweden, cannabis was associated with an increased risk of developing 
schizophrenia, with a dose response effect present (Zammit et al., 2002). In prospective 
longitudinal study, Arseneault and colleagues (Arseneault et al., 2002) also found a higher risk 
of developing psychosis with taking cannabis prior to experiencing psychotic symptoms, which 
suggests the association is not attributable to self-medicating against positive symptoms. In a 
meta-analysis examining overall effect size and consistency of the association between 
cannabis and psychosis, (Henquet et al., 2005) an effect was found to be consistent after 
controlling for any effects of self-medication, with a  pooled odds ratio of 2.1 (95% CI 1.7-2.5). 
Finally, in an overview of 5 systematic reviews (Minozzi et al., 2010) a consistent association 
between cannabis use and psychotic symptoms was detected. 
Overall, the evidence suggests that biological, psychological and societal factors all have a 
significant influence on the development of psychosis (Broome et al., 2005). Many of these 
factors are likely to be inter-related, and further work on the interaction between these 
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differing risk factors is needed. Such work may advance our understanding of how to detect 
those at most risk of developing the disorder, which is important given there is evidence to 
suggest early treatment of at-risk groups may help reduce the likelihood of transitioning to 
psychosis (Morrison et al., 2004). However, whilst such work may help reduce the proportion 
of people developing the disorder, a significant proportion of people at present still go on to 
develop the illness. Consequently, there is still an urgent need to develop new treatments, and 
to develop an appropriate framework in which therapeutics can be evaluated in the most 
efficient manner possible. 
 
1.1.4. The current diagnostic criterion for schizophrenia and implications for 
research 
In schizophrenia, diagnosis is determined by the presence of particular symptoms. Despite the 
existence of a number of diagnostic systems (for a review, see (Berner, 1983), the two most 
commonly implemented diagnostic tools at present are published by the ICD (International 
Classification of Diseases) and the DSM (Diagnostic and Statistical Manual of Mental Health 
Disorders). The DSM is the manual published periodically by the American Psychiatric 
Association (APA) and primarily adopted in the USA, whilst the ICD is the criterion adopted by 
the WHO and is most commonly used in the UK and throughout Europe. In both manuals, the 
concept of schizophrenia is defined as a spectrum disorder, including a number of variations of 
psychotic illnesses and different disorder subtypes. In order to qualify for a diagnosis of 
schizophrenia utilising the ICD-10 criteria, the following conditions must be met: 
At least one of the following “first rank” symptoms must be present: 
 a) Thought echo, thought insertion or withdrawal, or thought broadcasting.   
b) Delusions of control, influence or passivity, clearly referred to body or limb 
movements or specific thoughts, actions, or sensations; delusional perception.  
c) Hallucinatory voices giving a running commentary on the patient's behaviour, or 
discussing him between themselves, or other types of hallucinatory voices coming 
from some part of the body.  
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d) Persistent delusions of a different kind which are culturally inappropriate and 
completely impossible (e.g. being able to control the weather, or being in 
communication with aliens from another world).  
OR, at least two of the following “second rank” symptoms must be present: 
e) Persistent hallucinations in any modality, when occurring every day for at least one 
month, when accompanied by delusions (which may be fleeting or half-formed) 
without clear affective content, or when accompanied by persistent over-valued ideas.   
f) Neologisms, breaks or interpolations in the train of thought, resulting in incoherence 
or irrelevant speech.  
g) Catatonic behaviour, such as excitement, posturing or waxy flexibility, negativism, 
mutism and stupor.  
h) "Negative" symptoms such as marked apathy, paucity of speech, and blunting or 
incongruity of emotional responses. 
 
The symptoms should be present most of the time during an episode of psychotic illness, for a 
duration of at least one month. In addition, the symptoms must have occurred independently 
of a depressive or manic episode, and not be attributable to either an organic brain disease, or 
substance abuse withdrawal or intoxication.  
In the ICD-10 the diagnosis of schizophrenia is broken down into different subtypes, including 
paranoid, hebephrenic, catatonic, residual, simple and undifferentiated schizophrenia. 
Between these subtypes, differences in the presentation of symptoms are evident. In paranoid 
schizophrenia, delusions and hallucinations must be prominent, and negative symptoms (see 
section 1.2.3.) must not dominate the clinical picture. In hebephrenic schizophrenia, thought 
disorder and negative symptoms are dominant, relative to hallucinations and delusions. In 
catatonic schizophrenia, extremes of behaviour must be prominent for at least two weeks. 
These can include severe rigidity, stupor, bizarre posturing, command automatism or 
negativism, or, at the other end of the spectrum, extreme excitement and constant motor 
activity. In residual schizophrenia, the general criteria must have been met at some point in 
the past, and negative symptoms must have been present continuously over the past 12 
months. In simple schizophrenia a progressive deterioration of functioning and an increase in 
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negative symptoms must have occurred over at least 12 months, whilst delusions, thought 
disorder and hallucinations are absent. Lastly, in undifferentiated schizophrenia patients either 
meet none of the outlined subtypes, or would qualify for multiple subtypes.  
In the DSM-V (APA, 2013), the criteria for the diagnosis of schizophrenia include: 
At least two of the following symptoms (with at least one of them being A-C) being present for 
a significant proportion of time during a 1-month period. 
a) Delusions 
b) Hallucinations 
c) Disorganised speech 
d) Grossly disorganised or catatonic behaviour 
e) Negative symptoms 
 
In addition, some form of social or occupational dysfunction must be present for a significant 
portion of time since the onset of the disturbance, occurring over a period of at least 6 
months. Prior to receiving a diagnosis of schizophrenia, both schizoaffective and mood 
disorder must be ruled out. Furthermore, the disturbance must not be due to physiological 
effects of substance abuse, withdrawal, or intoxication. 
Whilst there is a significant degree of overlap between the diagnostic criteria for the DSM-V 
and the ICD-10, some differences do exist. In contrast to the ICD-10 criteria, in the DSM-V 
formulation no distinction between subtypes of the illness is made. In the DSM-V, evidence of 
social and occupational dysfunction from the point of disturbance onset is required. In the 
DSM-V, no distinction between Schneiderian first and second rank positive symptoms is made 
(see section 1.1.5 for a summary). Finally, in the DSM-V recent amendments to the criteria for 
schizophreniform disorder, schizoaffective disorder, and schizotypal disorder have implications 
on the specificity of the schizophrenia diagnosis. Given these differences are likely to have 
implications on who may and may not qualify for a diagnosis of schizophrenia, this may 
influence the characteristics of the sample evaluated. Consequently, specifying which criteria 
have been adopted for each part of the investigation should be considered important. In the 
meta-analysis completed in chapter 3 the aim was to pool a broad range of samples from as 
many countries as possible. As a result, patients diagnosed in accordance to either ICD or DSM 
criteria were considered. However in chapters 4-7, where all participants were recruited within 
Europe, all participants were diagnosed in accordance with ICD-10 criteria. 
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As specified previously, the ICD-10 criteria make distinctions between different subtypes of 
schizophrenia such as paranoid, hebephrenic, catatonic and residual schizophrenia. As a result, 
schizophrenia can either be evaluated as a single concept, or with the subtypes each evaluated 
separately. However, as reviewed by Tandon and colleagues (Tandon et al., 2013), a wealth of 
evidence exists which suggests that subtype classifications exhibit poor reliability, longitudinal 
stability, and poor prognostic value (Deister and Marneros, 1993) resulting in little distinction 
between subtypes (Linscott et al., 2010). Given these criticisms, subtypes were not considered 
in any of the analysis completed in this investigation. Whilst this is a divergence from the 
criterion from which all of the patients would have been diagnosed, this approach is reflective 
of current research practice, as indicated in a review by Braff (Braff et al., 2013).  
Related to diagnosis it is important to consider whether schizophrenia alone should be 
evaluated (ICD-10 criteria F20.0-F20.9), or if other psychotic disorders such as schizotypal 
disorder (F21), delusional disorders (F22-24), or schizoaffective disorder (F25) should also be 
included. In the analysis which aimed evaluate negative symptoms in relatively stable 
outpatients over different timepoints (chapter 3-6) only patients with schizophrenia were 
included. In the analysis of acute patients at the point of hospital admission (chapter 7) 
participants with any psychotic disorder were included.  
In schizotypal disorder (F21) negative and cognitive symptoms are typically less severe than in 
schizophrenia (Handest and Parnas, 2005), and patients are not required to exhibit any level of 
functional impairment to qualify for the diagnosis. In addition, the diagnosis of schizotypal 
disorder has been found to have relatively poor diagnostic stability over time (Shea et al., 
2002). Therefore, patients with schizotypal disorders were excluded from samples evaluating 
stable outpatients order to avoid over-stating the variability of negative symptoms, and/or 
under-reporting their severity in clinical samples. In delusional disorders (F22-24), patients do 
not typically present with negative symptoms, and they are not included as part of the 
diagnostic criteria. Given these symptoms were the primary focus of the analysis in chapters 3-
6, participants with this diagnosis were excluded. In chapter 7, other symptoms such as 
positive, depressive and manic symptoms were considered, therefore meriting the inclusion of 
other psychotic disorder as part of the investigation. 
Schizoaffective disorder (F25) shares many of the features of schizophrenia and have been 
included in trials evaluating the effectiveness of negative symptom treatments, such as the 
CONSIST study (Buchanan et al., 2007). In addition, patients diagnosed with schizoaffective 
disorder have been included in studies which evaluate primary negative symptoms and the 
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“deficit syndrome” (Amador et al., 1999, Carpenter et al., 1988) which is an important feature 
of any investigation into negative symptoms. However, patients with schizoaffective disorder 
were omitted from all analyses evaluating stable outpatients (i.e. chapters 3-6) for a number of 
reasons. Firstly, there is evidence to suggest that there are a range of symptomatic, clinical and 
demographic differences between schizophrenic and schizoaffective clinical samples, with 
negative symptoms in particular more severe in patients with schizophrenia (Cheniaux et al., 
2008). Secondly, schizoaffective disorder appears to follow a different longitudinal course, 
with significantly better long terms outcomes (Harrow et al., 1997). Thirdly, schizoaffective 
disorder has also been found to have poor diagnostic stability (Malhi et al., 2008), (Jäger et al., 
2011). Consequently, patients with schizoaffective disorder were omitted from the analysis 
completed in chapters 3-6. In chapter 7 the stability of symptoms over time was not a feature 
of the analysis, and so therefore patients with schizoaffective disorder were included in this 
part of the investigation. 
 
1.1.5. A history of the conceptual model of schizophrenia 
With no diagnostic physiological markers found in schizophrenia, our concept of the disorder 
has been built up by the presence and absence of particular behaviours and experiences. Over 
the years this concept has been repeatedly revised. Given the extensive re-conceptualisations 
of the illness, providing a full historical account of the disorder is beyond the scope of this 
thesis. Instead, with the focus of this project limited to the deficient (or negative) features of 
the illness, the aim is to explore the evolution of how these symptoms have been considered 
as part of the wider schizophrenia complex. From negative symptoms being defined as the 
central feature of the disorder at the turn of the 20th century, greater emphasis has been 
placed on the positive psychotic symptoms of the illness over time. However, in recent years 
there has been an increasing focus on negative symptoms again due to their impact on various 
social and functional outcomes. Understanding the evolution of schizophrenia should be 
considered important of this investigation as a number of recent developments in negative 
symptoms are rooted in earlier conceptions of the illness. 
In a review by Adityanjee and colleagues (Adityanjee et al., 1999), it was proposed that 
Phillippe Pinel drafted the first integrated description of schizophrenia in the medical literature 
(Pinel, 1806). Some 70 years later, Karl Kahlbaum (Kahlbaum, 1874) was one of the first to 
recognise the importance of course and outcome in the nosology of mental health disorders 
such as the “degenerative psychoses”. Kahlbaums approach was adopted by Emil Kraepelin 
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(Kraepelin, 1971), whose work has since been recognised as amongst the most significant 
advances in the field of mental health, forming the basis of modern psychiatry (Eysenck, 1960).  
Although not the first, Emil Kraeplin (1856-1926) was a major advocate of classifying mental 
health disorders into categories (Kraepelin, 1971). Central to his work was the distinction 
between manic depression, which would now be recognised as encompassing mood disorders, 
and ‘dementia praecox’, which forms the basis of what we recognise as schizophrenia today. 
Dementia praecox was characterised by a significant deterioration in attention, memory, and 
volition, starting during the individuals late teens or early twenties. In this conception of 
schizophrenia, symptoms relating to what would now be defined as cognitive and negative 
symptoms were recognised as central features of the disorder. 
Kraepelin linked a number of biological abnormalities to the cause of schizophrenia, such as 
severe lesions in the cerebral cortex. Originally Kraepelin believed that these symptoms 
typically followed a course of prolonged and progressive deterioration, however in later work 
this position shifted to recognise that remission or improvement may be possible in at least 
some cases. Kraeplin went on to validate the existence of dementia praecox cross culturally, 
and postulated a number of antecedent factors including genetic factors, family history, and 
obstetric complications. In later work, Kraeplin integrated hebephrenia, catatonia, and 
paranoia into the dementia praecox classification, proposing that the subtypes are different 
expressions of a single disease entity. 
Following Kraepelin, Eugene Bleuler (1857-1939) proposed an alternative, broader 
classification of the illness which focused more on the psychological aspects of the disorder 
(Bleuler, 1950). Bleuler rejected the idea that the illness follows a typically deteriorating course 
and so rejected the term dementia praecox, instead preferring schizophrenia, which literally 
translates to split-mind. This newly proposed name reflected the importance Bleuler gave to 
associative splitting as the central feature of the illness. For Bleuler, this splitting of 
associations gave rise to four features that he believed were central to the disorder, known as 
the “four A’s”. The four A’s include the loosening of associations, affective flattening, autism, 
and ambivalence. Other symptoms of schizophrenia, such as hallucinations and delusions, 
were believed to be accessory symptoms resulting from an inability to manage the core “four 
A” symptoms. Therefore, similar to Kraepelin’s definition of schizophrenia, Bleuler proposed 
that the primary features of the illness are related to a deficit in functioning, as opposed to the 
presence of symptoms such as hallucinations or delusions. Building on Kraepelin’s work which 
incorporated different subtypes with the singular entity of schizophrenia, Bleuler proposed 
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two other subtypes known as ‘latent’ and ‘simplex’ forms of the disorder, in which the 
accessory features were not typically present. The strength of reconceptualising schizophrenia 
in this manner meant that the concept was better able to capture the heterogeneity of the 
disorder. However, this also led to criticism that the concept became too expansive (Van 
Praag, 1976). 
Whilst the focus of his enquires were not specific to schizophrenia, the work of neurologist 
John Hughlings Jackson (1835-1911) was also highly influential to later conceptualisations of 
the illness (Jackson, 1958). Hughlings Jackson has been credited with developing the 
conceptual framework for clinical neurophysiology (York and Steinberg, 2011), framing the 
nervous system as an exclusively sensorimotor mechanism and rejecting metaphysical input. 
Hughlings Jackson proposed that the nervous system comprises of three levels; the highest 
level situated in the pre-frontal region, the mid-levels in the cortex, and lowest, least complex 
functions situated in the medulla and spinal cord.  The higher levels were believed to control 
and inhibit the lower levels, meaning that cortical disease could potentially result in two 
distinct types of symptoms; the loss of function of the cortex itself, and/or the loss of the 
ability to inhibit lower nervous system levels. Following the work of John Russell Reynolds 
(Eadie, 2007) the loss of cortex function was believed to lead to “negative” symptoms, which 
reflect the loss of higher level functioning. Alternatively, “positive” symptoms were believed to 
result from an inability to inhibit lower cortical level functioning, and therefore consisted of 
the appearance of previously inhibited functions. This theory influenced a later distinction 
made between “positive” and “negative” symptoms of schizophrenia, and also “subtypes” of 
schizophrenia (Strauss et al., 1974) (see section 1.2.4). 
As psychiatry moved towards the standardisation of diagnostic systems, the classification of 
different symptoms of schizophrenia proposed by Kurt Schneider (Schneider, 1959) became 
increasingly influential. Schneider proposed a hierarchy of symptoms based on the work of Karl 
Jaspers (Jaspers et al., 1997) which focused on the form, as opposed to the content of the 
symptom. In a departure from Kraepelin and Bleuler, greater emphasis was placed on 
particular positive symptoms of schizophrenia, such as command hallucinations and persistent 
delusions given they were easier to observe, and at the time were considered to be specific to 
psychotic disorders. These symptoms were defined as “first rank symptoms”, whilst other 
symptoms such as negative symptoms, thought disorders and other hallucinations were 
considered “second rank symptoms”. In the diagnostic criteria, fewer first rank symptoms 
were required to qualify for a diagnosis of schizophrenia, relative to second rank symptoms. At 
the time, it was thought that this distinction would improve the sensitivity and specificity of 
the schizophrenia diagnosis. This shift in emphasis towards positive symptoms was further 
25 
 
justified by the observed response of patients to the newly developed antipsychotic 
medications such as chlorpromazine, which were found to be particularly effective in the 
treatment of these particular symptoms.  
While Schneider’s conception of schizophrenia has underpinned the diagnostic criteria utilised 
over the past 50 years, the specificity of first rank symptoms to schizophrenia has been 
increasingly questioned (Crichton, 1996, Ihara et al., 2009, Nordgaard et al., 2008, Peralta and 
Cuesta, 1999a, Tanenberg-Karant et al., 1995). These limitations highlighted lead to the 
distinction being dropped in the most recent update of the DSM (APA, 2013), although to date 
it currently remains in the ICD formulation. In addition, with cognitive and negative symptoms 
being found to have a greater impact on functioning, relative to positive symptoms (Green et 
al., 2004a, Hunter and Barry, 2012), in recent years there has been there has been an 
increasing focus on the symptoms originally identified as the core features of the disorder by 
Kraepelin and Bleuler. 
In 1974, Strauss and colleagues attempted to go beyond the categorisation of symptoms 
proposed by Schneider by outlining a model to explain the pathological mechanisms of the 
disorder. In doing so, the aim was to enhance the specificity of diagnostic criterion, provide a 
framework in which treatments can be evaluated, and account for the significant 
heterogeneity which has consistently been found in the presentation of the disorder (Strauss 
et al., 1974). In contrast to the theories proposed both by Kraeplin (1919), and Bleuler (1950), 
Strauss argued that the presentation of schizophrenia is a consequence of multiple processes, 
as opposed to a singular process. Drawing on the work by Hughlings Jackson (Jackson, 1958) 
see section 1.1.4.), Strauss postulated that positive symptoms, negative symptoms, and 
disorders of relating may represent three semi-autonomous processes with different 
antecedents. Positive symptoms were considered to be a consequence of biological, family 
environment, and psychological factors. Negative symptoms were considered either to be 
related to a loss of functioning of higher order cortical function, or the consequence of 
prolonged isolation and social stigma that patients with chronic schizophrenia typically 
experience. Negative symptoms could therefore represent core psychopathology, which may 
in turn lead to accessory positive symptoms (as proposed by both Hughlings Jackson and 
Bleuler), or be accessory symptoms themselves resulting from external factors. Finally, 
disorders of relating were considered to be somewhat different, representing dysfunctions in 
psychological processes that typically precede the onset of psychiatric symptoms. 
Following the model outlined by Strauss and colleagues, Crow (Crow et al., 1980) built upon 
the idea of multiple processes existing within the schizophrenia complex and proposed the 
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existence of two syndromes of schizophrenia, called “type 1” and “type 2” schizophrenia. In 
type 1 schizophrenia patients primarily experienced positive symptoms, and was commonly 
seen in the acute phase of the disorder. Crow stated that type 1 schizophrenics exhibited a 
good response to neuroleptics, had a relatively good prognosis, and did not experience 
accompanying intellectual impairment. In contrast, type 2 schizophrenia was characterised by 
severe and chronic negative symptoms and intellectual impairment. Patients with type 2 
schizophrenia were thought to respond poorly to neuroleptics, and had a much poorer long-
term prognosis. Crow proposed differing pathological processes, attributing type I 
schizophrenia to increased dopamine receptor sensitivity, and type 2 schizophrenia to 
structural changes in the brain such as ventricular enlargement (Andreasen and Olsen, 1982). 
However, Crow also recognised that both syndromes can occur in the same patient, often at 
the same time, and suggested that the two dimensions may have the same aetiology (Crow, 
1985). This conclusion was supported by Andreasen and colleagues, who found over that three 
quarters of participants evaluated were found to present with a mixture of positive and 
negative symptoms (Andreasen et al., 1990, Peralta et al., 1992b). In later work, many of the 
neurological differences between the positive and negative subtypes found in earlier studies 
were not reproduced. Finally, it was evident that the subtypes of schizophrenia were not 
typically stable over time (Marneros et al., 1992).  
Following the work of Crow and Strauss (Crow, 1985, Strauss et al., 1974), a series of factor 
analytic studies were conducted in an attempt to validate the distinction between positive and 
negative symptoms as separate dimensions. Such work was conducted both as a means of 
model building (utilising explanatory factor analysis; EFA) and model validation (utilising 
confirmatory factor analysis; CFA). Whilst the majority of these studies supported a distinction 
between positive and negative symptoms, the majority of studies failed to uncover a 2-factor 
solution, with the positive symptom construct in particular being relatively unstable 
(Andreasen et al., 1990). As identified in a review of models (Peralta and Cuesta, 2001), a 
series of factor solutions were proposed, a summary of which is outlined in table 1. Whilst a 
large number of different factor solutions have been proposed, ranging from between 2-11 
factors depending on the statistical methodology employed and sample evaluated, a 
distinction between positive, negative, and disorganised symptoms were consistently 
proposed (Bilder et al., 1985, Brekke et al., 1994, Liddle, 1987, Peralta et al., 1992a, Toomey et 
al., 1997), which was later supported in a meta-analytic confirmatory factor analysis (Smith et 
al., 1998). In some of the more complex models, such as the 11 factor model proposed by 
Peralta and Cuesta (Peralta and Cuesta, 1999b), they suggested that the different factors could 
be combined into 3 super-ordinate themes of positive, negative, disorganisation symptoms. 
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These findings led to the proposal that schizophrenia disorder is characterised by three 
separate dimensions of positive, negative and disorganised symptoms. 
Whilst the distinction between positive, negative and disorganised symptom clusters were 
relatively consistent, a number of unresolved issues remained, not least the issue regarding 
the relative instability of the disorganisation symptom cluster (Peralta and Cuesta, 2001). In 
different factor analytic studies formal thought disorder, poverty of speech content, bizarre 
behaviour, alogia, inappropriate affect, conceptual disorganisation, difficulties in abstract 
thinking, disturbance of volition, stereotypical thinking and poor insight have all been included 
within the disorganization symptom construct (Hardy-Baylé et al., 2003). In an alternative 
approach to factor analytic studies, Hardy-Bayle instead proposed taking a pathogenic 
approach to understanding disorganisation in schizophrenia, suggesting that two distinct 
cognitive processes underpin the symptom dimension. These two processes included deficits 
in the integration of contextual information (Cohen et al., 1999, Widlöcher and Hardy-Bayle, 
1989), and theory of mind deficits (Corcoran et al., 1995, Frith and Corcoran, 1996). Following 
this work, Harvey (Harvey et al., 2006) further emphasised the distinction between negative 
and cognitive symptoms. 
The distinctions between cognitive, positive, and negative symptoms have now been 
consistently adopted in the literature, and this will provide the framework for how symptoms 
will be evaluated throughout this investigation. An outline of what symptoms these different 
dimensions are comprised of are presented in section 1.2. 
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Table 1: Summary of factor solutions conducted examining schizophrenia symptomsa 
 
Study N Scale 
Method of 
Analysis 
No of 
factors 
Factor loadings 
       Chronic patient sample 
    
 
(Lorr et al., 
1962) 
296 Inpatient 
Multi-
dimensional 
Rating Scale 
EFA 10 Mania, depression, negative, 
paranoid, hallucinations, 
catatonia, hostility, 
megalomania, mania, 
disorganisation 
 
(Overall and 
Woodward, 
1975) 
2000 BPRS Multi-
response 
analysis of 
variance 
11 Psychosis, disorganisation, 
hostility, anxiety, agitated, 
depression, depressive-
withdrawal, excitement, 
positive 
 
(Schuldberg et 
al., 1990) 
399 SAPS-SANS EFA 2 Positive, negative 
 
(Shtasel et al., 
1992) 
107 SAPS-SANS, 
BPRS 
EFA 4 Negative, disorganisation, 
psychotic, paranoid 
 
(Minas et al., 
1992) 
114 SAPS-SANS Multidimensi
onal scaling 
3 Psychosis, disorganisation, 
negative 
 
(Malla et al., 
1993) 
155 SAPS-SANS EFA 3 Psychosis, disorganisation, 
negative 
 
(Thompson and 
Meltzer, 1993) 
131 SADS and 
PSE 
EFA 3  Psychosis, disorganisation, 
negative 
 
(Minas et al., 
1994) 
114 SAPS-SANS EFA 5 Negative, social dysfunction, 
delusions, hallucinations, 
thought disorder 
 
(Lindenmayer et 
al., 1994) 
240 PANSS CFA 5 Negative, positive, excitement, 
cognitive, depression-anxiety 
 
(Peralta et al., 
1994) 
253 SAPS-SANS CFA 4 Psychosis, disorganisation, 
negative, social dysfunction 
 
(Murphy et al., 
1994) 
169 SCID, SANS EFA 3 Psychosis, disorganisation, 
negative 
 
(Bell et al., 
1994) 
146 PANSS EFA 5 Positive, negative, excitement, 
depressive, cognitive 
 
(Andreasen et 
al., 1995) 
243 SAPS-SANS EFA 3 Psychosis, disorganisation, 
negative 
 
(Maziade et al., 
1995) 
138 SAPS-SANS EFA 3 Psychosis, disorganisation, 
negative 
 
(Maziade et al., 
1995) 
131 SAPS-SANS EFA 3 Psychosis/disorganisation, 
apathy/anhedonia, affective 
blunting/alogia 
 
(Kitamura et al., 
1995) 
584 Checklist EFA 5 Psychosis, negative, mania, 
depression, catatonia 
 
(Johnstone and 
Frith, 1996) 
329 Manchester 
scale 
EFA 3 Psychosis, disorganisation, 
negative 
 
(Mellers et al., 
1996) 
114 PSE EFA 4 Hallucinations, delusions, 
negative, disorganisation 
 
(Cardno et al., 
1996) 
102 OCCPI EFA 5 Paranoid, disorganisation, 
negative, bizarre delusions, 
first-rank hallucinations 
 
(Lenzenweger 
and Dworkin, 
1996) 
192 SANS, 
Phillips 
scales, 
Venables-
O'Connor 
scale 
CFA 4 Psychosis, disorganisation, 
negative, poor premorbid social 
adjustment 
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(Harvey et al., 
1996) 
404 Social 
Behaviour 
Schedule 
EFA 4 Disorganisation, social 
withdrawal, depression, anti-
social behaviour 
 
(Serretti et al., 
1996) 
500 OCCPI EFA 4 Excitement, depression, 
disorganisation, delusional 
 
(Peralta et al., 
1997) 
314 SAPS-SANS EFA 3 Psychosis, disorganisation, 
negative 
 
(Toomey et al., 
1997) 
630 SAPS-SANS EFA 5 Negative, disorganisation, 
social dysfunction, bizarre 
delusions, auditory 
hallucinations 
 
(White et al., 
1997) 
1233 PANSS CFA 5 Negative, psychosis, 
excitement, depression, autism 
 
(Ratakonda et 
al., 1998) 
221 SAPS-SANS EFA 3 Psychosis, disorganisation, 
negative 
 
(van Os et al., 
1999) 
706 CPRS EFA 4 Depression, mania, psychosis, 
negative 
 
(van Os et al., 
1999) 
706 OCCPI EFA 5 Depression, mania, psychosis, 
negative, disorganisation 
 
(Hori et al., 
1999) 
258 Manchester 
scale 
EFA 3 Psychosis, disorganisation, 
negative 
 
(Peralta and 
Cuesta, 1999b) 
660 SAPS-SANS EFA 11 Poverty of affect and speech, 
thought disorder/ 
inappropriate affect, bizarre 
delusions, social dysfunction, 
paranoid delusions, bizarre 
behaviour, auditory 
hallucinations, manic thought 
disorder, attention 
Recent-onset of psychosis samples    
 
(Gureje et al., 
1995) 
60 SANS, BPRS EFA 3 Psychosis, disorganisation, 
negative 
 
(Vazquez-
Barquero et al., 
1996) 
86 SAPS-SANS EFA 4 negative, disorganisation, 
paranoid, nonparanoid 
 
(Van Os et al., 
1996) 
166 OCCPI EFA 7 Catatonia/ bizarre behaviour, 
bizarre delusions, mania, 
negative, depression, insight, 
other delusions  
 
(McGorry et al., 
1998) 
509 Multidiagn
ostic 
instrument 
for 
Psychosis 
EFA 4 Mania, depression, bleulerian, 
schneiderian 
Follow-up studies <1 yearb     
 
(Jackson et al., 
1990) 
53 Mancheste
r scale 
EFA T0: 3 
 
T1: 3 
Depression, mixed, positive 
 
Negative, positive, depression-
psychosis 
 
(Addington and 
Addington, 1991) 
41 SAPS-SANS EFA T0: 4 
 
 
 
T1: 3 
Avolition, disorganisation, 
poverty of affect and speech, 
psychosis 
 
Negative, psychosis, 
disorganisation 
 
(Goldman et al., 
1991) 
40 BPRS, SANS EFA T0: 3 
 
 
T1: 3 
Negative, psychosis, 
excitement 
 
Negative, psychosis, 
excitement 
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(Dollfus and Petit, 
1995a) 
57 SAPS-SANS EFA T0: 3 
 
 
T1: 3 
Negative, disorganisation, 
psychosis 
 
Negative, disorganisation, 
psychosis 
 
(Dollfus and Petit, 
1995a) 
57 PANSS EFA T0: 5 
 
 
T1: 5 
Negative, disorganisation, 
excitement, psychosis, anxiety 
 
Negative, excitement, 
psychosis, disorganisation, 
depression 
 
(Nakaya et al., 
1999) 
86 PANSS EFA  T0: 5 
 
 
 
T1: 3 
Negative, hostility, psychosis, 
disorganisation, stereotyped 
thinking 
 
Negative, mixed, abstraction 
Follow-up studies >1 yearb     
 
(Kulhara and 
Chandiramani, 
1990) 
89 SAPS-SANS EFA T0: 3 
 
 
T1: 3 
Negative, psychosis, 
disorganisation 
 
Negative, mixed, 
disorganisation 
 
(Rey et al., 1994) 163 PSE, SANS, 
PIRS 
EFA T0: 5 
 
 
 
T1: 5 
 
 
Poverty of affect and speech, 
anhedonia, neurosis, positive 
symptoms, psychosis 
 
Poverty of affect and speech, 
anhedonia, neurosis, positive 
symptoms, psychosis 
 
(Eaton et al., 
1995) 
90 PSE EFA T0: 3 
 
 
T1: 3 
Negative, psychosis, 
disorganisation 
 
Negative, mixed, 
disorganisation 
 
(Van der Does et 
al., 1995) 
65 BPRS-E EFA T0: 4 
 
 
T1: 4 
Manic, negative, psychosis, 
depression 
 
Disorganisation, negative, 
manic, depression 
 
(Arndt et al., 
1995) 
65 SAPS-SANS FA T0: 3 
 
 
T1: 3 
Negative, disorganisation, 
psychosis 
 
Negative, disorganisation, 
psychosis 
 
(Salokangas, 
1997) 
156 CPRS EFA T0: 5 
 
 
T1: 5 
Negative, delusions, anxiety, 
mania, hallucinations 
 
Depression, negative, 
disorganisation, psychosis, 
delusions 
              
aTable adapted from Peralta and Cuesta, 2001 
b In cases where multiple assessment points were evaluated, the first and last stage data are included. 
CPRS= Comprehensive Psychopathological Rating Scale; SANS= Scale of Assessment for Negative Symptoms; 
SAPS= Scale for Assessment for Positive Symptoms; PSE= Present State Examination; PIRS= Psychological 
Impairments Rating Scale; PANSS= Positive and Negative Syndrome Scale; BPRS= Brief Psychiatric Rating 
Scale; FA= Factor analysis; EFA=Explanatory Factor Analysis; CFA= Confirmatory Factor Analysis; OCCPI, SCID= 
Structured Clinical Interview for DSM Disorders. 
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1.2. The symptoms of schizophrenia 
The symptoms of schizophrenia as they are currently defined are separated into three distinct 
clusters, known as positive, negative and cognitive symptoms. The severity of these symptoms 
is defined by their frequency, persistence, and the degree to which they impact on functioning. 
An outline of what these different clusters constitute is summarised below. 
 
1.2.1. Positive symptoms 
The positive symptoms of schizophrenia include hallucinations, delusions, and thought 
disorders. These symptoms are known as “positive symptoms” due to the fact that their 
abnormality lies in their presence, as opposed to an absence, of typical human experience.   
Hallucinations are defined as “a sensory perception that has the compelling sense of reality of 
a true perception, but that occurs without external stimulation of the relevant sensory organ” 
(APA, 2013). Hallucinations can present in auditory, visual, olfactory, haptic, or gustatory form, 
with the perceived origin being either internal (“pseudohallucinations”) or external (“true 
hallucinations”) in nature (Jaspers et al., 1997). Schneider (Schneider, 1959) made a distinction 
between different forms of  auditory hallucinations, defining hallucinations of voices that 
communicate between themselves, provide a running commentary, or emanate from other 
parts of the body as specific to psychotic disorders, leading to an increased emphasis in these 
particular forms in some diagnostic criterion for schizophrenia (see section 1.1.3.). 
Approximately 70% of people diagnosed with schizophrenia are thought to experience 
hallucinations in the acute phase of their illness, with auditory hallucinations most common 
(Sartorius et al., 1974). In a review by Andreasen and Flaum (Andreasen and Flaum, 1991), the 
percentage of patients reporting experiencing audible thoughts of at least moderate severity 
ranged from 1.5% to 28% (Carpenter and Strauss, 1974, Koehler et al., 1977).   
A number of factors have been thought to influence the occurrence of hallucinations in people 
with schizophrenia including stress, predisposing factors, environmental stimulation, and 
reinforcement (Bentall, 1990, Slade, 1976). In addition, a number of theories that underlie the 
formulation and maintenance of experiencing hallucinations have been postulated, 
summarised in a review by Bentall (Bentall, 1990). These included classical conditioning 
(Davies, 1974), the seepage of preconscious material into consciousness (Frith, 1979, West, 
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1975), a consequence of vivid mental imagery (Mintz and Alpert, 1972), and the link between 
sub-vocalisation and hallucinations.  
Delusions are bizarre or irrational beliefs which are out of context from the society or culture 
from which they are part. In assessing the presence of delusions, Oltmanns (Oltmanns, 1988) 
suggested that six dimensions should be considered, including how implausible it is, how 
strongly it is held, what it is based upon, whether others also hold it, how pre-occupying it is, 
and the level of distress it causes. Delusions can take a number of forms, including somatic 
influence, thought withdrawal, thought insertion, thought broadcasting, projected feelings and 
impulses, delusions of control, and delusional perceptions. Of these, delusional perceptions 
relating to reference and persecution have been found to be amongst the most commonly 
reported psychotic symptoms (Sartorius et al., 1986), with persecutory delusions the most 
common type of delusion which people act upon (Wessely et al., 1993). The concept of 
persecutory delusions were operationalised by Freeman and Garety (Freeman and Garety, 
2000), suggesting that in order for the delusion to be considered persecutory in nature the 
individual must believe that harm is either occurring, or else will occur to them (meaning harm 
to friends and or family and not the individual does not count), and that the persecutor has an 
intention to cause harm. 
In addition to hallucinations and delusions, positive symptoms can take the form of thought 
disorder, the external manifestation of which presents itself in the form of disordered speech. 
In a review by Rule (Rule, 2005) a number of different terms were identified which cover the 
different expressions of disordered speech, with a significant degree of overlap and 
redundancy.  Rule summarised the different terms used to define thought disorder symptoms 
into four overarching themes, including faults in descriptive terminology, mental processing, 
idiosyncrasy in the use of words, and intelligible speech.  
Faults in descriptive terminology cover different symptoms all related to the formulation of the 
speech itself, and are not connected to underlying cognitive deficits. These include formal 
thought disorder, akataphasia, paralogia, alogia, laconic speech, poverty of thought, and 
bradyphasia. Poverty of thought content and empty speech both relate to the content of 
speech. Desultory thinking, loosening of associations, knights move thinking, and crowding of 
thought all relate in some form to a jumping from one theme to another without a logical 
connection. Derailment, tangentiality, “vorbeirden”, and loss of goal refer to an expected 
change in direction in a thought process. Transitory thinking is similar, albeit with additional 
words either added or omitted. Paragrammatism, and parasyntax are the inappropriate use of 
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words and sentence structure. Rule identified numerous terms to define of unintelligible 
speech including, drivelling, muddling, verbigeration, word salad, speech confusion, 
incoherence, aculalia glossolalia, catologia, cataphasia, jargon aphasia, and schiozophasia. 
With regards to the idiosyncratic use of words, Rule made a distinction between the use of 
words or phrases used in an unusual context, and the invention of new words. Neologisms and 
word approximations include either the unusual or invented use of words.  Metonymy relates 
to the use of imprecise expressions. Paraphasia, paraphemia, pseudoagrammatism, 
paraphrasia all relate to the substitution of one word for another with similar form. The last 
theme identified by Rule included symptoms which imply faults in mental processing. The 
different terms that are used that relate to this theme include condensation, fusion, 
displacement, substitution, omission, thought blocking, incoordination, asyndesis, 
interpenetration, overinclusion, and fragmentation.    
 
1.2.2. Cognitive symptoms 
The cognitive symptoms of schizophrenia include impairments in memory, attention, executive 
functioning, verbal fluency, and psychomotor performance, and are experienced by the 
majority of those diagnosed with the illness (Marder and Fenton, 2004). Historically, cognitive 
deficits have been recognised as a key feature of schizophrenia (Kraepelin, 1971), consistently 
identified both in the acute phase (McGhie and Chapman, 1961), and during periods of 
remission (Wohlberg and Kornetsky, 1973).  
Cognitive deficits are typically present during the prodromal period (Lencz et al., 2006), and 
unlike positive symptoms, are thought to be a highly stable feature of the disorder (Nopoulos 
et al., 1994, Rund, 1998). Whilst there is some evidence to suggest that second generation 
antipsychotics (SGA) may be a more effective treatment for cognitive symptoms,  relative to 
first generation antipsychotics (FGA), their response to treatment is typically poor (Harvey and 
Keefe, 2001). This this lack of treatment efficacy is seen as an important issue, given cognitive 
symptoms have been found to be strongly associated with functional impairment (Green et al., 
2000, Green et al., 2004a). 
In light of the minimal progress in developing treatments for cognitive symptoms, the National 
Institute for Mental Health (NIMH) initiated the Measurement And Treatment Research to 
Improve Cognition in Schizophrenia (MATRICS) collaboration. Under the auspices of the 
MATRICS initiative a multi-stage programme was initiated to improve the assessment of 
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cognitive symptoms, with the aim of providing a more robust framework by which new 
treatments could be evaluated. This process led to a systematic review to identify different 
dimensions of the cognitive symptom construct that are independent, reliable, and 
underpinned by the neuropsychological and cognitive neuroscience literature (Nuechterlein et 
al., 2004). In total, 7 different dimensions of cognitive impairments in schizophrenia were 
identified, including speed of processing, attention/vigilance, working memory, verbal learning 
and memory, visual learning and memory, reasoning and problem solving, and verbal 
comprehension. Whilst there was insufficient evidence at the time of the review, social 
cognition was added the list of constructs evaluated in the MCCB (MATRICS Consensus 
Cognitive Battery) (Kern et al., 2008, Nuechterlein et al., 2008), given its possible importance 
as a mediatory between neurocognitive deficits and functional outcomes (Brekke et al., 2005). 
Social cognition, whilst related to negative symptoms, appears to have a much stronger 
association with neurocognition and so was not considered part of the negative symptom 
construct (Kirkpatrick et al., 2006, Sergi et al., 2007). This construct is instead thought to 
contain 5 distinct domains, covering theory of mind, social perception, social knowledge, 
attributional bias, and emotional processing (Green et al., 2008). 
 
1.2.3. Negative symptoms 
Negative symptoms represent a pathological deficit in typical human experience and have 
been considered central to schizophrenia since the earliest conceptions of the disorder. 
Negative symptoms relate specifically to Bleuler’s core symptoms of schizophrenia, known as 
the “4 A’s” (loosening of associations, affective flattening, autism, and ambivalence) (Bleuler, 
1950) and Kraepelin’s “avolitional syndrome” (Kraepelin, 1971).  At present, the negative 
symptoms of schizophrenia include alogia, asociality, anhedonia, avolition, and blunted affect 
(Kirkpatrick et al., 2006). Recent work suggests that these negative symptoms comprise of at 
least two distinct subdomains, with alogia and blunted affect representing expressive deficits; 
and asociality, anhedonia and amotivation  representing experiential deficits (Blanchard and 
Cohen, 2006, Horan et al., 2011, Kring et al., 2013). 
Negative symptoms have been found to be highly prevalent in clinical samples, with Bobes et 
al (Bobes et al., 2010) finding that 57.6% of patients treated for schizophrenia in routine 
outpatient care present with at least one negative symptom of moderate severity or worse. A 
summary of the five different types of negative symptoms are outlined below. 
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1.2.3.1. Alogia 
Alogia relates to the reduction in the initiation and production of speech, and is distinct from 
irrelevant speech and incoherence which can either be attributable to thought disorder or 
cognitive deficits. In a recent meta-analysis significant deficits in speech production were 
found in patients with schizophrenia relative to healthy controls, particularly in regards to 
response latency (Cohen et al., 2014). 
A number of different theories have been postulated as an explanation for poverty of speech 
in schizophrenia. Berenbaum and colleagues (Berenbaum et al., 2008) suggest that alogia is a 
result of impairments in generating ideas and planning disturbances (Kravariti et al., 2003, 
Morris et al., 1995), as opposed to impairments in working memory (Barch and Berenbaum, 
1994), a general fluency disturbance (Stolar et al., 1994), or word finding difficulties (Alpert et 
al., 1994).  
 
1.2.3.2. Blunted affect:  
Blunted affect is the reduction in emotional expression, variation in vocal tone, and body 
movement. Different features identified include an unchanging expression, decreased 
movements, paucity of gestures, poor eye contact, affective non-responsivity, inappropriate 
affect, and lack of vocal inflection (Andreasen, 1983). This reduction in expressiveness is 
recognised to relate both to positive and negative emotion expression. In a meta-analysis 
comparing schizophrenia compared to healthy controls, schizophrenia patients were found to 
present with significant impairments in emotional expression (d=-1.11, 95% CI = -1.78 to -0.43) 
(Hoekert et al., 2007).   
As summarised by Kring and colleagues (Kring et al., 1993) there are two main theories which 
explain the reduction of emotional expression in schizophrenia. Bleuler (Bleuler, 1950) 
proposed the inhibition hypothesis, which suggests that schizophrenia patients experience 
emotion at a level comparable to controls, but experience significant impairments in the ability 
to express emotions. Rado (Rado, 1953) suggested that low expressivity was a reflection a 
reduced ability to experience emotions, and positive emotions in particular. Whilst the terms 
are sometimes used interchangeably, the former is characterised as blunted affect, whilst the 
latter is known as emotional blunting. The current evidence base appears to support the 
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inhibition hypothesis, with a number of laboratory studies finding that patients report 
experiencing both positive and negative emotional experiences to the same degree as healthy 
controls (Kring et al., 1993, Berenbaum and Oltmanns, 1992, Cohen and Minor, 2010). In 
addition, there is evidence to suggest that these deficits may relate to impairments in the 
amplification of emotional expression of experienced emotions, as opposed to any expression 
of emotions experienced being suppressed (Henry et al., 2007). 
Blunted affect in schizophrenia is associated with abnormalities in social behaviour, and are 
predicative of poor outcomes (Dworkin et al., 1998). Blunted effect has also been found to be 
associated in poorer premorbid adjustment, poorer quality of life, and worse outcome at 1-
year follow up (Gur et al., 2006). However, blunted affect was not found to be associated with 
deficits in social skills (Salem and Kring, 1999) or social functioning (Sayers et al., 1996). This 
suggests that any impairments in outcomes experienced may either be attributable other 
factors, such as their association with other symptoms (notably amotivation; (Sayers et al., 
1996), or the responses from people they are in contact with. 
 
1.2.3.3. Asociality:  
Asociality relates to reduced engagement with family members, partners, friends, and/or 
casual contacts (Blanchard et al., 2011). Asociality is a multifaceted concept in that it can relate 
both to a desire for relationships and or contact, and actual number of social activities 
conducted. Therefore, asociality can be evaluated both behaviourally (for example by counting 
up the amount and frequency of contacts over a specified period) or subjectively, by exploring 
the individuals interest in engaging with others. Given the fact that behavioural indicators of 
can be strongly influenced by extrinsic factors, Blanchard and colleagues (Blanchard et al., 
2011) emphasise the importance of tapping into the subjective component of this symptom 
construct. 
Understanding why patients with schizophrenia are more isolated appears to be somewhat 
complex, particularly given patients often report a desire to have friends, a vocation, and a 
family (Davidson and Stayner, 1997). Part of this is likely to be attributable to overlapping 
deficits in motivation, which explains why these symptoms are consistently reported to be part 
of the same overall construct in factor analytic studies (Blanchard and Cohen, 2006). In support 
of this hypothesis, Sayers and colleagues have found that amotivation is consistently positively 
associated with social dysfunction in patients with schizophrenia (Sayers et al., 1996). 
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However, increased asociality may also be attributable to other extrinsic factors, such as 
environmental under-stimulation and increased positive symptoms. Regarding the impact of 
positive symptoms on asociality, paranoid ideation has been found to be significantly 
associated with social anxiety (Rector, 2004), whilst formal thought disorder is linked to 
greater sensitivity to social rejection (Grant and Beck, 2009), both of which may result in 
patients being less engaged in their social environment. 
Other possible antecedents of asociality include skill deficits and dysfunctional beliefs. There is 
evidence to suggest that patients with schizophrenia exhibit significant deficits in social skills 
which can contribute to social isolation (Bellack et al., 1990). Patients with schizophrenia often 
mistake other people’s emotional states, which is associated with poorer social competence 
(Cramer et al., 1992, Mueser et al., 1996). People with schizophrenia have also been found to a 
report a greater number of asocial beliefs, which were found to be a strong predictor of 
asociality, both cross-sectionally and over time (Grant and Beck, 2010). In addition, Rector 
(Rector, 2004) found a significant association between negative symptoms and dysfunctional 
social performance beliefs. 
 
1.2.3.4. Anhedonia:  
Anhedonia is defined as the inability to experience pleasure from activities which are typically 
found to be enjoyable. In laboratory-based studies, schizophrenia patients appear to 
experience positive emotions as intensively as controls (Berenbaum and Oltmanns, 1992, Kring 
and Earnst, 1999, Kring and Neale, 1996). However, in both structured interviews and self-
report questionnaires patients report experiencing significantly lower levels of social and 
physical pleasure in comparison to healthy subjects (Blanchard et al., 1994, Blanchard et al., 
1998, Herbener and Harrow, 2002). In a review by Cohen and colleagues (Cohen et al., 2011), 
five different explanations for this apparent disconnect between state and trait experiences of 
anhedonia was proposed; a specific affective deficit in anticipatory hedonic experience; an 
affective regulation deficit; an encoding-retrieval deficit; a representational deficit; and a 
social-specific hedonic deficit. 
Of the five theories, a deficit in anticipatory hedonic experience is arguably the one that has 
received the greatest attention. Gard and colleagues (Gard et al., 2007) suggested that people 
with schizophrenia may experience deficits exclusively in anticipatory, as opposed to 
consummatory pleasure. These deficits in anticipatory pleasure extend both to the prediction 
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of experiencing pleasure in the future, and the experience of pleasure in the moment through 
the anticipation of future events. In support of this theory, Heerey and colleagues (Heerey et 
al., 2007) found that patients with schizophrenia are significant more likely to choose smaller 
immediate rewards over greater, delayed rewards. In addition, there is evidence to suggest 
that different neural pathways are involved for experiencing anticipatory and consummatory 
pleasure, supporting a distinction between these different types of experience (Berridge and 
Robinson, 1998, Berridge and Robinson, 2003). In neurobiology, serotonin and opioid systems 
are primarily linked with the experience of consummatory pleasure (Schultz, 2002, Wise, 
2002), whilst anticipatory pleasure has been found to be linked the dopamine system (Berridge 
and Robinson, 1998). This is significant, given dopamine dysregulation has long been 
implicated in the development and maintenance of psychosis and schizophrenia (Howes and 
Kapur, 2009).  
In the second possible explanation, an affective regulation deficit relates to the inability to 
minimise unpleasant experiences and enhance pleasurable ones, which are automatic 
strategies people unconsciously employ to enhance psychological wellbeing (Gross, 1998, 
Westen et al., 1997). Support for this hypothesis comes from the field of neuropsychology, 
where areas which are implicated in the affective regulation process such as prefrontal and 
anterior cingulate cortex (Kross et al., 2009) have been found to be substantially impaired in 
individuals with schizophrenia (Barch et al., 2003, Heckers et al., 2004). In the third 
explanation, it is proposed that dysfunctional encoding or retrieval of experiences may lead to 
inaccurate representations, a theory supported by evidence which suggests that people with 
schizophrenia can experience significant impairments in memory recall (Gold et al., 1992). In 
the fourth, a representational deficit relates to a deficit in the ability to assign an appropriate 
value to a stimuli (Gold et al., 2008). The final theory outlined in the review by Cohen and 
Colleagues (Cohen et al., 2011) relates to a social-specific deficit, where they suggest that 
hedonic impairments relate only to social experiences, whereas consummatory experiences 
remain largely intact. In their conclusion, Cohen and colleagues proposed that there is likely to 
be a significant degree of overlap between the theories, and highlighted the importance of 
considering the different systems together as a way to develop a fuller understanding of the 
mechanism of anhedonia in schizophrenia. 
Studies into the longitudinal course of symptoms of schizophrenia suggest that anhedonia is a 
relatively common feature of the disorder, with 76% of patients displaying at least mild 
anhedonia, and 23% showing marked or severe hedonic deficits (Fenton and McGlashan, 
1991). Historically, both Rado (Rado, 1956) and Meehl (Meehl, 1962) identified anhedonia as 
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the central feature of schizophrenia, and a reliable prognostic indicator for later developing 
the illness. In support of this, college graduates with high social anhedonia were found to be 
24 times more likely to be diagnosed with a schizophrenia-spectrum disorder within 10 years 
compared to participants who report low social anhedonia (Kwapil, 1998). In addition, family 
members of those diagnosed with schizophrenia have been found to experience significantly 
greater levels of trait anhedonia when compared with controls (Franke et al., 1994, Grove et 
al., 1991, Katsanis et al., 1990). 
 
1.2.3.4. Avolition:  
Avolition is defined as the lack of motivation to perform activities and pursue goals. According 
to Ryan and Deci (Ryan and Deci, 2000), motivation concerns “energy, direction, persistence, 
and equifinality”. Avolition can be characterised into two different components, relating either 
to a deficit in the individuals internal will to action, or the behaviours they display. In recent 
review determining how negative symptoms may be assessed, Blanchard and colleagues 
identified four different areas were avolition may be relevant to schizophrenia patients, 
including social activity, work/vocation, recreation, and self-care (Blanchard et al., 2011). 
Deficits in motivation have been seen as a core feature of schizophrenia since the earliest days 
of its conception. Emil Kraeplin identified avolition as the key feature of patients’ long term 
decline, whilst Bleuler identified avolition as one of one of the “4-A’s”. More recently, Foussias 
and Remmington (Foussias and Remington, 2010) proposed that avolition results in the clinical 
presentation of negative symptoms, and is the principle driver of functional decline.  
That patients with schizophrenia exhibit persistent deficits in goal-seeking behaviours have 
been recognised in the ealiest models of the disorder (Bleuler, 1950, Kraepelin, 1971). A 
number of theories have been proposed as to why such deficits occur. Gard and colleagues 
(Gard et al., 2014) found that schizophrenia patients experience difficulties in perceiving 
reward outcomes, which results in participants engaging in less effortful goals which earn 
lower rewards. Related to this, Heerey and Gold (Heerey and Gold, 2007) found that subjects 
show a deficit ability to associate their behaviour to motivational properties of a stimulus.  
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1.3. Primary and secondary negative symptoms of schizophrenia 
In 1974 Strauss and colleagues (Strauss et al., 1974) proposed that negative symptoms have 
different antecedents, suggesting that they may either constitute a fundamental feature of the 
disorder itself, or else may arise as a consequence of dealing with institutionalisation, social 
stigma, and isolation which can result from  the diagnosis. Carpenter and colleagues 
(Carpenter et al., 1985) further expanded upon the importance of identifying the antecedents 
of negative symptoms in order to explain the heterogeneity in treatment response. In addition 
to the primary negative symptoms of the disorder which were considered core 
psychopathology, Carpenter et al. suggested that negative symptoms can arise as a 
consequence secondary factors, including positive symptoms, the side-effects of antipsychotic 
medication, a response to under-stimulating environments (with particular reference to long 
term institutionalisation), and depressive symptoms. Whilst secondary negative symptoms 
usually improve relatively quickly once these factors are addressed, primary negative 
symptoms were considered to be highly stable, have a poor prognosis, and be largely non-
responsive to treatment.  
Differentiating between primary and secondary symptoms may be important for a number of 
reasons. Firstly, a distinction between these symptoms may explain the heterogeneity in 
longitudinal course and treatment response which has been recognised in respect to negative 
symptoms. Secondly, identifying the aetiology of the negative symptoms can inform the 
appropriate response with regards to treatment. Third, differentiating between these 
symptoms may be important with regards to evaluating therapeutics for core 
psychopathology. Finally, isolating symptoms specific to the core pathology of the disorder 
may help to uncover possible causes and risk factors of schizophrenia. 
In a study of consecutively admitted inpatients, the existence of persistent primary negative 
symptoms was detected in 25.7% of cases with a diagnosis of schizophrenia (Peralta and 
Cuesta, 2004), suggesting a significant proportion of patients may experience such symptoms. 
A summary of the different factors identified to cause secondary negative symptoms are 
summarised below.  
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1.3.1. Factors that induce secondary negative symptoms 
1.3.1.1. Environmental under-stimulation  
The link between under-stimulating institutional care and negative symptoms such as 
decreased spontaneity, reduced drive, and blunted affect have been recognised in concepts 
such as “institutional neurosis” (Barton, 1959)  and “social breakdown syndrome” (Gruenberg 
et al., 1966). In a study comparing different mental hospitals, Wing and Brown (Wing and 
Brown, 1970) found a strong association between the severity of the social environment with 
what they defined as “clinical poverty”, which included symptoms such as blunted affect, 
poverty of speech, and social withdrawal. In addition, they found that these symptoms 
reduced relatively quickly once their environment improved. In a replication of the study 
completed 30 years later (Curson et al., 1992), no association between length of stay and 
negative symptoms was detected, and only a weak association between environmental 
poverty and negative symptoms was found. Curson and colleagues attributed this weaker 
relationship to the improved hospital environment, supporting the conclusion that it is the 
environmental impoverishment, as opposed to incarceration itself, which exacerbates negative 
symptoms. In a cross-cultural validation of the original Wing and Brown study (Oshima et al., 
2003), the link between environment and negative symptoms was evaluated in 139 Japanese 
hospitals, where deinstitutionalisation and rehabilitative practices had not been adopted at 
the time (Mino et al., 1990). Whilst no association was detected between length of stay and 
negative symptoms, a significant association between negative symptoms and an under-
stimulating environment was found.   
Overall, these findings support the link between environmental under-stimulation and 
negative symptoms, and the importance of providing stimulating environments in order to 
minimise secondary negative symptoms. However, given only a very low association was 
detected in the study by Curson (Curson et al., 1992) it suggests that the negative symptoms 
induced in hospitals with good social and rehabilitative provision may be lower than previously 
thought. Regardless, given the potential impact of hospitalisation, and the fact that it is 
beyond the scope of this investigation to evaluate the environmental poverty of each 
institution, these findings highlight another issue in disentangling primary and secondary 
negative symptoms in inpatient settings. Consequently, this investigation focuses exclusively 
on outpatients, apart from the analysis conducted in chapter 7 which considers the impact of 
symptoms specifically in the acute phase of treatment. 
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1.3.1.2. Antipsychotic medication side effects:  
Since the discovery of antipsychotic medication in the 1950’s it has been recognised that these 
compounds can cause extra-pyramidal side effects (EPS) (Rifkin, 1987). Common extra-
pyramidal side effects include dystonia, parkinsonism, tardive dyskinesia, and akathisia. Other 
movement-disorders related to antipsychotic drugs include catatonia, and in very rare cases, 
neuroleptic malignant syndrome (Caroff, 1980). Akathisia is characterised by restlessness, 
anxiety, inner tension and the need to be in constant motion. Akathisia is thought to be 
relatively common, with prevalence estimated at between 20-35% of patients in routine 
practice (Kane et al., 2009). Dystonia is an acute involuntary movement disorder, characterised 
by prolonged muscle contractions causing twisting movements and abnormal postures 
(Berardelli et al., 1998). Drug-induced parkinsonism mimics Parkinson’s disease, and can result 
in tremors, postural or gait disturbances, hypersalivation, rigidity, and bradykinesia (slowness 
in the execution of movement), and akinesia (loss of movement power). Tardive dyskinesia is 
characterised by repetitive hyperkinetic movements, which, unlike most EPS symptoms, can be 
irreversible (Caroff et al., 2011). Catatonic symptoms associated antipsychotic side-effects 
include stupor, and states where patients find themselves unable to move and/or speak 
(akinetic mutism). In rarer cases, patients can experience catalepsy (which is a state whereby 
patients are outwardly unresponsive to external stimuli) and waxy flexibility (which is a rigid 
maintenance of body position) (Gelenberg and Mandel, 1977). EPS are positively associated 
with medication non-compliance (Fenton et al., 1997), which in turn is associated with a higher 
risk of relapse (Gilbert et al., 1995). In a review by Fenton and colleagues (Fenton et al., 1997) 
it was found that between 25%-66% of patients cite medication side effects as the primary 
reason for treatment non-compliance in schizophrenia 
When second generation antipsychotics (SGA’s) first became available, it was believed that a 
lower risk of EPS was one of their major benefits over the older first generation antipsychotics 
(FGA’s) (Kane et al., 1988, Safferman et al., 1991). However, in a meta-analysis comparing the 
side effects of typical and atypical antipsychotics (Leucht et al., 2009b) much of the difference 
previously reported was attributable to high potency FGA’s being used in the control arm 
conditions. When different SGA’s were compared to lower potency FGA’s (defined as 
equipotent or less potent than chlorpromazine) the difference in EPS was less marked, and less 
consistent. In another study comparing EPS levels between atypical antipsychotics and a lower 
potency FGA (perphenazine), no differences were detected (Lieberman et al., 2005). These 
findings suggest that issues related to EPS have not been eliminated by the advent of second 
43 
 
generation antipsychotics, and remain an important consideration in the treatment and 
research of schizophrenia.  
In addition to causing significant levels of distress to patients, EPS can mimic negative 
symptoms which can make assessing core psychopathology difficult (Carpenter et al., 1985). In 
animal studies, antipsychotic drugs have been found to be associated to behavioural changes 
comparable to negative symptoms such as apathy, and lack of spontaneity and affective 
arousal (McKinney et al., 1980, McKinney and Moran, 1981). In addition, both the dose and 
duration of antipsychotic medication received was found to be positively associated with 
negative symptoms (Perenyi et al., 1998). When individual negative symptoms were 
considered separately, Kelley found that medication effects appeared to be related primarily 
to expressive deficits such as blunted affect (Kelley et al., 1999). 
Regarding particular types of EPS, significant overlaps between parkinsonian symptoms such as 
bradykinesia and akinesia and negative symptoms have been identified (Allan et al., 1998). In a 
study by Kane (Kane et al., 1994), a significant correlation between akinesia and anergia was 
detected, which persists even after a washout period of at least two weeks prior to the 
assessment taking place. Similarly, Prosser reported that negative symptoms have been found 
to be significantly correlated with the parkinsonian symptoms akinesia and tremor (Prosser et 
al., 1987). Regarding individual negative symptoms, Allen suggested that the link between 
facial bradykinesia and blunted affect, and akinesia to avolition may be a considered a 
particular issue (Allan et al., 1998).  
In clinical practice, anticholinergic drugs have typically been prescribed to control or limit the 
impact of EPS (Ogino et al., 2014). In research, EPS can be measured using validated scales 
such as the Simpson-Angus Scale (SAS) (Simpson and Angus, 1970) or Barnes Akathisia Rating 
Scale (BARS) (Barnes, 1989) to either to specify maximum EPS inclusion criteria, or else be 
included as covariates in the model. Given the content overlap between negative symptoms 
and akinetic parkinsonian symptoms such as bradykinesia and akinesia, Peralta and Cuesta 
suggest that focusing on the non-akinetic symptoms such as tremor and hypersalivation may 
be a more useful in distinguishing primary from drug-induced negative symptoms (Peralta and 
Cuesta, 1999c). 
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1.3.1.3 Depression 
Depression is a state of low mood that can lead to changes in feelings, thoughts and 
behaviours. Symptoms include feelings of hopelessness, apathy, lethargy, changes in sleep 
patterns, guilt, suicidal thoughts and somatic complaints. Depression is considered to be 
relatively common in patients with schizophrenia. In a review by Siris (Siris, 1991), the 
prevalence of depression and prominent depressive symptoms ranged from 7%-70%, 
depending upon the criteria adopted and the sample evaluated. At the point of hospital 
admission for a first episode, 71% of participants presented with clinically meaningful 
depressive symptoms, and 23% fulfilled criteria for a diagnosed depressive episode (Häfner et 
al., 2005). Prior to onset, the lifetime prevalence of depressive mood for a period longer than 2 
weeks was found to be particularly high (83%; (Häfner et al., 2005). Overall, depression and 
depressive symptomology is considered to be highly prevalent in patients with schizophrenia. 
Whilst studies have consistently shown that negative and depressive symptoms  are distinct 
constructs (Blanchard and Cohen, 2006), there is a significant degree of overlap with regards to 
their clinical presentation (Mulholland and Cooper, 2000).  For example, both negative 
symptoms and depression can manifest as a lack of energy and drive, anhedonia, and social 
withdrawal. However, a number of differences are also apparent. As recognised in in section 
1.2.3.4., anhedonic deficits in schizophrenia appear to be confined specifically to anticipatory 
pleasure (Gard et al., 2007), whilst in depression anhedonia relates to experiencing pleasure 
overall (Snaith, 1993). In addition, depressive symptoms appear to be more associated to 
positive, rather than negative symptoms (Lindenmayer et al., 1991). Other differences include 
the fact that patients with severe negative symptoms often report relatively high subjective 
quality of life and satisfaction scores (Fitzgerald et al., 2001, Priebe, 2007). This is in contrast 
with depression, where the negative association between depressive symptoms and subjective 
quality of life is well documented (Priebe et al., 2000, Reine et al., 2003). 
Whilst a number of scales have been developed to measure depressive symptoms such as the 
Beck depression inventory (BDI) (Beck et al., 1988) and the Hamilton Depression Rating Scale 
(HRDS) (Hamilton, 1960), disentangling symptoms using these scales is considered 
problematic. Addington and colleagues (Addington et al., 1996) found significant correlations 
between the HRDS and assessments of negative symptoms in patients with schizophrenia. In a 
different study, the HRDS was found to contain a negative symptom factor which correlates 
strongly with the SANS (Goldman et al., 1992). In addition, there is evidence to suggest that 
global rating scales such as the Positive and Negative Syndrome Scale (PANSS) (Kay et al., 
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1987) are not to be able to distinguish between depression, negative symptoms, and EPS 
(Collins et al., 1996). 
In an attempt to disentangle ratings of depression and negative symptoms, the Calgary 
Depression Scale for Schizophrenia Scale (CDSS) (Addington et al., 1993, Addington et al., 
1992) was designed specifically for use in psychotic populations. In a study examining the 
divergent validity of the CDSS from negative symptomology (Addington et al., 1996), no 
significant associations were found both at hospital admission (r2=.02, P=.67), or at three 
months follow-up (r2=.06, P=.14). These findings are in contrast to an assessment of the 
relationship between the HDRS and negative symptoms, where significant associations were 
detected at both time points (r2=.28, P<.01, and r2=.23 P<.01 respectively). Overall, these 
findings highlight the importance and complexity of disentangling depressive and negative 
symptoms, and the importance of choosing appropriate methods to control for depressive 
symptoms when controlling for secondary negative symptoms. 
 
1.3.1.4. Positive symptoms: 
The positive symptoms of schizophrenia include hallucinations, delusions and thought disorder 
(for a detailed summary see 1.2.1.). In reformulations of the positive/negative symptoms 
dichotomy (Crow, 1980, Crow, 1985, Strauss et al., 1974) positive and negative symptoms 
were understood to be independent, with some studies suggesting they may even be inversely 
associated once general psychopathology is controlled for (Kay et al., 1987). However, later 
work has found positive correlations between the two symptom dimensions, both in the acute 
phase and during periods of remission (Addington and Addington, 1991). 
In an evaluation of the positive and negative “subtypes” of schizophrenia, Angrist and 
colleagues (Angrist et al., 1980) examined the effects of prescribing antipsychotics and 
amphetamines to patients with schizophrenia. As hypothesised, amphetamines increased the 
severity of positive symptoms but, contrary to expectations, negative symptoms also 
increased. When this was examined at an item level, the increase was found to be exclusively 
attributable to elevated emotional withdrawal. Angrist postulated that the increase in 
emotional withdrawal may be attributable to autistic preoccupations with increased 
persecutory delusions or auditory hallucinations, as opposed to any change in core 
psychopathology. In a more recent study, (Kelley et al., 1999) found that increases in positive 
symptoms predicted more severe avolition but not blunted affect, supporting the theory that 
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positive symptoms appear to influence the experiential features of negative symptoms in 
particular.  
Since the study by Angrist, a number of other researchers have reported on the improvement 
in negative symptoms being linked to improvements in positive symptoms (Tandon et al., 
1990, Tandon et al., 1993, van Kammen et al., 1987). Whilst no such association was detected 
in studies by Brier or Serban (Breier et al., 1987, Serban et al., 1992), Tandon suggested this 
may be attributable to small sample sizes and insufficient positive symptoms present at 
baseline to drive changes in negative symptoms (Tandon et al., 1993).  In an attempt to model 
for the impact of positive symptoms on negative symptoms in clinical trials, a number of path-
analytical studies have been completed (Alvarez et al., 2006, Moller et al., 1995, Tollefson and 
Sanger, 1997). Whilst direct effects of atypical antipsychotics on negative symptoms were 
detected in all studies, significant improvements in these symptoms were also found to be 
attributable to improvements in positive symptoms. For example, in the study by Alvarez et al. 
42.69% of the improvements detected in negative symptoms in patients prescribed with 
olanzapine over risperidone was found to be attributable in the improvement in positive 
symptoms (Alvarez et al., 2006). Such findings highlight the importance of either limiting, or 
controlling the severity of positive symptoms when attempting to evaluate core negative 
psychopathology. 
 
1.3.3. Deficit syndrome and persistent negative symptoms 
Following the distinction between primary and secondary negative symptoms, Carpenter and 
colleagues went on to suggest that those who experience primary negative symptoms may 
constitute a distinct subtype of schizophrenia, known as the “deficit syndrome” (Carpenter et 
al., 1988). As recognised in a review by Buchanan (Buchanan, 2007) the concept is based upon 
Kraepelin’s “avolitional syndrome” (Kraepelin, 1971). In a departure from the subtype 
definition proposed by Crow (Crow, 1980, Crow, 1985), a diagnosis of deficit syndrome is 
determined by the persistence of core psychopathology, as opposed to the presence of 
symptoms measured at a single time point. The operational criteria for the Deficit syndrome 
proposed by Carpenter (Carpenter et al., 1988) include: 
1) At least 2 of the following 6 symptoms present at a clinically significant level: flattened 
affect, diminished emotional range, alogia, impaired interest, diminished sense of 
purpose, asociality. 
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2) 2+ symptoms present for minimum of 12 months, present during periods of clinical 
stability. 
3) The above symptoms must not be a consequence of secondary factors 
4) A diagnosis of schizophrenia 
 
The distinction between deficit and non-deficit forms of schizophrenia has been found to be 
highly stable over time (Amador et al., 1999), with the diagnosis of deficit syndrome consistent 
in 83% of cases, and a non-diagnosis consistent in 88% of cases 3-4 years later. Over a longer 
period, Strauss and colleagues (Strauss et al., 2010), found that approximately 70% of deficit 
syndrome patients at baseline still qualified for the diagnosis 20 years later. The prevalence of 
the deficit syndrome has been estimated to be 20-30% of schizophrenia in clinical samples, 
and 14-17% in schizophrenia population samples (Kirkpatrick et al., 2006). The prevalence for 
the disorder appears to be significantly higher in older patient samples, with 37% of 
participants found to qualify for deficit syndrome in a sample of patients over 45 years old 
(Harris et al., 1991). 
In a review of deficit syndrome by Kirkpatrick, it was proposed that differences in the signs and 
symptoms, longitudinal course, risk and antecedent factors, treatment response, and 
pathophysiological correlates between deficit and non-deficit subtypes all support the theory 
that they constitute distinct disorders (Kirkpatrick et al., 2001, Kirkpatrick and Galderisi, 2008). 
Patients diagnosed with deficit syndrome have been found to present with lower positive 
psychotic symptoms and less severe depression relative to non-deficit patients, in addition to 
lower rates of less drug abuse, suicidality, anxiety, guilt and hostility (Kirkpatrick et al., 1996a, 
Kirkpatrick et al., 1994). As identified in section 1.1.3., winter birth is associated with non-
deficit schizophrenia, whilst deficit syndrome has a stronger association with summer birth 
(Messias et al., 2004). Deficit syndrome patients have been found to have a significantly lower 
age of onset relative to non-deficit patients (Kirkpatrick et al., 2000a). With regards to the 
course of the illness, the deficit syndrome has been found to be associated with poorer 
premorbid adjustment (Galderisi et al., 2002). Tek and colleagues found that patients 
diagnosed with deficit syndrome had a poorer quality of life, experienced a greater 
impairment in functioning, and had more severe negative symptoms 5 years later (Tek et al., 
2001). In studies that compare the symptoms of family members of people with deficit and 
non-deficit schizophrenia, sub-clinical negative symptoms are more severe in the families of 
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people with deficit syndrome (Hong et al., 2003), whilst symptoms of dysphoria and positive 
symptoms are higher in family members of non-deficit patients (Kirkpatrick et al., 2000b).  
Regarding any neurological differences between deficit and non-deficit syndrome there is 
evidence to suggest that non-deficit patients experience a greater reduction in frontal lobe 
white matter relative to both deficit patients and healthy controls (Buchanan et al., 1993), 
whilst there is also some evidence of electrophysiological differences between deficit and non-
deficit patients (Mucci et al., 2007, Turetsky et al., 1998). In addition, there is evidence to 
suggest that eye-tracking dysfunction appears to be significantly more impaired in deficit 
patients, relative to non-deficit patients (Ross et al., 1997, Ross et al., 1996). Overall, there is a 
substantial (and still emerging) evidence base to suggest that deficit syndrome may represent 
a distinct subtype of schizophrenia which emphases the importance of considering this 
distinction in any investigation of negative symptoms. 
 
1.3.4. Persistent negative symptoms as an alternative to the deficit syndrome  
Whilst assessment tools such as the Schedule for the Deficit Syndrome (SDS) have been found 
to be a reliable tool for identifying deficit patients (Kirkpatrick et al., 1989), Buchanan 
suggested that making such a distinction may be problematic in the context of a clinical trial 
(Buchanan, 2007). Firstly, accurate information regarding the presentation of symptoms is 
required over a period of 12 months, which is likely to be difficult to obtain in the majority of 
cases. Secondly, determining the aetiology of negative symptoms (i.e. whether they are 
primary in origin or attributable to secondary factors) requires a high degree of clinical 
expertise that assessors in clinical trials may not typically have. As an alternative, Buchanan 
proposed that clinical trials designed to evaluate treatments for negative symptoms should 
instead include those that experience what he defined as “persistent negative symptoms”. 
The criteria that Buchanan proposed to define what constitutes persistent negative symptoms 
differ from the criteria for deficit syndrome in two important respects. Firstly, the requirement 
that the negative symptoms considered must be present for 12 months is omitted. No 
predefined time period is specified, although 6 months is generally recommended. Secondly, 
patients with secondary negative symptoms may still qualify for eligibility so long as the 
negative symptoms experienced are persistent, and have failed to respond to usual treatments 
for causes of secondary symptoms which are adequately controlled for. To operationalise the 
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concept of persistent negative symptoms, Buchanan (Buchanan, 2007) proposed the following 
criteria: 
 
1) At least moderate severity of negative symptoms, measured on a validated symptom 
rating scale 
2) Demonstrated clinical stability for an extended period of time prior to the start of 
study 
3) A defined maximum threshold of positive symptoms as measured on a validated 
symptom rating scale 
4) No (or low level of)  depressive symptoms, as measured on a validated rating scale 
5) No (or low level of) extrapyramidal symptoms, as measured on a validated rating scale 
(Buchanan, 2007)p.1016) 
 
Adopting the criteria of persistent negative symptoms over deficit syndrome criteria has a 
number of advantages. By not having to disentangle the aetiology of the negative symptoms 
adopting persistent negative symptom criteria should be easier to implement, relative to 
deficit syndrome criteria. In addition, utilising the persistent negative symptom criteria should 
mean that a substantially larger pool of potential participants would be available, easing the 
challenge to recruit eligible participants. Related to this, with the eligible population being 
much closer to the clinical population, any subsequent findings could be considered to have 
greater ecological validity. As recognised in the NIMH-MATRICS consensus statement on 
negative symptoms (Kirkpatrick et al., 2006) symptoms that are highly persistent, irrespective 
of the aetiology, represent an unmet therapeutic need and so merit inclusion in clinical trials 
designed to treatment these symptoms.  
Whilst it may appear attractive to adopt the criteria of persistent negative symptoms in clinical 
trials, further work on how these criteria should be implemented is required. At present the 
criteria are broad, and it is not clear how the different ways in which they can be implemented 
may influence the association between negative symptoms and causes of secondary negative 
symptoms such as depression, positive symptoms, and EPS. In addition, recent work has 
suggested that the manner in which these criteria are adopted can have a substantial impact 
on the size of the potential sample pool (Dunayevich et al., 2014, Rabinowitz et al., 2013), 
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which can impact both the validity of the findings and the ease of recruitment. This area will be 
explored in greater depth in chapter 4. 
 
1.5. Longitudinal course of negative symptoms of schizophrenia 
A number of different conceptual models of schizophrenia have suggested that negative 
symptoms are either highly stable, or get progressively more severe over time. Kraepelin  
(Kraepelin, 1971) defined schizophrenia as a degenerative disorder, with all symptoms getting 
more severe over time. In contrast, Bleuler (Bleuler, 1950) adopted a much broader 
conception of schizophrenia arguing that outcome can be much more heterogeneous, albeit 
with negative symptoms being more stable than the “accessory” positive symptoms. More 
recently, Crow (Crow, 1980, Crow, 1985) thought negative symptoms were permanent, 
believing they were a result of morphological changes in the brain. 
In longitudinal assessments of symptoms over time, Pfhol and Winokur (Pfohl and Winokur, 
1983) catalogued the presence and absence of symptoms over 25 years in 52 chronic 
institutionalised hebephrenic and catatonic schizophrenia patients. In this study they found 
that the prevalence of avolition, impaired social interaction and flat affect increased over time, 
whilst positive symptoms reduced. In a series of investigations as part of the Chestnut Lodge 
study, Fenton and McGlashan found that that negative symptoms “accrue severity, stability 
and prognostic weight over time” (Fenton and McGlashan, 1991, McGlashan and Fenton, 
1992, McGlashan and Fenton, 1993). However, there is also a significant body of literature 
which suggests that negative symptoms are largely stable, with a minority of patients 
exhibiting small improvements over time. Pogue-Geile & Harrow (Pogue-Geile and Harrow, 
1985) found that the severity of negative symptoms were largely stable over a period of 5 
years, with a tendency towards remission. In a study spanning 4 years, Johnstone and 
colleagues (Johnstone et al., 1987) found that whilst negative are much more stable than 
positive symptoms, and that the deficits were not irreversible with all of features of negative 
symptoms improving in at least some cases. Over a period of 10 years, Eaton (Eaton et al., 
1995) found that the prevalence of both positive and negative symptoms reduced in the year 
following first hospitalisation, and were then stable hereafter. In a sample of neuroleptic-naïve 
patients at admission, Arndt (Arndt et al., 1995) found that negative symptoms were 
prominent at the baseline stage, and remained largely stable over a period of 2 years. In an 
evaluation of community outpatients over a period of 2 years, Quinlan (Quinlan et al., 1995) 
found that negative symptoms significantly reduced, whilst positive symptoms increased. 
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More recently, Whitty (Whitty et al., 2008) reported significant improvements in both positive 
and negative symptoms over a period of 4 years from first presentation, suggesting that the 
outcome may not be as pessimistic as once thought.  
In addition to examining the longitudinal course of negative symptoms as a singular construct, 
a number of studies have also examined the course of individual negative symptoms (Dollfus 
and Petit, 1995b, Eaton et al., 1995, Fenton and McGlashan, 1991, Pogue-Geile and Harrow, 
1985). There is some evidence to suggest that alogia and blunted affect  are more stable than 
other negative symptoms (Dollfus and Petit, 1995b, Johnstone et al., 1987, Kelley et al., 2008), 
which may be due to these symptoms being  less influenced by improvements in positive 
symptoms (Kelley et al., 1999).  
In the current investigation, the longitudinal course of negative symptoms will be examined by 
way of meta-analysis in an attempt to uncover broader trends regarding how these symptoms 
may change over time in chapter 3. 
 
1.5.1. Longitudinal course of negative symptoms in patients with deficit syndrome 
Whilst it is important to determine the longitudinal course of negative symptoms that patients 
typically experience irrespective of their aetiology, disentangling their origin may be helpful as 
a way to explain the heterogeneous findings highlighted in section 1.5. As stated previously, 
Carpenter (Carpenter et al., 1985) proposed that while secondary negative symptoms may 
fluctuate in accordance with the extrinsic factors which cause the symptoms change, primary 
negative symptoms should be considered a highly stable feature of the disorder. In order to 
evaluate the severity and stability of primary negative symptoms over time, a number of 
longitudinal studies have been completed in patients that qualify for the deficit syndrome. 
In one of the earliest evaluations of negative symptoms in deficit and non-deficit schizophrenia 
patients, Fenton and McGlashan (Fenton and McGlashan, 1994) found that negative and 
cognitive symptoms get significantly worse in patients that qualify for deficit syndrome over a 
period of 5 years. In addition, periods of symptomatic remission were found to be a lot less 
frequent in patients in these patients, with 78% showing a continuing course of illness, relative 
to 28% of non-deficit patients. These findings were similar to those reported in a later study by 
Kirkpatrick and colleagues (Kirkpatrick et al., 1996b) who found that deficit patients presented 
with more severe negative symptoms two years later, in addition to reporting poorer 
psychosocial functioning and greater global impairment.  
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In a prospective study evaluating the longitudinal course of negative symptoms over a much 
longer period (20 years) (Strauss et al., 2010), the results were broadly consistent with earlier 
studies. Deficit syndrome patients were found to experience significantly fewer periods of 
global recovery, and a greater degree of social and occupational impairment. However, in 
contrast to previous studies negative symptoms were not found to get significantly worse over 
time. Instead, negative symptoms were found to follow a fluctuating course in a similar 
manner to non-deficit patients.  
 
1.6. The impact of negative symptoms on quality of life 
Considerable attention has been paid to the impact of negative symptoms of schizophrenia on 
quality of life, despite the fact that there is no precise definition of what constitutes quality of 
life in this context (Priebe et al., 2010b). For the purposes of this investigation, quality of life is 
defined to include subjective components such as wellbeing and satisfaction with life, and 
objective components including daily life functioning and external resources, both material 
and social (Katschnig, 2000, Lehman et al., 1982). Consequently, a number of studies which do 
not specifically mention quality of life, but do evaluate concepts such as functioning, 
wellbeing, and satisfaction have all been deemed as relevant to this area of interest. 
With regards to the objective components of quality of life (OQOL), negative symptoms have 
been found to be significantly associated with less frequent social contacts, lower quality of 
social interaction, and poorer community participation (Lysaker and Davis, 2004). Hunter and 
Barry (Hunter and Barry, 2012) found a strong association between negative symptoms and 
impairments in various measures of functioning, including the quality of interpersonal 
relations, vocational role, intrapsychic foundations, and personal and social performance. In 
longitudinal studies, higher negative symptoms at baseline have been found to be associated 
with more substantial impairments in OQOL 2 to 7 years later in areas such as global 
functioning, psychosocial functioning, impairment in recreational activities and relationships, 
and work performance (Ho et al., 1998, Milev et al., 2005, Pogue-Geile and Harrow, 1985, 
Whitty et al., 2008). Such quality of life deficits have been found to be particularly severe in 
patients that qualify for deficit syndrome (Fenton and McGlashan, 1994, Tek et al., 2001). In an 
evaluation of individual symptoms, anhedonia in particular has been found to be a predictor of 
various features of lower quality of life, including psychological, social, and spiritual domains 
(Ritsner et al., 2011), whilst apathy has been found to be associated with poorer individual 
living skills (Kiang et al., 2003). 
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Whilst a strong association between various domains of OQOL and negative symptoms have 
been consistently detected, the association between negative symptoms and subjective 
quality of life (SQOL) is less clear. Somewhat counter-intuitively, patients with negative 
symptoms tend to report relatively high SQOL, despite experiencing a poor OQOL (Arns and 
Linney, 1993, Katschnig et al., 2006). As a result, the association between objective and 
subjective quality of life have been found to be only weak-to-moderate in schizophrenia, 
ranging from 0.04 to 0.57 (Priebe and Fakhoury, 2007). Fitzgerald and colleagues (Fitzgerald et 
al., 2001) found that whilst various observer-rated quality of life domains were found to be 
significantly associated to negative symptoms, subjective life satisfaction was not. In a meta-
analysis examining the cross-sectional association between symptoms of schizophrenia and 
SQOL, only a weak association was detected with negative symptoms (Eack and Newhill, 2007). 
In an assessment of the association between the change in subjective quality of life and 
anergia symptoms over time only a weak association was detected, and this was not significant 
after controlling for other symptoms, notably depression (Priebe et al., 2011b). 
Subjective quality of life can cover a number of concepts, such as ones satisfaction with their 
employment situation, finances, recreational activities, friendships, safety, housing, health, 
sex-life, family and overall life satisfaction (Priebe et al., 1999). Determining ones subjective 
appraisal of their life is thought to be influenced by three different factors, including a 
comparison between expectations and aspirations, a comparison with others, and adaptation 
over time (Priebe, 2007). As a result, Priebe suggested that patients may report relatively high 
levels of SQOL due to the fact that schizophrenia is a highly chronic illness, meaning patients 
may have had a long time to adapt to their present situation, in addition to peer comparison. 
However, an alternative explanation is that many scales which have been designed to measure 
negative symptoms focus primarily on behavioural referents (Blanchard et al., 2011), which 
may result in the association between SQOL and symptoms being under-reported. Regardless 
of the explanation, subjective quality of life reports are an important indicator of patients’ 
views and experiences which cannot be disqualified by any external measure, and so should be 
respected (Priebe, 2007). This relationship is further explored in chapter 6.  
 
1.7. The treatment of negative symptoms 
Whilst negative symptoms have been found to improve as a result of antipsychotic treatment 
(Goldberg, 1985, Kane et al., 1988, Marder and Meibach, 1994), this is considered primarily to 
be a consequence of improvement in the causes of secondary negative symptoms, such as 
54 
 
positive symptoms (Buchanan, 2007, Tandon et al., 1993). To date, any advances in the 
treatment of schizophrenia have been found to provide only limited benefits to negative 
symptoms directly. In a meta-analysis by Leucht which examined the efficacy of individual 
second generation antipsychotics, most were found not to provide a significant improvement 
relative to first generation drugs, and in those that did the effect sizes found were small 
(Leucht et al., 2009a). Meta-analyses into the efficacy of  adjuntive medications such as alpha-
2 receptor antagonists (Hecht and Landy, 2012) and glutamatergic compounds (Tuominen et 
al., 2005) show some promise, although since these publications a large-scale trial found no 
impact of either glycine or D-cycloserine (Buchanan et al., 2007). There is some evidence to 
suggest that adjunctive antidepressant medication may have some limited benefit (Singh et al., 
2010). In a broader review evaluating the different pharmacological approaches in treating 
negative symptoms (Arango et al., 2013), promising new drugs that act on the NMDA and 
alpha-7 nicotinic receptors are highlighted, but further work is required. 
 In evaluations of psychotherapeutic approaches, a meta-analysis of CBT reported a small 
effect on negative symptoms (Jauhar et al., 2014), a meta-analysis on social skills training 
reported a moderate effect size (Kurtz and Mueser, 2008), whilst a meta-analysis on social 
cognitive training found no effect (Kurtz and Richardson, 2012). In a meta-analysis of cognitive 
remediation therapy which evaluated overall symptoms, only a small effect was detected 
(Wykes et al., 2011). In the UK, NICE have recommended arts therapies as a treatment which 
has shown consistent efficacy in reduction of negative symptoms (NCCfMH, 2010), however 
this has since been challenged by the non-significant result of the MATISSE trial (Crawford et 
al., 2012b). In a broader meta-analysis  looking at the effectiveness of a number of different 
treatment for negative symptoms, some treatments were found to result in statistically 
significant improvements, but none were considered to result in clinically meaningful 
improvements (Fusar-Poli et al., 2015). Overall, this current lack of treatment efficacy has led 
to negative symptoms being recognised as an unmet therapeutic need, and an important 
target for new interventions (Kirkpatrick et al., 2006).  
 
1.8. The NIMH-MATRICs consensus statement on negative symptoms of 
schizophrenia  
Given the devastating impact of negative symptoms, combined with the limited progress in 
treatment development, in 2005 a consensus development conference was held on behalf of 
the National Institute of Mental Health (NIMH). The aim of this meeting was to further develop 
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the measures and methodologies adopted in negative symptom clinical trials (Kirkpatrick et al., 
2006). The meeting followed the success of the MATRICs conference on cognitive symptoms of 
schizophrenia (Green et al., 2004b), which helped form the basis for standardising the 
cognitive assessment battery. 
The consensus statement concluded that negative and cognitive symptoms are separate 
domains, with negative symptoms representing an unmet therapeutic need in a large 
proportion of cases. There was an agreement that blunted affect, alogia, asociality, anhedonia, 
and avolition should all be considered part of the negative symptom construct. In addition, 
they proposed that this construct may comprise of at least two distinct factors; expressive 
deficits, which include alogia and blunted affect, and experiential deficits, which include 
asociality, anhedonia and avolition (Blanchard and Cohen, 2006, Horan et al., 2011). Despite 
recognising that patients who experience primary and secondary negative symptoms can be 
differentiated with relatively good reliability (Kirkpatrick et al., 2001), it was suggested that 
making a distinction between these types of symptoms was not essential, so long test subjects 
presented with persistent negative symptoms with sources of secondary negative symptoms 
controlled for through study design. However, no specific details of what constitutes an 
appropriate strategy to limit the impact of positive, depressive or medication side effects were 
presented, an issue which will be further addressed in chapter 4.   
In research trials which evaluate the effectiveness of medications taken specifically for 
negative symptoms, it was agreed that the ideal design would be to conduct a double-blind, 
placebo-controlled comparison of parallel groups, including clinically stable patients 
maintained on second-generation antipsychotics. In the case of broad spectrum antipsychotics 
there was a consensus that it was not possible to establish superior efficacy for negative 
symptoms due to the “pseudospecificity problem”, which is the inability to disentangle 
improvements in negative symptoms from improvements in sources of secondary negative 
symptoms (see section 1.3.1.). There was also a consensus that whilst proof of concept studies 
may be relatively brief (4-12 weeks), full-scale trials should be much longer (6-months) in order 
to evaluate the persistent efficacy of treatments. The final point of agreement was that whilst 
the Scale for the Assessment of Negative Symptoms (SANS) (Andreasen, 1983) was preferable 
to single symptom-item scales such as the Positive and Negative Symptom Scale (Kay et al., 
1987), the information obtained from single-item scales should still be considered important 
and valid.   
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In addition to the points of agreement, the workshop also outlined recommendations for 
future research. Of these, the key recommendation was the need to develop of new 
instruments designed to measure negative symptoms which address the limitation of existing 
scales. This recommendation resulted in the development of the Collaboration to Advance 
Negative Symptom Assessment for Schizophrenia (CANSAS) (Blanchard et al., 2011), which in 
turn led to the develop of two new scales; the Brief Negative Symptom Scale (BNSS) 
(Kirkpatrick et al., 2011), and the more comprehensive Clinical Assessment Interview for 
Negative Symptoms (CAINS) (Forbes et al., 2010, Horan et al., 2011, Kring et al., 2013). Whilst 
the CAINS has since been found to have excellent psychometric properties (Kring et al., 2013), 
the report highlights the need to evaluate the sensitivity of the scale, which is explored in 
chapter 5 of this investigation. 
Other areas for research identified included the need for more research into the prevalence 
and longitudinal course of negative symptoms (which will be examined in chapter 3 of this 
investigation), and determining what improvement in negative symptoms constitutes a 
clinically meaningful effect size improvement. Whilst it has been suggested that a reduction of 
10 to 15 points on the PANSS corresponds to a Clinical Global Impressions (CGI) change of 
“minimally improved” (Leucht et al., 2006), this figure is dependent upon the baseline severity 
of symptoms, and more importantly only corresponds to the PANSS total score, as opposed to 
the PANSS negative subscale alone. In recent work regarding the SANS, a reduction of 
symptoms by 13-21% was found to correspond to “minimally improved” on the CGI, 42-50%  
reduction to “much improved” and 67-90% to “much improved” (Levine and Leucht, 2013).  
 
1.8.1. The ISCTM and NEWMEDS update on clinical trials in negative symptoms 
Following the original NIMH-MATRIC meeting for negative symptoms, two further workshops 
were held, one held by the International Society for Central Nervous System Clinical Trials and 
Methodology, (ISCTM) (Marder et al., 2011), and other held by the Novel methods leading to 
New MEdications in Depression and Schizophrenia collaboration (NEWMEDS) (Marder et al., 
2013).  These updates were deemed necessary for a number of reasons. Firstly, concerns were 
raised that the original 2006 consensus statement (Kirkpatrick et al., 2006) did not include 
sufficient representation from the pharmaceutical industry, which is important given their 
involvement in producing and evaluating new pharmacological treatments for negative 
symptoms. Secondly, there were concerns at the time that the Food and Drug Administration 
(FDA) were considering amending their guidelines, requiring clinical trials of treatments for 
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negative symptoms to include a co-primary outcome measure evaluating functional outcomes. 
Thirdly, it was felt that further consensus regarding trial design would be helpful, particularly 
given the developments in negative symptoms and lessons learnt from recent clinical trials. 
The meeting included individuals from academia, pharmacological industry, and from licensing 
bodies covering both the USA (FDA) and Europe (EMA; the European Medicines Agency). 
During the ISCTN meeting, one the main conclusions that was drawn was the recognition that 
given severe negative symptoms include functional impairment, improvements in negative 
symptoms alone should be deemed sufficient for drug approval. This conclusion therefore 
supports research which focuses on negative symptoms specifically as an outcome for 
research. 
In the ISCTN consensus statement, it was agreed that clinical trials need to be no less than 2 
months, and ideally at least 6 months in duration (not including pre-randomisation). Clinically 
meaningful change was defined as a d=.05, which Cohen described as an effect “visible to the 
naked eye”. Regarding the evaluation of negative symptom severity, the SANS (Andreasen, 
1982), PANSS negative subscale (Kay et al., 1987), and the NSA-16 (Axelrod et al., 1993) were 
all identified as appropriate for use in clinical trials. However, it was noted that the original 
PANSS negative symptom subscale does not provide sufficient coverage of the negative 
construct, which lead to the recommendation that  alternative factor solutions, such as the 
one proposed by Marder and colleagues (Marder et al., 1997), would be preferred (see section 
1.9.1.3.). The promising psychometric properties of the scales developed as a consequence of 
the CANSAS (Blanchard et al., 2011) were noted, and were identified as a potentially 
importance advance in the field. Last point of consensus was that in order to receive approval 
as a treatment for negative symptoms then a global improvement in negative symptoms must 
occur. Therefore, whilst there is evidence to suggest that negative symptoms may consist of at 
least 2 distinct constructs (Blanchard and Cohen, 2006) evaluating negative symptoms as a 
singular construct is still the preferred method in clinical trials. 
During the NEWMEDS meeting there was considerable debate regarding whether negative 
symptoms should be prominent or predominant at the point of recruitment. Predominance 
specifies that the negative symptoms of schizophrenia alone should be present to at least a 
moderate degree of severity, whilst participants who experience prominent negative 
symptoms may also experience other symptoms of schizophrenia, with particular reference to 
positive symptoms. Whilst there was an agreement that participants should present with 
negative symptoms above a minimum degree of severity and a maximum level of EPS and 
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depression, no consensus was reached on whether a maximum positive symptom threshold 
should also be implemented. This is an important issue in the design of clinical trials, and is 
further explored in chapter 4 of this investigation. 
 
1.9. Assessing negative symptoms   
Since positive and negative symptoms of schizophrenia have been identified as distinct 
constructs, a number of scales have been developed to measure the negative symptom 
domain. In the MATRICs consensus statement, the manner in which negative symptoms are 
assessed was recognised as a significant barrier in the development of new treatments 
(Kirkpatrick et al., 2006). 
In this section the scales which are currently used to evaluate the negative symptom construct 
will be summarised. Alternative assessment methods of negative symptoms which utilise self-
report, video, or laboratory assessments of negative symptoms are not included, however 
details of these are available elsewhere (Horan et al., 2006, Kupper et al., 2010). Older 
assessment scales which are no longer adopted in negative symptom research, such as the 
Krawiecka-Manchester Scale (Krawiecka et al., 1977), the Negative Symptom Scale produced 
by Lewine (Lewine et al., 1983), or the Negative Symptom Scale produced by Pogue-Geile and 
Harrow (Pogue-Geile and Harrow, 1985) are also not evaluated. Finally, only tools which 
evaluate the whole negative symptom construct will be summarised, meaning single symptom 
scales such as the Chapman physical and social anhedonia scales (Chapman et al., 1976), the 
Temporal Experience of Pleasure Scale (TEPS) (Gard et al., 2006), and the emotional blunting 
scale (Abrams and Taylor, 1978), have also not been considered.  
In an evaluation of any assessment tool it is important to consider which symptoms are being 
evaluated. This is particularly important in regards to negative symptoms, given the construct 
has undergone a number of substantial revisions over time (see section 1.1.5.). In addition, it is 
important to consider how these scales evaluate the different domains. For example, 
Blanchard and colleagues (Blanchard et al., 2011) suggest that for symptoms such as asociality, 
anhedonia and avolition it is important to evaluate the experiential components of these 
symptoms, rather than just relying on the behavioural aspects. This is because behaviours may 
be influenced by other factors such as finances, housing arrangements, and available support 
from family and friends, unlike an internal drive to action which may better represent core 
pathology. Lastly, dependent upon the nature of the enquiry it may be important to determine 
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the aetiology of symptoms, i.e. determining whether symptoms represent core pathology, or 
whether they are a consequence of other factors such as depression.  
 
1.9.1. Structured interviews of negative symptoms 
1.9.1.1. CGI-SCH: Clinical Global Impressions Scale (schizophrenia version) 
The Clinical Global Impressions scale (Guy, 1976) is a brief, 3-item questionnaire designed to 
evaluate symptom severity, change in symptoms over time, and therapeutic response. Each 
item relates to a global assessment of multiple constructs, rating symptoms, behaviour, and 
the impact of illness on functioning over a set period (typically the past 2 days). The symptom 
severity item is rated on a 7 item scale, ranging from 1 “not at all ill”, to 7 “Amongst the most 
extremely ill patients”. The change items range from 1- “very much improved” to 7- “very 
much worse”. 
In a later adaptation, Haro et al. (Haro et al., 2003) modified the scale to assess positive, 
negative, depressive, and cognitive symptoms of schizophrenia, in addition to providing a 
global assessment of the illness. The scale assesses the severity of the illness over previous 
week, and degree of change relative to the previous assessment. The convergent validity of 
the CGI-SCH with the PANSS was found to be high with the cognitive, negative, positive, and 
global items (ICC= .78, .80, .86 and .75 respectively), and moderate with the depressive item 
(ICC=.61) (Haro et al., 2003). In addition, the inter-rater reliability of the scale was high for the 
cognitive, positive, negative, and global items (ICC range= .73-.82), and moderate for the 
depressive item (ICC=.64).  
Given the scale only measures negative symptoms using a single item it was not identified in 
the MATRICS or ISCTM consensus report as an appropriate primary outcome for use in clinical 
trials for negative symptoms (Kirkpatrick et al., 2006, Marder et al., 2011). In addition, the CGI 
has been criticised for lacking standardised definitions given the scale scoring is framed in the 
context of other patients (Beneke and Rasmus, 1992). One significant advantage of the CGI is 
that it provides a result that translates into an easily interpretable clinical assessment 
(Nierenberg and DeCecco, 2000). Consequently, the scale has been used as a way to provide 
anchor points for measuring how changes in other measures such as the BPRS (Overall and 
Gorham, 1962) and the PANSS (Kay et al., 1987) translate into clinical response (Leucht and 
Engel, 2006, Leucht et al., 2005, Levine et al., 2008, Mortimer, 2007). 
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1.9.1.2 BPRS: Brief Psychiatric Rating Scale 
The Brief Psychiatric Rating Scale (BPRS) was developed by Overall and Gorham (Overall and 
Gorham, 1962) as an assessment tool to evaluate symptom change. The original model 
comprises of 16 items, measuring somatic concern, anxiety, emotional withdrawal, conceptual 
disorganisation, feelings of guilt, tension, mannerisms and posturing, grandiosity, depression, 
hostility, suspiciousness, hallucinations, motor retardation, uncooperativeness, unusual 
thought content, and blunted affect. Each item is rated on a scale of 1 (absent) to 7 (extremely 
severe). Severity is defined both by the frequency of symptoms experienced, and their impact 
on functioning over the past week. Five items are rated based on observations made during 
the interview and information from clinicians and caregivers, whilst 11 are based primarily on 
the verbal report of the interviewee. In an assessment of the item-level rater reliability, 
moderate to high correlations have been detected (r= .56 - .86) (Overall and Rhoades, 1982). 
Since the original model the scale has been expanded to include 18 items, adding 
disorientation and excitement (Overall and Klett, 1972). The scale was then later expanded to 
24 items, adding motor hyperactivity, elevated mood, distractibility, self-neglect, bizarre 
behaviour, and suicidality (Lukoff et al., 1986). Subsequent evaluations of the expanded 
version of the scale found the interview is a sensitive measure with good inter-rater reliability 
(Ventura et al., 1993)  
Whilst the original scale was designed to provide a single summary score, since its inception a 
series of factor analytic studies have been completed with schizophrenia patients which 
suggest the scale comprises of multiple symptom subdomains  (Burger et al., 1997, Dingemans 
et al., 1995, Long and Brekke, 1999, Malla et al., 1993, Mueser et al., 1997, Overall and Beller, 
1984, Ruggeri et al., 2005, Van der Does et al., 1993, Velligan et al., 2005, Ventura et al., 2000). 
A summary of the different factor loadings of the 24-item version of the scale are presented in 
table 2. These studies appear to suggest a 4 or 5 factor solution, covering negative/anergia 
symptoms, positive/psychosis symptoms, anxiety/depressive/affective symptoms, and 
hostility/activation symptoms. For the purposes of this investigation four factor solution 
proposed by Velligan (Velligan et al., 2005) was adopted for two reasons. Firstly, this study was 
completed on a significantly larger sample size than the others (1440 participants), which is 
important given all but the Ruggeri study included less than 200 participants, which has been 
deemed inadequate for factor-analytic studies (Comrey and Lee, 2013). Secondly, in the 
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Velligan study both exploratory and confirmatory factor analysis were conducted, meaning the 
findings are more robust. 
 
Table 2: Different configurations of the 24-Item BPRS-E from different factor analysis studiesa 
BPRS Items 
Study 
(Velligan 
et al., 
2005) 
(Dingemans 
et al., 1995) 
(Van der 
Does et 
al., 
1995) 
(Burger 
et al., 
1997) 
(Ventura 
et al., 
2000) 
(Ruggeri 
et al., 
2005) 
     
    
Somatic Concern 
  
5 5 
 
5 
Anxiety 5 5 5 5 5 5 
Emotional Withdrawal 1 1 1 1 1 1 
Conceptual disorganisation 2 4 4 2  
2 
Guilt 5 5 5 5 5 5 
Tension 4 4 4 4  
5 
Mannerisms and Posturing   
4 4 
 
4 
Grandiosity  
2 
 
2 4 2 
Depression 5 5 5 5 5 5 
Hostility 
  
4 3 4 4 
Suspiciousness  
2 2 3 2 2 
Hallucinations 2 2 2 2 2 2 
Motor retardation 1 1 1 1 1 1 
Uncooperativeness 
 
2 
 
3 
 
4 
Unusual thought content 2 2 2 2 2 2 
Blunted Affect 1 1 1 1 1 1 
Disorientation    
1 2 1 
Excitement 4 4 4 4 4 4 
Motor hyperactivity 4 4 4 4 4 4 
Elevated mood 
  
4 
 
4 4 
Distractibility 
 
4 4 
 
4 4 
Self-neglect 
 
1 1 1 1 4 
Bizarre behaviour 2 2 4 2 2 4 
Suicidality 5 5 5 5 5 5 
              
Factor loadings: 1= Negative / Anergia symptoms, 2= Positive symptoms/ thinking disorder 3= 
Hostility / suspiciousness 4=Excitement/activation symptoms 5= Depression/anxiety / affective 
symptoms 
aHighest factor loadings presented, with those lower than <.4 omitted. 
Grey highlighting indicates the negative symptom construct adopted in chapter 7. 
 
Despite being extensively used in clinical and research settings, the BPRS has a number of 
limitations with regards to negative symptom assessment. One significant issue is that the 
scale does not appear to tap into a number of domains which are considered part of the 
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negative symptom construct, such motivational and anhedonic deficits, as outlined in section 
1.2.3. In addition, whilst the item “emotional withdrawal” is included, it appears to relate 
specifically to how emotionally engaged the participant is during the interview, and so does 
not represent the broader concept of asociality. As a result it has been suggested that the 
BPRS insufficiently evaluates the experiential features of negative symptoms (Blanchard et al., 
2011). This was evident during the development of the Clinical Assessment Interview for 
Negative Symptoms (CAINS) (Kring et al., 2013) which found a moderate correlation between 
the BPRS and expressive symptoms (r=.52), but only a low correlation with experiential 
features of negative symptoms (r=.28). A second issue is that in a comparison to the Negative 
symptom Assessment scale (NSA) (Axelrod et al., 1993), and the Scale to Assess Negative 
Symptoms (SANS) (Andreasen, 1983) the BPRS was found to be a much less sensitive 
instrument in detecting symptom change (d=.32, in comparison to d=.70 and d=.78 for the 
SANS and NSA respectively) (Eckert et al., 1996). This is a significant issue given the lack of 
instrument sensitivity has been identified as one of the major barriers to treatment 
development in negative symptoms (Kirkpatrick et al., 2006). 
 
1.9.1.3 PANSS: Positive and Negative Symptom Scale 
The Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1987) is a structured clinical 
interview designed to measure the symptoms of schizophrenia, and along with the CGI and the 
BPRS is one of the most extensively used assessment tools in the field of schizophrenia 
research (Mortimer, 2007). The PANSS is based on items from the BPRS (Overall and Gorham, 
1962) and the Psychopathology Ratings Scale (Singh and Kay, 1975). In a similar fashion to the 
BPRS (Overall and Gorham, 1962), symptom severity is defined both by the frequency of 
symptoms experienced, and their impact on functioning over the past week The scale is 
composed of 30 items; 7 positive symptom items, 7 negative, and 16 general symptoms which 
include, amongst other things, affective symptoms and cognitive deficits. Each item is rated 
from 1 to 7, giving a range of 7-49 for the positive and negative subscales, and 16-112 for the 
general subscale. Obermeier and colleagues (Obermeier et al., 2010) recommend transforming 
the data to be re-scaled at ratio level (i.e. 1 subtracted from each item so they are scaled from 
0-6), which was completed in chapter 6 in sections where percentage changes were 
considered. However, this was not adopted in other sections given this has not consistently 
been adopted in the literature, meaning it would be harder to interpret any findings from this 
investigation in the context of other studies.  
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An early evaluation of the scale suggested it is possible to achieve high levels of inter-rater 
reliability (ICC>.8) (Kay et al., 1988, Peralta and Cuesta, 1994), which has been since been 
replicated in a series of major trials.  The scale has also been found to have high convergent 
validity to the SANS and the SAPS (Andreasen, 1983, Andreasen, 1984). 
Since the publication of the PANSS, a series of factor analytic studies have suggested that the 
positive, negative and general symptoms subscale structure is not sufficiently stable. Instead, 
the majority of studies appear to support a 5 factor solution comprising of negative, positive, 
disorganised/cognitive, excited, and depression/anxiety symptoms (see table 3 for a 
summary).  
These five domains have been found to be consistent over age, symptom severity, chronicity, 
and in patients both in the chronic and first-episode of the disorder (Emsley et al., 2003). 
However, as indicated in table 3 there has been some disagreement with regards to the 
different items which correspond to each factor. Given the negative symptom construct is the 
principle focus or this investigation, the priority was to adopt the most consistent factor 
solution for this domain. In the 9 studies evaluated (Emsley et al., 2003, Kay and Sevy, 1990, 
Lancon et al., 2000, Lancon et al., 1999, Lindenmayer et al., 1994, Lykouras et al., 2000, Marder 
et al., 1997, Mass et al., 2000, White et al., 1997) there was a consensus that five of the 
original negative items; affective blunting, emotional withdrawal, apathetic social withdrawal, 
poor rapport, and impaired conversation flow all related to the negative symptom construct. 
Of the remaining two, deficits in abstract thinking appeared to correspond to cognitive deficits, 
whilst stereotypical thinking appeared somewhat unstable and was found to relate to positive, 
cognitive, manic-excitement factors, or else did not load onto any factor at all. Instead, the 
general psychopathology items active social avoidance and motor retardation were found to 
consistently load on to the negative factor. Other items, such as preoccupation, disturbance of 
volition, mannerisms and posturing and poor attention were not found to load consistently 
onto negative symptoms and so were not considered. Following the results of these factor 
analytic studies, the 7-item negative subscale comprising of affective blunting, emotional 
withdrawal, apathetic social withdrawal, poor rapport, impaired conversation flow, motor 
retardation and active social avoidance was adopted throughout this investigation. This model, 
whilst proposed by a number of studies (Lancon et al., 2000, Lindenmayer et al., 1994, Marder 
et al., 1997), has been most commonly referred to as the Marder configuration, the term 
adopted in this thesis. 
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Table 3: Different configurations of the PANSS present from factor analytic studies according to highest factor loadingsa 
PANSS Items 
(configured in standard 
factor loadings) 
Study 
Marder 
et al., 
1997 
White 
et al., 
1997 
Linden-
mayer 
et al., 
1994 
Emsley 
et al., 
2003 
Kay & 
Sevy, 
1990 
Lancon 
et al., 
1999 
Lancon 
et al., 
2000 
Mass 
et al., 
2000 
Lykouras 
et al., 
2000 
Negative subscale: 
 
N1: Blunted affect 1 1 1 1 1 1 1 1 1 
 
N2: Emotional 
withdrawal 
1 1 1 1 1 1 1 1 1 
 
N3: Poor rapport 1 1 1 1 1 1 1 1 1 
 
N4: Passive social 
withdrawal 
1 1 1 1 1 1 1 1 1 
 
N5: Difficulty in 
abstract thinking 
3 3 3 3 3 3 3 3 3 
 
N6: Lack of 
spontaneity 
1 1 1 1 1 1 1 1 1 
 
N7: Stereotypical 
thinking 
2 3 4 3 - 4 - - 3 
Positive subscale: 
 
P1: Delusions 2 2 2 2 2 2 2 2 2 
 
P2: Conceptual 
disorganisation 
3 - 3 3 3 3 3 3 3 
 
P3: Hallucinations 2 2 2 2 2 2 2 2 2 
 
P4: Excitation 4 4 4 4 4 4 4 4 4 
 
P5: Grandiosity 2 2 2 2 2 2 2 4 2 
 
P6: Suspiciousness 2 - 2 2 - 2 2 - 2 
 
P7: Hostility 4 4 4 4 4 4 4 4 4 
General Psychopathology subscale: 
 
G1: Somatic concern 2 5 5 5 5 2 - - 4 
 
G2: Anxiety 5 5 5 5 5 5 5 5 5 
 
G3: Guilt Feelings 5 5 5 5 5 5 5 5 5 
 
G4: Tension 5 5 4 5 4 4 4 4 4 
 
G5: Mannerisms 
and posturing 
2 1 3 3 1 2 - 4 1/3 
 
G6: Depression 5 5 5 5 5 5 5 5 5 
 
G7: Motor 
retardation 
1 1 1 1 1 1 1 - 1 
 
G8: 
Uncooperativeness 
4 4 4 4 4 4 - 4 4 
 
G9: Unusual 
thought content 
2 2 2 2 2 2 2 2 2 
 
G10: Disorientation 3 - 3 3 3 3 3 - 3 
 
G11: Poor attention 3 3 3 3 1 3 3 3 3 
 
G12: Lack of 
judgement 
2 - 2 2 2 2 2 - 2/5 
 
G13: Disturbance of 
volition 
3 3 3 1 1 1 - - 1 
 
G14: Impulsivity 4 4 4 4 4 4 4 4 4 
 
G15: Preoccupation 3 3 5 3 5 1 - - 1 
 
G16: Active social 
avoidance 
1 - 1 1 1 1 1 1 1 
Factor loadings: 1= Negative symptoms, 2=Positive symptoms 3: Disorganised/cognitive symptoms 4=Excited symptoms 
5= Anxiety/ depressive symptoms 
aTable adapted from Emsley et al., 2003. Grey highlighting represents the negative symptom construct adopted in this 
investigation 
 
65 
 
Despite the widespread use of the scale, the PANSS has been recognised to have a number of 
limitations in measuring the negative symptom construct (Blanchard et al., 2011). Firstly, it has 
been suggested that the PANSS relies primarily on behavioural referents such as the range and 
frequency of activities, interviewer observations, and reports from family members or carers, 
and insufficiently taps into what the interviewees themselves experience. The problem of 
basing results exclusively on behavioural referents is the fact that other factors such as 
finances, depressive and positive symptoms, lack of social skill (Bellack et al., 1994), and social 
rejection (Corrigan, 2004) may contribute to a lack of social activity, independent of the will to 
engage in such activities. Secondly, by focusing on behavioural referents, the scale may under-
represent deficits in interviewee experiences which has been found constitute a distinct 
construct in negative symptoms (Blanchard and Cohen, 2006).  
1.9.1.4 SANS: Scale for the Assessment of Negative Symptoms  
Unlike the previous tools outlined, the Scale for the Assessment of Negative Symptoms (SANS) 
(Andreasen, 1983) is designed exclusively to measure the negative symptoms of schizophrenia. 
The scale comprises of 30 items covering five domains, with each symptom measured on a 6-
point scale ranging from 0 (none) to 5 (severe). The five domains evaluate affective flattening, 
anhedonia-asociality, alogia, avolition-apathy, and attention rated over the previous month. 
The affective flattening subscale comprises of 9 items, measuring reductions in facial, vocal, 
and gestural expressiveness; a decrease in spontaneous movements; poor eye contact; 
inappropriate affect; affective non-responsivity; and a subjective rating of affective flattening. 
The alogia subscale consists of 6 items, and rates the poverty of the quantity and content of 
speech; increased latency of response; the presence of blocking; and a subjective rating of 
alogia. Avolition-apathy includes 4 items, assessing motivation to address grooming and 
hygiene; vocational pursuits; physical anergia; and a subjective assessment of avolition-apathy. 
The anhedonia-asociality subscale measures deficits relating to interest and pursuit in 
recreational activities; sexual interest and activity; ability to feel intimacy; relationships with 
friends; and a measure of subjective awareness of anhedonia-asociality. The final subscale, 
attentional impairments, measures inattentiveness during work and assessment; in addition to 
a subjective measure of attentiveness deficits.  
In the original study the Interrater reliability of single items (ICC=.701-.926), subscale scores 
(ICC=.860-.925) and the overall summary score (ICC=.838) were all found to be high 
(Andreasen, 1982). In addition, the internal consistency of each of the subscales were all high 
(ɑ=.799 - .844), other than the anhedonia-asociality subscale score (ɑ=.632). In an examination 
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of the correlation of individual items, the subjective assessments were all found to correlate 
relatively poorly to the subscale scores, leading to Andreasen to suggest that these should be 
omitted in calculating the summary ratings.  
One major limitation of the SANS is the fact that some of the symptoms measured are now not 
considered to represent part of the negative symptom construct. For example, the SANS 
subscale “attention” is now considered to evaluate cognitive, rather than negative symptoms 
(Blanchard et al., 2011, Harvey et al., 2006, Milev et al., 2005). Consequently, a number of 
studies using the SANS have removed this subscale (Rabany et al., 2011), supported by 
evidence which suggests that omitting attention improves the internal consistency of the scale 
overall (Peralta et al., 1992b). In addition, a number of individual items have also been found 
to be problematic such as poor eye contact, which does not load on to any factor (Rabany et 
al., 2011), blocking, which is an expression of thought disorder and so therefore a positive 
symptom (Rule, 2005), and poverty of content of speech, which is understood to represent 
symptoms of cognitive impairment (Liddle, 1987). Another significant issue with the SANS is 
the fact that individual subscales can relate to multiple, conceptually distinct domains 
(Blanchard et al., 2011). The anhedonia-asociality subscale can reflect frequency of social 
contacts, interest, experience of pleasure and hostility, meaning it is unclear what 
psychological processes are reflected in the ratings given. Lastly, whilst the scale was designed 
to focus on behavioural referents due to evidence at the time which suggested this is a more 
reliable approach to measuring negative symptoms (Andreasen, 1979), this could also be 
considered somewhat problematic. Conceptually, symptoms such as avolition and asociality 
are defined by internal states, such as ones desire for relationships and contact, whilst the 
behavioural measures of these constructs, (i.e. the amount of friend contacts they have had) 
are representations of these internal states. However, these behaviours can potentially be 
influenced by a number of extrinsic factors such as social skill (Bellack et al., 1990), 
opportunities for social contacts, and the level of support they are given to encourage social 
encounters which do not represent core negative symptoms (Blanchard et al., 2011). 
 
1.9.1.5. NSA: Negative Symptoms Assessment scale 
In its original format the Negative Symptom Assessment scale (NSA) (Alphs et al., 1988) is a 26-
item tool evaluating 5 distinct domains, including impaired communication, disturbed 
affect/emotion, reduced social involvement, reduced motivation, and impaired gross 
cognition. Following a subsequent factor analytic study of the scale a number of minor 
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adjustments were made, including dropping the item “slowed movements”, and splitting the 
impaired communication domain into two distinct clusters, covering impaired communication 
and retardation (Axelrod et al., 1993). The inter-rater reliability and test-retest reliability of the 
scale was found to be excellent (Alphs et al., 1988), whilst the internal consistency was also 
found to be high (ɑ=0.94) (Axelrod et al., 1993). In addition, after only a 30 minute training 
session novice raters were able to complete assessments consistent with expert ratings 
(Axelrod and Alphs, 1993). 
In response to concerns regarding the length of the scale, a shorter 16-item version of the 
scale was devised (Axelrod et al., 1993). In this scale the gross cognition domain was dropped, 
whilst 4 other items were removed due to redundancy. In the alternative 16-item version 
impaired communication was assessed over 4 items, measuring quantity, content, and latency 
of speech. Three items assessed affect/emotion, measuring the range of emotions 
experienced, reduced emotional display, and reduced modulation. Social involvement was 
measured by 3 items assessing social drive, rapport, and sexual interest. Four items are 
included in the motivation domain, covering a reduced sense of purpose, daily activity, hobbies 
and interests, and poor grooming and hygiene. Finally, retardation was measured by 2 items, 
evaluating reduced expressive gestures and slow movements.  
In this amended version of the scale the internal consistency was found to be high (ɑ=.85). In 
addition, the scale was found to have good convergent validity with the PANSS negative 
subscale, and good discriminant validity from scales assessing depression, positive symptoms 
and quality of life (Alphs et al., 2011). In a further shortening of the scale, a 4-item version of 
the NSA was devised, designed for routine clinical use (Alphs et al., 2011). This scale was found 
have good convergent validity with the NSA-16, the PANSS negative subscale, and the Strauss-
Carpenter Level of Functioning scale (Strauss and Carpenter, 1977), in addition good 
discriminant validity from scales assessing depression, positive symptoms and quality of life 
scales. 
As with the PANSS and the BPRS, the NSA has been criticised for not representing what is 
currently understood to constitute the negative symptom construct, in addition to other 
conceptual issues (Blanchard et al., 2011). For example, the item “reduced emotional range” 
can theoretically lead to conflating anhedonic response with a lack of experiences, both 
positive and negative. In addition, this item can also result in the counter-intuitive position 
where people report experiencing more negative experiences at follow-up, relative to 
baseline, which would result in a lower symptom severity score. In addition, the scale also 
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explicitly instructs raters to focus on behaviours, meaning the experiential features of negative 
symptoms are under-represented. 
 
1.9.1.6. CAINS: Clinical Assessment Interview for Negative Symptoms of schizophrenia 
In the 2005 NIMH-MATRICS consensus meeting on negative symptoms of schizophrenia, issues 
regarding current negative symptom assessment scales were identified as a significant barrier 
to the development of new treatments (Kirkpatrick et al., 2006). In recognition of this problem, 
the Collaboration to Advance Negative Symptom Assessment Scales (CANSAS) (Blanchard et 
al., 2011) was established, which in turn developed two assessment scales; the Brief Negative 
Symptom Scale (BNSS) (Kirkpatrick et al., 2011) and the Clinical Assessment Interview for 
Negative Symptoms of Schizophrenia (CAINS) (Forbes et al., 2010, Horan et al., 2011, Kring et 
al., 2013).  
The CANSAS followed a process modelled on the original MATRICS collaboration that 
developed the MCCB for cognitive symptoms (Nuechterlein et al., 2008), which was similar to 
the method outlined by Clark and Watson (Clark and Watson, 1995). Clark and Watson 
emphasised the importance of developing a detailed conception of the construct, and its 
theoretical context, as the first step in the scale development process. In order to achieve this, 
the CANSAS group conducted a series of literature reviews and biweekly conference calls 
between members in order to develop the theoretical concept of the negative symptom 
construct that the scale would be designed to measure. As identified in the MATRICS 
consensus statement, the negative symptom construct was defined to include alogia, blunted 
affect, anhedonia, avolition and asociality (Kirkpatrick et al., 2006), with the possibility that the 
construct comprises of two distinct subdomains of expressive and experiential deficits. How 
these symptoms were evaluated was guided by related current neurobiological models, such 
as the recognition that different hedonic experiences have distinct neural circuits (Berridge 
and Robinson, 1998, Knutson et al., 2001), with negative symptoms related specifically to 
anticipatory pleasure (Gard et al., 2007). In a departure from earlier scales, the decision was 
taken that the interview would aim to evaluate interviewees’ descriptions of their internal 
states, in addition to behaviours and environmental factors. While it was originally considered 
that assessing behavioural rather than internal states may be a more reliable approach to 
measuring negative symptoms (Andreasen, 1979), later work has suggested that the subjective 
experiences of schizophrenia patients can be both reliable and valid (Jaeger et al., 1990, Liddle 
and Barnes, 1988). One significant advantage of assessing internal states is that they are 
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considered to be less influenced by external factors such as finances and input from family and 
carers, meaning this may represent a more accurate measure of core psychopathology 
(Blanchard et al., 2011).  
In the next stage, a pool of initial items for a clinical rating scale were generated, and were 
evaluated by group members, other (unspecified) clinical trial researchers, presented at 
national conferences, and posted to a public website where other academics and researchers 
from industry could provide further feedback. As recommend by Clark and Watson, in the 
initial stages the aim was to be over-inclusive in terms of the number of items, with particular 
attention paid to the wording of the questions presented (Clark and Watson, 1995). Following 
this feedback, a beta version of the scale was produced and validation of the scale was 
performed (Forbes et al., 2010).  
In the initial feasibility study of the CAINS scale by Forbes and colleagues (Forbes et al., 2010), 
a 23-item beta-version of the interview was evaluated. Items were rated on a 7-point scale 
(scored 0-6) with higher scores reflecting greater psychopathology. The scale was designed to 
cover the 5 symptoms of schizophrenia as specified in the MATRICs consensus statement 
review (Kirkpatrick et al., 2006), including avolition (4 items), asociality (3 items), anhedonia (9 
items), alogia (2 items) and blunted affect (5 items). The internal consistency, discriminant 
validity, and convergent validity of the overall scale appeared good. However, relatively poor 
interrater agreement with the avolition (ICC=.53) and alogia (ICC=.48) items, issues with the 
anchoring of the anhedonia items, and low internal consistency in the asociality (ɑ=.32) and 
avolition (ɑ=.47) items called for a significant amendments to the scale. In a revised version, 
outlined by Horan and colleagues (Horan et al., 2011), 16 of 23 items were retained within a 2-
factor solution, with each item rated on a scale of 0-4. The first factor covered experiential 
items, relating to anhedonia, amotivation and asociality, and the second factor expressive 
symptoms, including items relating to alogia and blunted affect. In this second iteration the 
items retained were found to have a better distribution, high interrater agreement, and good 
convergent and discriminant validity (Horan et al., 2011). An assessment of the categories 
using item response theory suggested that most of the anchor points for each item were able 
to provide useful distinctions (particularly with the expressive items), but did identify that 
revisions would be necessary to better demarcate symptom thresholds at lower levels.   
The final development and validation stage was outlined by Kring and colleagues (Kring et al., 
2013). In this iteration, a 13 item scale comprising to two factors, measuring emotional 
experience and expression was proposed. The experiential subscale comprises of nine items, 
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assessing the frequency, motivation and anticipated pleasure in activities and relationships 
around work and school, friends, and the family. The emotional expression subscale consists of 
four items, measuring the vocal and gestural features of expression. The subscales can be 
combined to provide one summary score of negative symptoms, thus adhering to the 
recommendations outlined in the ISCTM consensus statement (Marder et al., 2011). However, 
the authors recommend reporting the scores separately given the evidence suggests they 
appear to be represent distinct constructs (Horan et al., 2011).  
In the final version, the interrater reliability for the experiential and expressive subscales were 
high (ICC=.93 and ICC=.77 respectively). The test-retest reliability of the two subscales also 
demonstrated adequate reliability (ICC=.69), comparable to those found with the negative 
symptom subscale of the PANSS. In an assessment of the convergent validity of the scale, both 
CAINS subscales were positively correlated with the BPRS anergia subscale and the SANS, and 
negatively associated with the desire for close relationships and social engagement. In an 
assessment of the scales discriminant validity, both CAINS subscales were found not to be 
associated with depression, medication side effects, or cognitive impairment. A moderate 
association was detected between the experiential subscale and positive and agitation 
symptoms, however this association was significantly weaker than that detected between 
positive and agitation symptoms and both the SANS and BPRS anergia subscale. 
Despite the extensive validation process which went into the production of the CAINS, it is 
important to note the steps in scale construction which were not adopted. For example, while 
the opinions of a number of clinical and industry experts in the field were sought, this was not 
formalised using a process such as the Delphi technique. The Delphi technique, originally 
developed by the RAND corporation (Dalkey and Helmer, 1963) is a structured, iterative 
process by which to aggregate the opinions of experts in any particular field. Some of the main 
advantages of this process are that it allows a diverse panel of participants to be recruited, it is 
conducted anonymously which can reduce any possible “halo effect” of prominent 
participants, and that controlled, staged  feedback process can reduce any possible effect of 
noise which may distort the data by focusing on individual interests (Hsu and Sandford, 2007). 
As a result, adopting this method may have allowed for a consensus to be reached by 
incorporating a broader range of opinions than may otherwise have been the case.  
Conceptually, the CAINS appears to follow a much closer representation of what we currently 
understand negative symptoms to be, assessing anhedonia, asociality, avolition, alogia and 
blunted affect (Blanchard et al., 2011). However, at present it is not clear if the scale is more 
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sensitive in determining change relative to existing scales such as the SANS, or the PANSS. The 
lack of sensitivity of existing scales has been recognised as significant issue which impedes the 
evaluation new therapeutic interventions designed to treat these symptoms (Kirkpatrick et al., 
2006). In recognition of this current gap in the literature, the relationship between the CAINS 
and the PANSS negative subscale will be explored in greater depth in chapter 5.  
 
1.9.1.7. BNSS: Brief Negative Symptom Scale  
The Brief Negative Symptom Scale (BNSS) (Kirkpatrick et al., 2011) is the second scale 
produced as part of the CANSAS collaboration (Blanchard et al., 2011). Relative to the CAINS, 
the BNSS is a relatively brief instrument designed for routine clinical use, in addition to clinical 
trials. The scale itself consists of 13 items, covering the five domains of alogia, anhedonia, 
avolition, blunted affect and asociality recognised to cover negative symptoms. One of the 
main advantages of this particular scale is that given its brevity, the scale can be completed in 
approximately 15 minutes (Strauss et al., 2012). As with the CAINS, an examination of the 
factor structure of the scale yielded two distinct clusters reflecting expressive and experiential 
symptoms (Strauss et al., 2012).  
In an initial evaluation of the psychometric properties of the scale , the inter-rater reliability of 
the 5 subscales in addition to the global score were found to be high (global score ICC=.96, 
individual subscales ICC=.89 - .95). An assessment of the internal consistency of the scale was 
very high (ɑ=.93), and all items were moderately to highly correlated to the global BNSS score 
(r=.53 - .85), suggesting the scales measures a singular latent construct. The test-retest 
reliability over a period of 2 weeks was also found to be relatively high, both for the total score 
(r=.81), and the subscales (r=.76 – r=.90). In an assessment of the concurrent and discriminant 
validity of the scale, the BNSS was found to be highly correlated with the PANSS negative 
subscale and the SANS (r=.80 and r=.84 respectively), whilst not being correlated with the 
PANSS depression item (r=.14), or cognitive deficits. In a final validation of the scale (Strauss et 
al., 2012) internal consistency, temporal stability, and appropriate convergent and divergent 
validity were high. 
 
72 
 
1.9.2. Pooling negative symptom assessments  
 In this investigation negative symptoms will be measured by a number of different scales. 
Given the constructs evaluated in each scale are slightly different, combining scores evaluating 
individual negative symptoms is not straight forward. One way to pool different items 
measured by the SANS, PANSS and BPRS is the method proposed by Lyne (Lyne et al., 2012) 
(see table 4), which was adopted as part of the investigation completed in chapter 3.  
 
 
 
  
Table 4: How different items over different scales relate to each other* 
SANS PANSS BPRS 
Affective flattening Blunted Affect Blunted Affect 
Alogia Lack of Spontaneity/flow of 
conversation 
- 
Avolition/Apathy Passive social withdrawal Self-Neglect 
Anhedonia-Asociality - - 
   
*Method of combining items proposed by Lyne et al., 2012 
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Chapter 2. Rationale and research questions 
 
2.1. Rationale for investigation 
The negative symptoms of schizophrenia have been found to be largely resistant to current 
pharmacological and psychosocial treatments (Fusar-Poli et al., 2015). This is a significant 
issue, given these symptoms are associated with substantial impairments in functioning 
(Hunter and Barry, 2012). In an attempt to address a lack of progress in treatment 
development there have been considerable efforts to improve our understanding of the 
negative symptom construct, their assessment, and the manner in which clinical trials in this 
area are conducted (Kirkpatrick et al., 2006, Marder et al., 2013, Marder et al., 2011). The aim 
of this thesis will be to address a series of questions which either may inform the design of 
clinical trials, or else builds upon recent advances in negative symptom assessment to revisit 
areas of interest.  
Regarding the longitudinal course of negative symptoms, the evidence suggests that whilst 
secondary negative symptoms improve relatively quickly once the underlying causes are 
addressed, primary negative symptoms are highly stable. A number of observational studies 
and randomised controlled trials have reported differing trajectories in negative symptom 
course, with the heterogeneity likely to be a consequence of factors such as symptom 
antecedents, clinical variables, socio-demographic differences, and variations in the 
methodologies employed. The first aim of this investigation will be to uncover broad trends in 
how these symptoms may change over time in schizophrenia outpatients by pooling studies 
which utilise different treatment options and exploring the impact of factors considered to 
influence symptom course. Such an investigation could potentially be informative to future 
trial design, in addition to clinically relevant. 
Whilst conducting a meta-analysis may be useful in uncovering broader trends of negative 
symptoms over time, methodological limitations mean it it is difficult to determine what 
degree of change is attributable to transient secondary symptoms. In clinical trials there have 
been a number of different methods proposed to limit the variability of negative symptoms 
attributable to secondary sources (Buchanan, 2007, Kirkpatrick et al., 2006, Marder et al., 
2013, Marder et al., 2011). However, at present there does not appear to be a consensus on 
how these criteria  should be implemented, particularly with regards to limiting the impact of 
positive symptoms. There is evidence to suggest that adopting different criteria  can result in 
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large differences in the potential sample pool (Dunayevich et al., 2014, Rabinowitz et al., 
2013), whilst it is unclear whether adopting predominant criteria reduces the impact of 
positive symptoms on negative symptoms (Dunayevich et al., 2014, Stauffer et al., 2012). In 
this investigation a series of study inclusion criteria will be compared to determine their 
impact on the association between negative symptoms, and positive and depressive 
symptoms. Such an investigation may prove helpful in standardising the inclusion criteria used 
in negative symptom trials. 
In the MATRICs consensus statment (Kirkpatrick et al., 2006) the limitations of existing 
negative symptom assessment tools were identified as a significant barrier in the evaluation of 
new treatments. The report from this meeting recommended the development of new 
assessment tools which are both in line with our current conception of the negative symptom 
construct, and are more sensitive to detect symptom change compared to existing scales. This 
led to the development of the CAINS (Horan et al., 2011) which has been found to have 
excellent psychometric properties (Kring et al., 2013). However, at present it is not clear how 
the sensitivity of the CAINS compares with existing negative symptom scales. In this 
investigation the sensitivity of the CAINS will be compared to the PANSS negative subscale, 
both in terms of how the scales differentiate between participants with high and low 
symptoms, and how they measure the change in symptoms over time. In addition, the 
incremental validity of the CAINS will be compared to the PANSS negative subscale to 
determine which scale is a stronger predictor of indicators of social impoverishment. This 
investigation of the CAINS could be considered the important next step in validating the scale 
for use in clinical trials evaluating treatments for negative symptoms. 
Recent developments in our understanding of negative symptoms suggest that expressive and 
experiential deficits represent two distinct constructs (Blanchard and Cohen, 2006). However, 
at present the relationship between these separate subdomains and functional outcomes have 
not been fully explored, possibly due to limitations in earlier scales which have only recently 
been addressed by the development of the CAINS (Blanchard et al., 2011, Kring et al., 2013). 
One such area that may benefit from examining negative symptoms in this manner is 
reviewing the relationship between negative symptoms and quality of life (QOL). 
Whilst a strong inverse relationship between negative symptoms and OQOL has been 
consistently been reported, only weak associations have been detected between negative 
symptoms and SQOL (Fitzgerald et al., 2001). It has been proposed that a weak relationship 
between negative symptoms and SQOL may be attributable to the chronicity of the disorder or 
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peer group comparison (Priebe, 2007). However, another possibility is that the relationship 
may have been previously under-reported by earlier assessment tools insufficiently evaluating 
the experiential features of negative symptoms. In this investigation the relationship between 
SQOL, negative symptoms, and experiential and expressive deficits will be evaluated, both 
cross-sectionally and over time. These relationships will be compared to those reported by 
PANSS negative subscale, which measures negative symptoms as a singular construct.  
In addition to SQOL, other subjective reports from patients such as initial appraisal of inpatient 
treatment are important given they are associated with outcomes long after the patient has 
been discharged (Priebe et al., 2009). Therefore, it is important to understand the impact of 
symptoms on initial appraisal of treatment in the acute phase, regardless of whether they can 
be considered primary or secondary in origin. In this final section of the study the aim will be 
to look at the impact of negative symptoms, in addition to other symptoms, at the point of 
admission to examine their impact on subjective initial appraisal of inpatient treatment.  
 
2.2. Study aims and research questions 
In order to address the above questions, five different investigations were completed. A 
summary of each study is presented below. 
 
2.2.1. Examination of the longitudinal course of negative symptoms in schizophrenia 
outpatients 
To evaluate the course of negative symptoms over time a systematic search will be conducted 
to identify all studies which evaluated negative symptoms over at least two time points in 
schizophrenic outpatient samples. The identified studies will then be pooled together by way 
of meta-analysis to examine trends in negative symptom change over time. Next, a series of 
meta-regressions will be conducted in order to examine the impact of different eligibility 
criteria, study duration, and assessment scales used. In addition to the evaluation of negative 
symptoms as a single construct, individual symptoms were also examined. Finally, planned 
sub-group analyses will be conducted looking at negative symptom change between different 
assessment scales, in addition to studies which specify minimum negative and maximum 
positive and depressive symptoms as part of their eligibility criteria. Given the investigation 
will be exploratory in nature no specific hypothesis will be tested in the main part of the 
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analysis. In the subgroup analyses it is predicted that the SANS will be a more sensitive 
instrument to detect negative symptom change relative to the PANSS, and that a smaller 
change over time will be detected in studies which used criteria which controlled for sources 
or secondary negative symptoms, in comparison to those that did not. 
 
The principle aim of this chapter is to examine whether negative symptoms change over time, 
and if so, how. In order to answer this 4 different questions will be addressed: 
1a)  What is the course of negative symptoms in schizophrenia outpatients?  
1b) Is the change of negative symptoms over time lower in samples that control for 
sources of secondary negative symptoms? 
1c)  Does the SANS report a greater change in negative symptoms, relative to the PANSS 
and the BPRS? 
1d) Is there any variation in the longitudinal course of individual negative symptoms? 
  
2.2.2. Association between positive and depressive symptoms with negative symptoms 
after adopting different symptomatic inclusion criteria: A further consideration 
of the pseudospecificity problem 
In the second part of this investigation the impact of adopting different inclusion criteria in 
clinical trials for negative symptom treatments will be explored. Inclusion criteria identified in 
the systematic review, and those considered by Dunayevich and colleagues (Dunayevich et al., 
2014), will be used to generate different subsamples to assess their impact  on the potential 
sample pool size, and changes in negative symptoms over time. In the second part of the 
analysis a series of longitudinal regressions will be conducted to evaluate the association 
between negative symptoms, and depression and positive symptoms in the different 
subsamples generated. Following earlier findings (Dunayevich et al., 2014, Rabinowitz et al., 
2013) it is hypothesised that increasingly restrictive eligibility criteria would result in a 
substantial reduction in the number of eligible participants. The second part of the analysis is 
exploratory in nature, and so specific hypothesis will be tested.  
77 
 
In this chapter of the thesis, the impact of adopting different symptom inclusion criteria on the 
association between negative, and positive and depressive symptoms will be evaluated. In 
order to answer this question, 3 different areas will be addressed: 
2a) What is the change in negative symptoms over time in stable schizophrenia 
outpatients after excluding participants with prominent positive and depressive 
symptoms?  
2b) What is the impact of adopting different inclusion and exclusion criteria on the 
proportion of eligible participants? 
2c)   What is the impact of adopting different symptom inclusion and exclusion criteria on 
the association between negative symptoms, and positive and depressive symptoms? 
 
2.2.3. Comparing the CAINS and the PANSS; how they relate to indicators of social 
impoverishment 
In this part of the investigation, the first aim will be to assess the convergent validity of the 
CAINS subscales and the PANSS negative subscales, building upon the previous findings which 
have evaluated the relationship of this scale with the BPRS (Kring et al., 2013). The second aim 
will be to assess whether there are any systematic differences in how the CAINS and the PANSS 
capture negative symptoms. This includes a comparison of how the two scales differentiate 
high and low negative symptoms using Tukey-mean difference plots, and a comparison of how 
the scales measure symptom change over time. The third aim will be to examine the 
incremental validity of the CAINS by comparing its predictive ability of objective and subjective 
measures of social impoverishment with the PANSS negative subscale using dominance 
analysis. Negative symptoms relate specifically to deficits in motivation to take part in 
recreational activities and impairments in the quality and quantity of social networks, so the 
scale which better predicts these outcomes is likely to be a better indicator of the negative 
symptom construct. This investigation will test the hypothesis that the CAINS is a more 
sensitive instrument in detecting negative symptom change, and that the experiential subscale 
is a significantly better predictor of indicators of social impoverishment. 
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In an exploration of the relationship between the CAINS and the PANSS negative subscale, 4 
subordinate questions will be addressed: 
 
3a) What is the association between the CAINS and the PANSS negative subscale? 
3b)  Does the CAINS provide a greater differentiation between participants that report high 
and low symptoms, relative to the PANSS negative subscale? 
3c) Is the CAINS more sensitive in detecting symptom change over time, relative to the 
PANSS negative subscale? 
3d) Is the CAINS a better predictor of social outcomes, relative to the PANSS negative 
subscale? 
 
2.2.4. The relationship between negative symptoms and quality of life. 
The aim of this investigation will be to re-evaluate the link between negative symptoms of 
schizophrenia and subjective quality of life, using both the PANSS and the experiential and 
expressive subscales of the CAINS. A series of univariate regression analyses will be conducted 
to examine the relationship between SQOL and expressive and experiential deficits, in addition 
negative symptoms measured by the PANSS, and depressive symptoms measured by the 
Calgary depression scale. This analysis will be conducted both cross-sectionally, and in changes 
over time, with any predictors approaching significance included in a multivariate model. The 
aim of this investigation will be to test the hypothesis that the association between negative 
symptoms and subjective quality of life will relate specifically to experiential deficits, and not 
expressive deficits. In addition, it is hypothesised that this relationship will remain after 
controlling for depressive symptoms. 
In order to explore the association between expressive and experiential features of negative 
symptoms and subjective quality of life, 2 subordinate questions will be addressed: 
 
4a)  What is the cross-sectional association between experiential and expressive deficits 
and subjective quality of life, and how does this compare to an assessment of negative 
symptoms as a single construct using the PANSS negative subscale? 
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4b)  What is the association in changes over time between experiential and expressive 
deficits and subjective quality of life, and how does this compare to an assessment of 
negative symptoms as a single construct using the PANSS subscale? 
 
2.2.5. The Impact of negative symptoms on appraisal of treatment in acute services. 
In the final part of this investigation the relationship between subjective initial appraisal of 
acute inpatient treatment and negative, manic, positive, and affective symptoms will be 
explored. Using a pooled sample from three separate studies, the association between these 
symptoms and the appraisal of treatment will be evaluated in a multivariate regression 
analysis, controlling for various socio-demographic and clinical variables. All symptoms which 
approach significance will then be analysed in a single multivariate model to determine their 
individual impact on treatment appraisal. In the final part of the analysis, the impact of 
individual symptoms will be compared between those who are admitted voluntarily and 
involuntarily. 
In order to evaluate the association between symptoms and the initial appraisal of inpatient 
treatment, 2 subordinate research questions will be addressed: 
 
5a)  What is the association between negative symptoms and initial appraisal of inpatient 
treatment, and how does this compare to other symptoms of schizophrenia? 
5b)  Is the association between symptoms and initial appraisal of treatment different in 
those that were voluntarily and involuntarily admitted? 
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Chapter 3: The longitudinal course of negative symptoms 
 
3.1. Introduction 
Historically, schizophrenia symptoms relating to a deficit in typical human experience were 
believed to increase over time as patients experience a progressive deterioration in 
functioning (Kraepelin, 1971). Such theories were underpinned by the idea that these 
symptoms were attributable to morphological changes in the brain such as lesions, ventricular 
enlargement, or cortical atrophy (Andreasen et al., 1982, Crow, 1980, Crow, 1985, Kraepelin, 
1971). In observational studies which evaluated the progressive course of these symptoms 
however, the evidence suggested that negative symptoms are highly stable, with a slight 
tendency to improve over time in some cases (Dollfus and Petit, 1995b, Eaton et al., 1995, 
Fenton and McGlashan, 1991, Pogue-Geile and Harrow, 1985). Following the distinction 
between primary and secondary negative symptoms (Carpenter et al., 1985) it was suggested 
that secondary symptoms improve relatively quickly once the causes are addressed, whilst 
primary negative symptoms are thought to be highly persistent (Möller, 2007). Initially the 
evidence suggested that these primary negative symptoms may increase over time (Fenton 
and McGlashan, 1994, Kirkpatrick et al., 1996b), however this has since been challenged by a 
longer term follow-up study (Strauss et al., 2010). 
Broadly defined, primary negative symptoms are those that relate to core psychopathology, 
rather than as a consequence of depressive, psychotic or environmental factors. However, 
distinguishing between primary and secondary negative symptoms can be a complex 
undertaking in a research context, given the difficulties in obtaining sufficient historical 
information on the participant and the level of clinical expertise required by the assessors. In 
light of this, Buchanan (Buchanan, 2007) suggested the alternative broader distinction of 
“persistent negative symptoms”, which include negative symptoms which remain persistent 
after treatments for secondary negative symptoms have failed. In the NIMH-MATRICS 
consensus statement for negative symptoms, it was proposed that distinguishing between 
primary and secondary negative symptoms was not essential for the purposes of testing 
therapeutics so long as studies select participants with persistent symptoms and control for 
secondary sources of negative symptoms (Kirkpatrick et al., 2006). This position has since been 
supported by the ISCTM consensus statement (Marder et al., 2011), and adopted by the EMA 
(EMA., 2012). However, to date there appears to be no consensus on how these 
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recommendations should be implemented (Rabinowitz et al., 2013), nor it is clear how these 
criteria impact how these symptoms change over time. Given the current focus on developing 
new interventions for negative symptoms, understanding their longitudinal course may be 
important for future study design, as well as being clinically informative. 
In addition to identifying appropriate participants for clinical trials evaluating treatments for 
negative symptoms, issues around symptom assessment were also recognised as a significant 
issue in the MATRICS consensus statement (Kirkpatrick et al., 2006). As highlighted in section 
1.9., many of the scales designed to measure negative symptoms such as the PANSS (Kay et al., 
1987), SANS (Andreasen, 1983), and NSA-16 (Axelrod et al., 1993) have a number of 
conceptual and methodological problems, and may not be sufficiently sensitive to detect 
clinical meaningful change (Kirkpatrick et al., 2006). The MATRICS report suggests that a multi-
item scale (i.e. the SANS) may be preferable to tools which measure individual symptoms on a 
single item, such as the PANSS and the BPRS (Kirkpatrick et al., 2006). A comparison of the 
change in negative symptoms between trials which adopted different assessment tools would 
allow for a comparison between the sensitivity of these scales. 
The objective of this study was to examine how negative symptoms change over time, whilst 
exploring the impact of various study level factors. By pooling a wide variety of studies by way 
of meta-analysis, the aim was uncover broader trends in how these symptoms may change, as 
opposed to attempting to identify an estimate of effect size for a particular type of treatment, 
as has been done previously (ie. (Jauhar et al., 2014, Leucht et al., 2009a, Wykes et al., 2011). 
Many of the earlier observational studies which examined this question included inpatients, 
which is problematic given this population would typically receive far higher doses of 
antipsychotic medication, experience higher positive symptoms such as paranoid delusions 
(Kasckow et al., 2001), and may potentially be held in an underestimating social environment 
(Oshima et al., 2003), all of which may induce temporary secondary negative symptom. In 
addition, a number of the earlier studies included other illnesses such as schizoaffective 
disorder, which follows a different longitudinal course and can have poorer diagnostic stability, 
potentially influencing the reported change over time (Malhi et al., 2008).  
Following a systematic search, we conducted a meta-analysis of the within-group mean 
changes in negative symptoms. Following the reasons outlined in section 1.1.3., only samples 
comprising exclusively of schizophrenia patients were considered. Due to the expected 
heterogeneity between different interventions, separate effect size estimates were calculated 
for each treatment type. In the next stage, a series of planned meta-regressions were 
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conducted to explore any impact of factors which may lead to secondary negative symptoms 
(Carpenter et al., 1985), and possible sources of methodological bias. Following evidence 
which suggests that alogia and blunted affect may be more stable than other negative 
symptoms (Dollfus and Petit, 1995b, Johnstone et al., 1987, Kelley et al., 1999), the changes in 
individual symptoms were also evaluated. 
In the final part of the analysis, pre-planned sub group analyses were conducted to examine 
the impact of adopting inclusion criteria which specify a minimum level of negative symptoms, 
a maximum level of positive symptoms, and some form of restriction on either depressive 
symptoms or those who qualify for a diagnosis of depression. In doing so, the aim was to 
evaluate whether adopting such criteria reduces the change in negative symptoms course over 
time. Adopting such criteria may result in less change, given the impact of secondary negative 
symptoms should in theory be minimised. However, at present it is not clear whether this 
would be the case. In addition, it is possible that criteria specifying a minimum level of 
negative symptoms may result in a greater reduction through the removal of floor effects and 
a greater degree of regression to the mean. 
 
3.2. Research questions 
In order to answer the principle question “Do negative symptoms change over time and if so, 
how?” 4 subordinate questions were addressed: 
 
1) What is the course of negative symptoms in stable schizophrenia patients over a 
standard study period (i.e. 10 weeks-36 months)?  
2) Is the change of negative symptoms over time lower in samples which attempt to 
control for sources of secondary negative symptoms? 
3) Does the SANS report a greater change in negative symptoms, relative to the PANSS 
and the BPRS? 
4) Is there any variation in the longitudinal course of individual negative symptoms? 
 
3.3. Methods 
3.3.1. Search strategy 
The systematic review was conducted following PRISMA statement guidelines (Liberati et al., 
2009). An electronic search using the MEDLINE, PsycINFO, EMBASE and CENTRAL databases 
83 
 
was conducted dating back to 1962, which was when the Brief Psychiatric Rating Scale (BPRS) 
was first published (Overall and Gorham, 1962). The search was conducted on 26th April 2014 
and contained three parameters. The first related to diagnosis, the second to negative 
symptoms, and the third an indicator that the study took place over at least two time points. 
The terms used for the MEDLINE electronic search are presented in table 5. Minor variations 
were adopted in the PsychINFO, EMBASE and CENTRAL electronic searches, depending upon 
the available search options. The protocol for the search procedure is presented in Appendix 
III. 
 
Table 5: Search terms used for the MEDLINE search 
 1. Disorder  2. Symptoms 3. Treatment /Duration 
*Schizophren$ Negative symptoms Change$ 
Deficit syndrome Reduced affect Effect$ 
 Flattened affect Therap* 
  Blunted affect Intervention /Intervention studies 
  Emotional experience Efficacy 
  Emotional expression Impact 
  Alogia Treatment / *therapeutics 
  Anhedonia Medication 
  Avolition *Longitudinal 
  Asociality *Follow up /*Follow up studies 
 Motor retardation course  
 Amotivation Stability 
 Apathy Time 
  Progress$ 
  Persist$ 
  Year$ */treatment outcome 
   
* denotes an exploded term 
$ denotes an open term 
/ denotes a meshed term 
 
A hand-search of the American Journal of Psychiatry, Acta Scandinavica Psychiatrica, British 
Journal of Psychiatry, Schizophrenia Bulletin, JAMA-Psychiatry, the Lancet, and Schizophrenia 
Research was conducted, either from 1962 or the date of first issue. Reference lists from all 
selected papers were hand-searched. Screening was conducted in three stages. At the first 
stage a title screen was conducted with the aim of removing studies that were clearly not 
relevant (for example, case studies, non-human studies, and those which include non-
psychiatric samples), at the second stage an abstract screen was conducted, and at the third a 
full paper screen was conducted. Twenty percent of the abstract screen was independently 
replicated by a colleague in order to test the reliability of the original screening. At the full 
paper screening stage, two colleagues duplicated 50% of the screening each. All discrepancies 
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were resolved without the need for the lead supervisor to adjudicate as planned. During the 
data extraction phase all assessments of negative symptoms, study inclusion/exclusion criteria, 
demographic details, industry sponsorship, and study methodology details were extracted into 
a piloted extraction sheet (see Appendix IV). When necessary, corresponding authors were 
contacted for further information. In the case of missing standard deviations, a mean from the 
existing sample was imputed when possible. 
 
3.3.2. Eligibility criteria 
During the screening process studies were excluded if they were clearly not relevant, did not 
have repeated assessments of negative symptoms at set time points, included children (<18 
years) or older adults (>65 years), contained no usable data on an exclusively schizophrenic 
sample, were under ten weeks in length, or did not include a follow-up assessment within 3 
years. Studies which included inpatients were considered, so long as the study included one 
time-point where the sample was exclusively outpatients and was then followed up from a 
standardised time-point from this assessment. Symptoms were required to be measured on a 
validated scale. Qualitative studies, case reports, letters to the editor, conference abstracts, 
and book chapters were excluded. In order to aid translation, all articles were required to be 
published in a language which used Latin-based characters. Due to the analytic strategy 
adopted and the risk of small samples leading to biased estimates (Morris, 2000), studies with 
fewer than 50 participants were excluded. 
 
3.3.4. Analysis plan 
In the pooled analysis, the measure of effect size for each study was calculated using the 
standardised mean change (SMC; (Becker, 1988, Morris, 2000). The estimation of the variance 
was calculated using the large-sample approximation method recommended by Becker 
(Becker, 1988) (see figure 1), which has been found to provide reasonably accurate estimates 
provided the sample sizes are adequately sized (Morris, 2000). The estimate of the correlation 
between the baseline and end of study scores was set at 0.633, based upon datasets held at 
our research group (Priebe et al., 2007). In order to test the impact of using this estimate on 
the findings five other figures, ranging from P=.600 and P=.700, were also evaluated as a part 
of a sensitivity analysis. 
85 
 
 
Figure 1: Method used to determine the estimation of the variance. 
 
(Formula taken from Morris, 2000) 
In deciding the appropriate effects model to adopt, the decision was complicated by the 
likelihood that multiple arms of the same study would be separately eligible for inclusion. One 
method of addressing this which was recognised in the Cochrane Handbook (Higgins and 
Green), is to conduct a two-level, fixed-effect meta-analysis across arms within studies, 
followed by a random-effects meta-analysis across studies, as a way to account for the mix in 
fixed and random effects that are likely to be present. However, this model adds considerable 
complexity to the analysis, whilst the handbook itself acknowledges that “in practice the 
difference between different analyses is likely to be trivial” (section 16.5.5). This being the case, 
the method was not used, and the DerSimonion and Laird random effects model was adopted 
(DerSimonian and Laird, 1986). All analysis was completed using STATA version 11 (StataCorp, 
2009). 
In cases where multiple scales were used to measure negative symptoms, the primary 
outcome measure was selected. When negative symptoms were measured over more than 
two time points, only the baseline and the study endpoint data were selected.  
In the first stage of the analysis samples were grouped according to whether the intervention 
involved testing second generation antipsychotics (SGA), first generation antipsychotics (FGA), 
adjunctive medications, non-drug interventions, or placebo/treatment as usual arms. In the 
next stage a series of planned univariate meta-regressions were conducted, with those found 
to approach significance (p<.10) entered into a multivariate model. First, the impact of length 
of treatment was examined in order to assess whether there was any trend over time. Next, 
whether there was any difference between studies which incorporated a minimum negative 
and maximum positive and depressive symptom threshold was tested, compared to those that 
did not, in order to assess whether the degree of change in negative symptoms varied 
dependent upon how studies dealt with factors which can cause secondary negative 
symptoms. Finally, the impact of assessor blinding, a minimum negative symptom inclusion 
criterion, and whether the study received industry sponsorship was examined.  
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In any examination of the change in a continuous variable over time which only includes two 
time points (which is a requirement for meta-analysis) the issue of regression to the mean is an 
important one that must be considered (Chiolero et al., 2013). This being the case, the mean 
negative symptoms at baseline were added to the final multivariate model to determine the 
degree of additional variance which may be explained by a greater reduction in negative 
symptoms being caused by a higher initial level of symptoms. 
 
3.4. Results 
3.4.1. Summary of articles selected 
A flow diagram depicting the search strategy for studies is outlined in figure 2. Of the 9480 
articles screened, 49 eligible articles were found and 41 were included in the final analysis (see 
table 6). From these, a total of 89 separate samples were obtained. Of the 41 studies, five 
came from the USA; four each from Canada, Germany and the UK; three each from India, Spain 
and Turkey; two each from China, France and Italy; and one each from Brazil, Finland, Israel, 
Nepal, Poland and Serbia. Four studies were conducted in multiple countries, with sites in 
Northern America, Europe and Asia. Based on 51 samples, the median of study mean illness 
duration was 12.4 years (range 0.6 - 27.5 years). Twenty three studies measured negative 
symptoms using the Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1987), 14 used 
the Scale to Assess Negative Symptoms (SANS) (Andreasen, 1983), and four used the BPRS 
(Overall and Gorham, 1962). Studies which used alternative scales were screened, but none 
met eligibility criteria. After pooling all 89 samples, a final total of 5,944 participants were 
included in the meta-analysis.  
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Figure 2: Flow diagram outlining study selection procedure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
18309 articles found through 
database search 
497 full articles screened 
81 articles identified from other 
sources  
9885 excluded for not meeting 
inclusion criteria 
49 articles identified 
8 not able to synthesise due to lack 
of data 
 
8008 duplications removed 
10382 titles & abstracts screened 
41 articles included in quantitative 
synthesis 
448 excluded: 
 
197 included inpatients 
92 included schizoaffective/related 
disorders 
75 inadequate measure of negative 
symptoms over 2 time points 
26 insufficient numbers of participants 
22 duplicated data 
16 included patients outside ages 18-65 
9 insufficient study length 
3 study groups defined by outcome 
2 studies reportedly still ongoing 
6 articles not found 
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Table 6: Summary of eligible studies 
Authors Year Country 
Study 
duration 
(weeks) 
Outcome 
measurea 
 
 
Individual 
symptoms 
reported 
Intervention typeb n 
     
 
  
(Addington and 
Addington, 2000) 
2000 Canada 130 PANSS No TAU 65 
(Aguglia et al., 2002) 2007 Italy 52 SANS Yes Non-drug intervention: 
Psychoeducation 
69 
      TAU 66 
(Alptekin et al., 2005) 2005 Turkey 52 BPRS No TAU 382 
(Alvarez et al., 2006) 2006 Spain 48 SANS Yes SGA: Olanzapine 120 
      SGA: Risperidone 115 
(Cirici and Obiols, 2008a) 2008 Spain 46 PANSS Yes Non-drug intervention: 
Skills training group 
35 
      TAU 22 
(Bales et al., 2009) 2009 Nepal 18 PANSS No TAU 30 
      TAU + Betel nuts 30 
(Behere et al., 2011) 2011 India 16 PANSS No Non-drug intervention: 
Yoga group 
34 
      Non-drug intervention: 
Exercise Group 
31 
      TAU 26 
(Bhowmick et al., 2010) 2010 India 12 SANS No SGA: Amisulpride 40 
      SGA: Olanzapine 40 
(Bio and Gattaz, 2011) 2011 Brazil 26 PANSS No TAU 57 
(Bobes et al., 2009) 2009 Spain 34 BPRS No SGA: Risperidone 362 
(Bodkin et al., 2005) 2005 USA 12 SANS Yes Adjunctive: Selegiline 33 
      Placebo 34 
(Crawford et al., 2012a) 2012 UK 52 PANSS No TAU 137 
      Non-drug intervention: 
Activity group 
140 
      Non-drug intervention: Art 
therapy group 
140 
(Fleischhacker et al., 2003) 2003 Multi 52 PANSS No SGA: Risperidone 120 
      SGA: Risperidone 228 
      SGA: Risperidone 267 
(Gaebel et al., 2007) 2007 Germany 52 PANSS No SGA: Risperidone 77 
      FGA: Haloperidol 74 
(Gorna et al., 2008) 2008 Poland 52 PANSS No TAU 88 
(Hirsch et al., 2002) 2002 Germany 28 PANSS No SGA: Ziprasidone 110 
      FGA: Haloperidol 117 
(Kane et al., 2011) 2011 USA 26 PANSS No TAU: Remained on same 
drug 
194 
      Placebo: Switched to 
Placebo 
192 
(Kane et al., 2012) 2012 USA 24 PANSS No Adjunctive: Armodafinil 70 
      Adjunctive: Armodafinil 69 
      Adjunctive: Armodafinil 71 
      Placebo 70 
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(Kaphzan et al., 2014) 2014 Israel 12 PANSS No Placebo 22 
      Adjunctive: Entacapone 23 
(Klingberg et al., 2011) 2011 Germany 52 PANSS Yes Non-drug intervention: 
CBT 
99 
      Non-drug intervention: 
CRT 
99 
(Lasser et al., 2013) 2013 USA 10 SANS No Adjunctive: 
lisdexamfetamine 
dimesylate 
92 
(Lecrubier et al., 2006) 2006 France 26 SANS No Placebo 34 
      SGA: Olanzapine 70 
      SGA: Olanzapine 70 
      SGA: Amisulpride 70 
(Liu et al., 2014) 2014 China 16 PANSS No Placebo 40 
      Adjunctive: Minocycline 39 
(Loebel et al., 2007) 2007 India 64 PANSS No SGA: Ziprasidone 32 
      SGA: Ziprasidone 30 
(Loo et al., 1997) 1997 France 26 SANS Yes Placebo 72 
      SGA: Amisulpride 69 
(Meltzer et al., 2010) 2010 USA 52 BPRS No SGA: Clozapine 40 
      FGA: Various first 
generation drugs 
45 
(Olie et al., 2006) 2006 Multi 12 PANSS No SGA: Ziprasidone 59 
      SGA: Amisulpride 63 
(Pach et al., 1998) 1998 Germany 52 SANS Yes FGA: Flupenthixol 
Decanoate 
63 
(Peet and Horrobin, 2002) 2002 UK 12 PANSS No Placebo 31 
      Adjunctive: 
Eicosapentaenoic acid 
32 
      Adjunctive: 
Eicosapentaenoic acid 
32 
      Adjunctive: 
Eicosapentaenoic acid 
27 
(Purdon et al., 2000) 2000 Canada 54 PANSS No SGA: Olanzapine 21 
      FGA: Haloperidol 23 
      SGA: Risperidone 21 
(Ravanic et al., 2009) 2009 Serbia 52 PANSS No FGA: Haloperidol 70 
      FGA: Haloperidol 35 
      FGA: Chlorpromazine 65 
      FGA: Chlorpromazine 40 
      SGA: Clozapine 65 
      SGA: Clozapine 50 
(Richardson et al., 2007) 2007 UK 38 SANS No TAU 46 
      Non-drug intervention: Art 
therapy group 
43 
(Semiz et al., 2007) 2007 Turkey 12 SANS No SGA: Clozapine 97 
(Schoemaker et al., 2014) 2014 Multi 12 SANS Yes Adjunctive: Org25935 low 
dose 
71 
      Adjunctive: Org25935 high 
dose 
73 
      Placebo 70 
(Sumiyoshi et al., 2007) 2007 USA 26 BPRS No Adjunctive: Buspirone 30 
      TAU 29 
(Taiminen et al., 1997) 1997 Finland 12 PANSS No TAU 39 
      Adjunctive: Citalopram 36 
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3.4.2. Longitudinal course of negative symptoms 
As indicated in the forest plot (see figure 3), in all five intervention types a significant reduction 
in negative symptoms was found between the baseline and follow-up. SGA’s were found to 
result in the greatest reduction (ES 1.09, 95% CI’s 0.86 to 1.32, I2= 95.3%) whilst the smallest 
change was found in placebo/treatment as usual samples (ES 0.33, 95% CI’s 0.16 to 0.50, I2= 
92.1%). Substantial heterogeneity was found, as would be expected given the clinical and 
methodological differences which exist between the studies. In a sensitivity analysis examining 
the impact of different estimates of the correlation between the baseline and end of study 
(Turkington et al., 2008) 2008 UK 78 SANS No Non-drug intervention: 
CBT 
46 
      Non-drug intervention: 
Befriending 
44 
(Ucok et al., 2011) 2011 Turkey 52 SANS No TAU 52 
      TAU 41 
(Voruganti et al., 2007) 2007 Canada 52 PANSS No SGA: Olanzapine 42 
      SGA: Quetiapine 43 
(Xiang et al., 2006) 2006 China 34 PANSS No Non-drug intervention: 
Community re-entry 
48 
      Non-drug intervention: 
Counselling 
48 
(Zoccali et al., 2007) 2007 Italy 24 SANS Yes Adjunctive: Lamotrigine 26 
      Placebo 25 
List of studies not included in the main analysis due to insufficient data  
(Adams et al., 2013) 2013 Multi 24 NSA-16 No SGA: multiple types 130 
      SGA: LY2140023 131 
(Chouinard et al., 1975) 1975 Canada 12 BPRS No Placebo 24 
      FGA: Amitriptyline 
Hydrochloride 
24 
      FGA: Perphenazine 24 
      FGA: Amitriptyline 
Perphenazine 
24 
(Goff et al., 2005) 2005 USA 26 SANS Yes Adjunctive: D-cycloserine 26 
      Placebo 25 
(Hayes et al., 1995) 1995 Australia 44 SANS No Non-drug intervention: 
Skills training group 
n/s 
      Non-drug intervention: 
Discussion group 
n/s 
(Liberman et al., 1998) 1988 USA 156 BPRS No Non-drug intervention: 
Occupational therapy 
n/s 
      Non-drug intervention: 
Skills training group 
n/s 
(Lieberman et al., 2013) 2013 Multi 12 SANS No Adjunctive: TC-5619 94 
      Placebo 91 
(Marder et al., 2003) 2003 USA 104 SANS Yes SGA: Risperidone +  Skills 
training 
33 
      FGA: Haloperidol + Skills 
training 
30 
(Pinto et al., 1979) 1979 UK 78 BPRS No FGA: Flupenthixol 
decanoate 
34 
      FGA: Fluphenazine 
decanoate 
30 
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scores included in the model, minimal differences in the overall effect size was detected (see 
table 7).  
Figure 3: Forest plot of negative symptom change by treatment type 
 
NOTE: Weights are from random effects analysis
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0.49 (0.14, 0.83)
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1.26 (0.95, 1.57)
1.13 (0.75, 1.51)
2.69 (2.03, 3.34)
0.53 (0.31, 0.75)
0.52 (0.30, 0.73)
0.43 (0.21, 0.64)
1.17 (0.71, 1.63)
-0.10 (-0.41, 0.21)
0.93 (0.66, 1.21)
2.04 (1.51, 2.57)
1.91 (1.40, 2.41)
1.08 (0.79, 1.37)
1.22 (0.92, 1.52)
1.04 (0.81, 1.26)
1.39 (1.08, 1.69)
1.03 (0.76, 1.29)
1.27 (0.98, 1.56)
2.50 (2.02, 2.98)
0.56 (0.39, 0.74)
1.04 (0.90, 1.18)
2.39 (2.05, 2.73)
1.97 (1.67, 2.27)
0.44 (0.27, 0.61)
0.23 (0.12, 0.34)
0.40 (0.28, 0.52)
0.03 (-0.16, 0.22)
0.97 (0.67, 1.28)
1.02 (0.75, 1.29)
1.48 (1.07, 1.89)
1.56 (1.15, 1.98)
0.52 (0.11, 0.93)
0.14 (-0.24, 0.52)
0.71 (0.35, 1.06)
1.40 (0.94, 1.85)
0.71 (0.40, 1.02)
1.09 (0.87, 1.32)
0.73 (0.39, 1.07)
0.52 (0.19, 0.86)
0.94 (0.67, 1.21)
0.88 (0.55, 1.21)
0.16 (-0.20, 0.52)
1.28 (0.88, 1.67)
0.24 (-0.08, 0.56)
-0.34 (-0.71, 0.03)
0.48 (0.26, 0.69)
-0.01 (-0.34, 0.33)
0.39 (0.13, 0.64)
-0.41 (-0.54, -0.28)
0.00 (-0.12, 0.12)
1.03 (0.65, 1.41)
1.22 (0.93, 1.50)
-0.08 (-0.39, 0.24)
-0.23 (-0.60, 0.13)
0.03 (-0.17, 0.24)
0.12 (-0.01, 0.25)
-0.05 (-0.25, 0.15)
0.17 (0.02, 0.33)
0.36 (0.15, 0.58)
0.30 (0.06, 0.55)
0.38 (0.11, 0.65)
0.33 (0.16, 0.50)
0.63 (0.27, 1.00)
0.33 (-0.09, 0.76)
0.31 (-0.05, 0.67)
0.38 (0.08, 0.68)
0.42 (0.15, 0.68)
-0.26 (-0.51, -0.01)
-0.19 (-0.59, 0.21)
0.62 (0.39, 0.85)
0.57 (0.38, 0.76)
0.43 (0.25, 0.61)
0.23 (-0.03, 0.49)
0.74 (0.45, 1.03)
0.33 (0.17, 0.49)
0.25 (0.10, 0.41)
0.35 (0.22, 0.48)
0.58 (0.40, 0.75)
0.17 (-0.03, 0.36)
0.37 (0.07, 0.67)
0.33 (0.04, 0.63)
0.28 (0.07, 0.50)
0.38 (0.10, 0.66)
0.62 (0.39, 0.84)
0.24 (-0.20, 0.68)
0.75 (0.45, 1.04)
0.42 (0.29, 0.55)
ES (95% CI)
symptoms increase over time  symptoms reduce over time 
0-1 1 2 3
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Table 7:  Impact of different imputed correlations between T1 and T2 used in the calculation of the 
standardised mean change score 
Ρ Effect size 95% CI’s I2 
.600 0.572 0.462 - 0.681 93.7% 
.625 0.571 0.463 - 0.680 93.9% 
.633* 0.571 0.463 - 0.679 94.0% 
.650 0.571 0.463 - 0.678 94.1% 
.675 0.570 0.464 – 0.677 94.4% 
.700 0.569 0.464 - 0.675 94.6% 
*figure used in the model 
 
In order to explore the heterogeneity between studies a series of meta-regressions were 
conducted. In the univariate analyses the scale used, the intervention type evaluated, the 
study duration, and a minimum threshold of negative symptoms as an inclusion criterion were 
all associated with a larger reduction in negative symptom (see table 8). A maximum level of 
positive symptoms and previous non-response to treatment as exclusion criteria were found to 
approach significance (p<.10), whilst other variables were non-significant. In the multivariate 
model, only the type of scale used and the type of intervention received remained significant. 
Overall, the between-model variance accounted for by the covariates was 43.88%. In a 
sensitivity analysis the sample-level baseline negative symptoms were added to the model 
which was found to be a significant predictor (B= .010, SE=.004, 95% CI’s .002 to .018). 
However, the additional variance explained was relatively small (3.57%). 
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Table 8: Meta-regression exploring impact of clinical and socio-demographic study level factors on variability in 
negative symptom change  
Predictor of negative 
symptom change 
Univariate analysis    Multivariate analysis 
B SE 95% CI's P   B SE 95% CI’s P 
   
  
         Study Duration -0.01 0.00 -0.01  0.00 .035 
 
 0.00 0.00 -0.01  0.00 .421 
Scale used (compared to PANSS) 
    
.002 
      
 
SANS 0.49 0.14  0.21  0.77 
  
 0.43 0.13  0.16  0.70 .002 
 
BPRS -0.12 0.26 -0.63  0.40 
  
-0.07 0.23 -0.54  0.39 .760 
Intervention (compared to SGA) 
    
<.001 
      
 
Non-drug intervention -0.75 0.18 -1.11 -0.38 
  
-0.67 0.19 -1.04 -0.30 .001 
 
TAU/Placebo -0.76 0.16 -1.07 -0.45 
  
-0.73 0.16 -1.06 -0.41 <.001 
 
Drug- FGA -0.68 0.18 -1.10 -0.25 
  
-0.73 0.16 -0.93 -0.12 .011 
 
Drug- Augmentation -0.16 0.18 -0.52 -0.19 
  
-0.21 0.18 -0.57  0.16 .265 
Min negative symptoms  0.37 0.13  0.11  0.63 .007 
 
 0.10 0.12 -0.15  0.35 .413 
Max positive symptoms  0.26 0.14 -0.02  0.54 .071 
 
 0.07 0.13 -0.20  0.33 .608 
Industry sponsorship  0.15 0.14 -0.14  0.43 .309 
      
Exclusion: Prev. non-response   0.42 0.18  0.07  0.78 .019 
 
 0.05 0.17 -0.29  0.40 .765 
Raters blinded to allocationb -0.18 0.15 -0.47  0.12 .234 
      
Exc: mod levels of depression  0.13 0.17 -0.21  0.46 .452             
b One study not included due to lack of data 
 
Although a significant proportion of the studies evaluated extra-pyramidal symptoms (EPS) as 
part of their analysis (53.7%), only three studies specified an EPS maximum threshold as an 
exclusion criterion (Klingberg et al., 2011, Lasser et al., 2013, Schoemaker et al., 2014). Given 
the lack of data, this was not included in the meta-regression analysis. Of those studies that 
did report EPS, they were generally considered to be in the low range at study intake, 
suggesting that the impact of EPS on negative symptoms was likely to be small.  
 
3.4.3. Change in negative symptoms reported by different assessment measures 
In order to examine the impact of the different assessment tools used on negative symptom 
change, studies were grouped by the scale used and the effect sizes were compared. Twenty 
two Studies (56 samples) used the PANSS negative subscale, 15 studies (29 samples) used the 
SANS, and four studies (six samples) used the BPRS anergia subscale. A forest plot depicting 
the different estimates for each of the scales used is presented in figure 4. Studies which used 
the SANS found a significantly greater reduction in negative symptoms relative to those that 
used the PANSS or the BPRS (SANS: ES=1.02, 95% CI’s 0.77 to 1.28; PANSS: ES= 0.66, 95% CI’s 
0.56 to 0.77; BPRS: ES=0.41, 95% CI’s -0.03 to 0.85). 
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Figure 4: Forest plot comparison negative symptom change between different assessment tools used 
 
NOTE: Weights are from random effects analysis
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3.4.4. Comparing control arms between drug and non-drug trials 
The larger effect size improvements in second generation antipsychotics and adjunctive 
medications, relative to other types of treatment, appear to contradict earlier findings which 
suggest minimal advantages of these types of treatments (Leucht et al., 2009b, Tuominen et 
al., 2005). In order to examine whether this reduction over time is a feature of the studies they 
were part of, as opposed to a specific action of the intervention itself, in a post-hoc analysis 
the effect size reductions in control arms of studies which were and were not part of an SGA or 
adjunctive drug study were compared. In total, 12 non- SGA or adjunctive drug study control 
arms and 11 SGA or adjunctive drug study control arms were compared, with the findings 
presented in figure 5. Significantly larger reductions in the control arms of studies which were 
part of an SGA or adjunctive drug study, relative to those control arms which formed part of 
non-drug studies were detected (ES=0.65, 95% CI 0.56 to 0.75, I2=86.9%, in comparison to 
ES=0.15, 95% CI 0.08 to 0.21, I2=60.8%). 
Figure 5: Forest plot comparing the change in second generation antipsychotic drug studies and non-drug study 
control arms. 
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3.4.5. Examination of individual negative symptoms 
In 18 samples over nine studies the change in individual negative symptoms were also 
evaluated, with the results presented in figure 6. In seven studies the individual items were 
rated using the SANS, and in two studies symptoms were rated using the PANSS. Scores from 
different scales were combined using the method proposed by Lyne and colleagues (Lyne et 
al., 2012) (see section 1.9.2.). A significant reduction was found in all four of the symptoms 
measured (blunted affect, alogia, avolition and anhedonia). Of the 4, alogia appeared to 
reduce the least (ES= 0.64, 95% CI’s 0.45 to 0.83, I2= 90.4%) and avolition the most (ES= 0.77, 
95% CI’s 0.53 to 1.01, I2=93.0%), however the difference between the symptoms were 
minimal.  
 
 
 
3.4.6. Comparing those that do and do not adopt criteria in line with the diagnosis 
of persistent negative symptoms 
Twelve samples over five different studies adopted eligiblity criteria which specified a 
minimum level of negative symptoms, a maximum positive symptom eligiblity critierion, and 
some form of restriction on the severity of depressive symptoms. The different studies and the 
criteria they adopted are presented in table 9.  In the comparison of studies which did and did 
not adopt such criteria, a slightly larger reduction in negative symptoms over time was 
detected in patients that did (Criteria adopted ES= 0.85, 95% CI’s 0.56 - 1.08, I2= 90.2%; criteria 
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not adopted ES= 0.63, 95% CI’s 0.51 – 0.75, I2= 94.2%). As clear from the forest plot presented 
in figure 7, the difference between the two groups appeared to be largely attributable to one 
observational study (Lasser et al., 2013). When this study was omitted, the effect size change 
was more similar to those that do not adopt the criteria (ES=0.70, CI’s 0.54 - 0.85, I2= 79.1%)  
Overall, these findings corroborate with the results from the meta-regression (see table 8) 
which together suggest that adopting such criteria does not appear to reduce the reduction in 
negative symptoms over time.  
 
Table 9: Summary of different symptom inclusion/exclusion criteria 
Study Year Scales used Symptom inclusion and exclusion criterion 
     1 Bodkin 2005 SANS, BPRS Inclusion: SANS >12, two subscales >3. Exclusion: ≥5 on the 
BPRS thinking disturbance subscale, mood disorder 
2 Kane 2012 PANSS  Inclusion: ≥15 on the negative subscale. Exclusion: positive 
items ≥4, >10 Calgary 
3 Lasser 2013 SANS Inclusion: >54 on SANS 18, <2 on <1 SANS global score. 
Exclusion: >7 Calgary 
4 Schoemaker 2014 PANSS Inclusion: ≥4 on at least 3 items, ≥21 overall on the 
negative subscale. Exclusion: No more than ≤19 on the 
PANSS positive, <9 Calgary 
5 Klingberg 2011 PANSS Inclusion: At least 1 PANSS negative item ≥4. Exclusion: no 
positive or depressive item ≥6 
 
        
PANSS: Positive and Negative Syndrome Scale; SANS: Scale to Assess Negative Symptoms of Schizophrenia; 
CALGARY: Calgary depression scale for psychosis 
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Figure 7: Comparison of trial arms which did and did not specify a minimum negative and maximum negative and 
depressive symptom criterion. 
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3.4.7. Examination of publication bias 
Publication bias was examined by intervention group using Duval and Tweedie’s ‘trim and fill’ 
method via the STATA metatrim command (Duval and Tweedie, 2000). Possible bias was 
detected in the non-drug intervention group and the adjunctive medication group, suggesting 
a small over-estimation of the effect size. Two imputed studies in the non-drug intervention 
group and one in the adjunctive medication group reduced the effect sizes, but both remained 
significant (Non drug group: ES= 0.27, 95% CI’s 0.12 – 0.41; adjunctive medication group: ES= 
0.58, 95% CI’s 0.38 – 0.79). However, given the fixed effect differences between samples from 
the same study resulted in within-group clustering, it is important to recognise that this 
reported bias is difficult to interpret, and may be an artefact of the study design.  
 
3.4.8. Eligible studies not pooled into the main analysis 
In addition to those pooled, eight studies were found to be eligible but could not be included 
in the main analysis (see table 6). In line with the main results, 11 samples found some form of 
reduction in negative symptoms from baseline to end of study, five saw no change, and in two 
the change was not specified.  
 
3.5. Discussion 
3.5.1. Main findings 
The meta-analysis provided a clear result; negative symptoms of schizophrenia tend to 
improve significantly in an outpatient setting. A reduction in negative symptoms was found 
across all intervention types, with the effect sizes ranging from small to large depending upon 
the intervention type. In addition, a significant reduction was found in all four of the separate 
negative symptoms examined, representing both experiential and expressive features of the 
disorder. Whilst substantial heterogeneity was present in the sample, a series of planned 
meta-regressions indicated that there was no difference in the reduction between studies 
which did and did not exclude participants with at least moderate levels of positive or 
depressive symptoms. In addition, study-level methodological differences such as whether 
assessors were blinded, the symptom eligibility criteria, and whether the study received 
industry sponsorship also did not appear to influence the result. The largest changes in 
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negative symptoms were found in trial arms where participants were randomised to receive 
SGA’s or adjunctive medications. However, in these studies a significantly larger reduction was 
also found in the control arms of studies, suggesting there may be an unspecified feature of 
the trial itself which may drive at least part of this change. In studies which used the SANS 
(Andreasen, 1983) as opposed to the PANSS (Kay et al., 1987) or the BPRS (Overall and 
Gorham, 1962) a significantly larger change in negative symptoms was found, highlighting the 
impact of adopting different methods of negative symptom assessment. 
 
3.5.2. Strengths and limitations. 
One of the main strengths of the study is that, despite the broad range of study interventions 
considered, the findings are consistent. Of the 89 study arms included, only one found a clear 
significant increase in symptoms. In this case, the sample was part of a continuation study 
where patients who had previously responded well to their SGA medication were then 
switched to a placebo (Kane et al., 2011). When testing for the effect of regression to the 
mean, adding baseline negative symptoms to the multivariate model appeared to add 
relatively little additional explanatory power of the variance (3.87%), suggesting the findings 
are relatively robust to this effect. A further strength of this study is that despite the broad 
study inclusion criteria, removing samples which included inpatients at baseline, and other 
psychotic diagnoses, meant the participant inclusion criteria were relatively stringent in 
comparison to other observational studies that have looked at how negative symptoms change 
over time (Dollfus and Petit, 1995b, Eaton et al., 1995, Fenton and McGlashan, 1991, Pogue-
Geile and Harrow, 1985).  
One limitation of the study is that due to the variance estimation method adopted, a number 
of otherwise eligible studies were excluded due to them containing an insufficient number of 
participants (Morris, 2000). However, given there is evidence to suggest that smaller studies 
can often present larger effect sizes (i.e. (Zhang et al., 2013), our findings may have led to a 
more conservative estimate, with the reduction in negative symptoms possibly being even 
more substantial than reported here. Another limitation is that, despite the fairly large number 
of studies included in the analysis (41), the final sample of 5,944 patients was smaller than 
what was originally anticipated. This was due to the fact that a number of the larger studies in 
the field either contained inpatients (Lieberman et al., 2005), used a single item to measure 
negative symptoms rather than a validated scale (Dossenbach et al., 2004), or included 
patients with other psychotic disorders.  
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Another limitation is that due to the study design it is difficult to determine whether the 
changes detected are attributable to an improvement in primary negative symptoms, 
persistent negative symptoms, or secondary symptoms which one would expect to improve 
relatively quickly over time once the causes are addressed. No difference in the change in 
negative symptoms over time was detected between those that did and did not include some 
form eligibility criteria required to determine persistent negative symptoms (i.e. including a 
minimum level of negative symptoms, and a maximum level of positive and depressive 
symptoms in the eligibility criteria; (Buchanan, 2007). Consistent with the results by Stauffer et 
al. (Stauffer et al., 2012), these findings suggest that the change in negative symptoms are the 
same in samples that have attempted to minimise the presence of secondary negative 
symptoms, relative to those that have not. However, examining the change in symptoms 
between studies with very different criteria adopted is not a recognised method to determine 
persistent negative symptoms, and cannot provide any insight related to primary negative 
symptoms (Carpenter and Kirkpatrick, 2015). Consequently, further work is required to 
disentangle the both how primary negative symptoms change over time, and what the impact 
of different predominant inclusion criteria may be. 
Another important consideration is that it is difficult to determine the nature of the change 
detected. In the meta-regression the duration of the study was not found to be a predictor of 
greater negative symptom reduction which suggests that these symptoms do not gradually 
improve over time. This finding is supported by longitudinal studies over very long periods 
which have found that negative symptoms follow a fluctuating course and do not typically lead 
towards recovery (Jääskeläinen et al., 2013, Strauss et al., 2010). One possible reason for the 
detected improvement may be the impact of the participating in multiple assessments. In 
subsequent assessments the interviewee may be more relaxed if a rapport has been previously 
established with the interviewer, and they are likely to have a much better idea of the nature 
of the questions they would be asked. This could potentially lead to participants being more 
expressive in the interview, resulting in a less severe symptom rating.  
It is important to note that given the limitations of the within-group design, the results should 
not be interpreted as an assessment of treatment effectiveness. As highlighted earlier, a series 
of meta-analyses have been conducted to evaluate various treatments for schizophrenia 
(Jauhar et al., 2014, Kurtz and Mueser, 2008, Leucht et al., 2009a, Wykes et al., 2011) using 
between-group designs which offer a more appropriate assessment for treatment 
effectiveness. Overall, these reviews have detected relatively limited benefits for negative 
symptoms, contrasting with the large within-group effect sizes noted here. At least part of this 
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difference could be attributable to the fact that effect sizes in control arms of studies 
evaluating drug treatments appear to be significantly larger in comparison to non-drug studies, 
suggesting there is something inherent to the methodologies employed which makes drug 
studies more likely to detect symptoms improvements.  
Finally, due to the lack of available data, “no-medication” as a therapeutic option could not be 
evaluated, meaning it is not clear whether this reduction over time would also occur in non-
medicated patients. Given there is evidence to suggest that patients who do not immediately 
relapse upon termination of their antipsychotic regimen may experience improved global 
functioning over time (Harrow and Jobe, 2007), it is conceivable that improvements in this 
participant group may be possible also.  
 
3.5.4. Summary 
Based on the available data of almost 6,000 outpatients, negative symptoms of schizophrenia 
do not tend to be stable or deteriorate, but are instead likely to improve over time. This 
finding offers a further critique of the historical understandings of schizophrenia originally 
proposed by Kraepelin and Bleuler, and instead provides further support to the recovery 
model which suggests the functioning of patients with a diagnosis of schizophrenia can 
improve over time (Warner, 2009). Overall, these findings suggest that negative symptoms 
may not be as resistant to change as what has previously been assumed, and perhaps offer 
new hope to those who may experience such symptoms.   
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Chapter 4. Association between negative symptoms and positive 
and depressive symptoms after adopting different study inclusion 
criteria 
 
4.1. Introduction 
In the previous chapter it was found that negative symptoms of schizophrenia appear to 
significantly reduce in stable outpatients, including in samples which exclude patients with 
high depressive and positive symptoms. Whilst conducting a meta-analysis may be helpful in 
understanding broad trends regarding how symptoms may change over time, inherent to the 
study design exists a number of limitations. Most significantly, using heterogenous study-level 
criteria is not a recognised method to control for secondary sources of symptoms (Carpenter 
and Kirkpatrick, 2015), and as such it is unclear to what extent any change in negative 
symptoms detected may be secondary, rather than primary in origin. 
Differentiating between symptoms that are a direct manifestation of the disorder itself, as 
opposed to being a consequence of positive symptoms, depressive symptoms or medication 
side effects is seen as an important issue in the testing of new therapeutics for negative 
symptoms (Kirkpatrick et al., 2006, Marder et al., 2013, Marder et al., 2011). Whilst primary 
negative symptoms of schizophrenia are typically seen as highly enduring, those resulting from 
secondary sources are thought to improve relatively quickly if the causes of these symptoms 
can be addressed (Möller, 2007). Consequently, it is the chronic, persistent negative 
symptoms, as opposed to transient secondary symptoms, which are regarded as an unmet 
therapeutic need (Kirkpatrick et al., 2006). To determine the effectiveness of treatments for 
negative symptoms, it is important to filter out those that would experience improvements 
due to changes in secondary sources of these symptoms.  
Of the different methods proposed to minimise the impact of transient secondary negative 
symptoms, the criteria of persistent negative symptoms (Buchanan, 2007) is advocated by the 
NIMH-MATRICS consensus statement (Kirkpatrick et al., 2006). Persistent negative symptoms 
are defined by the presence of at least a moderate severity of negative symptoms; low positive 
symptoms, depressive symptoms, and EPS; and evidence of clinical stability. The main 
differences between these criteria and the deficit syndrome is that less historical information 
is required (evidence of clinical stability is only recommended  for six months, as opposed 
required for one year), and the distinction between primary and secondary negative symptoms 
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is dropped with maximum limits to depressive, positive and EPS proposed as an alternative. By 
using these criteria it means that persistent negative symptoms can be attributable to 
secondary, as well as primary causes. However, the stability componant ensures that 
symptoms are not transitory in nature, whilst the maximum EPS, positive and depressive 
symptoms should theoretically limit the impact of possible causes of secondary negative 
symptoms. 
While there appears to be a consensus that participants should be excluded from negative 
treatment clinical trials if they are either in the acute phase of the disorder, or present with 
notable EPS or depressive symptoms, there is still some debate regarding whether those that 
present with positive symptoms should also be omitted (Marder et al., 2013). Studies which 
specify maximum positive and minimum negative symptom levels are considered to adopt 
predominent eligiblity criteria, whilst studies which only specify a minimum level of negative 
symptoms are defined are considered to adopt prominent eligiblity criteria. Adopting 
predominent eligiblity criteria can be considered problematic given the association between 
positive and negative symptoms is relatively low (Horan et al., 2011), they have different 
neurobiological origins (Berman et al., 1997), follow different trajectories (Ventura et al., 
2004), and impact functional outcomes independently (Rabinowitz et al., 2012). In addition, 
there are concerns that participants that present with negative, but not positive symptoms 
may only consistitute a relatively small sample of patients, distinct from the broader 
population that such treatments would be designed for. However, by not specifying a 
maximum level of positive symptoms any issues related to the pseudospecificity problem may 
remain. 
Aside from whether it is more appropriate to adopt prominent or predominant symptom 
criteria in negative symptom trials, the issue is further complicated by the fact that there 
appears to be no clear consensus on how these criteria should be operationalised. For 
example,  in the systematic review completed in chapter 3, three of the 41 selected studies 
included contraints on the minimum level of negative symptoms, and eight implimented both 
a minimum negative and maximum positive symptom inclusion criterion (Alvarez et al., 2006, 
Bodkin et al., 2005, Cirici and Obiols, 2008b, Kane et al., 2012, Kaphzan et al., 2014, Klingberg 
et al., 2011, Lasser et al., 2013, Lecrubier et al., 2006, Loo et al., 1997, Olie et al., 2006, 
Schoemaker et al., 2014). The criteria were specified using the PANSS (Kay et al., 1987), SANS 
(Andreasen, 1983), SAPS (Andreasen, 1984), or a mixture of these scales. In all 11 cases 
different inclusion and exclusion criteria were adopted. In a recent study by Dunayevich which 
explored the impact of different inclusion criteria (Dunayevich et al., 2014), a further five 
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different methods which used the PANSS to determine dominance or predominance were 
identified (Kinon et al., 2006, Moller et al., 2004, Rabinowitz et al., 2013, Riedel et al., 2005, 
Stauffer et al., 2012). In all, the 16 studies identified used 16 different ways to determine 
either the prominance or predominence of negative symptoms. Furthermore, it is important to 
note that this is not an exhaustive list, with a literature search suggesting that other major 
trials may have adopted different critiera again (Buchanan et al., 2007, Priebe et al., 2013b).  
Adopting such a broard range of dominant and predominant inclusion criteria in negative 
symptom trials could be considered problematic. Rabinowitz (Rabinowitz et al., 2013) found 
that different symptom inclusion and exclusion criteria were found to result in very large 
differences in the amount of potentially eligible participants, ranging from 8.1%-62.% of the 
pooled sample according to different prominent symptom criteria, and 10.2%-50.2% criteria 
for predominant criteria. These findings have been replicated using the CATIE trial data 
(Lieberman et al., 2005), which found inclusion rates between 6%-37%  (Dunayevich et al., 
2014). These findings suggest that restrictive symptom inclusion criteria can result in a 
substantially smaller potential pool from which potential participants can be recruited from. As 
Dunayevich and Rabinowitz highlight (Dunayevich et al., 2014, Rabinowitz et al., 2013), this is 
likely to result in additional challenges in trial recruitment, and prehaps more concerningly, 
may result in the study samples being less generalisable to the clinical population who such 
treatments may be appropriate for. Dunayevich and colleagues (Dunayevich et al., 2014) found 
that correlations between the changes in negative and positive symptoms were largely 
consistent regardless of the severity of exclusion criteria used, which suggests that more 
restrictive criteria may not reduce the association as much as originally presumed. However, 
Rabinowitz (Rabinowitz et al., 2013) found larger treatment effects for negative symptoms in 
samples that included participants with both prominent negative and positive symptoms, 
relative to samples with predominant negative symptoms. These findings merit further 
consideration as such work may pave the way to appropriately standardising how such criteria 
are adopted in clinical trials. 
The aim of this study was to compare how different eligibility criteria impact the association 
between negative symptoms, and positive and depressive symptoms, whilst considering their 
effect on the potential sample pool. This work builds upon the work by Dunayevich 
(Dunayevich et al., 2014), but with a number of important differences. Firstly, given depressive 
symptoms have been found to both mimic and cause negative symptoms (see section 1.9.1.2. 
for a review), it is important to determine whether different eligibility criteria currently used 
influence the relationship between depressive and negative symptoms. Secondly, in the 
Dunayevich study the presence of blunted affect, avolition and impairments in conversation 
106 
 
flow were required in addition to the symptom levels specified by the different study criteria. 
While this may follow the EMA recommendations for negative symptom trials (EMA., 2012), 
implementing such criteria homogenises the subsamples and makes it difficult to evaluate the 
impact of the criteria which are being evaluated. Third, in the Dunayevich study the standard 
PANSS negative subscale was used, despite concerns that the latter formulation includes items 
which measure cognitive symptoms (Blanchard et al., 2011). In order to address this concern, 
in the present study the alternative negative subscale configuration proposed by Marder was 
adopted (Marder et al., 1997). Finally, Dunayevich adopted the last observation carried 
forward method of as a way of dealing with missing data, which may under-report the degree 
of change over time given the methods assumes responses remain constant (Hamer and 
Simpson, 2009). In this study, multi-level modelling was adopted. 
 
4.2 . Research Questions 
1) What is the change in negative symptoms over time in stable outpatients, after 
excluding participants with prominent positive and depressive symptoms?  
 
2) What is the impact of adopting different inclusion and exclusion criteria on the 
proportion of eligible participants? 
 
3)  What is the impact of adopting different symptom inclusion and exclusion criteria on 
the association between negative symptoms, and positive and depressive symptoms? 
 
4.3. Methods 
4.3.1. Sample 
The data used in this analysis was taken from the DIALOG Study, which is a cluster randomised 
controlled trial designed to evaluate the effectiveness of a computer-mediated intervention to 
structure patient-clinician dialogue (Priebe et al., 2007). The study took place in 6 European 
countries; Granada, Spain; Groningen, The Netherlands; London, United Kingdom; Lund, 
Sweden; Mannheim, Germany; and Zurich, Switzerland.  All participants were community 
psychiatric outpatients, in receipt of at least 3 months of continuous care from the same 
service. All participants were aged 18-65, required to be capable of providing informed 
consent, had a sufficient understanding of the first language from the host country, and were 
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routinely meeting their keyworker every 2 months with the plan of continuing this for the next 
12 months. Participants with either a severe organic psychiatric illness or primary substance 
abuse disorder were excluded. A more detailed description of the intervention is outlined 
elsewhere (Priebe et al., 2007). Various outcome measures, including symptoms were 
measured at baseline and at follow-up 12 months later. In DIALOG study the sample included 
patients diagnosed with schizophrenia-related disorders such as schizoaffective and 
schizophreniform disorders, however for the purposes of this study they were excluded from 
this investigation.  
 
4.3.2. Scales 
Socio-demographic details were obtained using the MANSA (Priebe et al., 1999). Symptoms of 
schizophrenia were measured using the PANSS (Kay et al., 1987), a full summary of which is 
presented in section 1.9.  
Whilst the majority of the original studies which used the PANSS to define their symptom 
inclusion and exclusion criteria used the standard negative subscale formulation, in one case a 
modified version was adopted (Klingberg et al., 2011). One significant limitation of the 
standard PANSS negative subscale is that it includes items which are now recognised to relate 
to cognitive deficits, rather than what we currently understand negative symptoms to 
constitute (Blanchard et al., 2011). Consequently, the PANSS Marder reconfiguration of the 
negative symptom subscale was adopted (Marder et al., 1997). This alternative structure 
replaces the abstract thinking and stereotypical thinking items with motor retardation and 
active social avoidance. In cases where more than 1 item was missing from each subscale, the 
summary score from removed from the analysis. 
 
4.3.3. Prominent and predominant symptom inclusion criteria under evaluation: 
The minimum negative symptom and maximum positive symptom inclusion and exclusion 
criteria evaluated in this study were either identified in the final sample of the systematic 
review completed in chapter 3, or were used in the analysis completed by Dunayevich 
(Dunayevich et al., 2014). Prominent symptom criteria refer to utilising a minimum threshold 
of negative symptoms, whilst predominant symptom criteria refer to utilising both a minimum 
negative symptoms criterion, and a maximum level of positive symptoms. Within these 
criteria, minimum negative symptoms can either be specified by the negative subscale score 
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being above a minimum level threshold, or a particular number of individual negative 
symptoms being above certain level of severity. The positive symptom exclusion criteria can 
either be determined by implementing a maximum threshold for positive symptoms, or else by 
specifying that a measure of negative symptoms be above a measure of positive symptoms by 
a set amount. 
 In this study, a different interpretation of what constitutes prominent and predominant 
criteria was adopted, compared to that used in the Dunayevich investigation. In the 
Dunayevich study, symptom criteria were only defined as “predominant” if maximum PANSS 
positive subscale thresholds were specified below the minimum negative symptoms. In criteria 
where the maximum level of positive symptoms were specified on a single item level, such as 
Möllers (i.e. that no more than two PANSS positive items could be above 4) there would be 
defined as a “prominent” negative symptom criteria. However, while such criteria can result in 
positive symptoms being higher than negative symptoms in theory, in reality this was rare. For 
example, in the subsample of participants eligible according to the criteria defined by Moller, 
no participants were found to have higher positive than negative symptoms.  Given it was 
found that such criteria typically resulted in negative symptoms being predominant, in this 
study they were defined as such. 
In total, 16 different methods to determine prominent or predominant negative symptoms 
were uncovered, the details of which are presented in table 10. All those that used either the 
SANS, SAPS or the BPRS in the inclusion/exclusion criteria were excluded from this analysis, 
leaving a total of 11 different methods (3 prominent and 8 predominant).  
Whilst no measure of EPS was recorded, data regarding the type and dose of medication 
prescribed was available. Using this data as a proxy-measure, the prescribed antipsychotic 
medication dose was transformed into the Defined Daily Dose measure in accordance with the 
WHO Anatomical Therapeutic Chemical Classification ATC/DDD index (WHO, 2013), which has 
been found to be a reliable tool for standardising antipsychotic dosages (Nose et al., 2008). 
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Table 10: Summary of different symptom exclusion criterion adopted in negative symptom trials  
Study Year Scales used Symptom inclusion criterion 
Criteria for prominent negative symptoms 
      
1 * Kinon 2006 PANSS At least three items of the PANSS negative subscale ≥4, 
or at least two ≥5 
2  Alvarez 2006 SANS Baseline SANS >10 
3 * Cirici 2008 PANSS At least three items of the PANSS negative subscale ≥4 
4 * Kaphzan 2014 PANSS  ≥19 PANSS negative subscale score. 
Criteria for predominant negative symptoms 
 
      
5   Bodkin 2005 SANS, BPRS SANS >12, two subscales >3, ≥5 on the BPRS thinking 
disturbance subscale 
6 * Kane 2012 PANSS  ≥15 on the negative subscale, no positive items ≥4  
7   Lasser 2013 SANS >54 on SANS 18, <2 on <1 SANS global score,  
8  Lecrubier 2006 SANS & PANSS negative symptoms:  ≥10 on SANS summary, >4 on any 
PANSS positive symptom item 
9   Loo  1997 SANS & SAPS Inclusion: score of ≥60 on SANS and ≤50 on the SAPS 
10 * Ollie 2006 PANSS PANSS negative subscale ≥6 points over positive 
subscale  
11 * Schoemaker 2014 PANSS ≥4 on at least 3 items, ≥21 overall on the negative 
subscale. No more than ≤19 on the PANSS positive  
12 * Rabinowitz 2013 PANSS PANSS negative subscale > positive subscale  
13 * Moller 2004 PANSS PANSS negative items “Blunted Affect” and 
“Conversation Flow” ≥4, with at least one other ≥4, 
and no more than two positive items ≥4  
14 * Riedal 2005 PANSS PANSS negative subscale ≥21 and ≥1 over the positive 
subscale score  
15 * Stauffer 2012 PANSS At least 3 PANSS negative subscale items ≥4, or at least 
two items ≥5, and a positive subscale score ≤19  
16 * Klingberg 2011 PANSS 1 PANSS negative item ≥4, no positive item ≥6 
 
          
 
* Included in the analysis 
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4.3.4. Analysis plan 
The subsamples were produced by implementing the different prominent and predominant 
criteria specified in table 10, and removing all participants that presented with at least 
moderately severe depressive symptoms (>4 on the PANSS). In the first part of the analysis, 
the change in negative symptoms over time was examined in each of the subsamples using a 
Students repeated-measures t-test. In the second part of the analysis, the association between 
negative, and positive and depressive symptoms were evaluated by using the xtreg command 
in STATA. In the third part of the analysis longitudinal modelling was used to explore the 
association between negative symptoms, and positive and depressive symptoms. PANSS 
Marder negative symptoms scores were included as a dependent variable, nested within 
participants included as a random effect. In the null model only time point was included as a 
covariate. Positive and depressive symptoms where then added to the model, and the change 
in the variance explained was calculated. 
Previous studies in this area suggest that symptom eligibility criteria can result in a substantial 
reduction in the eligible sample pool (Rabinowitz et al., 2013; Dunayevich et al., 2014). With 
regards to the minimum number of participants necessary to provide meaningful estimates in 
a regression model, a number of different thresholds have been proposed. Whilst a number of 
more complex models have been devised (Kelley and Maxwell, 2003), a minimum of 50 
participants was suggested a basic rule of thumb, with more participants needed when 
additional independent variables are added to the model (Green, 1991, Harris, 2014). Based on 
estimates produced by Miles and Shevlin (Miles and Shevlin, 2001), Field (Field, 2009) 
suggested that 40 participants would be a sufficient number when a large effect size is 
predicted and 3 predictors are included in the model (which is the maximum number added in 
this investigation). Following these guidelines, samples with fewer than 40 participants were 
omitted from the final summary. 
 
4.4. Results 
4.4.1. Summary of sample 
In total, 354 participants from the sample were eligible for this investigation, of which data 
were available for 351. The socio-demographic details are presented in table 11. On average, 
participants were 42.1 years old, predominantly male (67.8%), and reported a long history of 
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schizophrenia (mean=16.0 years). Participants had experienced a median of 3 psychiatric 
hospitalisations, and reported a mean defined daily dose of antipsychotic medication of 1.36 
(SD=0.95). Recruitment was split fairly equally between the 6 European countries, with the 
fewest recruited in Zurich (n=41, 11.7%), and the most in London (n=73, 20.8%). 
 
 
Table 11: Demographic details of sample 
 Variables Baseline n=351 
 
  
 Study centre (N, %)   
 
Granada 68 19.4% 
 
Groningen 57 16.2% 
 
London 73 20.8% 
 
Lund 50 14.3% 
 
Mannheim 62 17.7% 
 
Zurich 41 11.7% 
  
  
Socio-demographic details   
 
Age years (mean, SD) 42.1 11.5 
 
Female gender (n, %) 106 32.2% 
 
Illness Duration years (n, SD) 16.0 10.2 
 
Prev. number of admissions (median, IQR) 3 1-6 
 
Defined Daily Dose at baseline* 1.36 0.95 
        
*Equivalents calculated using WHO database estimates. 
 
Of the 351 participants that were included in the study, 310 participants were assessed 12 
months later, resulting in a study retention rate of 88.3%. Any differences in the baseline 
socio-demographic details, symptom scores and retention rates between countries are 
presented in table 12. A significant difference in study retention between research sites was 
detected (χ (5)= 16.3, P=.006). Groningen reported the highest study retention rate (98.2%), 
whilst Granada reported the lowest (77.9%). Significantly more females than males dropped 
out as a proportion of the sample (χ (1)=4.14, P=.042). No other significant differences in 
dropout were detected in either the baseline symptom scores, or the socio-demographic 
information. 
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4.4.2. Baseline and change in symptoms over time 
Mean symptom levels are presented in table 13. Negative symptoms at baseline were in the 
low to moderate-to-moderate range (mean=16.9, SD=7.2), and were slightly lower 12 months 
later (mean difference -1.6, t(309)= 3.93, P<.001). When compared to the results in chapter 3, 
this reduction was found to be slightly smaller than that detected in the control study arms (ES 
change in current study= 0.22, 95% CI 0.13 to 0.32; chapter 3 control arm change= 0.33, 95% CI 
0.16 to 0.50). Depressive (mean=2.6, SD=1.4) and positive (mean=15.3, SD=5.9) symptoms 
were also in the low-to-moderate range, which in both cases were significant lower at follow 
up (positive symptoms: mean difference -0.9, t(308)=2.31, P=.022; depressive symptoms: 
mean difference -0.9, t(309)=2.63, P=.009). 
 
Table 13: symptom levels at baseline and 12 months follow-up whole sample 
Table 12 comparison centre,  baseline sociodemographic, and symptom levels between those that did and did not 
attend the 12-month follow-up 
  
Non-dropouts 
 
Dropouts 
 
P* 
    N Mean SD / %   n  mean  SD / % 
 
           Study site (n, %)         
.006 
 
Granada 53  
77.9% 
 
15 
 
22.1% 
  
 
Groningen 56  
98.2% 
 
1 
 
1.8% 
  
 
London 63  
86.3% 
 
10 
 
13.7% 
  
 
Lund 48  
96.0% 
 
2 
 
4.0% 
  
 
Mannheim 53  
85.5% 
 
9 
 
14.5% 
  
 
Zurich 37  
90.2% 
 
4 
 
9.8% 
  
           Socio-demographic information          
 
Age years (mean, SD) 309 42.1 11.4 
 
41 42 12.2 
 
.929 
 
Female gender (n, %) 310 88 28.4% 
 
41 18 43.9% 
 
.042 
 
Illness Duration years (n, SD) 307 16.1 10.0 
 
41 15.6 12.0 
 
.750 
 
Prev. number of admissions (median, IQR) 303 3.0 1-6 
 
38 2 1-5 
 
.254 
 
DDD at baseline (mean, SD)* 282 1.37 0.95 
 
37 1.31 0.94 
 
.713 
           Symptom scores (mean, SD)          
 
Negative symptom subscale 309 17.1 7.0  
41 16 5.5 
 
.326 
 
Marder negative symptom subscale 309 17.0 7.4  
41 16.4 5.7 
 
.622 
 
Positive symptom subscale 310 15.3 6.0  
41 15.2 5.6 
 
.899 
 
General Psychopathology subscale 310 32.8 10.2  
41 31 8.5 
 
.272 
 
Depression item 310 2.6 1.4  
41 2.6 1.4 
 
.976 
                 
  *DDD=Defined daily dose, Determined through using the students-T, Mann Whitney U test or Chi square, depending 
upon whether the data was recorded as a mean, median or count value 
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  T1   T2 
t P 
  N Mean SD   N Mean SD 
 
         
Marder negative symptom subscale 350 16.9 7.2  
308 15.3 6.4 5.19 <.001 
Positive symptom subscale 351 15.3 5.9  
306 14.6 6.2 2.24 0.025 
General Psychopathology subscale 347 32.6 10.4  
307 30.7 9.8 4.01 <.001 
Depression item 351 2.6 1.4  
310 2.4 1.3 2.58 0.010 
                    
          
 
Prior to implementing the positive and negative symptom criteria, all participants presenting 
with moderately severe depressive symptoms at baseline as measured by a score of at least 5 
on the PANSS depression item were omitted. In this subsample the change in negative 
symptoms over time was marginally lower (mean difference -1.39, SE=0.33), with the majority 
of the sample remaining eligible (91.7%; n=321). 
Having removed all cases presenting with at least moderately severe depressive symptoms at 
baseline, the different prominent and predominant negative symptom eligibility criteria were 
then applied. The mean level of negative symptoms and their change over time in the different 
subsamples are presented in table 14. As would be expected given participants with low 
symptoms were omitted, in the 3 prominent symptom criteria subsamples negative symptoms 
were much higher compared to the whole sample at the baseline stage. In addition, a 
significantly larger reduction in the level of negative symptoms over time was detected in all 
three samples, ranging from a mean difference of -4.29 in the Kaphzan subsample, to -4.94 in 
the Cirici subsample. Of the three different prominent symptom criteria, the method adopted 
by Kaphzan was found to be the least restrictive, with 30.3% (n=104) of the whole sample 
being eligible at baseline. The most restrictive was the criteria adopted by Cirici, where 23.4% 
(n=82) were found to be eligible. 
In the 8 predominant symptom criteria subsamples, the mean level of negative symptoms at 
baseline increased as increasingly restrictive inclusion were adopted, as did the reduction in 
the proportion of eligible participants. In the broadest criteria (adopted by Rabinowitz et al., 
2013), 50.0% (n=175) of the whole sample was eligible, whilst in the most restrictive criteria 
(Moller et al., 2004) only 6.3% (n=23) were eligible. At baseline, the mean negative symptoms 
in the Rabinowitz subsample was 19.88 (SD=6.64), substantially lower than the Moller 
subsample (mean=26.86, SD=5.01). The largest mean reduction in symptoms was present in 
criteria which specified a high minimum negative symptoms subscale score (Riedal et al., 2005; 
Schoemaker et al., 2014). The lowest reduction occurred in criteria which either specified a 
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minimum threshold on single items (Moller et al., 2004; Klingberg et al., 2011) or criteria which 
merely specify predominance, rather than requiring any a minimum degree of negative 
symptom severity (Rabinowitz et al., 2013). 
 
 
4.4.3. Association between negative symptoms, and positive and depressive 
symptoms after adopting different eligibility criteria 
The association between negative symptoms, and positive and depressive symptoms over time 
in the whole sample are presented in table 15. Both positive and depressive symptoms were 
found to be positively associated with negative symptoms, with the covariates explaining 
19.2% of the variance (R2=.192). After removing participants with at least moderate depressive 
symptoms, the association between negative symptoms and depressive symptoms was slightly 
lower but, still remained significant (B=-1.03, 95% CI 0.65 to 1.41). In this subsample, positive 
and depressive symptoms explained 14.9% of the variance (see table 16). Even with the 
Table 14: Change in Marder negative symptoms by the exclusion criteria 
 
  
N at 
T1 
Negative 
symptoms T1  
Negative 
symptoms 
T2 
 
Change scores T2-T1 
    mean SD   Mean SD   mean SE P* 
            
 
All eligible data 350 16.99 7.38 
 
15.35 6.37 
 
-1.64 0.32 <.001 
 
Removing ≥5 depression 321 16.35 7.10 
 
14.96 6.27 
 
-1.39 0.33 <.001 
            Prominent symptoms criterion 
          
 
Kaphzan et al, 2014 criteria 106 24.48 4.72 
 
19.19 6.25 
 
-5.29 0.51 <.001 
 
Kinnon et al., 2006 criteria 84 25.43 4.79 
 
20.12 6.23 
 
-5.31 0.55 <.001 
 
Cirici et al, 2008 criteria 82 25.55 4.78 
 
20.16 6.31 
 
-5.38 0.56 <.001 
            Predominant symptoms criterion 
           Rabinowitz et al., 2013 criteria 175 19.88 6.64 
 
16.65 6.41 
 
-3.23 0.44 <.001 
 Klingberg et al, 2011 criteria 149 20.82 5.86 
 
17.57 6.21 
 
-3.25 0.49 <.001 
 Ollie et al., 2006 criteria 84 23.61 6.07 
 
18.59 6.55 
 
-5.01 0.59 <.001 
 Kane et al, 2012 criteria 71 20.48 4.85 
 
17.08 6.01 
 
-3.40 0.62 <.001 
 Riedal et al., 2005 criteria 70 26.17 4.54 
 
20.02 6.38 
 
-6.15 0.57 <.001 
 Stauffer et al., 2004 criteria 58 24.92 4.65 
 
19.33 6.41 
 
-5.59 0.66 <.001 
 Schoemaker et al, 2014 criteria 48 25.95 4.26 
 
20.02 6.55 
 
-5.93 0.73 <.001 
 
Moller et al., 2004 criteria 23 26.86 5.01 
 
23.00 5.83 
 
-3.86 1.03   .001 
                     
*Calculated by repeated measures t-test 
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inclusion of positive and negative symptoms as covariates, negative symptoms were found to 
significantly reduce over time (B=-1.16, 95% -1.75 to -0.57).  
 
Table 15: Association between positive and depressive symptoms and negative symptoms over time in 
the whole sample 
n=350 
Change over time 
 
Change over time + Covariates 
B 95% CI   B 95% CI 
 
         Cons 18.53 17.42 19.63 
 
10.67 8.92 12.42 
 Timepoint -1.61 -2.22 -1.00 
 
-1.16 -1.75 -0.57 
 Positive symptoms   
   
0.27 0.19 0.35 
 Depressive symptoms   
  
1.26 0.92 1.61 
 
        
Random Part  
       Sigma_u 5.55 5.04 6.11 
 
4.83 4.36 5.35 
 Sigma_e 3.90 3.60 4.22 
 
3.72 3.44 4.03 
 
        
Derived estimates  
       R 
    
.192 
   P 0.67 
   
0.627 
                   
   
Table 16: Association between positive and depressive symptoms and negative symptoms over time 
after removing participants with moderate depressive symptoms  
 
 
Change over time 
 
Change over time + Covariates 
 n=321 B 95% CI   B 95% CI 
 
         Cons 17.6 16.48 18.73 
 
10.93 9.15 12.72 
 Timepoint -1.35 -1.98 -0.72 
 
-1.10 -1.71 -0.49 
 Positive symptoms   
   
0.27 0.18 0.35 
 Depressive symptoms   
  
1.03 0.65 1.41 
 
        
Random Part  
       Sigma_u 5.28 4.77 5.85 
 
4.75 4.27 5.29 
 Sigma_e 3.87 3.57 4.20 
 
3.73 3.44 4.05 
 
        
Derived estimates  
       R 
    
.149 
   P 0.651 
   
0.619 
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4.4.4. Prominent negative symptom inclusion criteria: 
The association between negative symptoms, and positive and depressive symptoms over time 
in the subsamples which adopted prominent negative symptoms criteria are presented in 
tables 17 to 19. In all three cases, a substantial reduction in the association between negative 
symptoms and the covariates was detected, with only 8.1% (R2=0.81) of the variance explained 
in the Kaphzan subsample, and 11.7% (R2=0.81) in the Cirici subsample. This weaker 
association appears to be primarily attributable to a much weaker relationship between 
negative symptoms and depressive symptoms, which was no longer found to be significant in 
any of the three subsamples. 
 
Table 17: Association between positive and depressive symptoms and negative symptoms over time 
after adopting the Kaphzan eligibility criteria  
 
 
Change over time 
 
Change over time + Covariates 
 n=106 B 95% CI   B 95% CI 
 
         Cons 29.33 27.65 31.02  
24.24 21.47 27.02 
 Timepoint -5.16 -6.13 -4.20  
-4.93 -5.86 -3.99 
 Positive symptoms      
0.21 0.10 0.33 
 Depressive symptoms     
0.46 -0.11 1.03 
 
 
       
Random Part        
 Sigma_u 4.15 3.43 5.01  
4.00 3.31 4.84 
 Sigma_e 3.46 3.01 3.98  
3.29 2.86 3.79 
 
 
       
Derived estimates        
 R     
.081 
  
 P 0.590    
0.596 
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Table 18: Association between positive and depressive symptoms and negative symptoms over time 
after adopting the Kinnon eligibility criteria 
 
 
Change over time 
 
Change over time + Covariates 
 n=84 B 95% CI   B 95% CI 
 
         Cons 30.32 28.45 32.19 
 
24.78 21.79 27.77 
 Timepoint -5.19 -6.26 -4.13 
 
-4.99 -6.01 -3.98 
 Positive symptoms   
   
0.23 0.11 0.36 
 Depressive symptoms   
  
0.54 -0.09 1.17 
 
        
Derived estimates  
       Sigma_u 4.22 3.44 5.20 
 
4.01 3.24 4.97 
 Sigma_e 3.39 2.9 3.97 
 
3.20 2.72 3.76 
 
        
Derived estimates  
       R 
    
.098 
   P 0.608 
   
0.612 
                   
 
Table 19: Association between positive and depressive symptoms and negative symptoms over time 
after adopting the Cirici eligibility criteria 
 
 
Change over time 
 
Change over time + Covariates 
 n=82 B 95% CI   B 95% CI 
 
         Cons 30.60 28.69 32.51 
 
24.77 21.73 27.81 
 Timepoint -5.29 -6.37 -4.21 
 
-5.05 -6.08 -4.01 
 Positive symptoms   
   
0.25 0.12 0.37 
 Depressive symptoms   
  
0.57 -0.07 1.2 
 
        Random Part  
       Sigma_u 4.26 3.46 5.25 
 
4.00 3.22 4.96 
 Sigma_e 3.40 2.90 3.98 
 
3.20 2.72 3.76 
 
        Derived estimates  
       R 
    
.117 
   P 0.611 
   
0.609 
                   
 
4.4.5. Predominant negative symptom exclusion criteria 
The association between negative symptoms, and positive and depressive symptoms over time 
in the subsamples which adopted predominant negative symptoms criteria are presented in 
tables 20 to 27. Substantial differences in the association between the covariates and negative 
symptoms were found, depending upon the method employed.  
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In subsamples obtained by using criteria which determined predominance as negative 
symptoms being higher than positive symptoms by a specified amount (Ollie et al., 2006; 
Rabinowitz et al., 2013), the association between the covariates was found to be much higher 
than in the other subsamples (Rabinowitz criteria R2=.339; Ollie criteria R2=.333). This stronger 
relationship between the covariates and negative symptoms appears to be driven primarily 
between a greater association between positive and negative symptoms (Rabinowitz 
subsample: Positive symptoms B=0.60; 95% CI 0.48 to 0.71; Ollie subsample: positive 
symptoms B=0.54; 95% CI 0.39 to 0.69). 
 
Table 20: Association between positive and depressive symptoms and negative symptoms over time 
after adopting the Rabinowitz eligibility criteria 
 
 
Change over time 
 
Change over time + Covariates 
 n=175 B 95% CI   B 95% CI 
 
         Cons 22.83 21.32 24.34 
 
13.48 11.42 15.54 
 Timepoint -3.16 -4.01 -2.31 
 
-3.32 -4.08 -2.56 
 Positive symptoms   
   
0.60 0.48 0.71 
 Depressive symptoms   
  
0.76 0.30 1.21 
 
        Random Part  
       Sigma_u 5.07 4.40 5.83 
 
3.87 3.31 4.52 
 Sigma_e 3.87 3.46 4.32 
 
3.45 3.09 3.86 
 
        Derived estimates  
       R 
    
.339 
   P 0.632 
   
0.557 
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Table 21: Association between positive and depressive symptoms and negative symptoms over time 
after adopting the Ollie eligibility criteria 
 
 
Change over time 
 
Change over time + Covariates 
 n=84 B 95% CI   B 95% CI 
 
         Cons 27.96 25.93 29.98 
 
20.25 17.55 22.95 
 Timepoint -4.85 -5.98 -3.72 
 
-5.13 -6.13 4.13 
 Positive symptoms   
   
0.54 0.39 0.69 
 Depressive symptoms   
  
0.62 0.00 1.23 
 
        Random Part  
       Sigma_u 5.02 4.13 6.10 
 
3.93 3.18 4.87 
 Sigma_e 3.49 2.97 4.10 
 
3.08 2.61 3.63 
 
        Derived estimates  
       R 
    
.333 
   P 0.674 
   
0.620 
                   
 
In subsamples which were determined by separate minimum negative and maximum positive 
thresholds the findings are presented in tables 22 to 26. Across all five criteria, the association 
between the covariates and negative symptoms were found to be broadly similar, comparable 
to those detected in the prominent criteria samples. The smallest association between was in 
the Schoemaker subsample (R2=.080), while the largest association was detected in the Riedal 
subsample (R2=.153). Consistent with the findings derived from the prominent negative 
symptom subsamples, including positive and depressive symptoms as covariates did not 
significantly reduce the change in negative symptoms over time in any of the five predominant 
subsamples. 
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Table 22: Association between positive and depressive symptoms and negative symptoms over time 
after adopting the Klingberg eligibility criteria 
 
 
Change over time 
 
Change over time + Covariates 
 n=149 B 95% CI   B 95% CI 
 
         Cons 23.67 22.06 25.28 
 
17.24 14.68 19.79 
 Timepoint -3.13 -4.07 -2.19 
 
-2.99 -3.87 -2.1 
 Positive symptoms   
   
0.30 0.17 0.42 
 Depressive symptoms   
  
0.73 0.18 1.27 
 
        Random Part  
       Sigma_u 4.4 3.72 5.20 
 
4.23 3.59 5.01 
 Sigma_e 3.94 3.49 4.44 
 
3.65 3.24 4.13 
 
        Derived estimates  
       R 
    
.105 
   P 0.555 
   
0.574 
                   
 
 
Table 23: Association between positive and depressive symptoms and negative symptoms over time 
after adopting the Kane eligibility criteria 
 
 
Change over time 
 
Change over time + Covariates 
 n=71 B 95% CI   B 95% CI 
 
         Cons 23.6 21.56 25.63 
 
18.82 15.92 21.73 
 Timepoint -3.32 -4.49 -2.14 
 
-3.71 -4.81 -2.62 
 Positive symptoms   
   
0.32 0.14 0.51 
 Depressive symptoms   
  
0.68 -0.03 1.39 
 
        Random Part  
       Sigma_u 4.01 3.18 5.07 
 
3.95 3.16 4.95 
 Sigma_e 3.41 2.87 4.05 
 
3.11 2.62 3.7 
 
        Derived estimates  
       R 
    
.088 
   P 0.580 
   
0.618 
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Table 24: Association between positive and depressive symptoms and negative symptoms over time 
after adopting the Riedal eligibility criteria 
 
 
Change over time 
 
Change over time + Covariates 
 n=70 B 95% CI   B 95% CI 
 
         Cons 32.06 30.08 34.03 
 
24.6 21.57 27.63 
 Timepoint -6.08 -7.18 -4.99 
 
-5.89 -6.82 -4.95 
 Positive symptoms   
   
0.38 0.23 0.52 
 Depressive symptoms   
  
0.51 -0.10 1.13 
 
        Random Part  
       Sigma_u 4.36 3.51 5.41 
 
4.17 3.39 5.14 
 Sigma_e 3.19 2.69 3.78 
 
2.71 2.28 3.23 
 
        Derived estimates  
       R 
    
.153 
   P 0.651 
   
0.702 
                   
 
 
Table 25: Association between positive and depressive symptoms and negative symptoms over time after 
adopting the Stauffer eligibility criteria 
 
 
Change over time 
 
Change over time + Covariates 
 n=58 B 95% CI   B 95% CI 
 
         Cons 30.08 27.86 32.29 
 
23.78 20.51 27.06 
 Timepoint -5.47 -6.72 -4.22 
 
-5.51 -6.58 -4.43 
 Positive symptoms   
   
0.36 0.20 0.53 
 Depressive symptoms   
  
0.60 -0.17 1.36 
 
        Random Part  
       Sigma_u 4.30 3.37 5.48 
 
4.35 3.45 5.48 
 Sigma_e 3.26 2.69 3.94 
 
2.76 2.27 3.37 
 
        Derived estimates  
       R 
    
.089 
   P 0.635 
   
0.712 
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Table 26: Association between positive and depressive symptoms and negative symptoms over time after 
adopting the Schoemaker eligibility criteria 
 
 
Change over time 
 
Change over time + Covariates 
 n=48 B 95% CI   B 95% CI 
 
         Cons 31.52 29.08 33.95 
 
24.39 20.53 28.26 
 Timepoint -5.83 -7.21 -4.44 
 
-5.62 -6.81 -4.42 
 Positive symptoms   
   
0.42 0.21 0.62 
 Depressive symptoms   
  
0.50 -0.34 1.35 
 
        Random Part  
       Sigma_u 4.17 3.18 5.48 
 
4.27 3.31 5.51 
 Sigma_e 3.3 2.68 4.07 
 
2.79 2.25 3.46 
 
        Derived estimates  
       R 
    
.080 
   P 0.614 
   
.701 
                  
 
In the final predominant criteria adopted by Moller the association between negative 
symptoms and the covariates was found to be very small (R2=0.48, see table 27). However, due 
to the very small sample size (n=23) this analysis was omitted from the final summary due to 
concerns that the estimates were not sufficiently stable. In an examination for possible outliers 
(see figure 8) two estimates in particular (denoted by the red circles) were found to have a 
disproportionate impact on the association between positive and negative symptoms. When 
these were removed, the association between negative symptoms and the covariates was 
found to be substantially larger (R2=.192, in comparison to R2=.048), which further supported 
the decision to omit these findings. 
A summary of the associations between the covariates and negative symptoms over the 11 
different subsamples are presented in table 28.               
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Table 27: Association between positive and depressive symptoms and negative symptoms over time after 
adopting the Moller eligibility criteria 
 
 
Change over time 
 
Change over time + Covariates 
 n=23 B 95% CI   B 95% CI 
 
         Cons 30.19 26.73 33.65 
 
26.73 21.89 31.58 
 Timepoint -3.71 -5.67 -1.76 
 
-4.38 -6.25 -2.52 
 Positive symptoms   
   
0.21 -0.01 0.42 
 Depressive symptoms   
  
0.59 -0.59 1.77 
 
        Random Part  
       Sigma_u 4.11 2.77 6.10 
 
4.17 2.85 6.11 
 Sigma_e 3.26 2.41 4.40 
 
2.97 2.19 4.02 
 
        Derived estimates  
       R 
    
.048 
   P 0.614 
   
0.664 
                   
 
Figure 8: Scatterplot of positive and negative symptoms that participants experience in the 
Moller subsample.a 
 
acircles denote outliers. 
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Table 28: Association of depressive and positive symptoms to 
negative symptoms, after controlling for covariates 
Eligibility criteria N R2 
    
 
All eligible data 350 .192 
 
Removing ≥5 depression 321 .149 
    Prominent negative criteria 
 
Kaphzan et al, 2014 criteria 106 .081 
 
Kinnon et al., 2006 criteria 84 .098 
 
Cirici et al, 2008 criteria 82 .117 
    Predominant negative criteria 
 
Rabinowitz et al., 2013 criteria 175 .339 
 
Klingberg et al, 2011 criteria 149 .105 
 
Ollie et al., 2006 criteria 84 .333 
 
Kane et al, 2012 criteria 71 .088 
 
Riedal et al., 2005 criteria 70 .153 
 
Stauffer et al., 2004 criteria 58 .089 
 
Schoemaker et al, 2014 criteria 48 .081 
 Moller et al., criteria 23 ― 
        
 
 
4.5. Discussion 
4.5.1. Main findings 
Consistent with the findings presented in chapter 3, significant reductions in negative 
symptoms over time were detected even after different minimum negative and maximum 
depressive and positive symptom inclusion criteria were implemented on the overall sample. 
This reduction in negative symptoms over time was substantially larger in subsamples which 
resulted in higher mean negative symptoms at baseline. 
Excluding participants who present with at least moderately severe depressive symptoms and 
low negative symptoms resulted in a weaker association between depressive and negative 
symptoms. However, implementing a maximum positive symptom criterion did not appear to 
reduce the association between positive and negative symptoms, and in some cases even 
increased it. Adopting increasingly restrictive eligibility criteria substantially reduced the 
amount of eligible participants in a standard outpatient sample pool, but appeared to have a 
minimal effect on the association between these variables. These findings suggest that whilst 
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adopting such eligibility criteria may be effective in reducing the association between negative 
and depressive symptoms, it may not be an effective method to reduce the impact of positive 
symptoms on negative symptoms.  
 
4.5.2. Strengths and limitations 
One strength of this study is the relatively high number of different criteria evaluated (11), and 
the consistency of the findings between them which suggests the findings are relatively robust. 
Another strength of the study is the fact the sample evaluated had high follow up rates over a 
period of 12 months (88.3%), minimising a possible selection bias due to attrition. In addition, 
longitudinal modelling was adopted which allows for a more appropriate way to deal with any 
missing data, relative to other methods such as LOCF which was adopted by earlier studies 
(Dunayevich et al., 2014). 
Another strength of the study is the fact that the sample was obtained from a non-
pharmacological trial evaluating a treatment which was designed to improve quality of life, as 
opposed to clinical symptoms (Priebe et al., 2007). Consequently, participants were not 
randomised to receive a drug which may either significantly alter positive symptoms, or else 
result in side effects that can either mimic or exacerbate negative symptoms. In the Rabinowitz 
study (Rabinowitz et al., 2013), the sample was obtained from pooling a number of 
pharmacological studies all designed to treatment the symptoms of schizophrenia. In the 
CATIE study (Lieberman et al., 2005) which was the sample used by Dunayevich (Dunayevich et 
al., 2014), 5% of participants discontinued the randomised treatment due to side effects, 
whilst it is unclear what proportion experienced side effects but still continued with the 
medication. In both cases, changes in positive symptoms and extrapyramidal symptoms would 
be expected to be higher than in the sample used in this study which may present additional 
challenges in disentangling the antecedents of negative symptoms.  
One significant limitation of the study is that despite the relatively large initial sample size 
(n=350), adopting increasingly restrictive inclusion criteria resulted in a substantial loss of 
participants. Consequently, in the smallest sample obtained by implementing the criteria 
proposed by Möller (Moller et al., 2004) there were an insufficient number of participants 
upon which to establish reliable estimates. In addition, the low number of participants in a 
number of the subsamples meant that comparisons could not be drawn between groups when 
the R2 values were similar. Consequently, whilst this study concludes that adopting increasingly 
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restrictive inclusion criteria do not result in further changes in the association between 
negative symptoms and positive and depressive symptoms, small differences may become 
evident if the study was replicated in a far larger sample. However, this may not necessarily be 
informative in deciding what inclusion criteria to adopt if a small decrease in the association 
between negative and positive symptoms comes at the cost of a substantial reduction in the 
pool of potentially eligible participants, which is what this and earlier studies suggest 
(Dunayevich et al., 2014, Rabinowitz et al., 2013). 
Another possible limitation is that in the sample used clinical stability was defined as being an 
outpatient under the care of the same clinical team for at least three months. In both the EMA 
guidelines (EMA., 2012) and the persistent negative symptoms criteria (Buchanan, 2007) it is 
recommended that participants should exhibit clinical stability for six months. As a result, the 
shorter period of clinical stability required could have potentially impacted the findings. 
However, in this study participants typically had a very long illness duration (mean 16 years, 
SD=10.2) and all reported being in the same outpatient service for at least one year. As a 
result, it is highly unlikely that adopting the recommended 6 month clinical stability criteria 
would have substantially altered the sample. 
In this study, it is important to consider that all participants were considered stable 
outpatients, with the mean severity of symptoms at baseline low. As a result, it is not clear 
whether the eligibility criteria evaluated may have a greater impact in inpatients, or in samples 
which present with higher positive symptoms. However, there is a general consensus that 
patients in the acute phase of schizophrenia are not appropriate participants for negative 
symptom clinical trials (Marder et al., 2013). In addition, if the aim is to recruit such 
participants then it is likely that an even smaller proportion of participants would be eligible, 
further exacerbating issues regarding recruitment and sample generalisability.  
The final limitation of the study is that EPS were not assessed, and so were not included in the 
analysis. As outlined in section 1.3.1.2., EPS such as bradykinesia and akinesia can mimic 
negative symptoms such as blunted affect, so it is possible that at least some of the symptoms 
reported may be a consequence of medication effects, rather than core psychopathology. In 
this study the defined daily dose of antipsychotic medication in the sample was relatively high 
(mean DDD=1.37, SD=0.95), which may be problematic given high antipsychotic dose have 
been found to be associated with higher negative symptoms (Perenyi et al., 1998). If a 
significant proportion of the negative symptoms reported in this study were associated to EPS, 
then depending upon whether these were addressed following the baseline assessment this 
may have either caused a greater or lesser change in negative symptoms than may have 
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otherwise been the case. In future studies, including EPS either as a covariate in the model, or 
as part of the exclusion criteria may help to further disentangle how different eligibility criteria 
may change the association between negative symptoms and causes of secondary symptoms.  
 
4.5.4. Summary  
Implementing minimum negative and maximum depressive symptom eligibility criteria were 
found to reduce the association between these symptoms. These findings suggest adopting 
such criteria may be a helpful tool in helping to minimise secondary negative symptoms caused 
by depressive symptomology. However, adopting minimum negative and maximum positive 
symptom eligibility criteria was not found to reduce the association between these symptoms, 
and in some cases even increased it. In highly restrictive inclusion criteria the association 
between these symptoms did not change, but did result in a large proportion of the sample 
being ineligible. In conjunction with previous findings (Dunayevich et al., 2014), these results 
suggest that restrictive symptom inclusion criteria may not be an effective method to limit the 
impact of positive symptoms on negative symptom change. 
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Chapter 5. Comparing the CAINS and the PANSS as a measure of 
negative symptoms 
 
5.1. Introduction 
In the MATRICs consensus statement on negative symptoms (Kirkpatrick et al., 2006) the 
limitations of existing assessment tools were identified as a significant barrier in the 
development of new treatments (see section 1.8. for a full summary). As a consequence, the 
panel recommended forming a working group with the aim of developing and testing new 
scales, both in terms of their psychometric properties and their sensitivity to symptom change. 
Following the MATRICs meeting, the Collaboration to Advance Negative Symptom Assessment 
in Schizophrenia (CANSAS) was established (Blanchard et al., 2011), which in turn led to the 
development of two new scales; the Clinical Assessment Interview for Negative Symptoms 
(CAINS) (Horan et al., 2011), and the Brief Negative Symptom Scale (BNSS) (Strauss et al., 
2012). These scales have been designed to reflect our current conception of negative 
symptoms, which include alogia, blunted affect, asociality, anhedonia and avolition.  
Conceptually, the CAINS is viewed as a significant advance on earlier instruments such as the 
PANSS (Kay et al., 1987) and the SANS (Andreasen, 1983) which are currently the most used 
scales in negative symptom assessment. Despite their extensive use in schizophrenia research, 
the PANSS and the SANS are recognised to have a number of limitations (Blanchard et al., 
2011),. These include combining cognitive symptoms into negative symptom subscales, 
capturing multiple, conceptually distinct domains within a singular item, and not making an 
appropriate distinction between anticipatory and consummatory pleasure, which is important 
given it appears it is only the former which relates to negative symptoms (Gard et al., 2007). In 
addition, the PANSS and SANS largely rely on behavioural referents; be they either interviewer 
observations, or reports from the interviewee, a care giver, or clinicians, as evidence of 
experiential deficits. This is potentially problematic, given symptoms such as anhedonia and 
apathy relate primarily to experiential states, where what participants actually do can be 
affected a number of secondary factors.  
As summarised in section 1.9.1.7., the CAINS has been to have good psychometric properties 
(Kring et al., 2013). The interrater reliability for the CAINS experiential and expressive subscale 
was high (ICC=.93 and ICC=.77 respectively), whilst the test-retest reliability of the two 
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subscales was found to be comparable to that found with the negative symptom subscale of 
the PANSS (Kay et al., 1987). The CAINS subscales significantly correlated with the 
corresponding items on the SANS (Andreasen, 1983) and the BPRS (Overall and Gorham, 
1962), and was divergent from distinct concepts such as depression, IQ, positive symptoms 
and EPS. In addition, the CAINS was found to moderately correlate with indicators of 
functioning, relating specifically to what patients actually do, as opposed to what they 
physically capable of doing (Kring et al., 2013). 
With the CAINS scale exhibiting promising conceptual and psychometric characteristics, the 
next stage of evaluation proposed by the MATRIC consensus statement would be to determine 
the sensitivity of the scale (Kirkpatrick et al., 2006). This is important, as earlier negative 
symptom assessment scales have been found to report very different effect sizes (Eckert et al., 
1996). Further evidence for this is presented in chapter 3 of this investigation, where it was 
found that the SANS reported a significantly greater change in negative symptoms over time 
relative to the PANSS. If the CAINS is found to be a more sensitive instrument than existing 
assessment scales then this could represent a major step forward in the evaluation of new 
therapeutics given it would be more capable of detecting any treatment effects, and would 
also mean that smaller sample sizes would be required to detect meaningful changes. 
In a related issue to determining the sensitivity of the scale, assessing whether the measure 
adds predictive power above what can be predicted by other sources has been considered an 
important but neglected area in most areas of applied psychology (Hunsley and Meyer, 2003). 
This concept, known as incremental validity, was originally proposed by Sechrest (Sechrest, 
1963) who stated that in order for a new psychological test to be valid then it must result in an 
improvement in prediction over existing methods which are routinely adopted as part of the 
assessment process. Yates and Taub (Yates and Taub, 2003) went on to suggest that that the 
assessment of incremental validity needs to be considered against the associated costs (both 
time and financial) of using the measure over existing alternatives. Based on experiences from 
a recent full-scale trial which used both the CAINS and the PANSS as part of its full assessment 
battery (Priebe et al., 2013a), the CAINS scale at 13 items is slightly quicker to complete than 
the 30-item PANSS assessment, and requires an equivalent degree of training and experience, 
meaning the associated costs can be considered similar. Therefore, if the CAINS is found to 
provide greater predictive power of concepts related to the negative symptom construct, then 
it could be argued that this scale has greater incremental validity in this context.  
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As outlined in section 1.6., negative symptoms have been found to be associated with a 
reduced frequency of recreational activities, lower quality and frequency of social interactions, 
and reduced work performance (Hunter and Barry, 2012, Lysaker and Davis, 2004, Milev et al., 
2005). In this study, the degree to which the CAINS and the PANSS negative subscale could 
predict such outcomes was compared. These outcomes include the participant’s reported 
social network size, the number of activities they took part in over the previous week, and 
whether they could identify anyone as being close friend, which were collectively defined as 
indicators of social impoverishment. The term ‘social impoverishment’ is more typically used in 
social psychology, and refers to concepts such as community integration and participation 
(Gracia et al., 1995).The decision to adopt this particular label, rather than more common 
alternatives which include terms such as social or functional ‘impairment’, ‘deficit’ and/or 
‘disability’ was due to concerns that this might imply that reported behaviours are considered 
pathological, when may be problematic given the factors associated with these behaviours 
were not fully explored. 
In this part of the investigation three different aims will be addressed. First, the convergent 
validity between the CAINS and the PANSS negative subscale will be examined, given in the 
original study (Kring et al., 2013), the convergent validity was examined using the BPRS anergia 
scale. Whilst the PANSS negative and BPRS anergia symptom subscales have been found to be 
highly correlated (r=.82) (Bell et al., 1992), a number of negative symptoms are not assessed 
by the BPRS, such as apathy and asociality, and so it could be argued that the scale provides a 
poorer coverage of the negative symptom construct. It is notable that whilst the SANS and the 
PANSS were recognised as appropriate measures for use in clinical trials for negative 
symptoms in both the NIMH-MATRICs and the ISCTM consensus statements (Kirkpatrick et al., 
2006; Marder et al., 2011), the BPRS was not mentioned. The PANSS is recognised as one of 
the most extensively used scales in the field of schizophrenia research (Mortimer, 2007) and, 
as identified in the systematic review presented in chapter 3, has been used in a number of 
large trials designed to evaluate the effectiveness of treatments for negative symptoms. 
Consequently, understanding the relationship between the PANSS negative subscale and the 
CAINS may give a better understanding both of the CAINS scale itself, and also place earlier 
findings which have used the PANSS in better context in light of developments in our 
understanding of what constitutes negative symptoms. 
The second part of this investigation will assess the degree of agreement between the CAINS 
and the PANSS to examine whether there are any systematic differences in how they capture 
negative symptoms. This investigation will involve both comparing how the scales differentiate 
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between participants that present with high and low negative symptoms, and comparing how 
sensitive the two scales are in detecting changes in negative symptoms over time. 
The third aim will be to examine the incremental validity of the CAINS by comparing its 
predictive ability of objective and subjective measures of social impoverishment with the 
PANSS negative subscale using Dominance Analysis (Azen and Budescu, 2003, Azen and Traxel, 
2009). Negative symptoms relate specifically to deficits in motivation to take part in 
recreational activities and impairments in the quality and quantity of social networks, so the 
scale which better predicts these outcomes could be considered a better indicator of the 
negative symptom construct. Given the PANSS negative subscale in its standard form has been 
extensively used in negative symptom trials in the past, both this and the alternative Marder 
configuration was included in the analysis. 
 
5.2. Research questions 
1) What is the association between the CAINS and the PANSS negative subscale? 
2) Does the CAINS provide a greater differentiation between participants that report high 
and low symptoms, relative to the PANSS negative subscale? 
3) Is the CAINS more sensitive in detecting symptom change over time relative to the 
PANSS negative subscale? 
4) Is the CAINS a better predictor of objective social outcomes relative to the PANSS 
negative subscale? 
 
5.3. Method 
5.3.1. Sample 
The data for this study was taken from the NESS study (Priebe et al., 2013a), which was a 
multi-site randomised controlled trial designed to evaluate the effectiveness and cost 
effectiveness of body psychotherapy in the treatment of negative symptoms of schizophrenia.  
The inclusion criteria for the study included having an established diagnosis of schizophrenia 
according to ICD-10, displaying negative symptoms for a period of at least six months, not 
changing the type of antipsychotic medication six weeks prior the baseline assessment, and an 
ability and willingness to take part in a physically active group. In addition, participants were 
required to present with at least moderate levels of negative symptoms, indicated by a score 
of at least 18 on the negative subscale of the PANSS. Because this skewed the baseline 
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distribution of the PANSS negative subscale, in this study only the end of treatment and 6 
month follow-up data were analysed. A full summary of the study has been reported 
elsewhere (Priebe et al., 2013a) 
 
5.3.2. Scales 
The psychometric properties of the Clinical Assessment Interview for Negative symptoms 
(CAINS) (Horan et al., 2011, Kring et al., 2013) have been summarised in detail in section 
1.9.1.7. Whilst the authors have proposed reporting the experiential and expressive subscales 
separately given they appear to represent distinct constructs (Blanchard and Cohen, 2006), the 
current consensus regarding the evaluation of negative symptoms for clinical trials 
recommend evaluating this outcome as a singular construct (Kirkpatrick et al., 2006, Marder et 
al., 2011). Consequently, both the individual subscales and the overall summary score were 
evaluated. 
In this study the CAINS was compared to the PANSS negative subscale (Kay et al., 1987). A full 
summary regarding the details of this scale have been summarised in section 1.9.1.3. Given it 
is important to understand the relationship between the CAINS and the PANSS both in the 
context of earlier studies and in line with current recommendations (Marder et al., 2011), the 
original PANSS negative subscale and the Marder negative symptom subscale (Marder et al., 
1997) were included. In the standard version, the items which formulate the negative 
symptom construct include affective blunting, emotional withdrawal, apathetic social 
withdrawal, poor rapport, stereotypical thinking, difficulties in abstract thinking and impaired 
conversation flow. In the alternative Marder subscale, stereotypical thinking and difficulties in 
abstract thinking were removed, and replaced with the active social avoidance and motor 
retardation items.  
In order to capture objective and self-report indicators of social impoverishment, individual 
items from the Manchester Short Assessment Scale (MANSA) (Priebe et al., 1999), an adapted 
version of the Social Network Scale (SNS) (Dunn et al., 1990), and the Time Use Survey (TUS) 
(Lader et al., 2006) were used.  From the SNS, the question “Who did you see or speak to in 
the last week?” was asked, with the number of friend contacts added together. From the 
MANSA, item 4 was used which asked “Do you have anyone you would call a close friend?”. 
With the TUS, participants were asked whether they had taken part in activities like going out 
to eat, shopping for anything over than food, going to any place of entertainment, or going out 
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on any form of outdoor trip, with all activities added together to provide a final summary 
score.  
 
5.3.3. Analysis plan 
5.3.3.1. Associations between the CAINS and the PANSS 
In the first part of the analysis the correlations between the CAINS and the PANSS negative 
subscales were calculated. In the initial development phase of the CAINS (Horan et al., 2011) a 
significantly stronger correlation was detected between the BPRS anergia subscale and CAINS 
expressive subscale, relative to the experiential subscale. This fits with the limitations 
identified in the review of earlier scales (Blanchard et al., 2011) which state that scales such as 
the PANSS, BPRS and the SANS appear to insufficiently tap into experiential states. Whilst 
there is a substantial degree of overlap between the BPRS anergia subscale and the PANSS 
negative subscale, the PANSS includes extra items relating to social withdrawal and alogia, so 
at present it is unclear whether the relationship would be similar to that identified by Horan 
and colleagues (Horan et al., 2011).   
 
5.3.3.2. A comparison of how the PANSS and CAINS differentiates between high and 
low negative symptoms 
In the next part of the analysis, the relationship between the CAINS and the PANSS negative 
subscales were further explored. Tukey mean-difference plots were conducted to examine the 
degree of agreement between the two scales across the range of symptom severity. This form 
of plotting the data is extensively used in biomedical statistics in the form of Bland-Altman 
plots (Bland and Altman, 1986), where objective measures are taken (i.e. blood pressure) 
against which one can be compared to a recognised “gold standard”. However, in this context 
where there is no gold standard against which either scale can be compared, the aim instead 
will be to explore systematic differences between the scales. Given the different scaling of the 
subscale scores (0-4 in the CAINS, versus 7-49 for the PANSS negative subscale) the scores 
plotted were a proportion of their possible range. The Bland Altman plots were modelled in 
STATA using the batplot command. Trends in the degree of change between the scales were 
explored in a regression analysis, using the STATA regress command. Both the standard PANSS 
negative subscale, in addition to the alternative Marder configuration of the negative 
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symptom construct (Marder et al., 1997) were evaluated, in addition to both the CAINS total, 
and experiential and expressive subscales.  
 
5.3.3.3. Examination of the difference in negative symptom change scores between the 
CAINS and PANSS over time 
In order to explore the sensitivity of the PANSS and CAINS in detecting negative symptom 
change, the analysis was extended to look at the relationship between the change scores in 
the PANSS and CAINS over time. To achieve this, a comparison of the rate of change in one 
scale relative to the other was examined in a subsample of the dataset which included all 
participants that reported a clinically meaningful change in negative symptoms, in the same 
direction, over both the CAINS and PANSS. However, determining what constitutes a clinically 
meaning change in negative symptoms using these rating scales is a complex issue, particularly 
so in the case of the CAINS given the scale has not yet been extensively tested.  
In the PANSS total score, a 25% reduction in symptoms has been found to correspond to a 1 
point reduction in the CGI (Guy, 1976, Leucht et al., 2006), denoting observable clinical 
improvement. However, it is not clear how this reported figure translates to the negative 
symptom subscale, while at lower symptom levels the degree of improvement required 
appears to be substantially less. Regarding negative symptom change specifically, in the NESS 
trial (Priebe et al., 2013a) a 3-point reduction in the PANSS negative subscale score was 
deemed clinically significant in the power analysis calculation, which was the figure adopted to 
denote clinically meaningful change in this analysis. However, given the uncertainty around 
this as an appropriate figure, in a sensitivity analysis an equivalent 2-point and 4-point change 
in the PANSS negative symptom subscale was also examined. Given the analysis was 
conducted as a change in the proportional score of the scale, as opposed to raw-change 
scores, these figures were transformed into percentage changes in the PANSS negative 
subscale. The subscale has a range of 42 (7-49), meaning a 3-point change equates to a 
proportional change of at least ±7.14%, a 2-point change to at least ±4.76%, and a 4-point 
change to at least ±9.52%. 
Given all participants had previously been randomised to receive a treatment of either Pilates 
or Body Psychotherapy (see Priebe et al., 2013a for a full description of the original study) it is 
possible that the symptom trajectory may be different depending upon the treatment group 
they were randomised into. Consequently, trends were examined using a mixed effects models 
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fitted by maximum likelihood estimation. The mean percentage change scores were added as 
an independent variable; the difference in that change between the CAINS and the PANSS 
negative subscales were added as a dependent variable, and therapy group allocation was 
included as a random effect. 
 
5.3.3.4. Assessment of the incremental validity of the CAINS over the PANSS 
In the final part of the study the aim was to assess the incremental validity of the CAINS over 
the PANSS negative subscale as a predictor of social impoverishment, as defined by the 
number of friend contacts over the past, and the number of activities they have taken part in 
over the past week, and whether they have somebody they consider to be a close friend. In 
the first part of the analysis, these relationships were explored using logistic or Poisson 
univariate regression, depending upon whether the dependent variable was count or 
dichotomous in nature. Given there is likely to be substantial a correlation between the PANSS 
negative subscales and CAINS as they have been designed to measure the same construct (i.e. 
negative symptoms), multivariate regression analysis was not conducted given concerns 
regarding collinearity. As an alternative, dominance analysis was conducted, which has been 
used in the past to compare the predictive strength of two different scales designed to 
measure the same construct (Miller et al., 2012). 
Whilst in a traditional multivariate regression model the aim is to build the strongest predictive 
model, in dominance analysis the question instead focuses on “given X number of predictors, 
which is more useful in predicting the criterion Y?” (Pedhazur, 1982). To answer this question, 
the contribution of one individual variable is compared with the other independent variables 
in all possible subset models, in addition to the full model where all predictors are included. In 
doing so, the superiority of a predictor can be specified at three levels; the first (and lowest) 
level is conditional dominance, which is specified by the variable with the higher mean 
contribution of the explained variance over all the models (L1). If one variable dominates 
another at each model size then it is said to generally dominate (L2).  Lastly, if one variable 
provides greater explanatory power over another in every subset model then is recognised to 
completely dominate (L3). To test the reproducibility of complete dominance 50 bootstrapped 
samples were produced, which is a number considered adequate to calculate estimates of 
standard error (Mooney et al., 1993). Following the method proposed by Azen and Budescu 
(Azen and Budescu, 2003), in all bootstrapped replications the variable was given a score of 1 if 
it completely dominated the other variable, 0.5 if neither variable completely dominated, and 
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0 if it was completely dominated by the other variable. The figures reported denote the mean 
of these findings over all the bootstrapped samples. In this study the dependent variables 
were either binary or count outcomes, so a logistic or poisson statistic was adopted as 
appropriate, modelled within the STATA domin command (Luchman, 2014). Following the 
recommendations from Azen and Traxel (Azen and Traxel, 2009), McFadden’s pseudo R2 was 
adopted to provide an estimate of the measure of fit (McFadden). All analysis was conducted 
using STATA version 12.0 (STATA Corp, 2012). 
 
5.4. Results   
5.4.1. Description of sample 
The participant characteristics are presented in table 29. The mean age of participants was 
42.2 years, and were predominately male (74%), unemployed (96%), with a long history of 
schizophrenia (mean= 12.8 years, SD= 8.8). Participants presented with moderate levels of 
negative symptoms (PANSS negative=21.68, SD=5.04; CAINS total= 2.12, SD= 0.59) and low 
levels of positive symptoms (PANSS positive =13.21, SD=4.48).  
The inter-rater reliability for both the CAINS and the PANSS between raters measured at study 
end was high (PANSS total ICC= .85; CAINS total ICC= .80). The study retention between the 
two time points included in this study was found to be very high (252/264; 95.5%). 
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Table 29: Clinical and socio-demographic information  of the sample 
at baseline 
 Variable 
Total 
N=265. 
   
  
Age (mean, SD) 41.93 10.5 
    Gender (n, %) 
  
 
Male 194 73.5% 
 
Female 70 26.5% 
    Ethnicity (n, %) 
  
 
White 135 51.1% 
 
Black 78 29.5% 
 
Asian 30 11.4% 
 
Other 21 8.0% 
   Employment (n, %) 
  
 
Work/training/education 7 2.6% 
 
Other 258 97.4% 
    Living situation (n, %) 
  
 
Alone 149 56.4% 
 
With others 115 43.6% 
   No. of Children (median, IQR) 0 0-6 
   
PANSS total score (mean, SD) 64.76 12.82 
 
PANSS negative 21.68 5.04 
 
PANSS positive 13.21 4.48 
 PANSS Marder negative 20.51 5.42 
     CAINS total score (mean, SD)  2.12 0.59 
 
Expression Subscale 1.85 0.98 
 
Experience Subscale 2.34 0.64 
     
# Activities completed (median, IQR) 3 1-7 
     
Do you have a close friend (n, %)   
 Yes  167 64.5% 
 No  92 35.5% 
     
# friends contacts (median, IQR) 1 0-2 
          
SD, standard deviation; IQR, interquartile range;  
 
5.4.2. Association between variables 
A correlation matrix of the outcome variables assessed is presented in table 30. The 
correlation between the PANSS negative subscale and the CAINS expression subscale (r=.754) 
and CAINS total score (r=.742) was high, whilst the correlation with the CAINS experience 
subscale was moderate (r=.480). The four different methods in which to assess negative 
symptoms (the PANSS negative subscale standard format, the PANSS negative Marder 
configuration, the CAINS experiential subscale, and the CAINS expressive subscale) were all 
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positively associated with each other, and negatively associated with the number of friend 
contacts participants reported in the past week, whether they had a close friend, and the 
number of activities taken part in over the past week.  
 
Table 30: correlation matrix of the variables at end of treatment stage 
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CAINS Total ** .685 .870 .742 .730 -.159 -.304 -.347 
CAINS Expression  ** .237 .754 .777 -.091 -.081 -.208 
CAINS Experience   ** .480 .448 -.151 -.350 -.322 
PANSS Negative    ** .888 -.139 -.237 -.309 
PANSS Marder negative     ** -.114 -.204 -.346 
# Activities      ** .113 .046 
# Friend contacts       ** .263 
close friend (Y/N)  
      
** 
 
5.4.3. Relationship between the PANSS negative and the CAINS total subscales 
A mean of the proportional values of the CAINS total score and the PANSS negative subscale 
score, plotted against the difference between these values is presented in figure 9a. The CAINS 
was found to report negative symptoms at a proportionally higher level, relative to the PANSS 
negative subscale, as indicated by the dotted line. In addition, this proportionally larger score 
of the CAINS over the PANSS increased as the average of the CAINS total and PANSS negative 
subscale values increased (B=0.26, 95% CI 0.16 to 0.35, P<.001. R2=.101). This relationship, 
whilst still significant, was found to be slightly weaker in the comparison of the CAINS total and 
the PANSS Marder negative subscale (B=0.17, 95% CI 0.07 to 0.27, P=.001. R2=.047), with 
greater dispersion in the values evident (see figure 9b).  
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Figure 9a: Relationship between the CAINS total and the     Figure 9b:  Relationship between the CAINS total and 
the PANSS Negative subscale.        PANSS Marder Negative subscale. 
   
The x axis denotes the mean score the PANSS negative and CAINS subscale for each participant. The y axis denotes 
the degree of difference between the CAINS subscale and the PANSS negative subscale. The Solid line denotes 
where the proportional scale scores are equivalent. Scores below this line indicate that the participant was rated 
proportionately higher on the PANSS negative subscale in comparison to the CAINS subscale, whilst those higher 
than the dotted indicate that they scored proportionately higher on the CAINS. The Dotted line denotes the mean 
difference between the subscales over the sample.  
 
5.4.4. Degree of agreement between the PANSS negative subscale and the CAINS 
experiential and expressive subscales 
In order to assess the level of agreement between each of the CAINS subscales and the PANSS 
negative subscale, two further Tukey-mean plots were plotted comparing an average of the 
subscales against the difference between the scores (see figures 10a and 10b). In a similar 
fashion to the relationship between the CAINS total subscale score and the PANSS negative 
subscale, the mean difference between the two scales over the whole sample indicate that the 
CAINS experiential subscale scored participants substantially higher as a proportion of its 
range, relative to the PANSS negative subscale. In addition, this difference increased as the 
average of the CAINS total and PANSS negative subscale values increased (B=0.28; 95% CI 0.18 
to 0.37, P<.001. R2=.118). 
In figure 10b, which depicts the level of disagreement between the PANSS negative scale and 
the CAINS expression subscale, large differences between the scales were also evident. 
However, in contrast with the previous plots, a much clearer systematic difference was evident 
over the range of severity. When the mean level of negative symptoms between the PANSS 
negative subscale and the CAINS Expression subscale was low, the CAINS Expression subscale 
appeared to rate the symptoms as lower. When the mean score from the two scales was high, 
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the experience subscale proportional score was substantially larger. In the regression analysis 
a strong positive relationship between the difference in the subscale scores and the mean of 
the two subscales was evident (B=0.77; 95% CI 0.70 to 0.85, P<.001, R2=.606). Overall, this 
suggests that the CAINS expression subscale in particular provides a much greater 
differentiation between patients that report high and low symptoms, relative to the PANSS 
negative subscale. 
 
Figure 10a: Relationship between the CAINS    Figure 10b: Relationship between the CAINS 
experiential subscale and the PANSS negative    expressive subscale and the PANSS negative subscale 
subscale score       score 
  
The x axis denotes the mean score the PANSS negative and CAINS subscale for each participant. The y axis denotes 
the degree of difference between the CAINS subscale and the PANSS negative subscale. The Solid line denotes 
where the proportional scale scores are equivalent. Scores below this line indicate that the participant was rated 
proportionately higher on the PANSS negative subscale in comparison to the CAINS subscale, whilst those higher 
than the dotted indicate that they scored proportionately higher on the CAINS. The Dotted line is the mean 
difference between the subscales over the sample.  
 
In order to examine whether the differences are attributable to the PANSS negative subscale 
including items not recognised to be part of the negative symptom construct, the analysis was 
replicated using the PANSS Marder negative factor configuration (Marder et al., 1997). The 
relationship between the CAINS expressive and experiential subscales, and the PANSS Marder 
negative subscale are presented in figures 11a and 11b. In both the expressive and experiential 
subscales, the relationships detected were found to be highly consistent with the results 
reported in the PANSS negative symptom subscale analysis. In a comparison of the CAINS 
experiential subscale and the PANSS Marder negative subscale, the experiential subscale 
reported participants as having substantially higher negative symptoms as a proportion of its 
range, relative to the PANSS negative subscale. This difference increased as the average of the 
CAINS total and PANSS negative subscale values increased (B=0.30, 95% CI 0.16 to 0.45, 
P<.001. R2=.061). In the comparison between the CAINS expressive subscale and the PANSS 
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Marder negative subscale, when the two scales reported negative symptoms in the low range 
the expressive subscale reported symptoms as lower, and when a mean of the scales reported 
negative symptoms in the high range the expressive subscale score was again much higher. 
This relationship was found to explain a large proportion of the variance between the scoring 
of the two scales (B=0.69, 95% CI 0.61 to 0.77, P<.001, R2=.544). 
 
 
Figure 11a: Relationship between the CAINS  Figure 11b: Relationship between the CAINS 
experiential subscale and the PANSS Marder  expressive subscale and the PANSS Marder negative 
negative subscale score    subscale score 
   
The x axis denotes the mean score the PANSS negative and CAINS subscale for each participant. The y axis denotes 
the degree of difference between the CAINS subscale and the PANSS negative subscale. The Solid line denotes 
where the proportional scale scores are equivalent. Scores below this line indicate that the participant was rated 
proportionately higher on the PANSS negative subscale in comparison to the CAINS subscale, whilst those higher 
than the dotted indicate that they scored proportionately higher on the CAINS. The Dotted line is the mean 
difference between the subscales over the sample.  
 
5.4.5. A comparison of the change scores in the PANSS negative and the CAINS total 
score over time 
In the next part of the analysis, a comparison of the change over time assessed using the 
CAINS and the PANSS was compared. Meaningful change of negative symptoms was 
determined as a mean change of at least ±7.14% in the CAINS and PANSS subscale analysed, 
which corresponds to a change of 3 points in the PANSS negative subscale. In a sensitivity 
analysis, subsamples of participants who reported an equivalent mean change of at least 2 
points (mean proportional change of ≥±4.76%) and 4 points (mean proportional change of 
≥±9.52%) in the PANSS negative subscale over both scales were also examined. In addition to 
the CAINS total score and the PANSS negative subscale being compared, the analysis was 
extended to include the subscales of the CAINS, and the PANSS Marder negative symptom 
configuration. 
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5.4.5.1. A comparison of the PANSS negative subscale standard configuration and the 
CAINS total score 
Of the 241 participants who had complete data for both the CAINS total and PANSS negative 
subscale, 109 reported a reported a mean change of at least ±7.14%. Of these, 106 (97.2%) 
reported the change as occurring in the same direction in both scales and so were therefore 
eligible for analysis. 
A comparison of the degree of change over time in the PANSS negative subscale and the CAINS 
total score using a mean change of ≥±7.14% as an indicator of clinically meaningful change is 
presented in figure 12. The scatterplot suggests that as the mean change in symptom scores in 
the PANSS negative and CAINS total score increased, a greater magnitude of change in the 
CAINS was reported relative to the PANSS negative subscale. However, in a regression analysis 
this relationship was not found to be statistically significant (B= 0.34, 95% CI -0.04 to 0.74, 
P=0.081), instead only suggesting evidence of a possible weak effect. 
 
Figure 12. Relationship between the CAINS total and PANSS subscale change scores using a ±7.14% 
mean difference over time as an indicator of change  
 
The ‘x’ axis denotes the mean % change in both the PANSS negative and CAINS total score over 6 months. The ‘y’ axis denotes the 
degree in which the % change was larger in the CAINS subscale (>.0), or the PANSS negative subscale (<.0). 
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In the sensitivity analysis, a comparison of the change over time in the PANSS negative and 
CAINS total scores was completed in participants that reported a ≥±4.76% mean change, and a 
≥±9.52% mean change in negative symptom scores respectively. In both cases the findings 
were highly consistent with the original ±7.14% threshold, suggesting that as the magnitude of 
change measured in the PANSS negative subscale and the CAINS increases, the more the CAINS 
changes relative to the PANSS. In the sample obtained through adopting a change of at least 
±4.76% to determine a clinically significant change, this relationship was found to be significant 
(B= 0.37, 95% CI 0.06 to 0.68, P=.020). In the sample obtained through adopting a change of at 
least ±9.52% to determine a clinically significant change, the relationship was not found to be 
statistically significant (B= 0.47, 95% CI -0.03 to 0.96, P=.063), instead suggesting evidence of a 
weak effect. 
 
5.4.5.2. A comparison of the PANSS Marder negative subscale standard configuration 
and the CAINS total score  
The analysis completed in section 5.4.5.1. was replicated using the PANSS Marder negative 
subscale in place of the standard PANSS negative factor configuration. Complete data was 
available for 241 participants, of which 108 reported a mean change of at least ±7.14% in the 
CAINS total and PANSS Marder negative subscale scores. Of this subsample, 105 participants 
(97.2%) reported a change in the same direction in the both the CAINS total and PANSS Marder 
negative subscale and so were included in the analysis. 
The comparison of the degree of change over time in the PANSS Marder negative subscale and 
the CAINS total score is presented in figure 13. The magnitude of change in the CAINS total 
score was found to significantly increase as mean change in both the PANSS Marder negative 
subscale and CAINS total score increased (B=0.46, 95% CI 0.06 to 0.85, P=.020). In the 
sensitivity analysis, a comparison of the change over time in the PANSS Marder negative 
subscale and CAINS was completed in participants that reported a mean change of least 
±4.76%, and ±9.52%. In both cases the magnitude of change in the CAINS total score over the 
PANSS Marder negative subscale score was found to significantly increase as the mean change 
in both increased (≥±4.76% subsample: B= 0.32, 95% CI 0.03 to 0.63, P=.034; ≥±9.52% 
subsample: B= 0.57, 95% CI 0.11 to 1.03, P=.016) 
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Figure 13. Relationship between the CAINS total and PANSS Marder negative subscale change 
scores using a ±7.14% mean difference over time threshold as an indicator of change 
 
The ‘x’ axis denotes the mean % change in both the PANSS negative and CAINS total score over 6 months. The ‘y’ axis denotes the 
degree in which the % change was larger in the CAINS subscale (>.0), or the PANSS negative subscale (<.0). 
 
5.4.6. A comparison of the PANSS negative subscales and the CAINS experiential 
and expressive subscales over time 
Following the comparison of the PANSS negative and PANSS Marder negative subscales to the 
CAINS total scores, the relationship between the PANSS negative subscale and the CAINS 
expressive and experiential subscales were also examined. 
 
5.3.6.1. Comparison of the CAINS Experiential and the PANSS negative subscales 
Of the 242 participants who had complete data at both time points for the CAINS experiential 
and PANSS negative subscale, 103 reported a reported a mean change in symptoms of at least 
±7.14%. Of these, 95 (92.2%) were eligible for analysis. A comparison of the degree of change 
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over time in the CAINS experiential subscale and the PANSS negative subscale is presented in 
figure 14. The magnitude of change in the CAINS experiential subscale over the PANSS 
negative subscale was found to significantly increase as the overall mean change score 
increased (B= .71, 95% CI 0.32 to 1.11, P<.001). This significant increase was also found to be 
consistent when clinically meaningful change was set at ≥±4.76% and ≥±9.52% respectively 
(≥±4.76% criteria: B=0 .64, 95% CI 0.32 to 0.95, P<.001; ≥±9.52% criteria B= 0.62, 95% CI 0.08 
to 1.16, P=.024). 
 
Figure 14. Relationship between the CAINS experiential and PANSS negative subscale change scores 
using a ±7.14% mean difference over time as an indicator of change  
 
The ‘x’ axis denotes the mean % change in both the PANSS and CAINS subscales over 6 months. The ‘y’ axis denotes the degree in 
which the % change was larger in the CAINS subscale (>.0), or the PANSS negative subscale (<.0). 
 
In a comparison between of the degree of change over time in the CAINS experiential subscale 
and the PANSS Marder negative subscale, data was available for 242 participants. Of 113 
participants that reported a mean change of at least ±7.14% in the two subscales, 101 (89.4%) 
were eligible for analysis. 
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A comparison of the degree of change over time in the CAINS experiential subscale and the 
PANSS Marder negative subscale is presented in figure 18. The magnitude change in the CAINS 
experiential subscale over the PANSS Marder negative subscale was found to significantly 
increase as the mean change in both subscales increased (B=0.98, 95% 0.59 to 1.37, P<.001). 
This was found to be consistent in the sensitivity analysis where clinically meaningful change 
was set at ≥±4.76% and ≥±9.52% (≥±4.76% criteria: B=0.75, 95% 0.44 to 1.06, P<.001; ≥±9.52% 
criteria: B=0.91, 95% 0.41 to 1.41, P<.001) 
 
Figure 15. Relationship between the CAINS experiential and PANSS Marder negative subscale change 
scores using a ±7.14% mean difference over time as an indicator of change  
 
The ‘x’ axis denotes the mean % change in both the PANSS and CAINS subscales over 6 months. The ‘y’ axis denotes the degree in 
which the % change was larger in the CAINS subscale (>.0), or the PANSS negative subscale (<.0). 
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5.3.6.2. Comparison of the CAINS Expressive and the PANSS negative subscales 
Of the 247 participants who had complete data for both the CAINS expressive and PANSS 
negative subscale, 131 reported a reported a mean change of at least ±7.14%. Of these, 128 
(97.7%) were eligible for analysis. 
A comparison of the degree of change over time in the CAINS expressive subscale and the 
PANSS negative subscale is presented in figure 16. The magnitude of change in the CAINS 
expressive subscale over the PANSS negative subscale was found to significantly increase as 
the mean change in both scales increased (B= 0.94, 95% CI 0.66 to 1.21, P<.001). This increase 
was found to be consistent in the sensitivity analysis comparing the magnitude of change in 
subsamples which defined a clinically meaningful change at ≥±4.76% and ≥±9.52% respectively 
(≥±4.76% criteria: B=0 .88, 95% CI 0.66 to 1.11, P<.001; ≥±9.52% criteria: B= 1.03, 95% CI 0.68 
to 1.37, P<.001).  
 
Figure 16. Relationship between the CAINS expressive and PANSS negative subscale change scores using 
a ±7.14% mean difference over time as an indicator of change  
 
The ‘x’ axis denotes the mean % change in both the PANSS and CAINS subscales over 6 months. The ‘y’ axis denotes the degree in 
which the % change was larger in the CAINS subscale (>.0), or the PANSS negative subscale (<.0). 
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In a comparison between of the degree of change over time in the CAINS expressive subscale 
and the PANSS Marder negative subscale, complete data was available for 248 participants. 
One hundred and thirty one participants reported a mean change of symptoms of at least 
±7.14%, of which 129 (98.4%) were eligible. 
A comparison of the degree of change over time in the CAINS expressive subscale and the 
PANSS Marder negative subscale is presented in figure 17. The change in the CAINS expressive 
subscale over the PANSS Marder negative subscale was found to significantly increase as the 
mean change in both subscales increased (B=0.83, 95% CI 0.57 to 1.09, P<.001). This was found 
to be consistent in the sensitivity analysis comparing the magnitude of change in subsamples 
which defined a clinically meaningful change at >±4.76% and >±9.52% (B=0.91, 95% 0.69 to 
1.11, P<.001; B=0.96, 95% 0.64 to 1.29, P<.001). 
 
Figure 17. Relationship between the CAINS expressive and PANSS Marder negative subscale change 
scores using a ±7.14% mean difference over time as an indicator of change  
 
The ‘x’ axis denotes the mean % change in both the PANSS and CAINS subscales over 6 months. The ‘y’ axis denotes the degree in 
which the % change was larger in the CAINS subscale (>.0), or the PANSS negative subscale (<.0). 
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5.4.7. An assessment of the incremental validity of the CAINS over the PANSS 
negative subscales 
In the final part of this investigation the incremental validity of the CAINS over the PANSS 
negative subscale in three indicators of social impoverishment was examined. These include 
the number of activities participants reported taking part in over the previous week, whether 
they could identify somebody they considered to be a close friend, and the number of friends 
they have been in contact with over the past week. Univariate regression analyses examining 
the associations between these indicators and the CAINS total and experiential and expressive 
subscales, the PANSS negative standard configuration, and alternative PANSS negative Marder 
factor loading are presented in table 31. In all 5 forms of negative symptom assessment a 
significant negative association was detected with all three outcomes. In the outcome “how 
many activities did you take part in over the past week” the CAINS expressive subscale was 
found to explain the smallest proportion of the variance (B=-0.18, 95% CI -0.23 to -0.12, 
P<.001; R2=.014), and CAINS total score the largest (B=-0.43, 95% CI -0.52 to -0.35, P<.001; 
R2=.032). Regarding whether participants report having a close friend, the CAINS expressive 
subscale again explained the lowest proportion of the variance (B=-0.47, 95% CI -0.74 to -0.20, 
P<.001; R2=.036) and the CAINS total scale the highest (B=-1.45, 95% CI -1.96 to -0.93, P<.001; 
R2=.108). In the last outcome, assessing the number of activities participants reported taking 
part in over the past week,  the CAINS expressive subscale again explained the smallest degree 
of variance (B=-0.15, 95% CI -0.27 to -0.04, P<.010; R2=.007), and the CAINS experiential 
subscale the highest (B=-0.90, 95% CI -1.07 to -0.74, P<.001; R2=.118). 
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Table 31: Univariate  analysis of the association between assessments of negative symptoms and 
indicators of social impoverishment 
  
Predictor variables 
  
Univariate analysis  
B 95% CI P Ra 
 
    
 
How many activities did you take part in 
last week?     
 
 
CAINS Expression -0.18 -0.23 -0.12 <.001 .014 
 
CAINS Experience -0.35 -0.43 -0.28 <.001 .026 
 CAINS total score -0.43 -0.52 -0.35 <.001 .032 
 
PANSS Negative -0.05 -0.06 -0.04 <.001 .027 
 PANSS Marder negative -0.04 -0.05 -0.03 <.001 .019 
 
      
 
Do you have a close Friend?     
 
 
CAINS Expression -0.47 -0.74 -0.20  .001 .036 
 
CAINS Experience -1.28 -1.77 -0.80 <.001 .096 
 CAINS total score -1.45 -1.96 -0.93 <.001 .108 
 
PANSS Negative -0.15 -0.20 -0.09 <.001 .083 
 PANSS Marder negative -0.15 -0.21 -0.10 <.001 .103 
 
     
 
Number of reported friend contacts in 
past week     
 
 
CAINS Expression -0.15 -0.27 -0.04  .010 .007 
 
CAINS Experience -0.90 -1.07 -0.74 <.001 .118 
 CAINS total score -0.90 -1.09 -0.71 <.001 .091 
 
PANSS Negative -0.09 -0.11 -0.06 <.001 .062 
 PANSS Marder negative -0.07 -0.09 -0.04 <.001 .046 
             
The pseudo R2 was calculated using logistic or poisson regression depending upon whether the 
independent variable was count or dichotomous in nature. 
 
5.4.7.1. Incremental validity using the whole CAINS score 
The dominance analysis comparing the CAINS total score and the PANSS negative subscale is 
presented in table 32. Overall, the CAINS total subscale score was found to dominate the 
PANSS negative subscale in all three cases. Both scales were found to be a weak predictor of 
the number of activities participants took part in over the past week (R2M = .033). Of this 
association, only a negligible amount of unique variance was explained by the PANSS negative 
subscale (R2 =.001), relative to the CAINS total score (R2 =.009). The CAINS total subscale was 
found to completely dominate, albeit with a relatively low degree of reproducibility (.627). 
Relative to the number of activities undertaken, the CAINS total and PANSS negative subscale 
was found to be a stronger predictor of whether they report having a close friend (R2M = .114). 
Whilst the majority of this association was shared (R2 =.081), the CAINS total score explained a 
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larger degree of unique variance in comparison to the PANSS negative subscale (R2 =.026, in 
comparison to R2 =.007). The CAINS total subscale was found to completely dominate with a 
moderately degree of reproducibility (.740).  
In the number of reported friend contacts, the CAINS total and PANSS negative subscale 
explained a moderate proportion of the variance (R2M = .092). Of this variance, a relatively 
large proportion was explained uniquely by the CAINS total score (R2 =.031), whilst only a 
negligible amount was determined uniquely by the PANSS negative subscale (R2 =.001). In the 
bootstrapped estimates the CAINS was found to dominate with a very high degree of 
consistency (.923).  
 
Table 32: Dominance Analysis comparing the PANSS negative subscale and CAINS total score as predictors of 
indicators of social impoverishment 
  
  
No. additional 
variables in 
existing model 
  
 
Dominance 
weight 
 
Standardised 
weight 
  
 
Rank 
Bootstrapped 
reproducibility of 
complete 
dominance 
  
0 1     
CAINS 
total 
PANSS 
Negative 
           How many activities did you take part in last week? 
    X1 CAINS total .032 .009 
 
.020 .615 
 
1a - .627 
X2 PANSS Negative .024 .001 
 
.013 .385 
 
2 .373 - 
Overall fit R2M = .033 
         
           Do you have a close Friend? 
     X1 CAINS total .108 .026 
 
.067 .586 
 
1a - .740 
X2 PANSS Negative .088 .007 
 
.047 .414 
 
2 .260 - 
Overall fit R2M = .114 
         
           Number of reported friend contacts in past week 
    X1 CAINS total .091 .031 
 
.061 .661 
 
1a - .923 
X2 PANSS Negative .061 .001 
 
.031 .339 
 
2 .077 - 
Overall fit R2M = .092 
                            
a Variable completely dominated all other predictors in the full model 
 
The dominance analysis of the PANSS Marder negative subscale and the CAINS total score is 
presented in table 33. In how many activities participants completed in the past week, the 
CAINS total score was found to explain a substantially larger proportion of unique variance 
relative to the PANSS Marder negative subscale (R2 =.015, in comparison to R2 =<.001), and be 
completely dominant to a moderately high degree of reproducibility (.808). In the number of 
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friends contacts reported over the past week, the proportion of unique variance explained by 
the CAINS total score was even higher (R2=.047, in comparison to R2=<.001), and was 
completely dominant in a large proportion of the bootstrapped samples (.961). In whether 
participants report having a close friend, the CAINS total and PANSS Marder negative subscale 
together explained a moderate proportion of the variance (R2M = .125), with both scales 
explaining an equal proportion of the unique variance (R2= .017). However, the PANSS Marder 
negative subscale was found to marginally dominate the CAINS total score (standardised 
weight=.502, to .498), which was found to reproduced in 62.7% of bootstrapped samples  
 
Table 33: Dominance Analysis comparing the PANSS Marder negative subscale and CAINS total score as 
predictors of indicators of social impoverishment 
  
No. variables in 
existing model 
  
 
Dominance 
weight 
 
Standardised 
weight 
    Bootstrapped 
reproducibility of 
complete 
dominance 
  
Rank 
0 1     
CAINS 
total 
PANSS 
Marder 
           How many activities did you take part in last week? 
    X1 CAINS total .032  .015 
 
.023 .728 
 
 1a - .808 
X2 PANSS Marder .017 <.001 
 
.009 .272 
 
2 .192 - 
Overall fit R2M = .032 
         
           Do you have a close Friend? 
        X1 CAINS total .108 .017 
 
.062 .499 
 
2 - .627 
X2 PANSS Marder .108 .017 
 
.063 .502 
 
 1a .373 - 
Overall fit R2M = .125 
         
           Number of reported friend contacts in past week 
    X1 CAINS total .091  .047 
 
.069 .760 
 
1a - .961 
X2 PANSS Marder .043 >.001 
 
.022 .240 
 
2 .039 - 
Overall fit R2M = .091 
                            
a Variable completely dominated all other predictors in the full model 
    
 
5.4.7.2. Incremental validity using the CAINS experience and expression subscales 
The dominance analysis of the separate CAINS subscales and the PANSS negative subscale is 
presented in table 34. In all three cases, the CAINS experiential subscale was found to 
dominate the other two subscales, with the CAINS expressive subscale explaining the smallest 
proportion of the variance. 
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In a measure of how many activities participants took part in over the past week, the three 
subscales together were only able to explain a relatively small proportion of the variance (R2M 
= .034). The largest proportion of the variance was explained by the CAINS experiential 
subscale (standardised weight .492), with both the CAINS expression subscale (R2 <.001), and 
the PANSS negative subscale (R2 =.002) accounting for only a very small proportion of unique 
variance. In the bootstrapped estimates, the complete dominance of the CAINS experiential 
subscale completely dominated the CAINS expressive subscale in 76.5% of cases, and the 
PANSS negative subscale in 56.9% of cases. In whether participants report having a close 
friend, a moderate proportion of the total variance was explained by the three subscales (R2M = 
.126). The CAINS experiential subscale explained both the largest degree of variance 
(standardised weight .497), and largest proportion of unique variance (R2=.035). The CAINS 
experiential subscale was found to completely dominate the CAINS expressive subscale to a 
high degree of reproducibility (.980), and the PANSS negative subscale to a moderate degree 
(.657). In the number of friend contacts participants report having over the past week, the 
three subscales explained a moderate degree of variance (R2M = .134). The CAINS experiential 
subscale explained the largest degree of variance (standardised weight .630), including unique 
variance (R2=.049). The experiential subscale was found to dominate the CAINS expressive 
subscale to a high degree of reproducibility (.951), and the PANSS negative subscale to a 
moderate degree of reproducibility (.725). 
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Table 34: Dominance Analysis comparing the PANSS negative and CAINS subscales as predictors of indicators of social 
impoverishment 
  
No. variables in existing 
model (K) 
Dom 
weight 
Std. 
weight 
Rank 
Bootstrapped reproducibility of 
complete dominance 
0 1 2 
CAINS 
Express. 
CAINS 
Exper. 
PANSS 
Neg. 
           How many activities did you take part in last week? (n=248) 
    X1 C. Expression .013 .003 <.001 .005 .154 3 - .235 .216 
X2 C. Experience .026 .015 .010 .017 .492 1 .765 - .569 
X3 PANSS Negative .024 .010 .002 .012 .353 2 .784 .431 - 
Overall fit R2M = .034 
         
           Do you have a close Friend? (n=254) 
      X1 C. Expression .035 .009 <.001 .015 .117 3 - .020 .108 
X2 C. Experience .096 .057 .035 .063 .497  1a .980 - .657 
X3 PANSS Negative .088 .043 .015 .049 .386 2 .892 0.343 - 
Overall fit R2M = .126 
                    Number of reported friend contacts in past week (n=255) 
    X1 C. Expression .006 .012 .010 .009 .068 3 - .049 .108 
X2 C. Experience .117 .088 .049 .085 .630  1a .951 - .725 
X3 PANSS Negative .061 .044 .017 .041 .302 2 .892 .275 - 
Overall fit R2M = .134 
                               
a Variable completely dominated all other predictors in the full model 
 
The dominance analysis of the CAINS subscales and the PANSS Marder negative subscale is 
presented in table 35. The CAINS experiential subscale was found to dominate as a predictor of 
how many activities the participant took part in, and the number of friend contacts they made 
over the past week, whilst the PANSS Marder subscale was found to dominate as a predictor of 
whether the participants report having somebody they consider to be a close friend. 
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Table 35: Dominance Analysis comparing the PANSS Marder negative and CAINS subscales as predictors of indicators 
of social impoverishment 
Additional 
contribution of  
No. additional variables in 
existing model (K)    
Bootstrapped reproducibility 
Dom. 
weigh
t 
Std. 
weight 
Rank 
of complete dominance 
0 1 2 
CAINS 
Express. 
CAINS 
Exper. 
PANSS 
Neg. 
           How many activities did you take part in last week? (n=248) 
    X1 C. Expression .013 .003 .002 .006 .179 3 - .245 .471 
X2 C. Experience .026 .016 .015 .019 .591  1a .755 - .657 
X3 PANSS Marder .017 .005 <.001 .007 .231 2 .529 .343 - 
Overall fit R2M = .032 
                   Do you have a close Friend? (n=254) 
     X1 C. Expression .035 .013 .005 .018 .120 3 - .069 .000 
X2 C. Experience .096 .055 .028 .060 .406 2 .931 - .324 
X3 PANSS Marder .108 .065 .037 .070 .475  1a 1.000 .676 - 
Overall fit R2M = .147 
                   Number of reported friend contacts in past week (n=255) 
    X1 C. Expression .006 .009 .006 .007 .054 3 - .010 .115 
X2 C. Experience .117 .095 .066 .093 .729  1a .990 - .904 
X3 PANSS Marder .043 .030 .010 .028 .217 2 .885 .096 - 
Overall fit R2M = .127 
                              
a Variable completely dominated all other predictors in the full model 
 
Regarding how many activities the participants took part in over the past week, the three 
subscales together explained a relatively small proportion of the variance (R2M = .032). In a 
similar manner to the PANSS negative subscale, the PANSS Marder negative subscale explains 
only a minimal amount of unique variance (R2<.001). In the bootstrapped estimates the 
experiential subscale was found to dominate both the CAINS expressive subscale in 75.5% of 
cases, and the PANSS Marder negative subscale in 65.7% of cases. In whether participants 
report having a close friend, contrasting with the PANSS negative subscale the PANSS Marder 
negative subscale was found to dominate the CAINS expressive subscale with a moderate 
degree of reproducibility in the bootstrapped analysis (.676). Whilst the CAINS expressive 
subscale was only found to explain a relatively small proportion of unique variance (R2=.005), 
both the CAINS experiential and the PANSS Marder negative subscale explained a relatively 
large proportion of the unique variance (R2=.028 and R2=.037 respectively). 
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5.5. Discussion 
5.5.1. Main findings 
Overall, the association between the CAINS total score and the PANSS negative subscales was 
found to be high. When the CAINS experiential and expressive subscales were considered 
separately, the PANSS negative subscales were found to be strongly associated to the 
expressive subscale, but only moderately associated to the experiential subscale. This finding 
was consistent both with the original configuration of the PANSS negative subscale, and the 
alternative proposed by Marder (Marder et al., 1997) which is considered to be a closer 
representation of the negative symptom construct (Marder et al., 2011). These results appear 
to support earlier findings which suggest the PANSS insufficiently tap into the experiential 
features of negative symptoms (Blanchard et al., 2011). 
In a comparison of the sensitivity of the two scales, the CAINS was found to report a greater 
distinction between participants that reported high and low symptoms, and a larger degree of 
symptom change as the mean change in both scales increased . This relationship was found to 
be particularly robust in the comparison between the CAINS expressive subscale and the 
PANSS negative subscales. In an assessment of incremental validity, the findings suggest that 
the CAINS total and the CAINS experience subscale in particular is a superior predictor to both 
the PANSS negative standard and Marder configuration in a range of indicators relating to 
social impoverishment. However, this relationship was not found to be consistent throughout, 
with the PANSS Marder negative subscale found to be a superior predictor of whether 
participants report having a close friend. 
 
5.5.2. Strengths and limitations: 
The trial from which this data was obtained was a rigorous, multisite trial with a high degree of 
inter-rater agreement on the instruments under investigation. The minimal dropout between 
the two stages assessed means the result is unlikely to have been influenced by a selection 
bias due to attrition. Despite the fact the methodologies undertaken here have been 
extensively used in other disciplines, this study appears to be the first to use either dominance 
analysis or the Bland-Altman plot method to evaluate the properties of this important new 
scale in relation to the PANSS negative subscales. In addition, whilst the convergent validity of 
the CAINS with the BPRS and the SANS has been evaluated (Kring et al., 2013), the scale has 
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not yet been compared to the PANSS despite the instruments extensive use in schizophrenia 
research (Mortimer, 2007). In the assessment of symptom change sensitivity, the direction and 
the effect sizes of the relationships detected were broadly consistent over the three different 
thresholds evaluated, suggesting the results are robust. 
One important limitation of the study is the fact that the sample included only outpatients 
with at least a moderate level of negative symptoms, assessed ten weeks prior to first time 
point included in this analysis. As a result, it is unclear whether the difference detected 
between the CAINS and PANSS negative subscales detected here would be consistent during 
either a period of acute psychotic exacerbation, or in samples where the mean level of 
negative symptoms are very low. In addition, this study was completed with participants that 
were diagnosed with schizophrenia only, and so it is not clear whether these findings would 
extend to patients with other psychotic disorders. Evaluating these outcomes in different 
populations would be helpful in determining the generalisability of these findings. 
Another issue to consider is the fact that the threshold used to determine meaningful negative 
symptom change at 7.14% is substantially lower than the 25% change proposed following a 
comparison of PANSS and the CGI (Leucht et al., 2006). As stated previously, this figure was not 
adopted given the figure corresponds to the PANSS total score, as opposed to the negative 
subscale specifically. In addition, this 25% change score figure was not linear, with smaller 
changes required with participants who reported lower symptoms at baseline. From a practical 
standpoint, adopting a 25% change threshold would have resulted in the vast majority of the 
sample not being eligible, meaning such an analysis would not be feasible in this dataset. As an 
example of this, only five participants experienced a >25% in the PANSS negative subscale. In 
the sensitivity analysis looking at a higher change score threshold (≥±9.5%) slightly larger 
coefficients were reported, even if the estimates were less stable due to the smaller sample 
overall. This suggests that the differences between the CAINS and the PANSS negative subscale 
may be even larger if more stringent change thresholds were adopted.  
In the assessment of incremental validity, one limitation to consider is the fact that social 
impoverishment, determined in this study by social network size, frequency of activity, and the 
closeness of friendships, may be significantly influenced by environmental factors such as 
finances, geography, and the behaviour of friends and family. As a result, it is possible that 
while these findings appear to support the improved incremental validity of the CAINS, this 
improvement may be attributable to the fact that it is influenced to a greater extent by 
environmental factors, rather than a better representation of core negative symptom 
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psychopathology. This argument is supported by the finding that the incremental validity of 
the CAINS experiential subscale appears to be more prominent in determining social network 
size and the frequency of activities conducted, which would be more strongly influenced by 
environmental factors, relative to how close they feel to friends. However, while this is 
possible, it could be considered somewhat surprising given the development process of the 
scale. As outlined in the initial CANSAS review (Blanchard et al., 2011), one of the main 
limitations of earlier scales is the fact that they appear to rely predominantly on observational 
and behavioural indicators. In response to this, the CAINS was designed to focus more on the 
experiential features of negative symptoms, rather than relying on observational referents, 
with the aim of limiting possible environmental effects. This being the case, further work 
examining the incremental validity of the CAINS over the PANSS negative subscale in 
alternative areas, including those less influenced by environmental effects, would be 
informative. 
This study suggests that the CAINS may represent an important advance in negative symptom 
assessment over the PANSS, both in terms of its sensitivity and incremental validity. This is 
important, given the PANSS is recognised to be one of the most established assessment tools 
used in schizophrenia research (Mortimer, 2007). However, in the NIMH-MATRICs consensus 
statement it has been suggested the SANS may be a more sensitive instrument than the 
PANSS, given multiple items are used to measure single constructs (Kirkpatrick et al., 2006), a 
conclusion supported by the findings reported in chapter 3.  Therefore, while this study 
supports the use of the CAINS over the PANSS negative subscale in assessing negative 
symptoms, at present it is not clear whether this improvement in sensitivity and incremental 
validity also extends to the SANS. A replication of this study using the SANS in place of the 
PANSS would be important in determining whether the CAINS is a more sensitive instrument 
than the best of those previously available.   
The final limitation is that given there was no effect of treatment in the original trial from 
which the data was obtained (Priebe et al., 2013a), it was not possible to assess whether the 
CAINS was a more sensitive instrument to evaluate treatment effects, relative to the PANSS 
negative subscale. The finding that the CAINS total and subscale scores appears to better 
differentiate between participants that report high and low symptoms, both cross-sectionally 
and in terms of clinically meaningful change over time, supports the argument that the CAINS 
may be a more sensitive instrument. However, it is not clear whether or how this may 
translate into larger effects sizes in clinical trials.  
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5.5.4. Summary 
In comparison to earlier negative symptom assessment tools such as the PANSS negative 
subscale and the SANS, the CAINS assessment tool is recognised to represent a much closer 
conception of the negative symptom construct as it is currently understood (Blanchard et al., 
2011). In addition, a recent evaluation of the scale suggest excellent psychometric properties, 
with high test-retest reliability, good convergent and divergent validity and, with appropriate 
training, excellent inter-rater reliability (Kring et al., 2013). The current study supports both the 
incremental validity and the sensitivity of the scale relative to one of the most extensively used 
scales in negative symptom assessment (the PANSS), adding further weight to the current 
body of evidence supporting the CAINS as an alternative measure of negative symptoms. In 
addition, the findings support the conclusion that reporting expressive and experiential 
subscales separately may yield further insights, given their heterogeneous association to 
outcomes relating to social impoverishment (Horan et al., 2011). Given the limitation of 
existing scales have been identified as a major barrier in the development of new treatments 
for these symptoms (Kirkpatrick et al., 2006), the CAINS may be considered an important 
advance in the field of schizophrenia research. 
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Chapter 6. Association between negative symptoms and 
subjective quality of life 
 
6.1. Introduction 
The findings in chapter 5 suggest that the CAINS (Kring et al., 2013) may be a more sensitive 
instrument to detect changes in negative symptoms, and that examining experiential and 
expressive deficits as separate constructs may yield new insights in the field. One such area 
that may benefit from examining negative symptoms in this manner is reviewing the 
relationship between negative symptoms and quality of life (QOL). For decades there has been 
a consensus that improving psychopathological symptoms alone should not be deemed a 
sufficient outcome in schizophrenia (Priebe, 2007). In addition to symptom remission, 
objective (OQOL) and subjective (SQOL) quality of life domains such as the ability to manage 
ones needs, maintain satisfying relationships, and participate in productive and enjoyable 
activities are seen as central to the concept of recovery (Liberman et al., 2002). In order to 
achieve these aims, understanding the relationship between quality of life and 
psychopathological symptoms is important. 
Quality of life is typically defined to comprise of two separate constructs, including subjective 
components such as wellbeing and satisfaction with life, and objective components such as 
daily life functioning and external resources, both material and social (Katschnig, 2000, 
Lehman et al., 1982, Priebe, 2007). As highlighted in section 1.6, there is a wealth of evidence 
to suggest there is a strong association between negative symptoms and various aspects of 
objective quality of life (Ho et al., 1998, Hunter and Barry, 2012, Milev et al., 2005, Whitty et 
al., 2008), and either a weak or no association with subjective quality of life (Eack and Newhill, 
2007, Fitzgerald et al., 2001, Priebe et al., 2011b) 
The absence of a strong relationship between negative symptoms and subjective quality of life 
may appear somewhat surprising given the their impact on functional outcomes. However, 
only weak-to-moderate associations between objective and subjective indicators of quality of 
life have been detected in the past (r=.04–.57; Priebe and Fakhoury, 2007). This finding 
extends to patients who exhibit good insight their illness, suggesting this is not attributable to 
merely to a lack of awareness (Doyle et al., 1999). One reason for this weak association may be 
that subjective quality of life appears to be determined by multiple processes, including the 
comparison between expectations and aspirations, a comparison with others, and adaptation 
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over time (Priebe, 2007). Given schizophrenia is highly chronic in nature, with functional 
impairments usually present long before the first psychotic episode (Cornblatt et al., 2007), 
patients are likely to have had a long time to adapt to their current situation. Regarding 
comparison with others, patients with schizophrenia have been found to have small friendship 
networks, with the majority of members being other mental health service users (Harley et al., 
2012), who may well have experienced similar disadvantages and impairments. Consequently, 
whilst the quality of life in these patients may be objectively low, it may not appear so when 
considered in the context of earlier experiences, or to those they are typically in contact with. 
However, it may also be possible that the relationship between subjective quality of life and 
negative symptoms has previously been under-reported due to the manner in which negative 
symptoms have previously been assessed.  
As noted in a review by Blanchard (Blanchard et al., 2011), many of the current assessment 
tools used to measure negative symptoms such as the BPRS (Overall and Gorham, 1962), the 
SANS (Andreasen, 1983), and the PANSS (Kay et al., 1987) insufficiently tap into what the 
interviewees themselves experience, instead relying primarily on behavioural referents. As a 
result, there is evidence to suggest that these scales appear to relate much more to the 
expressive features of negative symptoms, rather than to deficits in experience (Horan et al., 
2011), which is supported by the findings presented in chapter 5.  This being the case, it is 
perhaps unsurprising that scales which primarily focus on external, behavioural referents of 
negative symptoms report a much stronger association with external, objective indicators of 
QOL, in comparison to an individuals subjective experiences. In order to examine the link 
between negative symptoms and SQOL properly, it is important to utilise an assessment tool 
which appropriately captures the experiential features of negative symptoms. 
With this in mind, the aim of this study is to re-evaluate the link between negative symptoms 
of schizophrenia and SQOL using the the two subscales of the CAINS which measure expressive 
and experiential deficits in schizophrenia separately, in addition to the PANSS negative 
subscale. We tested the hypothesis that the association between negative symptoms and 
SQOL relate specifically to experiential deficits, as opposed to expressive deficits, both cross 
sectionally and over time. In addition, we hypothesised that this relationship would maintain 
after controlling for depressive symptoms. Controlling for depression is important, given the 
associations consistently detected between low mood and subjective quality of life (Eack and 
Newhill, 2007, Priebe et al., 2011b) 
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6.2. Research questions 
1) What is the cross-sectional association between experiential and expressive deficits and 
subjective quality of life, and how does this compare to an assessment of negative symptoms 
as a single construct using the PANSS negative subscale? 
2) What is the association in changes over time between experiential and expressive deficits 
and subjective quality of life, and how does this compare to an assessment of negative 
symptoms as a single construct using the PANSS subscale? 
 
6.3. Method 
6.3.1. Sample 
The data used in this analysis was taken from the NESS Study (Priebe et al., 2013a), which is a 
multisite randomised controlled trial designed to evaluate the effectiveness and cost-
effectiveness of body psychotherapy as a treatment for schizophrenia. All participants were 
community outpatients diagnosed with schizophrenia (F20.0-F20.9). The inclusion criteria for 
the study included displaying negative symptoms for a period of at least six months, not 
changing the type of antipsychotic medication six weeks prior the baseline assessment, and an 
ability and willingness to take part in a physically active group. In addition, all participants were 
required to present with at least moderate levels of negative symptoms at the baseline 
assessment stage, defined by a score of at least 18 on the PANSS negative subscale (Kay et al., 
1987). Further details regarding the procedures, inclusion and exclusion criteria are described 
elsewhere (Priebe et al., 2013a).  
 
6.3.2. Assessment tools 
Assessments were conducted at three timepoints; baseline, end of treatment 10 weeks later, 
and then at six months follow-up. At each stage the CAINS (Horan et al., 2011), the PANSS (Kay 
et al., 1987), the Manchester Short Assessment of Quality of Life scale (MANSA) (Priebe et al., 
1999), and the Calgary depression scale (Addington et al., 1993) were completed.  
The CAINS (Horan et al., 2011) is a scale designed to address the conceptual and 
methodological limitations of earlier negative symptom assessment tools (Blanchard et al., 
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2011). Although the scale can provide a single summary score, the authors recommend 
reporting the emotional experience and expression subscales seperately given the evidence 
that they are measure distinct constructs (Kring et al., 2013). The PANSS (Kay et al., 1987) is a 
30-item semi-structured interview designed to provide an overall measure of the symptoms of 
schizophrenia. In this study, the Marder factor solution of the PANSS negative subscale was 
adopted (Marder et al., 1997). This subscale excludes the abstract thinking and stereotypical 
items from the negative subscale given they are understood to relate more to cognitive 
defecits (Bryson et al., 1999), and are replaced by the active social withdrawal and motor 
retardation items.  
Subjective quality of life was measured by the MANSA (Priebe et al., 1999). The questionnaire 
consists of 16 items; 12 subjective and 4 objective. The 12 subjective items are rated on a 1-7 
scale, and cover self-rated satisfaction regarding employment, finances, recreational activities, 
friendships, safety, housing, health, sex-life, family and overall life satisfaction. The 4 objective 
items are rated as yes or no, and cover whether they have been a victim of a crime, been 
accused of crime, have anyone they consider a close friend, or have seen a friend in the past 7 
days. In this analysis, a mean total of the 12 subjective items were calculated to create a 
summary score. In cases where more than 1 item was not completed, the summary score was 
not included in the analysis. 
Given the substantial overlap between low mood and a reduced subjective quality of life, it has 
been recommended that any investigation of subjective indicators of social outcomes be 
controlled for mood as a potential confounder (Priebe, 2007). This being the case, depressive 
symptoms were assessed using the Calgary depression scale (Addington et al., 1993), which a 
scale designed to measure such symptoms specifically in schizophrenia populations. The 
questionnaire comprises of 9 items, rated from 0-2, with a higher score indicating more severe 
depressive symptoms.  
 
6.3.3. Analysis 
In the first part of the analysis the association between SQOL and expressive deficits, 
experiential deficits, depressive symptoms, and a summary of the overall negative symptom 
construct was examined cross-sectionally using univariate regression analysis. Any predictors 
approaching significance (p<.10) were then included in a multivariate regression model. In 
order to test the robustness of any associations detected, this part of the analysis was 
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replicated using both the end of treatment and six month follow up data in a sensitivity 
analysis. 
In the second part of the analysis, longitudinal modelling was used to explore the association 
between the change in negative symptoms and SQOL over time. Symptom change-scores were 
calculated by subtracting the follow-up stage assessment scores (T3) from the end of 
treatment scores (T2), and then the end of treatment scores (T2) from the baseline scores (T1), 
resulting in two panels of change-score data. The univariate associations between the change 
scores in SQOL and different measures of negative symptoms were then evaluated by way of 
multi-level modelling, with each change score (level-1) nested within participants (level-2) 
included as a random effect.  Variables significant in univariate analysis were then analysed in 
a multivariate model, including the change scores of the Calgary depression scale to control for 
the association between depression and SQOL. All analysis was conducted using STATA version 
11.0 (StataCorp, 2009). 
 
6.4. Results 
6.4.1. Description of sample 
The participant characteristics are presented in table 36. Participants were mostly male 
(73.8%) with a relatively long history of illness (mean=13.6 years, SD=9.1). At study intake, 
participants reported depressive symptoms in the low range (Calgary scale mean=4.70, 
SD=4.37), and negative symptoms in the moderate range (PANSS Marder negative subscale 
total score=22.1, SD=4.8). A total of 275 participants completed the baseline assessment and 
255 were successfully followed up, resulting in a retention rate of 92.7%. No significant 
differences were detected between completers and drop-outs at the baseline assessment in 
either the MANSA, CAINS, or PANSS negative standard or Marder subscale scores. The inter-
rater reliability scores between the assessors in both the CAINS and the PANSS was high 
(PANSS ICC=.850; CAINS total ICC=.802). At all three timepoints the Calgary depression mean 
score distributions were found to be highly positively skewed, so a square root transformation 
of the data was performed. 
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Table 36: socio-demographic details of the sample 
  Variable   Total 
       N=275. 
    
  
Age (mean, SD) 42.2 10.65 
   
  
Gender (n, %) 
 
  
 
Male 
 
203 73.8% 
 
Female 
 
72 26.2% 
   
  
Ethnicity (n, %) 
 
  
 
White 
 
142 51.6% 
 
Black 
 
80 29.1% 
 
Asian 
 
30 10.9% 
 
Other 
 
23 8.4% 
   
  
Employment (n, %)   
 
Unemployed 263 95.6% 
 
Other 
 
12 4.4% 
   
  
Living situation (n, %)   
 
Alone 
 
156 56.7% 
 
With others 119 43.3% 
   
  
Duration of illness in years (mean, SD) 13.6 9.1 
     
Number hospitalisations (median, IQR) 3 1-5 
     
 
The mean values of the CAINS subscales, the PANSS Marder negative subscale, the Calgary and 
the MANSA are presented in table 37. A small significant reduction was detected in the CAINS 
experience subscale, and the PANSS Marder negative subscale. No signifcant difference was 
detected in the Calgary scale, the MANSA, or the CAINS expressive subscale. 
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Table 37: Mean scores and change over time. 
 
T1 T2 T3 
 
F P 
Variable Mean SD Mean SD Mean SD 
 
          MANSA SQOL 4.44 0.93 4.58 0.89 4.52 0.95 
 
1.51 0.221 
PANSS Negative (Marder) 22.07 4.83 20.51 5.43 20.13 5.61 
 
10.07 <.001 
CAINS Expression  1.94 0.92 1.85 0.98 1.78 1.04 
 
1.76 0.174 
CAINS Experience 2.42 0.62 2.24 0.64 2.29 0.71 
 
4.92 0.008 
Calgary Depression scale 4.69 4.36 3.92 4.30 4.11 4.15 
 
2.37 0.094 
              
 
  
 
6.4.2. The association between negative symptoms and subjective quality of life 
The associations between negative symptoms and SQOL are reported in table 38. In the cross-
sectional analysis at baseline a significant negative association was found between SQOL and 
the CAINS experiental subscale (B=-0.43, 95% CI=-0.62 to -0.25, R2=.083). No association was 
detected between the SQOL and the PANSS Marder negative subscale (B=-.01, 95% CI=-0.04 to 
0.01, R2=.004), or the CAINS expression subscale (B=-0.09, 95% CI=-0.03 to 0.22, R2=.009). As 
expected, a strong negative association between depressive symptoms and SQOL was 
detected (B=-0.10, 95% CI= -0.12 to -0.08, R2=.220). In the multivariate analysis, a significant 
negative association was detected between experiential symptoms and SQOL after controlling 
for depressive symptoms (adj. B= -0.25, 95% CI -0.42 to -0.08).  
 
Table 38: Cross sectional associations between negative symptoms, depression and SQOL at baseline 
  
  
Univariate model 
 
Multivariate model 
B SE B 95% CI P R² 
 
Adj. B SE B 95% CI P 
             
CAINS 
Experiential  
-0.434 0.092 -0.616 -0.252 <.001 .083 
 
-0.254 0.087 -0.425 -0.083 .004 
CAINS 
Expressive  
0.093 0.064 -0.033 0.218 .147 .009 
 
- 
    
PANSS 
Negative  
-0.013 0.012 -0.037 0.012 .306 .004 
 
- 
    
Calgary  
Scale 
-0.098 0.012 -0.122 -0.075 <.001 .220 
 
-0.090 0.012 -0.114 -0.066 <.001 
                          
 
In the sensitivity analysis, the association between negative symptoms and SQOL are 
presented in table 39. Overall, the findings were broadly consistent with those reported at the 
baseline stage. At both the end of treatment and 6 months follow-up, the Calgary depression 
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scale and the CAINS experiential subscale was found to be negatively associated with SQOL. 
After controlling for depressive symptoms, an inverse association between SQOL and the 
CAINS experiential subscale remained significant at  6-months follow-up (adj. B=-0.20, 95% CI=-
0.36 to -0.04, P=.014). At the end of treatment stage the relationship between experiential 
symptoms and SQOL was not found be significant (adj. B=-0.15, 95% CI=-0.32 to 0.01, P=.061), 
however evidence of a weak effect was detected. 
 
Table 39: Sensitivity analysis exploring the cross sectional associations at end of treatment and 6 months follow up 
  
  
Univariate model 
 
Multivariate model 
B SE B 95% CI P R² 
 
Adj. B SE B 95% CI P 
            
Associations at end of treatment          
CAINS 
Experiential 
-0.314 0.087 -0.486 -0.143 <.001 .053 
 
-0.154 0.082 -0.316 0.007 .061 
CAINS 
Expressive 
0.049 0.059 -0.068 0.166 .414 .003 
 
 -     
PANSS 
Negative 
-0.018 0.011 -0.040 0.003 .093 .012 
 
 -     
Calgary 
Scale 
-0.095 0.012 -0.118 -0.071 <.001 .217 
 
-0.089 0.012 -0.113 -0.065 <.001 
             
Associations at 6 months follow-up       
CAINS 
Experiential 
-0.373 0.086 -0.541 -0.204 <.001 .077 
 
-0.200 0.081 -0.359 -0.042 .014 
CAINS 
Expressive 
0.098 0.596 -0.019 0.215 .102 .012 
 
 -     
PANSS 
negative 
-0.008 0.011 -0.031 0.014 .452 .002 
 
 -     
Calgary 
Scale 
-0.114 0.013 -0.140 -0.087 <.001 .234 
 
-0.103 0.014 -0.131 -0.075 <.001 
  
 
6.4.3. The association between the changes in negative symptoms and subjective 
quality of life over time 
The association between the change in negative symptoms and SQOL over time are reported 
in table 40. A negative association was detected between SQOL and experiential symptoms 
(B=-0.21, 95% CI= -0.34 to -0.09, P=.001), depressive symptoms (B=-04, 95% CI= -0.05 to -0.02, 
P<.001), and the PANSS Marder negative subscale (B=-02, 95% CI= -0.03 to 0.00, P=.044). No 
significant association was detected between the changes in expressive symptoms and SQOL. 
In the multivariate analysis, experiential symptoms, depressive symptoms and the PANSS 
Marder negative subscale were all included in the model. Significant negative associations 
between SQOL and depressive symptoms (adj. B=-0.03, 95% CI= -0.05 to -.01, P=014), and 
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experiential symptoms (adj. B=-0.18, 95% CI= -0.31to -.04, P=.008) were detected, whilst the 
relationship between the PANSS Marder negative subscale and SQOL was no longer significant 
(adj. B= 0.00, 95%  CI= -0.02 to 0.02, P=.882). 
 
Table 40: Associations between the change in negative symptoms, depression and SQOL over time 
 
Univariate model 
 
Multivariate model 
  B SE B 95% CI P R² 
 
Adj. B SE B 95% CI P 
            
CAINS 
Experiential 
-0.212 0.063 -0.336 -0.089 .001 .027 
 
-0.175 0.067 -0.306 -0.045 .008 
CAINS 
Expressive 
-0.048 0.052 -0.150 -.0533 .352 .002 
 
-     
PANSS 
negative 
-0.016 0.008 -0.321 .000 .044 .009 
 
-0.001 0.009 -0.019 0.016 .882 
Calgary 
Scale 
-0.035 0.010 -0.055 -0.015 <.001 .028 
 
-0.026 0.010 -0.046 -0.005 .014 
                         
 
6.5. Discussion 
6.5.1. Main findings 
These findings suggest that there is a stronger association between SQOL and negative 
symptoms than has been previously reported (Eack and Newhill, 2007), however this 
relationship appears to relate specifically to experiential deficits. In the cross-sectional 
analysis, a significant negative association was detected between subjective quality of life and 
the experiential deficits in negative symptoms of schizophrenia, which remained significant 
after controlling for depressive symptoms. In an analysis of the association between negative 
symptoms and SQOL over time, again only the experiential features of negative symptoms 
were found to be a significant predictor. These findings suggest that relationship between 
SQOL and negative symptoms may have previously been under-reported due to a number of 
assessment tools not adequately assessing experiential deficits, and the way in which negative 
symptoms have been typically examined as a singular construct.  
 
6.5.2. Strengths and weaknesses 
The data came from a large, multi-centre trial with excellent study retention rates (92.7% from 
baseline to the final follow-up assessment). The inter-rater reliability between the assessors on 
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both the PANSS and the CAINS was high (PANSS ICC=.85; CAINS ICC=.80). In the sensitivity 
analysis, the findings were broadly consistent at all three assessment stages. The specificity of 
the results (i.e. that only the relationship to experiential deficits, and not expressive deficits, 
was significant) suggest that the effect over time is not a consequence of regression to the 
mean. Lastly, a significant association was detected between the change scores in expressive 
symptoms and SQOL, despite only a small reduction in these variables over time, which 
suggests that the findings are robust.  
The main limitation of the study relates to a possible selection bias. The data came from a 
study evaluating participants which all reported at least moderate levels of negative symptoms 
at baseline, and were all outpatients at study intake. Consequently, it is not clear whether 
similar estimates would be present in either acute samples, or in participants with lower 
negative symptoms at study intake. In addition, the sample is predominantly male, and chronic 
in nature with an average duration of illness of 13.6 years. This being the case, it is not clear 
whether the findings are generalisable to females, which may be significant given there is 
some evidence which suggests that different factors may influence subjective quality different 
between genders (Röder-Wanner and Priebe, 1998). In addition, evaluating the relationship in 
samples with a less chronic duration of illness may also be important given SQOL appears to be 
lower in newly treated patients (Priebe et al., 2000),  with evidence to suggest that the impact 
of symptoms on SQOL appears to be more prominent in the early stages of the illness (Browne 
et al., 2000).  
 
6.5.4. Conclusion 
The link between SQOL and negative symptoms appears to be stronger than what was 
originally presumed, however this relationship appears to exist almost exclusively with 
experiential deficits. These findings support the model which suggests that an improvement in 
symptoms can result in improvements in SQOL, and so have important implications for 
treatment development. In the future, it may be important to focus on interventions which are 
effective at ameliorating experiential symptoms if the aim is to improve quality of life as part 
of a wider programme to support patient recovery. In addition, these findings lend further 
support for the use of the CAINS over other assessment tools for negative symptoms such as 
the PANSS, and highlight the importance of assessing the experiential and expressive 
subdomains of negative symptoms separately. 
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Chapter 7. The impact of negative symptoms on the subjective 
initial appraisal of psychiatric inpatient treatment 
 
7.1. Introduction  
Following the examination of the link between negative symptoms and subjective quality of 
life, in this investigation the aim is to extend this to another patient reported outcome, namely 
the appraisal of treatment. The evidence suggests that patients with schizophrenia who have a 
more positive initial appraisal of their treatment are likely to benefit more from that treatment 
eventually. This applies to pharmacological treatment (Awad et al., 1995, Bartkó et al., 1987, 
Van Putten et al., 1981, Van Putten and May, 1978) and complex interventions (Bröker et al., 
1995, Priebe and Gruyters, 1994, Priebe and Gruyters, 1995, Priebe et al., 2010a). In 
inpatients, a more positive initial appraisal of treatment was associated with lower symptom 
levels after one month (Richardson et al., 2011a), at discharge (Bröker et al., 1995), lower 
social impairment at 3 and 12 months (Priebe et al., 2011a), and lower subsequent involuntary 
readmission rates (Priebe et al., 2009). Developing a greater understanding of the factors 
which influence how patients appraise their hospital treatment in the initial stages would help 
identify those at risk of being less satisfied with their treatment, and could assist in the 
development of new interventions to maximise patients’ initial appraisal of treatment. 
Factors which may significantly impact the initial appraisal of inpatient treatment are the 
symptoms that patients experience at the point of admission. Regarding how symptoms may 
impact the initial appraisal of treatment, a number of different theories could be considered. 
One argument is that subjective initial appraisal may be inversely related with mood, given the 
consistent association detected between depressive symptoms and other patient reported 
outcomes (Fakhoury et al., 2002, Priebe et al., 1998). However, an alternative argument could 
be that appraisal of inpatient treatment is closely related to insight, which has been found to 
be positively associated with positive and negative symptoms, and inversely associated with 
depressive symptoms (Mintz et al., 2003). This may be significant, as lower insight has been 
found to be associated with a less positive attitude to treatment such as the medication 
prescribed (Freudenreich et al., 2004). In an examination of the temporal ordering of 
symptoms and inpatient treatment satisfaction (Richardson et al., 2011a) inverse correlations 
were detected between initial appraisal of treatment and positive, manic, and depressive-
anxiety symptoms. However, these relationships were not considered in a multivariate model, 
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so it is unclear whether this association reflects a specific action to that symptom domain, or 
represents a shared association with other symptom types.  
Whilst any links between symptoms and subjective initial response (SIR) may not yet be clear, 
the association between the appraisal of treatment and the legal status of the hospital 
admission is a lot more established. In a review comparing involuntary and voluntary hospital 
treatments, involuntary patients were found to be more dissatisfied with treatment, and were 
more likely to report that the hospitalisation was not justified (Greenwood et al., 1999, Kallert 
et al., 2007). This difference does not appear to be attributable to more severe 
psychopathology, given only minimal differences in the presentation of symptoms have been 
found at the point of admission (Kallert et al., 2008).  However, while the severity of symptoms 
may be similar between voluntary and involuntary symptoms, their impact on the appraisal of 
treatment may not be. Experiencing positive symptoms such as paranoid delusions and manic 
symptoms such as agitation may be more difficult when there is a greater restriction in 
autonomy. Patients with negative symptoms who experience severe apathy and social 
withdrawal may struggle with being placed in a busy ward against their will. Consequently, in 
the analysis the impact of symptoms will be compared between those who are admitted 
voluntarily and involuntarily. 
During an acute episode when schizophrenia patients would typically be admitted, positive 
symptoms can often dominate the picture, masking other features of the disorder such as 
negative symptoms (Möller, 2007). In addition, the severity of symptoms experienced is likely 
to be temporary in nature as symptoms are controlled with drug treatment. Consequently, 
implementing the inclusion criteria to determine either persistent negative symptoms 
(Buchanan, 2007) or disentangling primary and secondary symptoms (Carpenter et al., 1985) is 
highly challenging in newly admitted patients. However, given the aim of this investigation is to 
examine the impact of symptoms over a very short period (i.e. the point of admission) 
determining antecedents of negative symptoms may not be of primary importance in this 
context, whilst conducting multivariate analysis can control for the impact of other symptoms. 
As a result, no attempt at a distinction between primary and secondary negative symptoms 
will be made. 
In this study the aim is to identify what types of symptoms are associated with the initial 
appraisal of hospital treatment in patients with schizophrenia, after adjusting for the influence 
of socio-demographic and other clinical characteristics given their impact on patient reported 
outcomes.  
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7.2. Research questions 
1) What is the association between negative symptoms and initial appraisal of inpatient 
treatment, and how does this compare to other symptoms of schizophrenia? 
2) Is the association between symptoms and initial appraisal of treatment different in 
those that were voluntarily and involuntarily admitted? 
 
7.3. Methods 
7.3.1. Design 
This investigation is an exploratory, cross-sectional study examining the association between 
symptoms and the initial appraisal of inpatient treatment, after controlling for other 
sociodemographic and clinical variables. All the assessments took place within the first week 
following the admission, and were conducted by a researcher not involved in the patients’ 
treatment. The diagnosis was obtained from the participants’ medical notes at the point of 
discharge.  
 
7.3.2. Sample 
The current sample was obtained from pooling data from three studies. The InvolvE study 
(Priebe et al., 2009) assessed characteristics and experiences of in-patients in 22 hospitals 
across England. The EUNOMIA study (Kallert et al., 2005, Priebe et al., 2010a) was a related 
study with a similar design conducted at sites in 11 European countries. Both studies had a 
focus on involuntarily admitted patients, but also included voluntary patients who felt coerced 
to treatment. The EUNOMIA data from the London site was included as part of the InvolvE 
study, and so these were omitted from the EUNOMIA sample to ensure that participants were 
not included twice. The third study, EDEN (Kallert et al., 2007), was a randomised controlled 
trial comparing outcomes of voluntary patients in day hospitals with those in conventional in-
patient settings. Details of the rationale, methods and findings of each of the three studies 
have been described in in detail in the referenced papers. 
All three studies included consecutively admitted patients aged between 18 and 65 who had 
the capacity to provide informed consent. The exclusion criteria consistent over all three 
studies included being admitted because of acute intoxication, being a forensic patient, and 
being transferred from another hospital. In the EDEN study patients requiring 1-to-1 
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supervision were excluded, whilst in the EUNOMIA and InvolvE studies voluntary patients who 
did not report a coercion level of at least 3 on the MacArthur Admission Experience Survey 
were excluded. For this study, only participants with a primary diagnosis of schizophrenia or a 
related disorder according to ICD-10 (F20-29) were included. Therefore, participants with 
other psychotic disorders such as schizoaffective disorder were included in this study, unlike 
with other investigations completed in this body of work. In the previous investigations 
completed in this study participants were omitted given concerns regarding both the 
diagnostic stability of schizoaffective disorder (Malhi et al., 2008), and the fact that the 
disorder appears to follow a different longitudinal course (Harrow et al., 1997). However, given 
symptoms in the current investigation were only considered cross-sectionally, the longitudinal 
course of symptoms was not deemed as relevant. With respect to the EDEN study, only 
patients treated in conventional inpatient hospital settings were included.  
Whilst the substantially larger samples that can be derived from pooling multiple studies has 
benefits in terms of detecting very small effects and interpreting non-significant results, the 
technique is also considered to have a limitations. The most significant problem is that such a 
technique can ignore important subgroup characteristics (Bravata and Olkin, 2001), which can 
in turn result in either generate associations that do not exist, or hide associations that do 
(Pearson et al., 1899, Robinson, 1950, Yule, 1903). Therefore, in order to test the robustness of 
the estimates obtained from the pooled analyses, the analysis will also be conducted on the 
largest single study sample (EUNOMIA). 
 
7.3.3. Measures  
An assessment of the initial appraisal of hospital treatment was obtained using the Client Scale 
for Assessment of Treatment (CAT) (Priebe and Gruyters, 1995). The questionnaire has seven 
items and asks the patient whether they believe they are receiving the right care, whether 
their psychiatrist understands them and if other staff are pleasant to them, if they believe they 
are on the right medication, if they feel well respected and regarded, whether the care 
received has been helpful, and whether they feel other elements of their care are appropriate. 
Scores range from 0 (“not at all”), to 10 (“yes entirely”). Patients with missing data on four or 
more items were excluded from the analysis. Recent factorial analysis supports the use of the 
CAT as a meaningful unidimensional scale, stable over three different European countries 
(Richardson et al., 2011b). In previous research the CAT has been found to have excellent 
internal consistency (α=.90) (Priebe et al., 2009). 
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Symptom severity was measured on the 24-item version of the Brief Psychiatric Rating Scale 
(BPRS-E) (Overall and Gorham, 1962). While the scale is recognised to have a number of 
significant limitations in the measurement of negative symptoms (as summarised in section 
1.9.1.2), the instrument was adopted given the need to capture a broader clinical picture, 
assessing manic, positive and depressive symptoms in addition to negative symptoms. Whilst 
the scale may not be recommended as a primary outcome for negative symptom trials in 
either the MATRICS or ISCTM consensus statements (Kirkpatrick et al., 2006, Marder et al., 
2011), the scale has been successfully used as a measure of negative symptoms in other recent 
major investigations (Kring et al., 2013) suggesting the use of the scale is appropriate. 
With the BPRS, various 4 and 5 factor models have been proposed, with a summary of these 
outlined in section 1.9.1.2. In this study, the model proposed by Velligan (Velligan et al., 2005) 
was adopted, given the study was one of the few to be completed with a sufficiently large 
sample size in which to conduct factor-analysis, and the fact that both confirmatory factor 
analysis and exploratory analysis was completed. The Velligan model includes 4 different 
factors, assessing negative, positive, manic/activation, and affective symptoms separately. The 
negative symptom subscale comprises of 3 items, including “blunted affect”, “motor 
retardation” and “social withdrawal”. The positive subscale comprises of 4 items, including 
“conceptual disorganisation”, “hallucinations”, “bizarre behaviour” and “unusual thought 
content”. The mania subscale includes 3 items, assessing “excitement”, “motor hyperactivity” 
and “tension”.  Finally, the depressive-anxiety subscale includes the “anxiety”, “depression”, 
“suicidality” and “guilt” items. In the BPRS a mean of the items in each subscale are calculated 
to determine a summary score, with scores ranging from 1 (“Not present”) to 7 (“extremely 
severe”). In the original studies the inter-rater reliability between researchers using the BPRS 
was high, with researchers on the InvolvE project achieving a Cohen’s Kappa score of .90, while 
researchers on the EDEN and EUNOMIA studies achieved an intra-class coefficient score of .78.  
Socio-demographic details including age, gender, marital status, previous admission history 
and employment status were obtained using the MANSA (Priebe et al., 1999) in the InvolvE 
and EUNOMIA studies, and the Clinical History Schedule (Kallert et al., 2000) in the EDEN 
study. The categories used were identical in the three studies. The employment and marital 
status the variables were dichotomised i.e. “employed, in training or education” vs. 
“unemployed/other”, and “married” vs. “unmarried” (which included those divorced, single 
and widowed). This was done for two reasons. Firstly, in the case of employment the aim was 
to differentiate between those who did and did not having a regular occupation, rather than 
focusing on whether participants received a payment for employment. Secondly, a number of 
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the groups contained only a small number of individuals (i.e. in training or education totalled 
less than 4% of participants, whilst housewife/househusband totalled less than 3%), meaning 
the groups would be insufficiently powered to detect small differences. 
  
7.3.4. Analysis 
In the first part of the analysis correlations between the different symptom factors were 
explored, given concerns that symptoms such as depression and negative symptoms can be 
difficult to distinguish in scales that have not been designed specifically for this purpose 
(Addington et al., 1993, Collins et al., 1996) (See section 1.3.1.3 for a review). While there is 
evidence to suggest that the measurement of depression can be conflated with negative 
symptoms in instruments such as the Hamilton Depression Scale (Addington et al., 1996), this 
has finding has been inconsistent, with other studies suggesting that these constructs can be 
measured independently by scales such as the BPRS (Newcomer et al., 1990). 
In the next part of the analysis, the association between symptoms and the initial appraisal of 
impatient was assessed, after controlling for a number of clinical and sociodemographic 
variables. These included age, gender, employment status, marital status, and the legal status 
of admission. Any association between symptoms and SIR that were found to approach a level 
of significance (P<.10) were then added to a multivariate model in order to determine whether 
the association was specific to that symptom cluster. In the final part of the analysis, 
interaction effects between legal status and each BPRS subscale score were added to the 
multivariate model separately in order to examine whether the effect of symptom severity on 
the appraisal of treatment differed between those legally detained and those admitted 
voluntarily.  
The impact of different studies was not controlled for, given one study (EDEN) included only 
voluntary patients. Since one aim was to assess the impact of legal status, entering this 
variable would have confounded this part of the analysis. In order to rule out the possibility of 
any bias in the results occurring due to the heterogeneity of the samples used, a subgroup 
analysis was conducted on the largest dataset (EUNOMIA).  
To tackle any potential issues which could arise through a listwise deletion of incomplete cases 
(Little and Rubin, 1989) a multiple imputation using a chained equation of 10 cycles was 
conducted. All values included in the analysis were entered both as predictors and for 
imputing, other than the dependent variable which was included as a predictor only. Following 
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the recommendations by Spratt (Spratt et al., 2010), 25 imputations were conducted with the 
analysis conducted on the pooled data. R2 scores were obtained from the imputed data in 
accordance with Rubin’s rules by calculating the estimate from each imputed sample and then 
calculating an overall mean of these estimates (Rubin, 1987). All the analysis was conducted in 
SPSS version 20. 
 
7.4. Results 
7.4.1. Sample characteristics 
In total, 2316 patients met the inclusion criteria. 211 patients were omitted due to missing or 
incomplete CAT scores, leaving 2105 patients in the final sample. The clinical and socio-
demographic characteristics of this sample are presented in Table 41. The mean age of 
participants was 38.5 years (SD=11.24), with a fairly even split between males and females 
(56.9%-43.1%). Participants experienced a relatively long duration of illness (7.84 years, 
SD=9.11), most had experienced at least one previous inpatient admission (76.6%), and in the 
current hospital stay the majority were admitted involuntary (72.7%). The most severe 
symptoms experienced were positive symptoms (mean=2.92, SD=1.26), and the least severe 
were manic symptoms (mean=1.97, SD=1.11). Overall, participants reported being moderately 
satisfied with their treatment (CAT mean=6.00, SD=1.28). 
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Table 41: Socio-demographic and clinical characteristics of the patients 
 Characteristics  n or mean % or SD 
          
     
Patients (N)  2105  
     
% detained involuntarily  1530 72.7% 
     
Age (years)  38.49 11.24 
     
Gender (% female)  906 43.1% 
     
Number married (n, %)  454 22.0% 
     
Employed/training/education  465 22.4% 
     
Previous psychiatric admission (%Yes)  1517 76.7% 
     
Illness Duration (mean, SD)  7.84 9.11 
    
BPRS (mean, SD)    
 Depression/anxiety subscale score  2.24 1.08 
 Mania subscale score  1.97 1.11 
 Negative subscale score  2.14 1.08 
 Positive subscale score  2.92 1.26 
     
CAT mean score  6.00 1.28 
          
BPRS= Brief Psychiatric Rating Scale; CAT= Client Assessment of Treatment 
scale 
 
As stated previously, the sample was pooled from three different studies, with the socio-
demographic and clinical breakdown studies presented in table 42. In total, 1556 participants 
were recruited as part of the EUNOMIA project, 393 as part of the InvolvE study, and 156 as 
part of the EDEN study. As anticipated, given the nature of the three projects some differences 
were noted between the studies. In the InvolvE and EUNOMIA studies, a substantial 
proportion of participants were admitted on an involuntary basis, whilst 100% of the sample 
was admitted voluntarily in the EDEN study. Although the proportion of participants who had 
been previously experienced a psychiatric admission (71.4-77.5%), and age (35.83 years – 
39.17 years) were similar between studies, a number of other differences were evident. In the 
EDEN study participants were more likely to be female, either employed and/or in training, 
married, and with a lower duration of illness. Regarding symptoms, in the EDEN study the 
sample was found to include experience more severe depressive symptoms, and less severe 
negative, positive and manic symptoms. In a comparison of the InvolvE and EUNOMIA 
datasets, manic and negative symptoms were found to be slightly higher in the EUNOMIA 
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sample, whilst depressive/anxiety symptoms were slightly higher in the InvolvE sample, with 
positive symptoms being broadly similar. Participants reported being the least satisfied in the 
InvolvE sample (CAT mean=5.36, SD= 2.91), and most satisfied in the EDEN sample (CAT 
mean=7.69, SD=1.98) 
A missing value analysis indicated that 2.8% of all predictor values (653 in total) were missing, 
with 21.1% of cases (445) missing at least one. Of the 653 values missing in total, 53.9% (352 in 
total) related to the duration of illness. 
 
Table 42: demographics by study 
Variables 
Studies 
Eunomia InvolvE Eden 
N or mean  % or SD N or mean  % or SD N or mean  % or SD 
   
 
 
 
 
 
n 
 
1556  393  156  
   
 
 
 
 
 
% detained involuntarily 1169 75.1% 361 91.9% 156 0% 
  
 
 
 
 
 
 
Age (years) 39.17 11.09 35.83 11.10 38.38 12.15 
  
 
 
 
 
 
 
Gender (% female) 689 44.3% 116 29.5% 101 64.7% 
  
 
 
 
 
 
 
Marital status (% married) 328 21.4% 67 17.5% 59 39.9% 
  
 
 
 
 
 
 
Employed/in training 327 21.3% 71 18.4% 67 43.8% 
  
 
 
 
 
 
 
Prev. admission (%Yes) 1179 77.5% 288 74.6% 50 71.4% 
  
 
 
 
 
 
 
Illness Duration 8.41 9.38 6.91 8.45 4.68 7.05 
       
BPRS 
 
 
 
 
 
 
 
Depression/anxiety 2.09 1.01 2.43 1.20 3.20 0.90 
 
Mania 1.93 1.00 1.63 0.84 1.55 0.51 
 
Negative 2.27 1.11 1.77 0.92 1.85 0.89 
 
Positive 3.07 1.22 3.01 1.21 1.35 0.50 
  
 
 
 
 
 
 
CAT 6.00 2.69 5.36 2.91 7.69 1.98 
             
BPRS= Brief Psychiatric Rating Scale; CAT= Client Assessment of Treatment scale 
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7.4.2. Symptoms and other patient characteristics associated with initial appraisal 
of treatment  
Correlations between symptoms and the initial appraisal of treatment are presented in table 
43. A moderate negative correlation was detected between the initial appraisal of treatment 
and positive and manic symptoms (r=-.228 and r=-.233 respectively). A weak negative 
correlation was found between negative symptoms and SIR (r=-.041), and a weak positive 
correlation was detected between depressive symptoms and SIR (r=.049). Although moderate 
correlations were detected between some symptoms, these were not of a sufficient level to 
suggest that collinearity may be an issue in the multivariate analysis. The strongest correlation 
was detected between positive and manic symptoms (r=.422), whilst the correlation between 
negative and depressive/anxiety symptoms was much lower than what was originally 
anticipated (r=.127). 
 
Table 43: Correlation table of symptoms subscales and appraisal of treatment 
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Subjective initial appraisal (CAT) ** .049 -.233 -.041 -.228 
Depression/Anxiety symptoms 
 
** -.028 .127 -.080 
Manic symptoms 
  
** .104 .422 
Negative symptoms 
   
** .250 
Positive symptoms 
    
** 
 
 
The associations between symptoms and the initial appraisal of treatment are presented in 
table 44. After controlling for age, gender, admission history, illness duration, legal status, 
employment situation and marital status, higher mania and positive symptoms were found to 
be associated with a lower initial appraisal of treatment (manic symptoms adj. B= -0.474, 95% 
CI -0.577 to -0.372, P<.001, R2=.036; positive symptoms adj. B= -0.367, 95% CI -0.460 to -0.274, 
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P<.001, R2=.027). A negative relationship between negative symptoms and initial appraisal of 
treatment was detected, however this was not significant, with the estimates found to be just 
outside the specified threshold to be included in the multivariate analysis (adjusted 
coefficient= -0.089, 95% CI -0.197 to -0.019, P=.106). No relationship between 
depressive/anxiety symptoms and initial appraisal of treatment was found. 
In the multivariate analysis, both higher mania and positive symptoms were found to be 
significantly associated with a lower assessment of the appraisal of treatment (mania adj. B= -
.358, -0.469 to -0.247, P<.001; positive symptoms adj. B =-0.250, 95% CI -0.350 to -0.151, 
P<.001). However, including both symptoms into the model appeared to only explain a 
relatively small proportion of additional variance (R2=.045). 
 
In order to ensure the findings are not attributable to subgroup differences between studies 
(Bravata and Olkin, 2001) a subgroup analysis was completed on just the largest dataset, 
namely the EUNOMIA study. The findings are presented in table 45. Overall, the findings were 
broadly consistent with those reported in the pooled analysis. When symptoms were 
considered separately, a significant negative association was detected between SIR, and mania 
and positive symptoms (mania adj. B= -0.521, 95% CI -0.633 to -0.408, P<.001, R2=.050; 
positive adj. B= -0.416, 95% CI -0.524 to -0.308, P<.001), whilst no relationship between 
depressive/anxiety symptoms and SIR was detected (adj. B= 0.023, 95% CI -0.111 to 0.158, 
P=.735). In a slight change to the pooled analysis, the negative symptom subscale was found to 
be significantly associated with SIR, albeit only explaining a very small proportion of the 
variance (adj. B= -0.157, 95% CI -0.278 to -0.035, P=.012, R2=.002). When symptoms were 
included in the model together, the findings were consistent with the original findings, with 
significant negative associations detected between mania an positive symptoms (mania 
symptoms adj. B= -0.401, 95% CI -0.526 to -0.277, P<.001; positive symptoms adj. B= -0.239, 
Table 44: Associations between symptoms and subjective initial response 
Predictor variablesa 
Univariate analysis  Multivariate analysisB 
B 95 %CI P R2  B 95 % CI P 
         
Depressive/anxiety 0.028 -0.082 to 0.138   .619 <.001     
Mania -0.474 -0.577 to -0.372 <.001   .036  -0.358 -0.469 to -0.247 <.001 
Negative -0.089 -0.197 to 0.019   .106   .001     
Positive -0.367 -0.460 to -0.274 <.001   .027  -0.250 -0.350 to -0.151 <.001 
               
aAssociation between SIR and symptoms, after adjusting for age, gender, admission history, illness duration, legal status, 
employment status, and marital status. 
BR2 change after adding symptoms= .045 
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95% CI -0.360 to -0.117, P<.001), whilst the relationship to negative symptoms was non-
significant (negative symptoms adj. B= -0.102, 95% CI -0.225 to 0.021, P=.104). In the 
multivariate model, the symptoms again explained only a relatively small proportion of the 
total variance in appraisal of treatment (R2=.061). 
 
Table 45: Associations between symptoms and subjective initial response in the EUNOMIA dataset 
Predictor variablesa 
Univariate analysis  Multivariate analysisB 
B 95 %CI P R2  B 95 % CI P 
         
Depressive/anxiety 0.023 -0.111 to  0.158   .735 <.001     
Mania -0.521 -0.633 to -0.408 <.001 .050  -0.401 -0.526 to -0.277 <.001 
Negative -0.157 -0.278 to -0.035   .012 .004  -0.102 -0.225 to  0.021  .104 
Positive -0.416 -0.524 to -0.308 <.001 .036  -0.239 -0.360 to -0.117 <.001 
               
aAssociation between SIR and symptoms, after adjusting for age, gender, admission history, illness duration, 
legal status, employment status, and marital status. 
BR2 change after adding symptoms in the multivariate model= .061 
 
 
7.4.4 Legal status of admission, symptom severity and initial treatment evaluation 
The next stage of the analysis explored whether symptom levels had a different predictive 
value in voluntary and involuntary patients. In order to achieve this, an interaction effect 
between legal status and each symptom subscale score was separately entered into the 
model. Amongst the four symptom subtypes, a significant interaction effect was found for 
manic symptoms (adj. B=0.407, 95% CI 0.138 to 0.676, P=.003), with the results presented in 
figure 18.  The graph suggests that whilst SIR is broadly similar between voluntary and 
involuntary patients when manic symptoms were very low; as they increase the appraisal of 
treatment reduces far more in involuntarily admitted patients, relative to those admitted 
voluntarily. No difference in the impact of symptoms between those that were and were not 
admitted involuntarily were detected in positive symptoms (adj. B= 0.116, 95% CI -0.092 to 
0.325, P=.274), negative symptoms (adj. B= -0.123, 95% CI -0.365 to 0.119, P=.320) or 
depressive/anxiety symptoms (adj. B= -0.112, 95% CI -0.343 to 0.120, P=.345). 
In a post-hoc analysis separating those admitted involuntarily from those admitted on a 
voluntary basis, a significant negative association between manic symptoms and SIR was 
detected in those admitted involuntarily (adj. B=-0.548, 95% CI -0.666 to -0.430, P<.001, R2 
change=.053), whilst the relationship was non-significant in the voluntary sample (adj. B=-
0.124, 95% CI -0.340 to 0.093, P=.263. R2change=.002). 
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Figure 18: Association between manic symptoms and SIR between those that have been voluntarily and 
involuntarily admitted. 
 
 
7.5. Discussion 
7.5.1. Main findings 
The negative symptoms of schizophrenia were not found to be associated with the subjective 
initial appraisal of impatient treatment. Instead, manic and positive symptoms were found to 
be negatively associated how hospital treatment is perceived in the initial stages, after 
controlling for other clinical and sociodemographic variables. The impact of manic symptoms 
appeared to be particularly strong in those patients who were detained involuntarily, as 
opposed to those who are voluntarily admitted. Somewhat surprisingly, no association 
between depressive symptoms and appraisal of treatment was detected, despite the 
consistent negative association between patient reported outcomes and mood which has 
previously been found (Fakhoury et al., 2002, Priebe et al., 1998). 
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7.5.2. Strengths and limitations 
Regarding the strengths of the study, the large sample size (2105 patients) provides sufficient 
statistical power to detect even small effect sizes, thus allowing the interpretation of negative 
findings. In this study observer-ratings of symptoms were used to predict patient-rated 
appraisals of the appraisal of treatment, meaning the associations detected are not a 
consequence of a generalised tendency to provide more or less positive ratings in different 
self-reporting measures (Fakhoury et al., 2002, Hansson et al., 2007). In addition, results were 
consistent in the sensitivity analysis evaluating the EUNOMIA dataset in isolation, suggesting 
the findings are robust. Finally, the Interrater reliability was high in all three studies. In the 
InvolvE study all researchers achieved an interrater reliability of Cohen’s Kappa =.90 in the 
BPRS, whilst in both the EDEN and EUNOMIA an interrater reliability score of ICC=.78 was 
reported. 
One significant limitation of the study is the fact that there appears to be a number of 
differences between the study samples pooled, both in terms of sociodemographic and clinical 
characteristics. In two of the three studies (InvolvE and EUNOMIA), voluntary patients were 
included only if they expressed a level of being coerced. In the third study (EDEN) no 
involuntary patients were recruited. In the EDEN study participants appeared to report lower 
symptoms in all domains, other than in depression/anxiety, and reported a more positive 
appraisal of treatment, whilst a number of sociodemographic differences were evident. As 
highlighted previously, one significant issue with the pooling multiple studies is the fact that it 
can ignore important subgroup characteristics, which can in turn influence any associations 
between variables (Bravata and Olkin, 2001, Pearson et al., 1899, Robinson, 1950, Yule, 1903). 
However, given the findings of the pooled sample were found to be highly consistent with 
those in an analysis of the single largest dataset (EUNOMIA). it suggests that this may not be as 
significant an issue as may first have been assumed.  
Another significant limitation of the study relates to the context in which participants were 
recruited. Given the aim of all three studies was to recruit and assess all participants within the 
first week of an inpatient admission,  it is likely that there may have been a small subsample of 
patients who were too acutely unwell to be eligible for recruitment due to a lack of capacity. 
Whilst problematic, this particular issue is common to all studies which aim to recruit 
participants in this phase of treatment. In a related issue, it is also possible that patients who 
were highly dissatisfied with treatment may be less likely to co-operate in research being 
conducted in this setting. However, his may not be as significant an issue as first assumed 
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given all assessors were independent to the clinical team. This being the case, it is quite 
possible that this sub-group of patients may be more keen to be involved in the research as it 
provides an independent platform in which to discuss their dissatisfaction with aspects of their 
treatment. 
Another limitation is due to the lack of available data, it was not possible to consider what 
treatment participants received during the first days of hospital treatment, and whether 
specific treatments were linked a more positive or negative appraisal of treatment. For 
example it has been recognised that patients with high positive symptoms are significantly 
more likely to be prescribed a high dose of antipsychotic medication (Sim et al., 2004), while 
involuntary admissions have been found to be a significant predictor of antipsychotic 
polypharmacy and high-dose (Lelliott et al., 2002). High-dose and polypharmacy have been 
both been recognised to increase adverse side effects (Centorrino et al., 2004), which in turn 
are considered to be a significant source of discomfort and treatment non-compliance (Cabeza 
et al., 2000, Fenton et al., 1997), which could in turn impact treatment appraisal. Future work 
assessing the nature of treatments that participants receive during the initial hospitalisation 
period may help determine possible mediating factors in associations between symptoms and 
the appraisal of hospital treatment. 
 
7.5.3. Summary 
The findings suggest that patients with different symptom profiles experience and respond to 
psychiatric hospital treatment in different ways and, as a result, express different appraisals of 
treatment within a few days after admission. Patients with schizophrenia experiencing more 
severe manic and positive symptoms, and manic symptoms in particular if detained 
involuntarily, are more likely to report a more negative initial evaluation of treatment. Higher 
negative symptoms do not appear to impact the appraisal of inpatient treatment.  
The findings underline the importance of assessing patients’ initial appraisal of treatment as a 
relevant process variable in both research and routine practice. Further studies may explore 
environmental factors, processes of interaction between service users and staff, treatment 
components and mediating processes as an explanation into the association of manic and 
positive symptoms with more negative appraisals of hospital treatment after only a few days. 
In a recent review Mullen (Mullen, 2009) has suggested that acute inpatient settings are at 
present too custodial and over reliant on medication, and suggests that providing more 
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psychosocial interventions as an alternative may be a way in which to try and address these 
issues.  If these are problems which disproportionally affect those experiencing higher positive 
and manic symptoms, then this possible solution may go some way to addressing the more 
negative experiences these particular patients report. 
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Chapter 8. Discussion 
 
8.1. Thesis aims 
The main aim of this thesis was to explore areas which could either inform the design of 
negative symptom clinical trials, or build upon the current developments in symptom 
assessment. This included examining how negative symptoms change over time, the impact of 
different symptom inclusion criteria adopted in clinical trials, a comparison of different scales 
designed to measure negative symptoms, and the nature of their association to other 
constructs such as subjective quality of life and the initial appraisal of treatment. 
In the first part of this investigation the aim was to explore the longitudinal course of negative 
symptoms in stable schizophrenia outpatients over a period of up to 3 years, pooling a broad 
array of studies by way of meta-analysis. In a meta-regression, study-level variables such as the 
assessment scale used and the eligiblity criteria adopted were examined as predictors of 
differing longitudinal course. Despite symptom inclusion criteriafor negative symptom trials 
being consistently recommended in the literature (Kirkpatrick et al., 2006, Marder et al., 2013, 
Marder et al., 2011), there has been substantial variation in the manner in which they have 
been adopted (Dunayevich et al., 2014, Rabinowitz et al., 2013). Therefore, in Chapter 4 the 
aim was to further explore the impact of adopting differen symptom inclusion criteria on the 
associations between these negative, and positive and depressive symptoms. 
As stated previously, one of the major recent advances in the field has been the development 
of new instruments to measure negative symptoms, such as the  CAINS (Kring et al., 2013) and 
the BNSS (Kirkpatrick et al., 2011). Whilst it is recognised that CAINS has highly promising 
psychometric properties (Kring et al., 2013) and represents an important advance on earlier 
scales such as the PANSS and the SANS from a conceptual point of view (Blanchard et al., 
2011), to date little work has been conducted examining the sensitivity of the scale. In chapter 
5, a comparison of how the PANSS and the CAINS differentiate between participants that 
report high and low negative symptoms, and differences in the degree to which both scales 
report symptom change over time was conducted. In addition, the incrimental validity of the 
CAINS was compared to the PANSS negative subscales in various indicators of social 
improvishment. The main aim of this investigation was to determine whether the CAINS is a 
more sensitive instument than the PANSS negative subscale, and whether the CAINS is a 
stronger pedictor of outcomes known to be related to the negative symptom construct. 
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One important feature of the CAINS is the fact that the scale is designed to measure expressive 
and experiential features of negative symptoms as distinct constructs. Measuring these two 
features of negative symptoms seperately allows us to examine whether associations between 
negative symptoms and other constructs may relate specifically expressive or experiential 
deficits, or both. In chapter 6 the association between subective quality of life and the 
expressive and experiential components of negative symptom was explored, which has 
previously been found to be relatively weak (Eack and Newhill, 2007, Priebe et al., 2011b). The 
aim of this investigation was determine whether the association between SQOL and negative 
symptoms have previously been underreported due to limitations in existing scales which do 
not sufficiently tap into the experiential features of negative symptoms (Blanchard et al., 
2011). 
In the final part of the investigation (chapter 7), the impact of negative symptoms was 
extended to another patient report outcome, namely the initial appraisal of inpatient 
psychiatric treatment. Subjective initial appraisal is an important outcome given it has been 
found to have significant implications on later treatment response (Bartkó et al., 1987, Bröker 
et al., 1995, Priebe and Gruyters, 1994, Priebe et al., 2009). The aim of this investigation was to 
determine whether negative, positive, manic or depressive symptoms are associated with SIR. 
 
8.2. Summary of findings and comparisons to the literature 
8.2.1. The change in negative symptoms over time in outpatients 
The meta-analysis presented in chapter 3 suggests that there is a significant reduction in the 
severity of negative symptoms over time in all treatment contexts. This finding was supported 
in the analysis completed in chapter 4, where a reduction in negative symptoms over time was 
present regardless of the eligibility criteria adopted. In chapter 6, a significant reduction over 
time was detected in the PANSS negative subscale and the CAINS experiential subscale, but not 
in the expressive subscale. Collectively, the findings from chapters 3, 4 and 6 all point to the 
conclusion that there is a significant reduction in negative symptoms over time in stable 
outpatients diagnosed with schizophrenia, including in samples which are selected to minimise 
the impact of secondary negative symptoms. However, due to the inconsistent evidence it is 
unclear whether this reduction is consistent across all types of negative symptoms, or whether 
expressive and experiential symptoms follow a different trajectory. 
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The findings that negative symptoms significantly reduce over time are contrary both to the 
earliest conceptions of schizophrenia, which suggested that negative symptoms follow a path 
of progressive deterioration (Bleuler, 1950, Kraepelin, 1971), and our current understanding of 
negative symptoms which suggest that they are highly stable in the non-acute phase (Möller, 
2007). Instead, these results appear to mirror the findings of a study by Quinlan (Quinlan et al., 
1995), who evaluated the longitudinal course of symptoms in chronic schizophrenic 
outpatients. Over two years significant reductions in negative symptoms were detected, 
leading Quinlan to propose that the notion of a progressive downward course of schizophrenia 
may need to be reconsidered. 
In the assessment of individual negative symptoms in chapter 3, the reduction in alogia, 
anhedonia, blunted affect and avolition all appeared very similar. These findings are in contrast 
with the findings in chapter 6 where significant reductions in experiential, but not expressive 
symptoms were evident. The reasons for the differences between these findings are not clear. 
One possible theory could be that the non-significant reduction in expressive symptoms 
detected in chapter 6 could be attributable to floor effects, given the level of expressive 
symptoms were relatively low at baseline (mean= 1.94, SD= 0.92). However, it also possible 
that the lack of any differences between the types of symptoms uncovered in chapter 3 may 
be attributable the limitations of the assessment scales used. As stated previously, the SANS 
and PANSS is recognised to merge conceptually distinct experiential symptom domains into 
single subscales such as anhedonia-asociality, in addition to including features now not 
recognised to be part of the negative symptoms construct (Blanchard et al., 2011). In addition, 
these scales insufficiently tap into experiential symptoms of the disorder (Blanchard et al., 
2011, Kring et al., 2013), a theory further supported by the findings presented in chapter 5 
which only found a moderate association between the PANSS negative and CAINS experiential 
subscales (r=.480). This being the case, it is quite possible that a reduction in the experiential 
symptoms may be under-reported when these scales are used. The third possibility it that 
expressive symptoms such blunted affect and alogia are more stable than experiential 
symptoms such as anhedonia, avolition and asociality. Greater stability in expressive 
symptoms have been reported in the past (Johnstone et al., 1987; Meuser et al., 1991; Dollfus 
and Petit, 1995; Kelley et al., 2008), possibly because they are less affected by causes of 
secondary negative symptoms such as positive symptoms and medication side effects (Angrist 
et al., 1980; Kelley et al., 1999).  
Participants who were allocated to receive SGA’s or adjunctive medications reported a greater 
reduction in negative symptoms, relative to those allocated to other conditions. At first glance, 
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these findings appear to suggest that these medications may be more effective in the 
treatment of negative symptoms, contrasting with earlier studies which have not found a 
consistent difference in the efficacy of SGA’s over other treatments (i.e. Leucht et al., 2009; 
see section 1.7 for a review).  However, this  finding is complicated by the fact that in the 
placebo/control/treatment as usual samples a greater reduction in negative symptoms were 
detected in those that were part of a second generation antipsychotic or adjunctive 
medication drug trial. This suggests that there may be undetermined features of these types of 
studies which result in a greater change in negative symptoms being detected, rather than the 
effectiveness of the treatments themselves. Given a number of the SGA and adjunctive drug 
studies that were completed more recently, it is possible that this finding relates to an 
increasing placebo effect which has been found in psychiatric pharmacological trials (Kinon et 
al., 2011, Rutherford and Roose, 2013, Walsh et al., 2002). 
 
8.2.2. The impact of adopting different symptom inclusion criteria in negative 
symptom trials 
In the meta-regression completed in chapter 3, studies that adopted a minimum negative 
symptom inclusion criterion reported a small but significant increase in the reduction of 
negative symptoms over time. However, this difference was not significant in the multivariate 
model. In chapter 4, a substantial reduction in negative symptoms over time was evident as 
the minimum negative symptom eligibility criteria increased. These reductions were present 
despite maximum depressive and positive symptom eligibility criteria also being adopted, 
which should theoretically minimise secondary symptoms and so increase the stability of 
negative symptoms over time (Möller, 2007). The reason why the minimum negative symptom 
inclusion criterion appeared to have a much greater impact in the analysis completed in 
chapter 4, relative to the meta-regression completed in chapter 3 is not clear. One possibility is 
that in chapter 3 the substantial variation in the manner in which these criteria are 
implemented, in addition to the large degree of heterogeneity between the pooled studies 
themselves may have resulted in a number of extraneous factors and a substantial loss of 
power, masking any differences which may exist. If this is the case, then the findings of chapter 
4 may be a closer representation of the impact of adopting such criteria. 
Over the different inclusion criteria examined in chapter 4, the association between positive 
and negative symptoms appeared to be largely consistent regardless of how restrictive the 
inclusion criteria were. Of the 11 criteria examined, the only difference that appeared to exist 
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was when predominant criteria were determined by negative symptoms being over positive 
symptoms by a specified amount. In these cases (Olie et al., 2006, Rabinowitz et al., 2013) the 
association between positive and negative symptoms substantially increased. These findings 
are broadly consistent with those reported by Dunayevich (Dunayevich et al., 2014), who 
found that adopting different inclusion criteria did not minimise the association between 
positive and negative symptoms . In other work, Stauffer (Stauffer et al., 2012) found that 
negative symptom change was not different between participant samples that reported 
prominent or predominant negative symptoms. Whilst these findings merit further 
exploration, they point to the conclusion that most symptom inclusion criteria adopted in 
clinical trials may not be effective in reducing the association between positive in negative 
symptoms and, based on the findings of the current study, may even increase it in some cases. 
Regarding the association between depressive and negative symptoms, it is interesting to note 
that this was reduced both by implementing a minimum negative, and maximum depressive 
symptom criterion. In the whole sample the association between negative and depressive 
symptoms was found to be relatively large. This association was found to decrease slightly 
when all participants with at least moderate depressive symptoms were omitted, which in turn 
resulted in a small reduction in the severity of negative symptoms. This finding supports earlier 
work which suggests that high levels of depressive symptoms may either mimic or exacerbate 
negative symptoms (Carpenter et al., 1985). However, a larger decrease in the association 
between these symptoms occurred when a minimum negative symptom criterion was 
implemented, the reason for which is not entirely clear. One theory is that implementing a 
minimum negative symptom threshold means that participants would be required to present 
with a broader range of negative symptoms, some of which have not found to be significantly 
elevated in depressed verses non-depressed schizophrenia patients such as affective flattening 
(Barnes et al., 1989). A second possibility is that participants may need to present with more 
severe individual symptoms, making it easier to distinguish between depressive and negative 
symptoms. One example of this may be in anhedonia, where an inability to experience 
pleasure is a feature of both negative symptoms and depression. However, in depression this 
manifests itself as an overall anhedonic deficit, whilst in negative symptoms this is limited 
specifically to anticipatory pleasure, with the experience of sensory pleasure remaining largely 
intact (Gard et al., 2007, Strauss et al., 2011). Given this distinction is somewhat nuanced, it is 
likely to be more challenging to determine when the symptoms experienced are relatively 
mild. A reduction in the association between negative symptoms and depression was similar 
when a number of individual negative symptoms were required to be above a mild level of 
severity, and in criteria that specified an overall negative symptom subscale score be over a 
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certain threshold, making it difficult to determine whether either (or if indeed both) 
mechanisms may be involved. 
The findings in chapter 4 appear to support the conclusions outlined in the NEWMEDS 
consensus statement (Marder et al., 2013). In this report it was recommended that 
participants who present with depressive symptoms that do not overlap with negative 
symptoms should be excluded from negative symptom clinical trials, whilst no consensus was 
reached regarding excluding participants with high positive symptoms. This conclusion is in 
contrast to the NIMH-MATRICS consensus statement (Kirkpatrick et al., 2006), the criteria of 
persistent negative symptoms outlined by Buchanan (Buchanan, 2007), and the current 
guidelines of the European Medicines Agency (EMA., 2012) which all recommend excluding 
participants with at least moderate levels of positive symptoms.  
 
8.2.3. A comparison of the different negative symptom assessment scales. 
In chapter 3 participants that were assessed using the SANS were found to report a 
significantly greater reduction in negative symptoms, relative to those assessed by either the 
PANSS negative subscale or the BPRS anergia subscale.  This difference was relatively large, 
even after controlling for a range of other study-level factors (ES=0.43). In chapter 5, the CAINS 
was found to provide a greater differentiation between participants that report high and low 
symptoms, and reported a greater change in negative symptoms relative to the PANSS as the 
mean change in both scales increased. In addition, the CAINS was found to be a stronger 
predictor in a range of outcomes relating to social impoverishment. 
The findings in chapter 3 and 5 suggest that different assessment tools can result in a large 
variation in the severity and change in negative symptoms reported. This supports the 
conclusions of the recent MATRICS consensus report which suggested that inappropriate 
scales may act as a significant barrier to the development of new treatments (Kirkpatrick et al., 
2006). They concluded that new scales should be developed that adhere to our current 
conception of the negative symptom construct, and be a more sensitive instrument to detect 
symptom changes. Prior to developing the CAINS and the BNSS, a review of the negative 
symptom construct outlined the conceptual requirements of the scales (Blanchard et al., 
2011). In follow up work, the CAINS was developed, evaluated and refined, with the final scale 
being found to have excellent psychometric properties (Forbes et al., 2010, Horan et al., 2011, 
Kring et al., 2013). In the current study, the findings suggest that the CAINS may be a more 
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sensitive instrument to detect changes in negative symptoms relative to the PANSS, thus 
fulfilling the final parameter outlined in the consensus report (Kirkpatrick et al., 2006). 
The findings from chapter 3 which suggest that the SANS is a more sensitive instrument to 
detect negative symptom change over the PANSS and the BPRS is in consistent with 
recommendations outlined in the MATRICS consensus statement (Kirkpatrick et al., 2006). In 
the report, they suggest that the SANS may be preferable given multiple items are used to 
measure separate constructs which should improve the psychometric properties of the scale. 
However in the same report it is also recognises that the scale has a number of limitations, 
including items which are not considered part of the negative symptom construct such as 
attention deficits, inappropriate affect, and poverty of speech content (Buchanan and 
Carpenter, 1994), and not specifying between anticipatory and consummatory hedonic deficits 
(Gard et al., 2007). If the advantages of the SANS are attributable to the fact that multiple 
items are used (as proposed by Kirkpatrick and colleagues) (Kirkpatrick et al., 2006), then it 
follows that this same advantage would also extend to other scales with adopt multiple items 
such as the CAINS.  
 
8.2.4. The Impact of adopting different eligibility criteria on the sample pool size 
Consistent with the findings from Rabinowitz and Dunayevich (Dunayevich et al., 2014, 
Rabinowitz et al., 2013), the results of chapter 4 suggest that adopting more restrictive 
inclusion criteria can result in a substantial reduction in the eligible sample pool. In the current 
study, adopting the most restrictive criteria (Moller et al., 2004) resulted in only 6.6% of the 
total sample being eligible. This figure is comparable to similar studies by Dunayevich and 
Rabinowitz which found that only 6.0% and 8.1% were eligible in the most stringent criteria 
adopted. This is in stark contrast to the broadest criteria examined in the current investigation, 
which resulted in 50% of the sample still being eligible. With so many participants deemed 
ineligible in the most restrictive criteria, this could have two major implications. Firstly, 
excluding so many potential participants can make it substantially harder to recruit the 
required number of participants, which is already recognised to be a challenging and complex 
issue for clinical trials (McDonald et al., 2006). Secondly, it could potentially result in trial 
samples not being sufficiently generalisable to populations that these treatments would ideally 
be designed to treat. Over 60% of patients have been found to present with at least one 
moderate negative symptom in routine care (Bobes et al., 2010), and between 20-30% are 
thought to present with deficit syndrome (Kirkpatrick et al., 2006). In the current study, the 
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participants were older (mean age 42.1 years), where the prevalence of deficit syndrome in 
clinical populations is thought to be even higher (37% in those over 45) (Harris et al., 1991). 
Therefore, it is likely that implementing such criteria is likely to result in a substantial 
proportion of participants who either present with persistent negative symptoms or deficit 
syndrome not being eligible for negative symptom trials that adopt these criteria, despite the 
fact that the treatments under evaluation would be designed precisely for this patient group. 
Utilising more broad criteria may aid ease of trial recruitment, whilst also producing study 
samples which are more generalisable to the treatment target population. It is possible that 
this lack of generalisability may in part explain why such a difference was found between 
pragmatic trials which utilised broader criteria such as the CUtLASS (Jones et al., 2006) and the 
CATIE (Lieberman et al., 2005) studies, compared to the early industry studies.  
 
8.2.5. What is nature of the relationship between the CAINS and PANSS negative 
subscale? 
In chapter 5, the CAINS total and the PANSS negative subscale was found to be highly 
correlated (r=.742). Consistent with earlier studies which examined the relationship between 
the BPRS and the CAINS (Horan et al., 2011), the PANSS negative subscale was found to relate 
primarily to the expressive features of negative symptoms (r=.754), with only a moderate 
correlation between experiential subscale and the PANSS negative subscale present (r=.480). 
These findings are consistent with the conclusions outlined in a review by Blanchard and 
colleagues (Blanchard et al., 2011), which suggested that older scales such as the PANSS 
insufficiently tap into experiential features of negative symptoms, instead relying primarily on 
behavioural referents. These referents can include the frequency of activities, interviewer 
observations, and reports from family members or carers, and mean the experiential features 
of symptoms such as anhedonia and avolition are not directly addressed. This is important, as 
it means that link between outcomes with negative symptoms that one would expect to relate 
more to experiential than expressive deficits may have been under-reported in studies that 
have used older scales. This conclusion is supported by the findings presented in chapter 6, 
where significant associations were detected between experiential deficits and subjective 
quality of life using the CAINS, whilst no relationship was detected using the PANSS negative 
subscale.  
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8.2.6. The association between the negative symptom construct and other 
variables when measured by the CAINS, PANSS and BPRS 
In chapter 7, negative symptoms were not found to be associated with subjective initial 
response. In chapter 5, significant associations between negative symptoms and indicators of 
social impoverishment such as the number of activities participants took part in over the past 
week, the number of friend contacts made over the past week, and whether they had anyone 
they considered a close friend were detected. In the majority of cases, the CAINS was found to 
be a better predictor of these outcomes than the PANSS negative subscale score. In chapter 6, 
no relationship was detected between negative symptoms and subjective quality of life when 
it was measured as a singular construct using the PANSS, however significant associations 
between experiential deficits and SQOL were present.  
In chapter 5, the CAINS total subscale was found to be a better predictor of the number of 
friends they have made contact with, the number of activities they have taken part in over the 
past week, and whether participants reported having a close friend. Given the PANSS has been 
criticised for focusing primarily on behavioural referents (Blanchard et al., 2011), it is 
somewhat surprising that while the scale explained only a minimal degree of unique variance 
in the two behavioural outcomes (both =.001), at least some unique variance was explained in 
the subjective outcome which related to whether participants had somebody they would 
consider as being a close friend (=.007). This was more apparent in the comparison between 
the PANSS Marder negative subscale and the CAINS, where similarly little unique variance was 
explained by the PANSS subscale in the two behavioural outcomes (both <.001), but explained 
a relatively large proportion in reporting whether they had a close friend (=.017). In this item, 
the degree of shared and unique variance explain by the PANSS Marder negative subscale was 
slightly higher than the CAINS total score, with the Marder subscale being dominant in 62.7% 
of cases.  
These findings point to a number of conclusions. Firstly, the PANSS Marder negative subscale 
was found to be a superior predictor of whether participants have a close friend whilst the 
PANSS negative subscale was not, lending further support to recommendations which suggest 
that the Marder subscale may be a more appropriate method to adopt in clinical trials 
evaluating negative symptoms (Marder et al., 2011, Marder et al., 1997). Secondly, despite the 
PANSS Marder negative subscale being marginally better than the CAINS at predicting whether 
participants report have a close friend, in the other 5 comparisons made the CAINS total score 
was found to be dominant with the PANSS typically explaining little to no additional variance. 
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This suggests that the CAINS should be considered as superior at predicting functional 
impairments related to the negative symptom construct. Somewhat contrary to expectations, 
this advantage appears to be particularly strong in predicting more concrete, behavioural 
outcomes related to the negative symptom construct. This is important, as determining the 
incremental validity of new psychometric scales should be considered a crucial step in the 
scale development process (Hunsley and Meyer, 2003), despite it often being neglected  
(Haynes and Lench, 2003). 
In chapter 7, higher negative symptoms were not found to result in a lower subjective initial 
appraisal of inpatient psychiatric treatment. Instead, it was found that positive and manic 
symptoms were associated with a more negative assessment. Given the impact of subjective 
initial appraisals on various social and psychopathological outcomes (Bröker et al., 1995, 
Priebe et al., 2010a, Richardson et al., 2011a) this study suggests that a greater consideration 
of these symptoms during the admission stage may help longer term outcomes. These findings 
are partly consistent with the results of Richardson and colleagues (Richardson et al., 2011a) 
who reported a less positive initial treatment appraisal for patients with higher levels of mania, 
positive and depression/anxiety symptoms. The findings from the current study are in contrast 
to a body of literature in psychiatry which has typically found that mood symptoms have the 
greatest impact on patient reported outcomes (Priebe, 2007). It has been suggested that this 
reflects a negative rating bias of patients with high levels of depression, rather than a specific 
experience of treatment (Fakhoury et al., 2002, Hansson et al., 2007, Priebe et al., 1998).  
One possibility for the finding that positive and manic symptoms lead to a more negative 
assessment of treatment may relate to how these symptoms might impact upon being placed 
in the confined environment of a hospital ward. In a qualitative review of involuntary inpatient 
experiences of treatment (Katsakou and Priebe, 2007), a number of features of treatment 
were recognised to negatively impact upon a patient’s experience of admission. Of these 
experiences, a number may particularly resonate with those suffering more intense manic and 
positive psychotic symptoms. Patients experiencing greater levels of positive symptoms such 
as paranoia or hallucinations may struggle more in an unfamiliar setting which may feel 
frightening or insecure. Patients with severe manic symptoms are likely to be more agitated, 
and struggle more with being contained in an enclosed space with rigid rules and limited 
opportunities for activities. The finding that manic symptoms influence patients’ appraisal 
even more in those involuntarily admitted, who therefore would experience an even greater 
restriction to their autonomy, lends further support to this argument. Patients who exhibit 
‘disturbed behaviour’ or experience acute positive symptom exacerbation are also more likely 
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to receive combined antipsychotics and high doses of antipsychotic medication (Paton et al., 
2008), which can lead to a higher side effect burden (Centorrino et al., 2004), potentially 
impacting the appraisal of the treatment they receive further.  
 
8.2.7. The association between negative symptoms and other constructs when 
expressive and experiential constructs are considered separately 
Whilst the relationship between negative symptoms of schizophrenia and subjective quality of 
life (SQOL) has been examined in the past (Eack and Newhill, 2007, Priebe et al., 2011b) this is 
the first time the link between SQOL and expressive and experiential deficits as separate 
constructs have been considered. As anticipated, the association between experiential deficits 
and SQOL detected in this investigation appears to be significantly stronger than in previous 
studies which have examined the relationship to negative symptoms as a singular construct.  
This stronger association was found both cross-sectionally and in changes over time, and in 
contrast to earlier investigations, remained present after controlling for depressive symptoms. 
These findings support the current developments in negative symptom assessment which 
advocate measuring experiential and expressive symptoms as distinct negative symptom 
constructs (Blanchard and Cohen, 2006, Horan et al., 2011, Kring et al., 2013), suggesting that 
new insights in the field of negative symptoms may be uncovered by utilising the new CAINS 
assessment instrument. In addition, this finding suggests that if the primary aim of treatment 
is to improve the patients’ quality of life, then the focus on treatment should be on the 
experiential, as opposed expressive features of the illness. 
In the comparison of the PANSS negative and CAINS subscales, the experiential scale was 
found to be the strongest predictor of the number of friends contacts and social activities 
completed in the past week, in addition to whether participants report having somebody they 
consider to be a close friend. The finding that the expressive subscale explains little variance in 
these outcomes is not surprising, given the outcomes evaluated would be considered to relate 
more to experiential deficits, such as asociality and avolition. One interesting finding was that 
in the outcome concerning the number of reported friend contacts, the experiential subscale 
was found to explain a slightly greater proportion of variance than the whole CAINS subscale 
(R2=.118 in comparison to R2=.091), further supporting the argument that in some situations it 
may be beneficial to utilise the subscales separately. 
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Overall, these findings support an emerging evidence base which suggests that experiential 
and expressive symptoms represent distinct constructs (Blanchard and Cohen, 2006), and as 
such should be measured separately (Horan et al., 2011). Not only does assessing these 
symptoms in this manner better resemble the negative symptom construct as it is currently 
understood, the findings here suggests that assessing symptoms in this manner may yield new 
insights which may have previously been missed when negative symptoms were measured as a 
singular concept. 
8.3. Project Strengths and Limitations 
One strength of this study is that the investigation comes at a time when there are significant 
developments in the field of negative symptoms of schizophrenia. Recent consensus 
statements have placed increasing focus on refining methodological and conceptual issues 
around trials designed to evaluate treatments for negative symptoms (Marder et al., 2013, 
Marder et al., 2011). The work of this project builds upon these findings, providing further 
insight on how negative symptoms may change over time in the context of a research trial, and 
the impact of different symptom inclusion criteria on the associations between negative 
symptoms and factors known to exacerbate these symptoms. In addition, the current 
investigation uses date from one of the first large-scale studies to use the CAINS, which have 
been considered an important advance in the field. Whilst earlier validation studies suggest 
that the scale as excellent psychometric properties (Horan et al., 2011, Kring et al., 2013), this 
investigation suggests the scale be a more sensitive instrument, be a stronger predictor of 
social and functional impairment, and by disentangling expressive and experiential deficits, 
may lead to further important insights in the field. 
One significant limitation of the investigation as a whole is that all of the analysis has been 
completed using data from existing studies, either through pooling them by way of meta-
analysis, or conducting analysis on datasets obtained from previous studies. Consequently, the 
scope of the analysis was limited by the nature of the data available. In chapter 3, an 
insufficient number of studies used a maximum level of EPS as an inclusion criterion for 
eligibility, meaning the impact of these criteria on negative symptom change could not be 
included in the meta-regression. In addition, a substantial degree of heterogeneity between 
the pooled studies was unexplained, which resulted in considerable imprecision in the 
estimates. This may account for the differences in the findings between chapters 3 and 4, 
where minimum negative and depressive symptom criteria were evaluated. In chapter 4, 
whilst the original dataset was relatively large (N=507), there was insufficient power to obtain 
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meaningful estimates from the most restrictive criteria evaluated due to the fact that the trial 
had not been powered for this purpose. In addition, the lack of any assessment of EPS meant 
these could not be considered as a third factor associated with secondary negative symptoms. 
In this sample the mean DDD was found to be relatively high, meaning it is possible that some 
participants may have experienced notable EPS. As a result, it is possible that parkinsonian 
symptoms such as akinesia may have mimicked expressive symptoms, resulting in a higher 
rating of negative symptoms that may not represent core psychopathology. Finally, using an 
assessment scale for depressive symptoms designed specifically for schizophrenia populations, 
such as the Calgary (Addington et al., 1992), would have been preferable given the issues in 
disentangling depressive and negative symptoms with the PANSS (Collins et al., 1996). 
Given the meta-regression from chapter 3 had found that the SANS may be a more sensitive 
instrument to detect negative symptom change, relative to the PANSS, in chapter 5 it may 
have been preferable to compare the SANS to the CAINS in the analysis. However, given the 
extensive use of the PANSS in negative symptom treatment trials, as evidenced in the meta-
analysis in chapter 3, determining the relationship between the two scales should still be 
regarded as an important step forward. In chapter 7, given the BPRS provides a relatively poor 
coverage of the negative symptom construct, the PANSS may have been a preferable 
assessment tool, given factor analytic studies have suggested the scale can provide relatively 
good coverage of various symptom clusters (see section 1.9.1.3. for a review).  
Whilst prospective studies designed to address the stated aims would have meant that many 
of these limitations could have been addressed from the outset, this would have required 
significant resources far in excess of what would be available in an investigation of this scale. 
 
8.4. Implications 
8.4.1. Implications on research 
The findings from chapters 3, 4 and 6 all suggest that negative symptoms appear to reduce 
over time to a greater extent than originally presumed, with the meta-analysis suggesting that 
there is a substantial degree of heterogeneity in the rate of change that exists between 
studies. These results could be considered to have a number of important implications to 
future research. Firstly, these findings underline the importance of comparing outcomes to an 
appropriate control, and the difficulty in determining whether within-group reductions found 
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in negative symptoms are attributable to treatment. This is important, given the assumption 
that negative symptoms are highly stable and treatment-resistant have previously led some 
researchers to conclude that within-group pre-post reductions suggest a clinically significant 
improvement as an effect of treatment (Sensky et al., 2000). Secondly, if there is more 
variability and a greater reduction in negative symptoms over time, and/or a larger placebo 
effect than previously assumed, then this suggests it may be harder to detect treatment 
effects than was previously thought, suggesting larger samples sizes may be required in some 
cases. 
Building upon recent developments in our understanding of the negative symptom construct 
(Blanchard and Cohen, 2006, Blanchard et al., 2011), the CAINS  is considered to represent a 
significant advance on older scales used to measure these symptoms (Kring et al., 2013). In an 
assessment of incremental validity, the CAINS was found to be more strongly associated to 
functional impairments related to negative symptoms, relative to the PANSS negative subscale. 
In chapter 6, the CAINS experiential subscale was negatively associated with subjective quality 
of life, whilst no relationship to the PANSS negative subscale was detected. In chapter 5, the 
CAINS was found to be a more sensitive than the PANSS, both in differentiating between 
participants with high and low negative symptoms, and in measuring changes in these 
symptoms over time. Given the limitations of earlier negative symptom assessment scales 
have been identified as a major barrier in the development of new treatments (Kirkpatrick et 
al., 2006), these findings suggest the CAINS may be a superior scale to adopt in clinical trials for 
negative symptom treatments. If so, then this may represent an important advance in 
treatment evaluation in an area which been identified as an unmet therapeutic need 
(Kirkpatrick et al., 2006). The findings from chapters 5 and 6 also suggest that the ability of the 
CAINS to evaluate expressive and experiential deficits as separate constructs may open up new 
insights and opportunities in the research of negative symptoms. 
The results of chapter 4 suggest that adopting minimum negative and maximum depressive 
symptom study inclusion criteria reduces the association between negative and depressive 
symptoms. This supports the recommendations outlined in both the MATRICS and NEWMEDS 
reports (Kirkpatrick et al., 2006, Marder et al., 2013), and highlight the importance and 
effectiveness of adopting such criteria to minimise secondary negative symptoms attributable 
to depressive symptomology in future clinical trials. By contrast, adopting predominant 
negative symptom criteria was not found to reduce the association between negative and 
positive symptoms, and in most cases resulted in a substantial reduction in the sample pool 
size. If these inclusion criteria are not effective, then it suggests that alternative methodologies 
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may need to be considered to disentangle co-occurring changes in positive symptoms from 
negative symptoms in clinical trials for negative symptom treatments. Once such method may 
be to adopt a path analysis design, which has been adopted in a number of earlier 
pharmacological studies evaluating SGA’s for negative symptoms (Alvarez et al., 2006, Moller 
et al., 1995, Tollefson and Sanger, 1997). However, such a method comes with the drawback 
that much larger samples may be required (MacCallum et al., 1996). 
The findings in chapter 6 suggest the association between negative symptoms and SQOL may 
be significantly stronger than previously assumed, however the relationship appears to relate 
specifically to experiential subdomain of these symptoms. Such findings appear to support a 
model proposed by Priebe (Priebe, 2007) which suggests that quality of life may be improved 
by treatment indirectly via an improvement in symptoms. Given improvements in quality of 
life are considered central to the concept of recovery (Liberman et al., 2002) these findings 
suggest it is important to develop and evaluate new treatments which focus on the 
experiential symptoms of the negative symptom construct in particular. Given the initiation 
and development of social relationships are seen as a key feature of all resource-orientated 
models of psychiatric interventions (Priebe et al., 2014), such treatments may represent a 
promising area which could address experiential deficits such as amotivation and asociality, 
and merit further consideration. 
 
8.4.2. Implications on policy 
At present, both the FDA and EMA policy guidelines state that for negative symptom 
treatments to be considered eligible for approval then their effectiveness needs to be 
determined in clinical trials which evaluate negative symptoms as a singular construct (Marder 
et al., 2011). However, there is increasing evidence to suggest that negative symptoms 
comprise of at least two distinct domains, namely expressive and experiential symptoms 
(Blanchard and Cohen, 2006, Horan et al., 2011, Kring et al., 2013). In the current investigation 
completed in chapters 5 and 6, experiential deficits were found to be uniquely associated to 
objective indicators of social impoverishment, such as the participation of activities and friend 
contacts made over the past week, in addition to other important outcomes such as impaired 
subjective quality of life. Such links between experiential deficits and functional disability have 
been noted elsewhere, and have in turn led to efforts towards developing treatments 
specifically for experiential symptoms (Reddy et al., 2015). If such treatments prove to be 
effective at reducing experiential symptoms, and any functional disability which derive from 
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these symptoms, then the current policy guidelines may merit reconsidering. As outlined in the 
MATRICS consensus statement (Kirkpatrick et al., 2006), if the subdomains of negative 
symptoms respond differently to treatment, then it is possible that a combined negative 
symptom assessment may underreport clinically meaningful improvements in an individual 
symptom.  
The current EMA guidelines require clinical trials evaluating adjunctive medications for 
negative symptoms to recruit participants that present with predominant, as opposed to 
prominent negative symptoms (EMA., 2012). The rationale for implementing such a policy is to 
determine that changes in negative symptoms are not attributable to co-occurring changes in 
positive symptoms. However, in chapter 4 it was found that adopting various different 
maximum positive symptom exclusion criteria did not reduce the association between positive 
and negative symptoms, and in some cases actually increased it. Furthermore, the increasingly 
restrictive criteria adopted appeared to result in a substantial reduction in the available sample 
pool which may have implications on trial recruitment and the generalisability of findings. 
Given that adopting maximum positive symptom criteria was found to be ineffective, these 
findings suggest that if the aim is to reduce the association between the variables then 
alternative methods may need to be proposed in new policy guidelines.  
 
8.4.3. Implications on practice 
The findings from chapters 3, 4, and 6 all suggest that negative symptoms may significantly 
reduce over time in stable outpatients, even after adopting criteria which aims to reduce the 
impact of secondary negative symptoms. Whilst acknowledging that the changes in negative 
symptoms were relatively small, and the fact it is difficult to determine what the nature of this 
measured change actually is, this improvement over time appears to lend support to the 
recovery model of schizophrenia (Warner, 2009), given these symptoms links to functional 
outcomes (Hunter and Barry, 2012, Lysaker and Davis, 2004, Whitty et al., 2008). Such findings 
may provide hope to those that experience these symptoms, in addition to those who work 
with patients to help try and alleviate the impact of this devastating disorder.  
The findings in both chapters 5 and 6 suggest that the experiential and expressive subdomains 
of negative symptoms appear to be related to outcomes differently. In support of these 
findings, the link between functional disability and experiential symptoms in particular has 
been noted in the literature (Reddy et al., 2015). In chapter 5, experiential symptoms were 
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found to have a stronger inverse relationship to how socially engaged the participants reports 
to be, relative to experiential symptoms. In chapter 6, experiential symptoms were found to be 
significantly associated to subjective quality of life, whilst no relationship to expressive 
symptoms was apparent. Given the the ability to maintain satisfying relationships and 
participate in productive and enjoyable activities are seen as central to the concept of recovery 
(Liberman et al., 2002), these findings suggest that extra consideration should be given to 
addressing experiential symptoms in routine practice. 
The findings in chapter 7 emphasise the importance of measuring symptoms at the point of 
inpatient admission, and considering the impact of manic and positive symptoms in particular 
during the initial phase of acute treatment. Whilst no association between negative symptoms 
and initial appraisal of impatient was detected, the results underline the importance of 
assessing patients’ initial appraisal of treatment as a relevant process variable in routine 
practice. In a recent review Mullen (Mullen, 2009) has suggested that acute inpatient settings 
are at present too custodial and over reliant on medication, and suggests that providing more 
psychosocial interventions as an alternative may be a way in which to try and address these 
issues. If these are problems which disproportionally affect those experiencing higher positive 
and manic symptoms, then this possible solution may go some way to addressing the 
experiences these particular patients report. 
 
8.5. Future directions 
The results in this investigation point to a number of possible future directions for research. 
The findings in chapter 3, 4 and 6 all suggest that negative symptoms improve during the study 
period. However, understanding the nature of the improvement in negative symptoms over 
time requires further attention. The duration between time points was not found to be a 
significant predictor, but with the considerable variability in treatment duration, post 
treatment follow-up duration, and post treatment provision between studies, this is perhaps 
not surprising. In longitudinal studies assessing persistent negative symptoms over very long 
periods of time, there has been little evidence of a gradual linear improvement towards 
symptom remission (Strauss et al., 2010), whilst the rate of recovery in schizophrenia remains 
low (Jääskeläinen et al., 2013). One explanation of the improvement in negative symptoms 
noted throughout this investigation could be the non-specific effects of being involved in the 
research, possible related to the “trial effect” (Braunholtz et al., 2001). However, the 
mechanism that drives change in this context is unclear.  One possibility is that a reduction in 
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negative symptoms found between the first and subsequent assessments may be a 
consequence of increased familiarity with the assessor and the assessment process itself. If a 
good rapport was established in the first assessment, then it is possible that this may result in 
the participant being less anxious in subsequent assessments. This is significant, given 
symptoms of anxiety in schizophrenia are positively associated with passive withdrawal and 
poorer psychosocial functioning (Lysaker and Salyers, 2007). If this is the case, then it suggests 
that the improvement detected between assessments may be secondary rather than primary, 
in nature. Studies exploring the possibility that secondary negative symptoms may be more 
prominent in initial assessments may be merited, given the importance attached to minimising 
transient secondary negative symptoms in clinical trials of treatments for these symptoms 
(Kirkpatrick et al., 2006). 
Another possible reason for the reduction in negative symptoms typically found in research 
settings, regardless of the type of intervention administered, may be related to the type of 
social interactions which occur within these studies. If the improvement in negative symptoms 
is related to increased social contact during studies, then treatments that promote social 
interactions such as befriending schemes and group psychotherapies may be a possible step 
forward. Recent findings suggesting a non-specific effect of group therapies on negative 
symptoms (Orfanos et al., 2015) appear to support this possibility. As a result, additional 
studies which examine the impact of these more socially-oriented treatments may be 
informative.  
Whilst the meta-analysis did consider studies that implemented criteria which aimed to limit 
the impact of secondary negative symptoms, none used criteria which would qualify as 
determining a diagnosis of deficit syndrome (Carpenter et al., 1988, Kirkpatrick et al., 1989). 
The principle reason for this is that studies that did adopt these criteria often included 
participants with schizoaffective disorder or inpatients (Buchanan et al., 2007). Amending the 
inclusion criteria to focus on these particular studies would allow for a greater understanding 
of any change in primary negative symptoms. Due a lack of available data the impact of extra-
pyramidal side effects on the variability of negative symptom change could not be explored, 
which would be informative in further determining longitudinal course. In addition, as more 
studies are completed using the newer BNSS and CAINS scales, an evaluation of these tools 
would be helpful in determining their sensitivity to other assessment tools. 
The findings in chapter 4 suggest that adopting a maximum positive symptom exclusion 
criterion does not appear to result in a reduction in the association between positive and 
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negative symptoms. However, given much of the criteria evaluated resulted in a substantial 
number of participants being excluded, the samples on which many of the estimates were 
based on were small. Therefore, replicating this study in a far larger sample would be 
informative, particularly given larger sample sizes would allow for a greater comparison 
between the different R2 values through calculating narrower confidence intervals. Larger 
sample sizes would also allow for the possibility of conducting path analysis, looking at the 
proportion of change in negative symptoms over time associated with co-occurring changes in 
positive, depressive, and extra-pyramidal symptoms in subsamples obtained using the 
different eligibility criteria. 
The results in chapter 5 suggest that the CAINS may be a more sensitive instrument than the 
PANSS in measuring changes in negative symptoms. However, given the results from the meta-
regression in chapter 3 suggest that the SANS may also be more sensitive than the PANSS, a 
comparison of the CAINS and the SANS would be informative in determining whether the new 
scale represents a significant advance over all previously available scales. Another step 
forwards would be a comparison of the results obtained from different scales within a clinical 
trial where a treatment effect is present. If the CAINS produces larger effect sizes than other 
scales used, then this may go some way improving the evaluation of treatments designed to 
treatment these symptoms. 
In chapter 6, the finding that experiential symptoms were primarily linked to subjective quality 
of life suggest that it may be beneficial to revisit the link between the different subdomains of 
negative symptoms and other functional outcomes. In addition, it emphasises the pressing 
need to develop treatments that are particularly effective at treating experiential symptoms, 
namely asociality, anhedonia and avolition. Following the findings in chapter 7, further studies 
may explore environmental factors, processes of interaction between service users and staff, 
treatment components, and mediating processes as an explanation into the association of 
manic and positive symptoms with more negative appraisals of hospital treatment after only a 
few days. 
 
8.6. Concluding Statement 
Over the years the concept of negative symptoms have undergone a number of important 
revisions, from the “avolitional syndrome” proposed by Kraepelin (Kraepelin, 1971), to the 
current model of negative symptoms which include alogia, blunted affect, avolition, anhedonia 
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and asociality (Blanchard et al., 2011). The findings of this thesis suggest that the CAINS, which 
was developed to better represent our current interpretation of the negative symptom 
construct (Kring et al., 2013), may represent a significant advance in older assessment tools. 
This is important, as the limitations inherent to earlier assessment scales have been identified 
as a significant barrier in the development of new treatments for negative symptoms 
(Kirkpatrick et al., 2006).  
In this study CAINS was found to be a more sensitive instrument in detecting negative 
symptom change, reported a greater differentiation between participants who reported high 
and low symptoms, and reported stronger association to functional outcomes and SQOL 
relative to the PANSS negative subscale. The fact that the CAINS is designed to measure the 
expressive and experiential features of negative symptoms as distinct constructs may be 
particularly important, given the evidence presented here which suggests the subdomains may 
be independently associated to functional outcomes. The finding that it is only the experiential 
deficits of the negative symptom construct that are associated to SQOL suggest that more 
targeted treatments which focus on these particular symptoms may represent a new way 
forward in supporting the recovery of patients with schizophrenia. 
Overall, many of the findings in this investigation could be considered to offer renewed 
optimism to those who experience the negative symptoms of schizophrenia. Collectively the 
results suggest that negative symptoms may improve more than was originally assumed, 
challenging earlier models of schizophrenia which have either suggested negative symptoms 
are either highly stable, or get progressively more severe. This improvement over time was 
found in stable outpatient samples with relatively low positive and depressive symptoms, 
suggesting that improvements in these symptoms may be achievable at all phases of the 
disorder.   
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Do negative symptoms of schizophrenia change over
time? A meta-analysis of longitudinal data
M. Savill*, C. Banks, H. Khanom and S. Priebe
Unit for Social and Community Psychiatry, WHO collaborating Centre for Mental Health Service Development, Queen Mary University of London,
London, UK
Background. Negative symptoms are a core component of schizophrenia which can severely impact quality of life and
functional outcomes. These symptoms are understood to be highly stable but this has not been tested in a meta-analysis,
despite the wealth of longitudinal data available.
Method. A systematic review of the literature was conducted, with eligible studies pooled into a random-effects meta-
analysis. Planned meta-regressions were conducted to evaluate the impact of factors known to induce secondary nega-
tive symptoms, in addition to other possible sources of heterogeneity.
Results. The main analysis included 89 samples from 41 studies, totalling 5944 participants. Negative symptoms were
found to signiﬁcantly reduce in all treatment interventions, including in placebo and treatment as usual conditions, with
a medium effect size (ES) present across all study conditions (ES = 0.66, 95% conﬁdence interval 0.56–0.77, I2 = 94.0%). In a
multivariate meta-regression, only the type of scale used was found to signiﬁcantly inﬂuence negative symptom change.
No difference in outcome was found between studies that excluded patients with a high level of positive or depressive
symptoms, compared to those that did not.
Conclusions. Negative symptoms were found to reduce in almost all schizophrenia outpatient samples. A reduction
was found across all conditions, with effect sizes ranging from small to large depending upon the condition type.
These ﬁndings challenge the convention that negative symptoms are highly stable and suggest that they may improve
to a greater extent than what has previously been assumed.
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Introduction
Since Bleuler coined the term schizophrenia in the
early 1900s negative symptoms have been recognized
as a core feature of the disorder (Bleuler, 1950). The
symptoms include alogia, asociality, blunted affect,
anhedonia and amotivation (Blanchard et al. 2011),
and have been found to severely impact both quality
of life and social functioning (Norman et al. 2000).
Historically, negative symptoms were believed to
increase over time as patients experience a progres-
sive deterioration in functioning (Kraepelin, 1971).
However, in observational studies which evaluated
the progressive course of these symptoms the evidence
initially suggested that these are largely stable over
time (Pogue-Geile & Harrow, 1985; Fenton &
McGlashan, 1991; Dollfus & Petit, 1995; Eaton et al.
1995). Later work recognized that the course was
highly heterogenous, with some negative symptoms
improving, often in tandem with improvement in posi-
tive symptoms (Addington & Addington, 1991). In an
attempt to explain this heterogeneity Carpenter and
colleagues proposed a distinction between those at-
tributable to factors such as hospitalization, medication
side-effects, depression, and elevated positive symp-
toms (known as secondary negative symptoms), from
primary symptoms which were regarded as a core fea-
ture of the disorder itself (Carpenter et al. 1985). While
secondary symptoms tend to improve relatively
quickly once the causes are addressed, primary nega-
tive symptoms are thought to be largely persistent
(Möller, 2007).
Broadly deﬁned, primary negative symptoms refer
to negative symptoms which are present both within
and during periods of positive symptom exacerbation.
However, distinguishing between primary and sec-
ondary negative symptoms can be a complex under-
taking given the challenges in obtaining sufﬁcient
historical information and the level of clinical expertise
required by the assessors. In light of this, Buchanan
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(2007) suggested the alternative, broader distinction of
‘persistent negative symptoms’, which include nega-
tive symptoms which remain present after usual treat-
ments for secondary negative symptoms have failed. In
the consensus statement for negative symptoms, it was
proposed that distinguishing between primary and
secondary negative symptoms was not essential for
the purposes of testing therapeutics, as long as studies
select participants with persistent symptoms and con-
trol for secondary sources of negative symptoms
(Kirkpatrick et al. 2006).
To date, any advances in the treatment of schizo-
phrenia have been found to provide only limited
beneﬁt to negative symptoms. In a meta-analysis
which examined the efﬁcacy of different second-
generation antipsychotics, most were found not to
provide a signiﬁcant beneﬁt over and above
ﬁrst-generation drugs, and in those that did the effect
sizes were small (Leucht et al. 2009). Meta-analyses
into the efﬁcacy of adjunctive medications such as α2
receptor antagonists (Hecht & Landy, 2012) and gluta-
matergic compounds (Tuominen et al. 2005) show
some promise, while there is some evidence to suggest
that adjunctive antidepressant medication may have
some limited beneﬁt (Singh et al. 2010). In a broader re-
view evaluating the different pharmacological
approaches in treating negative symptoms (Arango
et al. 2013), new drugs that act on the NMDA and α7
nicotinic receptors are highlighted as promising, but
again more research is needed. In a series of
meta-analyses on psychotherapeutic interventions,
CBT was reported to have a small effect (Jauhar et al.
2014), social skills training a moderate effect (Kurtz &
Mueser, 2008), while no effect was found for social
cognitive training (Kurtz & Richardson, 2012). In a
meta-analysis of cognitive remediation therapy which
evaluated symptoms overall, a small effect was de-
tected (Wykes et al. 2011). In the UK, NICE have pre-
viously recommended Arts therapies (NCCMH,
2010); however, this has since been challenged by the
non-signiﬁcant result of the MATISSE trial (Crawford
et al. 2012). Overall, a lack of treatment efﬁcacy has
led to negative symptoms to be recognized as an
unmet therapeutic need, and an important target for
new interventions (Kirkpatrick et al. 2006).
Given the current focus on developing new interven-
tions for negative symptoms, understanding their
longitudinal course is important for future study de-
sign. Many of the earlier observational studies in-
cluded inpatients, which is problematic given this
population would typically receive far higher doses
of antipsychotic medication and experience higher
positive symptoms (Kasckow et al. 2001), and may re-
side in an under-stimulating environment (Oshima
et al. 2003), which may induce negative symptoms
secondary to the disorder itself. In addition, a number
of the earlier studies included other illnesses such as
schizoaffective disorder, which follows a different
longitudinal course and can have poorer diagnostic
stability, which again may inﬂuence symptom change
over time (Malhi et al. 2008).
The objective of this study was to examine how
negative symptoms change over time in schizophrenia
outpatients, while exploring the impact of factors
known to induce secondary negative symptoms. By
pooling a wide variety of studies by way of
meta-analysis, the aim was uncover broader trends in
how these symptoms may change, as opposed to
attempting to identify an estimate of effect size for
a particular type of treatment. Following a system-
atic search, we conducted a meta-analysis of the
within-group mean changes in negative symptoms.
Only samples comprising exclusively of schizophrenia
patients from the ﬁrst assessment point were con-
sidered. Due to the expected heterogeneity between
different interventions, separate effect size estimates
were calculated for each treatment type. Finally, a ser-
ies of planned meta-regressions were conducted to
explore any impact of factors which may lead to
secondary negative symptoms (Carpenter et al. 1985),
and possible sources of methodological bias.
Method
Research in context
The systematic review was conducted following
PRISMA statement guidelines (Liberati et al. 2009).
An electronic search using the Medline, PsycINFO,
EMBASE and CENTRAL databases was conducted
dating back to 1962, which was when the Brief
Psychiatric Rating Scale (BPRS) was ﬁrst published
(Overall & Gorham, 1962). The search was conducted
on 26 April 2014 and contained three parameters.
The ﬁrst related to diagnosis, the second to negative
symptoms, and the third an indicator that the study
took place over at least two time points.
A hand-search of the American Journal of Psychiatry,
Acta Scandinavica Psychiatrica, British Journal of
Psychiatry, Schizophrenia Bulletin, JAMA Psychiatry,
The Lancet, and Schizophrenia Research was conducted,
either from 1962 or the date of ﬁrst issue, and reference
lists from all selected papers were hand-searched.
During extraction, all assessments of negative symp-
toms, study inclusion/exclusion criteria, demographic
details, industry sponsorship, and study methodology
details were recorded. When necessary, corresponding
authors were contacted for further information. In the
case of missing standard deviations, a mean from the
existing sample was imputed when possible. M.S.
2 M. Savill et al.
conducted the abstract screening, 20% of which was
duplicated by C.B. with minimal discrepancies in selec-
tion detected. In the full paper screening phase M.S.
conducted 100% of the screening, duplicated by H.K.
and C.B. screening 50% of the sample each. All discre-
pancies were resolved without the need for S.P. to ad-
judicate as planned. At the full screening phase, all
data were independently extracted onto a piloted ex-
traction sheet.
Eligibility criteria
During the screening phase studies were excluded if
they were clearly not relevant, did not have repeated
assessments of negative symptoms at set time points,
included no usable data on an exclusively schizo-
phrenic sample, children or older adults, or were either
under 10 weeks in length or over 3 years in length from
the ﬁrst follow-up assessment. Studies which included
inpatients were considered, as long as the study in-
cluded one time-point where the sample was exclus-
ively outpatients, and then followed up from a
standardized time-point from this assessment.
Symptoms were required to be measured on a vali-
dated scale. Qualitative studies, case reports, letters
to the editor, conference abstracts and book chapters
were excluded. All articles were required to be pub-
lished in a language which used Latin-based charac-
ters. Due to the analytical strategy adopted and the
risk of small samples leading to biased estimates
(Morris, 2000), studies with fewer than 50 participants
were excluded.
Analysis plan
In the pooled analysis, the measure of effect size for
each study was calculated using the standardized
mean change (SMC) (Becker, 1988; Morris, 2000). The
estimation of the variance was calculated using the
large-sample approximation method recommended
by Becker (1988), which can provide accurate estimates
provided the sample sizes are adequately sized
(Morris, 2000). The estimate of the correlation between
the baseline and end of study scores was set at 0.633,
based upon datasets held at our research group
(Priebe et al. 2007) and a subsequent sensitivity
analysis.
In deciding the appropriate effects model to adopt,
the decision was complicated by the likelihood that
multiple arms of the same study would be separately
eligible for inclusion. One method of addressing this
which was recognized in the Cochrane Handbook
(Higgins & Green, 2011), is to conduct a two-level,
ﬁxed-effects meta-analysis across arms within studies,
followed by a random-effects meta-analysis across
studies, as a way to account for the mix in ﬁxed and
random effects that are likely to be present. However,
this model adds considerable complexity to the analy-
sis, while the handbook itself acknowledges that ‘in
practice the difference between different analyses is
likely to be trivial’ (section 16.5.5). This being the
case, the method was not used, and the DerSimonion
and Laird random-effects model was adopted
(DerSimonian & Laird, 1986). All analysis was com-
pleted using Stata version 11 (StataCorp, 2009).
In cases where multiple scales were used to measure
negative symptoms, the primary outcome measure
was selected. When negative symptoms were mea-
sured over more than two time points, only the base-
line and the study endpoint data were selected.
In the ﬁrst stage of the analysis samples were
grouped according to whether the intervention
involved testing second-generation antipsychotics,
ﬁrst-generation antipsychotics, adjunctive medications,
non-drug interventions, or placebo/treatment as usual
(TAU) arms. In the next stage a series of planned uni-
variate meta-regressions were conducted, with those
found to approach signiﬁcance (p < 0.10) entered into
a multivariate model. First, we examined the impact
of length of treatment in order to assess whether
there was any trend over time. Next, we tested whether
there was any difference between studies which incor-
porated a maximum threshold for positive and de-
pressive symptoms, compared to those that did not,
in order to assess whether the degree of change in
negative symptoms varied dependent upon how stu-
dies dealt with factors which can cause secondary
negative symptoms. We also tested the impact of
blinding the assessors, a minimum negative symptom
inclusion criterion, and whether the study received in-
dustry sponsorship.
In any examination of the change in a continuous
variable over time which only includes two time points
the issue of regression to the mean should be con-
sidered (Chiolero et al. 2013). This being the case, the
mean negative symptoms at baseline were added to
the ﬁnal multivariate model to determine the degree
of additional variance that may be explained by a
greater reduction in negative symptoms being caused
by a higher baseline symptom levels.
Results
A ﬂow diagram depicting the search strategy for stu-
dies is included in Fig. 1. Of the 9480 articles screened,
49 articles were found and 41 were included in the
ﬁnal analysis (see Table 1). From these, a total of 89
separate samples were obtained. Of the 41 studies,
ﬁve came from the USA; four each from Canada,
Germany and the UK; three each from India, Spain
and Turkey; two each from China, France and Italy;
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and one each from Brazil, Finland, Israel, Nepal,
Poland and Serbia. Four studies were conducted in
multiple countries, with sites in Northern America,
Europe and Asia. Based on 51 samples, the median
of study mean illness duration was 12.4 years (range
0.6–27.5 years). Twenty-three studies measured nega-
tive symptoms using the Positive and Negative
Syndrome Scale (PANSS; Kay et al. 1987), 14 used
the Scale to Assess Negative Symptoms (SANS;
Andreasen, 1983), and four used the BPRS (Overall &
Gorham, 1962). While studies which used alternative
scales were screened, none met eligibility criteria.
After pooling all 89 samples, a ﬁnal total of 5944 parti-
cipants were included in the meta-analysis.
As indicated in the forest plot (see Fig. 2), in all ﬁve
intervention types a signiﬁcant reduction in negative
symptoms was found between the baseline and the
follow-up assessment stage. Large effect sizes (ES)
were detected in second-generation antipsychotics
[ES = 1.09, 95% conﬁdence interval (CI) 0.86–1.32, I2 =
95.5%] and the adjunctive medication (ES = 0.97, 95%
CI 0.68–1.26, I2 = 91.7%) arms, while a small effect
size was noted in the placebo/TAU group (ES = 0.33,
95% CI 0.17–0.49, I2 = 91.8%).
Next, a series of meta-regressions were conducted.
In the univariate analyses the scale used, intervention
type, study duration, and a minimum negative symp-
toms inclusion criterion were all associated with nega-
tive symptom change heterogeneity (see Table 2). A
maximum level of positive symptoms and previous
non-response to treatment as exclusion criteria were
found to approach signiﬁcance (p < 0.10), while other
variables were non-signiﬁcant. In the multivariate
model, only the type of scale used and the type of in-
tervention received remained signiﬁcant. Studies
which used the SANS found a signiﬁcantly greater re-
duction in negative symptoms relative to those that
used the PANSS (SANS: ES = 1.02, 95% CI 0.77–1.28;
PANSS: ES = 0.66, 95% CI 0.56–0.77). Collectively, the
scale used and the intervention type accounted for
43.65% of the variance. In a sensitivity analysis, the
sample-level baseline negative symptoms were added
to the model which was found to be a signiﬁcant pre-
dictor (B = 0.01, S.E. = 0.00, 95% CI 0.00–0.02). However,
Fig. 1. Flow diagram outlining study selection procedure.
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Table 1. Characteristics of eligible studies
Authors Year Country
Study duration
(weeks)
Outcome
measurea
Individual
symptoms
reported Intervention typeb n
Addington &
Addington (2000)
2000 Canada 130 PANSS No TAU 65
Aguglia et al. (2002) 2007 Italy 52 SANS Yes Non-drug intervention:
psychoeducation
69
TAU 66
Alptekin et al. (2005) 2005 Turkey 52 BPRS No TAU 382
Alvarez et al. (2006) 2006 Spain 48 SANS Yes SGA: olanzapine 120
SGA: risperidone 115
Amell & Llandrich
(2008)
2008 Spain 46 PANSS Yes Non-drug intervention: skills
training group
35
TAU 22
Bales et al. (2009) 2009 Nepal 18 PANSS No TAU 30
TAU + betel nuts 30
Behere et al. (2011) 2011 India 16 PANSS No Non-drug intervention: yoga
group
34
Non-drug intervention:
exercise group
31
TAU 26
Bhowmick et al. (2010) 2010 India 12 SANS No SGA: amisulpride 40
SGA: olanzapine 40
Bio & Gattaz (2011) 2011 Brazil 26 PANSS No TAU 57
Bobes et al. (2009) 2009 Spain 34 BPRS No SGA: risperidone 362
Bodkin et al. (2005) 2005 USA 12 SANS Yes Adjunctive: selegiline 33
Placebo 34
Crawford et al. (2012) 2012 UK 52 PANSS No TAU 137
Non-drug intervention:
activity group
140
Non-drug intervention: art
therapy group
140
Fleischhacker et al.
(2003)
2003 Multi 52 PANSS No SGA: risperidone 120
SGA: risperidone 228
SGA: risperidone 267
Gaebel et al. (2007) 2007 Germany 52 PANSS No SGA: risperidone 77
FGA: haloperidol 74
Gorna et al. (2008) 2008 Poland 52 PANSS No TAU 88
Hirsch et al. (2002) 2002 Germany 28 PANSS No SGA: ziprasidone 110
FGA: haloperidol 117
Kane et al. (2011) 2011 USA 26 PANSS No TAU: remained on same drug 194
Placebo: switched to placebo 192
Kane et al. (2012) 2012 USA 24 PANSS No Adjunctive: armodaﬁnil 70
Adjunctive: armodaﬁnil 69
Adjunctive: armodaﬁnil 71
Placebo 70
Kaphzan et al. (2014) 2014 Israel 12 PANSS No Placebo 22
Adjunctive: entacapone 23
Klingberg et al. (2011) 2011 Germany 52 PANSS Yes Non-drug intervention: CBT 99
Non-drug intervention: CRT 99
Lasser et al. (2013) 2013 USA 10 SANS No Adjunctive: lisdexamfetamine
dimesylate
92
Lecrubier et al. (2006) 2006 France 26 SANS No Placebo 34
SGA: olanzapine 70
SGA: olanzapine 70
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Table 1 (cont.)
Authors Year Country
Study duration
(weeks)
Outcome
measurea
Individual
symptoms
reported Intervention typeb n
SGA: amisulpride 70
Liu et al. (2014) 2014 China 16 PANSS No Placebo 40
Adjunctive: minocycline 39
Loebel et al. (2007) 2007 India 64 PANSS No SGA: ziprasidone 32
SGA: ziprasidone 30
Loo et al. (1997) 1997 France 26 SANS Yes Placebo 72
SGA: amisulpride 69
Meltzer et al. (2010) 2010 USA 52 BPRS No SGA: clozapine 40
FGA: various ﬁrst-generation
drugs
45
Olie et al. (2006) 2006 Multi 12 PANSS No SGA: ziprasidone 59
SGA: amisulpride 63
Pach et al. (1998) 1998 Germany 52 SANS Yes FGA: ﬂupenthixol decanoate 63
Peet & Horrobin
(2002)
2002 UK 12 PANSS No Placebo 31
Adjunctive: eicosapentaenoic
acid
32
Adjunctive: eicosapentaenoic
acid
32
Adjunctive: eicosapentaenoic
acid
27
Purdon et al. (2000) 2000 Canada 54 PANSS No SGA: olanzapine 21
FGA: haloperidol 23
SGA: risperidone 21
Ravanic et al. (2009) 2009 Serbia 52 PANSS No FGA: haloperidol 70
FGA: haloperidol 35
FGA: chlorpromazine 65
FGA: chlorpromazine 40
SGA: clozapine 65
SGA: clozapine 50
Richardson et al.
(2007)
2007 UK 38 SANS No TAU 46
Non-drug intervention: art
therapy group
43
Semiz et al. (2007) 2007 Turkey 12 SANS No SGA: clozapine 97
Schoemaker et al.
(2014)
2014 Multi 12 SANS Yes Adjunctive: Org25935 low
dose
71
Adjunctive: Org25935 high
dose
73
Placebo 70
Sumiyoshi et al. (2007) 2007 USA 26 BPRS No Adjunctive: buspirone 30
TAU 29
Taiminen et al. (1997) 1997 Finland 12 PANSS No TAU 39
Adjunctive: citalopram 36
Turkington et al.
(2008)
2008 UK 78 SANS No Non-drug intervention: CBT 46
Non-drug intervention:
befriending
44
Ucok et al. (2011) 2011 Turkey 52 SANS No TAU 52
TAU 41
Voruganti et al. (2007) 2007 Canada 52 PANSS No SGA: olanzapine 42
SGA: quetiapine 43
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the additional variance explained was relatively small
(4.10%).
Although many of the studies evaluated extra-
pyramidal symptoms (EPS) as part of their analysis
(53.7%), only three studies speciﬁed an EPS maximum
threshold as an exclusion criterion (Klingberg et al.
2011; Lasser et al. 2013; Schoemaker et al. 2014).
Given the lack of data, this was not included in the
meta-regression analysis. Of those studies that did re-
port EPS, they were generally considered to be in the
low range at study intake, suggesting that the impact
of EPS on negative symptoms was likely to be
minimal.
Given the ﬁnding that second-generation antipsy-
chotics and adjunctive medication arms resulted in
much larger effect sizes than other treatment types,
contrary to our expectations based on the existing
literature (i.e. Leucht et al. 2009; Arango et al. 2013),
the TAU and placebo control arms that they were com-
pared to were explored in more depth. A substantially
larger effect size was detected in TAU/placebo control
arms which were part of the drugs trials, in
Table 1 (cont.)
Authors Year Country
Study duration
(weeks)
Outcome
measurea
Individual
symptoms
reported Intervention typeb n
Xiang et al. (2006) 2006 China 34 PANSS No Non-drug intervention:
community re-entry
48
Non-drug intervention:
counselling
48
Zoccali et al. (2007) 2007 Italy 24 SANS Yes Adjunctive: lamotrigine 26
Placebo 25
List of studies not included in the main analysis due to insufﬁcient data
Adams et al. (2013) 2013 Multi 24 NSA-16 No SGA: multiple types 130
SGA: LY2140023 131
Chouinard et al.
(1975)
1975 Canada 12 BPRS No Placebo 24
FGA: amitriptyline
hydrochloride
24
FGA: perphenazine 24
FGA: amitriptyline
perphenazine
24
Goff et al. (2005) 2005 USA 26 SANS Yes Adjunctive: D-cycloserine 26
Placebo 25
Hayes et al. (1995) 1995 Australia 44 SANS No Non-drug intervention: skills
training group
n/s
Non-drug intervention:
discussion group
n/s
Liberman et al. (1998) 1988 USA 156 BPRS No Non-drug intervention:
occupational therapy
n/s
Non-drug intervention: skills
training group
n/s
Lieberman et al. (2013) 2013 Multi 12 SANS No Adjunctive: TC-5619 94
Placebo 91
Marder et al. (2003) 2003 USA 104 SANS Yes SGA: risperidone + skills
training
33
FGA: haloperidol + skills
training
30
Pinto et al. (1979) 1979 UK 78 BPRS No FGA: ﬂupenthixol decanoate 34
FGA: ﬂuphenazine decanoate 30
a PANSS, Positive and Negative Syndrome Scale; BPRS, Brief Psychiatric Rating Scale; SANS, Scale to Assess Negative
Symptoms; NSA-16, Negative Symptom Assessment – 16.
b TAU, treatment as usual; SGA, second-generation antipsychotic; Adjunctive, adjunctive medication in addition to
antipsychotic medication received; FGA, First-generation antipsychotic; CBT, cognitive behaviour therapy; CRT, cognitive
remediation therapy.
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Fig. 2. Forest plot of the change in negative symptoms, by intervention type.
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comparison to those thatwerenot (ES = 0.67, 95%CI0.41–
0.93, in comparison to ES = 0.15, 95% CI 0.04–0.25). In a
subsequent meta-regression this difference was found
not to be attributable to either higher negative symptoms
at baseline, or the type of assessment tool used, which
were signiﬁcant predictors in the full model.
Examination of individual negative symptoms
In 18 samples over nine studies the change in individual
negative symptoms were also reported (see Table 1).
Seven studies used the SANS as the rating tool, while
two used the PANSS. Scores from different scales were
combined using the method proposed by Lyne and col-
leagues (2012). A signiﬁcant reduction was found in all
four of the symptoms measured (affective blunting, alo-
gia, avolition-apathy, anhedonia-asociality). Of the four,
alogia appeared to reduce the least (ES = 0.64, 95% CI
0.45–0.83) and avolition-apathy the most (ES = 0.77, 95%
CI 0.53–1.01); however, the difference between the
items appeared minimal.
Eligible studies not pooled into the main analysis
Eight studies were found to be eligible, but could not
be included in the main analysis (see Table 1). In line
with the main results, 11 samples found some form
of reduction in negative symptoms from baseline to
end of study, ﬁve saw no change, and in two the
change was not speciﬁed.
Discussion
Main results
The meta-analysis provided a clear result; negative
symptoms of schizophrenia tend to improve signiﬁ-
cantly in an outpatient setting. A reduction in negative
symptoms found across all intervention types, with the
effect sizes ranging from small to large. A signiﬁcant
reduction was found in all four of the separate negative
symptoms examined, covering both experiential and
expressive features of the disorder. While substantial
heterogeneity was present in the sample, a series of
planned meta-regressions indicated that there was no
difference in the reduction between studies which
did and did not exclude participants with higher levels
of positive or depressive symptoms. In addition,
study-level methodological differences such as
whether assessors were blinded, the symptom eligi-
bility criteria, or whether the study received industry
sponsorship did also not appear to inﬂuence the result.
Strengths and limitations
One of the main strengths of the study is that, despite
the broad range of study interventions considered, the
Table 2. Univariate and multivariate meta-regressions examining the heterogeneity of negative symptom change
Predictor of negative symptom change
Univariate analysis Multivariate analysis
Coefﬁcient 95% CI p Coefﬁcient 95% CI p
Study duration −0.01 (0.00) −0.01 to −0.00 0.035 −0.00 (0.00) −0.01 to 0.00 0.388
Scale used (compared to PANSS) 0.002
SANS 0.49 (0.14) 0.21 to 0.77 0.43 (0.13) 0.16 to 0.70 0.002
BPRS −0.12 (0.26) −0.63 to 0.40 −0.07 (0.23) −0.54 to 0.39 0.760
Intervention type (compared to SGA) <0.001
Non-drug intervention −0.75 (0.18) −1.11 to −0.38 −0.67 (0.18) −1.04 to −0.30 0.001
TAU/placebo −0.76 (0.16) −1.07 to −0.45 −0.72 (0.16) −1.04 to −0.40 <0.001
Drug: FGA −0.68 (0.18) −1.10 to −0.25 −0.53 (0.20) −0.93 to −0.13 0.010
Drug: augmentation −0.12 (0.18) −0.48 to 0.23 −0.17 (0.18) −0.54 to 0.19 0.336
Min negative symptoms 0.37 (0.13) 0.10 to 0.63 0.007 0.11 (0.12) −0.13 to 0.36 0.356
Max positive symptoms 0.26 (0.14) −0.02 to 0.54 0.071 0.05 (0.13) −0.21 to 0.32 0.685
Study supported by industry sponsorship 0.15 (0.14) −0.14 to 0.43 0.309
Exclusion: previous non-response 0.42 (0.18) 0.07 to 0.78 0.019 0.05 (0.17) −0.29 to 0.40 0.752
Raters blinded to allocationa −0.18 (0.15) −0.47 to 0.12 0.234
Exclusion: moderate levels of depression 0.13 (0.17) −0.21 to 0.46 0.452
CI, Conﬁdence interval; PANSS, Positive and Negative Syndrome Scale; SANS, Scale to Assess Negative Symptoms;
BPRS, Brief Psychiatric Rating Scale; SGA, second-generation antipsychotic; TAU, treatment as usual; FGA, ﬁrst-generation
antipsychotic.
Values within parentheses are standard errors.
a One study not included due to lack of data.
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ﬁndings are consistent. Of the 89 study arms included,
only one found a clear signiﬁcant increase in symp-
toms. In this case, the sample was part of a continu-
ation study where patients who had previously
responded well to their SGA medication were then
switched to a placebo (Kane et al. 2011). In addition,
when testing for the effect of regression to the mean,
adding baseline negative symptoms to the multivariate
model appeared to add relatively little additional ex-
planatory power of the variance (4.1%), suggesting
the ﬁndings are relatively robust. A further strength
of this study is that despite the broad study inclusion
criteria, removing samples which included inpatients
at baseline, and other psychotic diagnoses, meant the
participant inclusion criteria were relatively stringent
in comparison to other observational studies that
have looked at how negative symptoms change over
time (i.e. Pogue-Geile & Harrow, 1985; Fenton &
McGlashan, 1991; Dollfus & Petit, 1995; Eaton et al.
1995). When testing for heterogeneity, no difference
in the effect size was detected between studies which
excluded participants with elevated positive and de-
pressive symptoms, which suggests the change un-
likely to be attributable to a reduction in these factors
which can induce secondary negative symptoms.
One limitation of the study is that because of the
variance estimation method adopted a number of stud-
ies were excluded due being too small. However, given
there is evidence to suggest that smaller studies can
often present larger effect sizes (i.e. Zhang et al.
2013), our ﬁndings may have led to a more conserva-
tive estimate of the effect size. Another limitation is
that, despite the number of studies included in the
analysis (n = 41), the ﬁnal sample of 5944 patients
was smaller than what was anticipated. This was due
to a number of the larger studies either containing
inpatients (Lieberman et al. 2005), not using a validated
negative symptoms scale (Dossenbach et al. 2004), or
including patients with other psychotic disorders.
Another important issue to consider is that it is difﬁ-
cult to assess to what extent the reduction in severity is
attributable to improvements in primary or secondary
negative symptoms. However, difﬁculties making this
distinction in research trials is not new (Buchanan,
2007), and the consensus statement suggests that
such a distinction is not essential in trials as long as
the symptoms are persistent and causes of secondary
negative symptoms are adequately controlled for
(Kirkpatrick et al. 2006). In this analysis, the eligible
studies typically reported participants as being highly
chronic in nature, reﬂected in the large median dur-
ation of illness (12.4 years), and many deﬁned their
sample as treatment-resistant, stable, non-acute, or in
a maintenance period. Regarding whether secondary
negative symptoms can be adequately controlled for
using study-level inclusion/exclusion criteria in a
meta-regression of the heterogeneity present in a
meta-analysis, this is also up for debate. However, de-
spite these issues the high consistency of the direc-
tional change in negative symptoms in an outpatient
sample, and the fact that there was no difference in
this change between studies which did and did not
control for factors which induce secondary negative
symptoms does suggest that the improvement appears
to occur to a greater extent to what was previously
assumed. Further work examining the longitudinal
course of negative symptoms in a study with clearly
deﬁned inclusion criteria relating to the persistence of
negative symptoms, with appropriate controls for sec-
ondary negative symptoms, would provide stronger
evidence for whether primary negative symptoms of
the disorder are less stable than previously assumed.
Another limitation is that due to the substantial het-
erogeneity of the study designs, the fact that multiple
arms of single studies were included which would nat-
urally cluster together, and possible issues relating to
the regression of the mean complicating the interpret-
ation further, it was recognized that conducting an
examination of publication bias important in typical
meta-analytical studies (Higgins & Green, 2011)
would have limited utility in this context. This being
the case, such analysis was omitted so we cannot be
certain as to whether publication bias inﬂuenced the
results signiﬁcantly. However, given a number of the
studies were non-inferiority trials, dose–response stu-
dies, observational studies, and that control arms
were used in this study as equivalent to experimental
conditions, it would be unlikely that any publication
bias would systematically inﬂate the overall effect
sizes in the same manner as would typically be
expected in a normal meta-analysis.
Finally, due to the lack of data, no-medication as a
therapeutic option could not be evaluated, meaning it
is not clear whether a reduction in negative symptoms
would also occur in non-medicated patients. It is poss-
ible, however, that such an improvement could occur
given there is some evidence to suggest that patients
who do not immediately relapse upon termination of
their antipsychotic regimen may experience improved
global functioning over time (Harrow & Jobe, 2007).
Interpretation
These ﬁndings are contrary both to the earliest concep-
tions of schizophrenia, which suggested that negative
symptoms follow a path of progressive deterioration
(Bleuler, 1951; Kraepelin, 1971), and our current under-
standing of negative symptoms which suggest that
they are highly stable in the non-acute phase (Möller,
2007). While acknowledging that the improvement in
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negative symptoms were relatively small in the TAU,
non-drug intervention arms and typical antipsychotic
study arms, the improvement of negative symptoms
over time appear to lend support to the recovery
model of schizophrenia, particularly given the relation-
ship of these symptoms to psychosocial functioning
(Norman et al. 2000; Warner, 2009).
Given the limitations of the within-group design, the
effect sizes presented cannot be used as an assessment
on the effectiveness of any one treatment. As high-
lighted earlier, a series of meta-analyses have been con-
ducted to evaluate treatments for schizophrenia using
more appropriate designs (i.e. Kurtz & Mueser, 2008;
Leucht et al. 2009; Jauhar et al. 2014). Overall, these
reviews have detected relatively limited treatment ben-
eﬁts for negative symptoms, contrasting with the large
within-group effect sizes noted here in the example of
second-generation antipsychotic and adjunctive drug
medication trials. Further investigation into the TAU
and placebo study arms indicate that the effect sizes
of drug study control arms are substantially larger
than non-drug study controls , which suggest there is
something inherent in the methodologies employed
which makes these drug studies more likely to detect
and report symptoms improvements. Many drug stu-
dies used placebo, as opposed to TAU, so a placebo ef-
fect may account for at least part of this difference.
However, while it has been noted that the placebo ef-
fect is an increasing issue in schizophrenia drug trials
(Kinon et al. 2011), given the effect size differences be-
tween drug and non-drug studies are so large (ES =
0.67, in comparison to ES = 0.15) it suggests that other
factors inherent to the design and assessment may
also be important. Regardless, the highly varied nature
and outcomes study arms which fall under the heading
of TAU and placebos merits further investigation.
Disentangling how regression to the mean issue
relates to negative symptoms in an exclusively out-
patient sample is complex issue worthy of further con-
sideration. Higher mean levels of negative symptoms
at baseline did predict a greater reduction. However,
the additional proportion of the variance explained
over and above the intervention type and assessment
scale used was fairly small (4.1%), suggesting that
the regression to the mean may not be as large as
one might typically expect. This could be due to a
number of factors. First, primary negative symptoms
are thought to be highly stable (Möller et al. 2007) so
it is perhaps unlikely that a substantial ﬂuctuation
around the mean level of symptoms over time would
be expected, presuming secondary factors are appro-
priately considered. Second, by omitting samples
which contained inpatients at baseline (but not necess-
arily at study end), the patients were a lot less likely to
have been recruited during their most severe phase of
their disorder, further minimizing the regression to the
mean effect (Morton & Torgerson, 2003).
When testing for sources of heterogeneity in the
course of negative symptoms, only the impact of as-
sessment scale type remained signiﬁcant, after control-
ling for intervention type. In comparison to studies
which used the PANSS or the BPRS, a signiﬁcantly
greater change in negative symptoms was detected in
studies that used the SANS. The ﬁnding that the
SANS is a more sensitive instrument to detect change
is in line with recommendations outlined in the
MATRICS consensus statement (Kirkpatrick et al.
2006) and is perhaps unsurprising given the scales
focus on negative symptoms, despite the conceptual
and methodological issues that the scale is recognized
to have (Blanchard et al. 2011). No eligible studies used
either the Clinical Assessment Interview for Negative
Symptoms (Horan et al. 2011) or the Brief Negative
Symptom Scale (Strauss et al. 2012), therefore it is un-
known how these new scales compare.
Understanding how negative symptoms change
over time requires further attention given the duration
between time points was not found to be a signiﬁcant
predictor. However, with the considerable variability
in treatment duration, post-treatment follow-up dur-
ation, and post-treatment provision between studies,
this is perhaps not surprising. In longitudinal studies
assessing negative symptoms over very long periods
of time, there has been little evidence of a linear im-
provement towards symptom remission (Strauss et al.
2010), while the rate of recovery in schizophrenia re-
mains low (Jääskeläinen et al. 2013). Overall, this sug-
gests that the trajectory of this improvement may be
complex. One possible explanation of the improvement
uncovered could be the non-speciﬁc effects of
increased attention derived from being involved in re-
search. Patients with prominent negative symptoms
are typically very socially isolated, so increased contact
time with researchers in itself may provide some thera-
peutic beneﬁt.
Conclusions
Based on the available data of almost 6000 outpatients,
negative symptoms of schizophrenia do not tend to be
stable or deteriorate, but are instead likely to improve
over time. This ﬁnding offers a further critique of
the historical argument which suggests schizophrenia
is a disorder of continual decline (Bleuler, 1950;
Kraepelin, 1971) and instead provides further support
to the recovery model of schizophrenia (Warner,
2009). Overall, these ﬁndings suggest that negative
symptoms may not be as resistant to change as what
has previously been assumed, and perhaps offer new
hope to those who may experience such symptoms.
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a b s t r a c t
The initial appraisal of treatment by inpatients with schizophrenia has been found to be a signiﬁcant
predictor of clinical outcomes. The study aim was to examine whether speciﬁc types of symptoms are
associated with the initial appraisal of treatment after controlling other patient characteristics. Data of
2105 inpatients with schizophrenia (ICD-10 F20-9) were pooled from three national and international
multi-centre studies. Patients were interviewed within the ﬁrst week of their inpatient admission.
Higher levels of manic and positive symptoms were signiﬁcantly associated with a less favourable
initial appraisal of treatment, whilst no association was found with depression/anxiety and negative
symptoms. Detained patients had more negative initial treatment appraisals, and the association with
manic symptoms was signiﬁcantly stronger in detained patients compared to those admitted
voluntarily. Whilst patient reported outcomes in psychiatry are usually associated with mood
symptoms, this appears not to be the case for the initial appraisal by inpatients with schizophrenia.
The association with manic and positive symptoms may be explained by the inﬂuence of such
symptoms on the hospital experience. Focusing on the initial management of mania and positive
symptoms might improve patients’ appraisal of treatment in the inpatient environment.
& 2012 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Evidence indicates that patients with schizophrenia who have
a more positive initial appraisal of their treatment are likely to
beneﬁt more from that treatment eventually. This applies to
pharmacological treatment (Van Putten and May, 1978; Van
Putten et al., 1978; Bartko´ et al., 1987; Awad et al., 1995) and
complex interventions (Priebe and Gruyters, 1994, 1995a; Bro¨ker
et al., 1995; Priebe et al., 2009, 2010c). In inpatients, a more
positive initial appraisal of treatment was associated with lower
symptom levels after one month (Richardson et al., 2010), at
discharge (Bro¨ker et al., 1995), lower social disability at 3 and 12
months (Priebe et al., 2010a), and lower subsequent involuntary
readmission rates (Priebe et al., 2009). Developing a greater
understanding of the factors which inﬂuence how patients initi-
ally appraise their hospital treatment would help identify those at
risk of being less satisﬁed with their treatment, and could assist in
the development of new interventions to maximise patients’
initial appraisal of treatment.
Whilst previous studies have controlled the predictive associa-
tion of initial treatment assessments with later clinical outcomes
for socio-demographic and clinical characteristics, at present it is
unclear whether speciﬁc types of symptoms are associated with a
more or less favourable initial assessment of treatment. The
importance of analysing the inﬂuence of symptom types, rather
than global levels of psychopathology, has been emphasised in
the literature (Shafer, 2005; Richardson et al., 2010). Previous
ﬁndings suggest other patient reported outcomes, including
patients’ overall appraisal of psychiatric treatment, are negatively
associated with mood, and that this could be due to a negative
rating bias in people with higher levels of depressive symptoms,
as opposed to speciﬁc experiences of treatment (Priebe et al.,
1998; Fakhoury et al., 2002; Hansson et al., 2007). In this study
we aimed to identify what types of symptoms are associated with
the initial appraisal of hospital treatment in patients with
schizophrenia, after adjusting the inﬂuence of socio-demographic
and other clinical characteristics.
2. Methods
An exploratory cross-sectional study examining the association between
patients’ initial appraisal of inpatient treatment and various socio-demographic
and symptom severity measures, analysing a pooled data set speciﬁcally collated
Contents lists available at SciVerse ScienceDirect
journal homepage: www.elsevier.com/locate/psychres
Psychiatry Research
0165-1781/$ - see front matter & 2012 Elsevier Ireland Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.psychres.2012.04.011
n Correspondence to: Unit for Social and Community Psychiatry, Newham
Centre for Mental Health, London E13 8SP, United Kingdom.
Tel.: þ44 20 7540 4210.
E-mail address: s.priebe@qmul.ac.uk (S. Priebe).
Please cite this article as: Savill, M., et al., Symptom levels and initial appraisal of hospital treatment in patients with schizophrenia.
Psychiatry Research (2012), http://dx.doi.org/10.1016/j.psychres.2012.04.011
Psychiatry Research ] (]]]]) ]]]–]]]
for this purpose. All the data was obtained within the ﬁrst week of treatment apart
from the diagnosis, which was recorded from patient notes at the point of
discharge.
2.1. Sample
The current sample was obtained from pooling data from three studies. The
InvolvE study (Priebe et al., 2009) assessed characteristics and experiences of in-
patients in 22 hospitals across England. The EUNOMIA study (Kallert et al., 2005;
Priebe et al., 2010b) was a related study with a similar design conducted at sites in
11 European countries. Both studies had a focus on detained patients but also
included voluntary patients who felt coerced to treatment. The EUNOMIA study’s
data from London was included as part of the InvolvE study, and so these were
omitted from the EUNOMIA sample to ensure that participants were not included
twice. The third study, EDEN (Kallert et al., 2007), was a randomised controlled
trial comparing outcomes of voluntary patients in day hospitals with those in
conventional in-patient settings. Details of the rationale, methods and ﬁndings of
each of the three studies have been described elsewhere.
All three studies included consecutively admitted patients who had the
capacity to provide informed consent, aged between 18 and 65. Consistent
exclusion criteria were as follows: admitted because of acute intoxication, being
a forensic patient, and being transferred from another hospital. In the EDEN study
patients requiring 1-to-1 supervision were excluded, whilst in the EUNOMIA and
InvolvE study voluntary patients who did not report a coercion level of at least
three on the MacArthur Admission Experience Survey were excluded. For this
study, only patients with a main diagnosis of schizophrenia or a related disorder
according to ICD-10 (F20-29, WHO, 1998) were included. With respect to the
EDEN study, only patients treated in conventional hospital settings were included.
2.2. Measures
Initial appraisal of treatment was obtained using the Client Scale for Assess-
ment of Treatment (CAT; Priebe and Gruyters, 1995b; Richardson et al., 2011). The
questionnaire has seven items and asks the patient whether they believe they are
receiving the right care, whether their psychiatrist understands them and if other
staff are pleasant to them, if they believe they are on the right medication, if they
feel well respected and regarded, whether the care received has been helpful, and
whether they feel other elements of their care are appropriate. Scores range from 0
(‘‘not at all’’), to 10 (‘‘yes entirely’’). Patients with missing data on four or more
items were excluded from the analysis. Recent factorial analysis supports the use
of the CAT as a meaningful unidimensional scale, stable over three different
European countries (Richardson et al., 2011), and in previous research the CAT has
been found to have excellent internal consistency (a¼0.90, Priebe et al., 2009).
Symptom severity was measured on the 24-item version of the Brief
Psychiatric Rating Scale (BPRS; Ventura et al., 1993). Scores range from 1 (‘‘not
present’’) to 7 (‘‘extremely severe’’). In examining the severity of symptoms at a
sub-syndrome level with the BPRS a number of different 4 and 5 factor models
have been postulated (Van der Does et al., 1995; Berger et al., 1997; Ventura et al.,
2000; Velligan et al., 2005). Of those, Velligans 4-factor model was selected. Inter-
rater reliability was high in all the three studies, with researchers on the InvolvE
project achieving a Cohen’s Kappa score of 0.90, whilst researchers on the EDEN and
EUNOMIA studies achieved an intra-class coefﬁcient score of 0.78.
Socio-demographic details including age, gender, marital status, previous
admission history and employment status were obtained using the MANSA
(Priebe et al., 1999) in the InvolvE and EUNOMIA studies and the Clinical History
Schedule (Kallert et al., 2000) in the EDEN studies. The categories used were
identical in the three studies.
All the assessments took place within the ﬁrst week following the admission
(in the EDEN study always within the ﬁrst two days), and were conducted by a
researcher not involved in the patients’ treatment.
2.3. Analysis
In univariate analyses linear regressions were conducted with the initial appraisal
of treatment as the dependant variable. In addition to the BPRS subscale scores, the
following variables were tested as potential predictors: age, gender, employment
status, marital status, and the legal status of admission. For the employment and
marital status the variables were dichotomised i.e. ‘‘employed’’ vs. ‘‘unemployed’’
(students were treated as employed for this analysis), and ‘‘married’’ vs. ‘‘unmarried’’
(which included those divorced, single and widowed). The patient was deﬁned as
involuntarily held if they were initially admitted on a voluntary basis but later
detained within the ﬁrst week, prior to the research assessment taking place. We did
not test whether differences in the initial appraisal of treatment were explained by
the study from which the data were taken, because in one of the three studies (EDEN)
there were only voluntary patients. Since we aimed to analyse the impact of legal
status, we did not enter study as a predictor as it would have confounded part of the
analysis.
In the next step a multiple linear regression was conducted with all the
considered predictor variables entered into the model simultaneously. In the ﬁnal
part of the analysis, interaction effects between legal status and each BPRS
subscale score were added to the multivariate model separately in order to
examine whether the effect of symptom severity on the appraisal of treatment
differed between those legally detained and those admitted voluntarily. In order
to rule out the possibility of any bias in the results occurring due to the
heterogeneity of the samples used, a subgroup analysis was conducted on the
largest dataset (EUNOMIA).
To tackle any potential issues which could arise through a listwise deletion of
incomplete cases (Little and Rubin, 1987) a multiple imputation using a chained
equation of 10 cycles was conducted. All values included in the analysis were
entered both as predictors and for imputing. Twenty-ﬁve imputations were
conducted (Spratt et al., 2010), with the analysis conducted on the pooled data.
R2 scores were obtained from the imputed data using the method outlined by
Harel (2009), which involves conducting a Fisher’s r-to-z transformation for each
imputed R score, combining them in accordance with Rubin’s rules (Rubin, 1987),
before transforming them back to R2. All the analysis was conducted on SPSS
version 18.
3. Results
3.1. Sample characteristics
Around 2316 patients met the inclusion criteria. Of which
about 211 patients were omitted due to missing or incomplete
CAT scores, leaving 2105 patients in the ﬁnal sample. The clinical
and socio-demographic characteristics of this sample are pre-
sented in Table 1. Of the ﬁnal total, 1556 were recruited as part of
the EUNOMIA project, 393 as part of the InvolvE study, and 156 as
part of the EDEN study. A missing value analysis indicated that
2.8% of all predictor values (653 in total) was missing, with 21.1%
of cases (445) missing at least one. Of the 653 values missing in
total, 53.9% (352 in total) related to the duration of illness.
3.2. Symptoms and other patient characteristics associated with
initial appraisal of treatment
The univariable and multivariable associations of symptoms
and other patient characteristics with the initial appraisal of
treatment are shown in Table 2.
Higher levels of mania and positive symptoms, lower levels of
depression/anxiety symptoms, being involuntarily admitted,
unemployed and unmarried were all signiﬁcantly associated with
a less favourable initial appraisal of treatment in univariable
analyses. After simultaneously adjusting for potential confound-
ing by other variables; older age, being male, not being detained,
Table 1
Socio-demographic and clinical characteristics of the patients.
Characteristics n or Mean % or SD
Patients (N) 2105
% Detained involuntarily 1530 72.7%
Age (years) 38.49 11.24
Gender (% female) 906 43.1%
Marital status (% married) 454 22.0%
Employment
Standard paid employment 385 18.5%
Unemployed (incl. disability beneﬁts) 1554 74.9%
Other (e.g. student, home-maker) 138 6.7%
Previous psychiatric admission (%yes) 1517 76.7%
Illness duration 7.84 9.11
BPRS
Depression/anxiety subscale score 2.24 1.08
Mania subscale score 1.84 0.96
Negative subscale score 2.14 1.08
Positive subscale score 2.92 1.26
CAT mean score 6.00 1.28
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being employed, and having a low level of manic and positive
symptoms were associated with a more favourable appraisal of
treatment. The variance explained by the multivariable model
was R2¼0.106, with manic symptoms, with a detained legal
status of admission and mania symptoms explaining the greatest
proportion.
In the subgroup analysis with data from the EUNOMIA study
only, the effect of the variables remained broadly consistent, with
all of the 95% conﬁdence intervals falling inside those from the
full sample and with the same variables signiﬁcant and in the
same direction. The only exception to this was ‘employment
status’ (B¼0.305, 95%, CI¼0.589 to 0.021, P¼0.036 in the
full sample, in comparison to B¼0.230, 95%, CI¼0.561 to
0.100, P¼0.172).
3.3. Legal status of admission, symptom severity and initial
treatment evaluation
The next stage of the analysis explored whether symptom
levels had a similar predictive value in voluntary and involuntary
patients. An interaction effect between legal status and each
symptom subscale score was separately entered into the existing
multivariable model (presented in Table 2). Such interaction
effect was found only for manic symptoms (B¼0.372, 95%,
CI¼0.067–0.677, P¼0.017). A post hoc analysis was conducted
in order to identify the direction of the interaction. In detained
patients the association between more manic symptoms and less
positive treatment appraisal was stronger (R2¼0.062, Po0.001)
than in voluntary patients (R2¼0.012, P¼0.009).
4. Discussion
4.1. Main ﬁndings
Mania, depression/anxiety and positive BPRS subscale scores
were signiﬁcantly associated with patients’ initial appraisal of
treatment in the univariate analysis. When the inﬂuence of all
tested variables was considered however, only two types of
symptoms remained signiﬁcant: patients with higher levels of
mania and positive symptoms tended to appraise hospital treat-
ment more negatively. Younger age, female gender, being unem-
ployed and being detained involuntarily were also linked with
less positive appraisals in multivariable analyses.
4.2. Strengths, limitations and methodological considerations
Whilst previous research emphasised the importance of patients’
initial appraisal of treatment as a predictor of treatment outcome,
this is the ﬁrst large study focusing on understanding the factors
that determine more or less favourable initial appraisals of hospital
treatment. The sample size (2105 patients) provides sufﬁcient
statistical power to detect even small effect sizes, thus allowing
the interpretation of negative ﬁndings. We tested observer-ratings
of symptoms as predictors of the patient-rated initial appraisal of
treatment. This avoided obtaining associations as a mere effect of a
generalised tendency to provide more or less positive ratings in
different self-reporting measures (see Hansson et al., 2007;
Fakhoury et al., 2002). The same measures of symptoms and
treatment appraisal were used in all studies from which the data
were pooled, and that all ratings were provided by well trained
researchers who were not involved in treatment.
The major limitation of the study is a potential selection bias.
In two of the three studies (InvolvE and EUNOMIA), voluntary
patients were included only if they expressed a level of being
coerced. In the third study (EDEN), there were no involuntary
patients. Also, not all eligible patients could be recruited in the
three studies. This may have inﬂuenced the absolute levels of
symptoms and initial treatment appraisals, however associations
between variables are assumed to be more robust against a
selection bias, and exploring associations was the aim of this
analysis. Another limitation is that we did not consider in the
analysis what exact treatment was administered during the ﬁrst
days of hospital treatment and whether speciﬁc treatment com-
ponents were linked with patients’ appraisal of treatment. We did
not have consistent data on what type and dose of antipsychotic
medication patients had taken at the time of the interview, so that
medication was not examined as a possible inﬂuencing or
mediating factor. Finally, the multivariable model explained only
about 10% of the variance of the initial assessment of treatment.
Whilst such an amount of explained variance is common for this type
of research, it still leaves about 90% of the variance unexplained.
4.3. Comparison with previous research
Patients’ initial statements about the appropriateness of their
psychiatric treatment have been the subject of research for more
than 30 years. They have been referred to using terms such as
initial subjective response (Van Putten and May, 1978), early
subjective reactions (Priebe, 1987), and initial treatment satisfac-
tion (Priebe et al., 2009). In this study, we used initial appraisal.
Table 2
Univariate and multivariate analysis of variables associated with patients’ initial appraisal of treatment.
Predictor variables Univariate analysis Multivariate analysis
B 95% CI p B 95% CI p
Socio-demographic data
Age 0.010 0.000 to 0.020 0.061 0.021 0.009 to 0.033 0.001
Female vs. male 0.214 0.450 to 0.022 0.076 0.346 0.581 to 0.111 0.004
Past admission (Yes/No) 0.178 0.235 to 0.473 0.235 0.022 0.338 to 0.293 0.889
Illness duration 0.014 0.028 to 0.000 0.056 0.012 0.030 to 0.005 0.172
Detained legal status 1.207 1.464 to 0.949 o0.001 0.984 1.247 to 0.722 o0.001
Unemployed 0.441 0.726 to 0.156 0.002 0.305 0.589 to 0.021 0.036
Married 0.319 0.034 to 0.604 0.028 0.135 0.155 to 0.426 0.360
BPRS symptom clusters
Depressive/anxiety subscale 0.130 0.021 to 0.239 0.019 0.017 0.091 to 0.125 0.758
Mania subscale 0.674 0.794 to 0.554 o0.001 0.490 0.620 to 0.360 o0.001
Negative subscale 0.190 0.218 to 0.000 0.051 0.005 0.114 to 0.104 0.929
Positive subscale 0.465 0.557 to 0.372 o0.001 0.226 0.330 to 0.122 o0.001
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It reﬂects the type of questions asked in the CAT and mirrors the
nature of assessing a treatment that has just started and is
unlikely to have yet had a major effect. However, when compar-
ing the ﬁndings with the literature, one has to consider that other
studies may have used a different terminology.
The literature on treatment satisfaction in psychiatry, i.e. not
initial but later appraisals of treatment, suggests that mood symp-
toms have the greatest impact on patients’ ratings. Patients who are
more depressed tend to express a more negative view of their
treatment. It has been suggested that this reﬂects a negative rating
bias of patients with high levels of depression rather than a speciﬁc
experience of treatment (Priebe et al., 1998; Hansson et al., 2007;
Fakhoury et al., 2002; Fakhoury and Priebe, 2002). In this study, the
multivariable analysis did not identify depression, but mania and
positive symptoms as inﬂuential. This is unlikely to be explained by a
mood dependent rating bias, but may reﬂect how patients with
different symptoms of schizophrenia experience the in-patient set-
ting. Given patients level of insight into their disorder has been found
to negatively correlate with both positive and negative symptoms
(Minz et al., 2003; De Hert et al., 2009), whilst in our study negative
symptoms were found to have no impact on treatment appraisal, the
ﬁnding is also unlikely to be attributable to simply how aware the
patients were of their illness and the need for treatment.
The ﬁnding is partly consistent with the results of Richardson
and colleagues (2010) who reported a less positive initial treat-
ment appraisal for patients with higher levels of mania, positive
and depression/anxiety symptoms. That analysis however had a
different focus, used a smaller sample of exclusively involuntary
patients, a different factor analysis of the BPRS to deﬁne the sub-
syndromes, and did not adjust for other symptoms and patient
characteristics.
Patients with higher levels of manic and positive symptoms
may have greater difﬁculty in coping with being placed in the
conﬁned environment of a hospital ward. In the ward they have
reduced autonomy and limited space. They have to conform to
the organisational requirements of the ward and are surrounded
by other patients who are also acutely ill, many of whom can be
noisy and aggressive. Manic and positive symptoms may lead to
less satisfactory interactions with other service users and staff
members and greater conﬂict, which in turn may negatively
impact upon their perception of treatment still further. Patients
who exhibit ‘disturbed behaviour’ or experience acute positive
symptom exacerbation are also more likely to receive combined
anti-psychotics and high doses of antipsychotic medication
(Paton et al., 2008), which can lead to a higher side effect burden
(Centorrino et al., 2004), which could result in a lower appraisal of
the treatment they receive. In a qualitative review of experiences
of involuntary inpatient treatment (Katsakou and Priebe, 2007) a
number of features were highlighted that can negatively impact
upon a patient’s experience of admission, and these may parti-
cularly resonate with those suffering from more intense manic
and positive psychotic symptoms. Patients experiencing greater
levels of positive symptoms such as paranoia or hallucinations
may struggle more in an unfamiliar setting which may feel
frightening or insecure. Patients with severe manic symptoms
are likely to be more agitated, and struggle more with being
contained in an enclosed space with rigid rules and limited
opportunities for activities. The ﬁnding that manic symptoms
inﬂuence patients’ appraisal even more in those involuntarily
admitted, who therefore would experience an even greater restric-
tion to their autonomy, lends further support to this argument.
4.4. Implications
The ﬁndings suggest that patients with different symptom
proﬁles experience and respond to psychiatric hospital treatment
in different ways and, as a result, express different appraisals
within a few days after admission. Patients with schizophrenia
experiencing more severe manic and positive symptoms, and
manic symptoms in particular if detained involuntarily are more
likely to report a more negative initial evaluation of treatment.
This suggests that it is symptom characteristics which may relate
speciﬁcally to being in a ward environment that have a greater
impact on the initial appraisal of treatment, as opposed to mood
which has been found to be the most important in predicting a
range of other patient self-reported outcomes (Priebe et al., 1998;
Fakhoury et al., 2002).
The ﬁndings underline the importance of assessing patients’
initial appraisal of treatment as a relevant process variable in both
research and routine practice. Further studies may explore envir-
onmental factors, processes of interaction between service users
and staff, treatment components and mediating processes as an
explanation of the association of manic and positive symptoms
with more negative appraisals of hospital treatment after only a
few days. In a recent review Millon (2009) has suggested that
acute inpatient settings are at present too custodial and over
reliant on medication, and suggests that providing more psycho-
social interventions as an alternative may be a way to try and
address these issues. If these are problems which disproportion-
ally affect those experiencing higher positive and manic symp-
toms, then this possible solution may go some way in addressing
the more negative experiences these particular patients report.
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Appendix III: Systematic review protocol  
 
 
 
 
 
 
 
 
 
 
  
Systematic review protocol 
 
Objectives: 
1) What is the course of negative symptoms in stable schizophrenia patients over a 
standard treatment period (i.e. 10 weeks-36 months)?  
2) On a study-group level, what changes in negative symptoms can actually be achieved? 
3) Do any patient or treatment characteristics influence the course of negative 
symptoms? 
4) Does the method of assessment impact upon how stable the course of negative 
symptoms is recorded to be? 
5) Is there any variation between the courses of individual negative symptoms? 
 
Search process: 
Electronic databases: MEDLINE, PsychINFO, EMBASE, CENTRAL.  
Reference lists from selected papers hand-searched 
Key journal search: American Journal of Psychiatry, Acta Scandinavica, British Journal of 
Psychiatry, Schizophrenia Bulletin, Schizophrenia Research, The Lancet. Hand-searched, back 
to 1962: 
 
Selection Criteria: 
Database selection: 
Diagnosis: 100% of sample diagnosed with Schizophrenia. 
Patient status: assessments conducted exclusively with outpatients 
Age: 18-65  
Sample size: minimum 50 participants total. 
Length of time between first and last assessment points: minimum 10 weeks. 
Methods: Quantitative research only. Not reviews, case-studies, or papers which have not 
used a validated symptom measurement scale. 
Assessment methods: Any peer reviewed assessment tool used to establish the severity of 
specific negative symptoms of schizophrenia (including motor retardation), or the severity of a 
general schizophrenia negative symptom subscale. Examples measuring negative symptom as 
a singular subscale include (but are not exclusive to): BPRS, PANSS, SANS, NSA-16, NSA-4, PNS-
Q. Measures of individual symptoms include (but not excluded to): SANS, Emotional Blunting 
scale, Chapman Anhedonia scales, TEPS, Fawcett-Clark Pleasure scale, Snaith-Hamilton Scale or 
individual items on the above subscale measures. 
Publication date: Start from when standardised assessment of negative symptoms was 
initiated (i.e. BPRS, 1962). 
Language: Include non-English papers where possible (German, Italian, French, Spanish). 
Articles written in non-Latin characters excluded  
Abstracts and ‘Grey literature’ excluded.  
Search terms: 
1 + 2 + 3 
Medline search terms: 
 1. Disorder  2. Symptoms 3. Treatment /Duration 
*Schizophren$ Negative symptoms Change$ 
Deficit syndrome Reduced affect Effect$ 
 Flattened affect Therap* 
  Blunted affect Intervention /Intervention studies 
  Emotional experience Efficacy 
  Emotional expression Impact 
  Alogia Treatment / *therapeutics 
  Anhedonia Medication 
  Avolition *Longitudinal 
  Asociality *Follow up /*Follow up studies 
 Motor retardation course  
 Amotivation Stability 
 Apathy Time 
  Progress$ 
  Persist$ 
  Year$ */treatment outcome 
   
* denotes an exploded term 
$ denotes open  
/ denotes a meshed term 
 
PsychINFO variation in mesh terms: 
Efficacy: efficacy, * Treatment effect evaluation 
Intervention: intervention, /intervention 
Treatment: treatment, /treatment 
Medication: Medication, *drug therapy 
 
EMBASE variation in mesh terms: 
 Deficit syndrome, *negative syndrome/ 
 Blunted affect, /blunted affect 
 Motor retardation, /motor retardation 
Anhedonia, /anhedonia 
Effect, *therapy effect/ 
Intervention, *intervention study/ 
Efficacy, *drug efficacy/ 
Treatment, /treatment outcome* 
Medication, /drug therapy* 
 
CENTRAL full search terms list: 
(schizophren* OR deficit syndrome) AND (negative symptoms OR reduced affect OR flattened 
affect OR blunted affect OR emotional experience OR emotional expression OR alogia OR 
anhedonia OR avolition OR asociality OR motor retardation OR amotivation OR apathy) AND 
(change* OR effect* OR therap* OR intervention OR efficacy OR impact OR treating OR 
medication OR longitudinal OR follow up OR course OR stability OR time OR progres* OR 
persist* OR year*):ti,ab,kw in Clinical Trials 
 
-Screening (3 stage process: title, abstract, and full paper screen) 
 Exclude if:  
- Non-human, neuro-imaging or neurobiology study 
-If the title indicates it is clearly not relevant (i.e. nothing to do with topic area, 
schizophrenia, negative symptoms etc.) 
-Study published in a non-Latin character language 
-The study is a case report, letter to the editor, conference abstract, book chapter, 
qualitative study, or review† 
-Clearly no repeated assessments (i.e. straight comparison between two samples in 
one time period) 
-includes inpatients 
-No repeated assessments of schizophrenia symptoms OR repeat defined by outcome 
rather than standardised time-point (i.e. re-admission) 
-<50 participants total 
-A structured assessment of negative symptoms was not undertaken, using a 
psychometrically validated assessment tool. 
-No details on exclusively schizophrenic samples presented 
-total study length <10 weeks, or no details reported within 3 year interval 
-Child/older adult (ie >65 years old) included in sample 
 
  
* Note; if the study is a review concerning the longitudinal course of negative symptoms then 
source data should be obtained, and reference list screened. 
  
  
 
 
 
 
 
 
Appendix IV: Systematic review extraction sheet
  
 
      Data at each level: measure 1             
Assessors blinded? Multiple Raters? management of  
Symptoms 
measured 
intervention recruited T1 
  
 
drop out?   number timepoint assessment method mean 
std 
dev no# parts 
                      
 
 
 
 
Study Characteristics
# Screener date Authors Year Title Journal Included? Reason for exclus ion Des ign Inclus ion/exclus ion cri teria
1 2 3
Indentification features
Country Total Method ofDx Randomised? participants  bl inded
4 5 6 7 8 9 10 participants i f so, how?
Data at each level: measure ….
intervention recruited
timepoint assessment methodmean std dev no# parts number timepoint assessment method mean std dev no# parts
T1T… Symptoms 
measured
  
 
 
Participant characteristics 
Gender Ethnici ty %
timepoint assessment methodmean std dev no# parts Mean std dev (% male) 1- White 2- Black Carribean 3- Black African 4- Black other 5- Indian
T… Age
Group level  
6-Pakistani 7- Bangladeshi 8- Chinese 9-Other co-morbidities Anxiety Disorder Depress ive disorder Substance abuse disorder Personal i ty Disorder
Co-morbidity %
% employed Anti -psychotic med Stated conflict of 
mean std dev mean std dev mean std dev mean std dev (chlorprom equiv, mg) Interests?
Age of onset no# prev admislength of education Il lness  duration
 
